{
    "questions": [
        {
            "body": "Which are the most widely reported side-effects in the treatment of Crohn's disease?", 
            "concepts": [
                "http://www.disease-ontology.org/api/metadata/DOID:8778", 
                "http://www.disease-ontology.org/api/metadata/DOID:8577"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21453886", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21317611", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21254868", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20919963", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20458240", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19420815", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18989561", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18788068", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17628557", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17667053", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18469440", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12603508", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11205659", 
                "http://www.ncbi.nlm.nih.gov/pubmed/10981226", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9399771", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9097825", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9005529", 
                "http://www.ncbi.nlm.nih.gov/pubmed/3069176", 
                "http://www.ncbi.nlm.nih.gov/pubmed/6139796", 
                "http://www.ncbi.nlm.nih.gov/pubmed/7084615", 
                "http://www.ncbi.nlm.nih.gov/pubmed/30666"
            ], 
            "id": "511a20f3df1ebcce7d00000c", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21453886", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 173, 
                    "offsetInEndSection": 266, 
                    "text": "Different cutaneous side effects have been described for anti-TNF-\u03b1 therapy such as psoriasis"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21317611", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 165, 
                    "offsetInEndSection": 252, 
                    "text": "Anti-TNF drug-induced alopecia is a less well-known side effect of this class of drugs."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21317611", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 432, 
                    "offsetInEndSection": 471, 
                    "text": "3 patients who developed scalp alopecia"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21254868", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 99, 
                    "text": "Psoriasis and psoriatic arthritis induced in a patient treated with infliximab for Crohn's disease"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20919963", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 220, 
                    "offsetInEndSection": 322, 
                    "text": "side effects appearing in about a fifth of the patients, including myelosuppression and liver toxicity"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20458240", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 94, 
                    "text": "Persistent corneal endothelial deposits associated with rifabutin therapy for Crohn's disease"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19420815", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 93, 
                    "offsetInEndSection": 204, 
                    "text": "complained of alopecia 3 days after starting 6-mercaptopurine (6-MP) and then developed severe myelosuppression"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18989561", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 965, 
                    "offsetInEndSection": 1042, 
                    "text": "Leucopoenia was the more frequent side effect observed, occurring in 36 (34%)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18989561", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 766, 
                    "offsetInEndSection": 820, 
                    "text": "Nausea, vomit, although slight, occurred in 29 (27.4%)"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18788068", 
                    "endSection": "title", 
                    "offsetInBeginSection": 1, 
                    "offsetInEndSection": 103, 
                    "text": "Nodular regenerative hyperplasia as a side effect of azathioprine in a patient with Crohn's disease"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18788068", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 152, 
                    "offsetInEndSection": 253, 
                    "text": "The whole blood count revealed a pancytopenia, hyperbilirubinemia and slightly elevated transaminases"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18788068", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 465, 
                    "offsetInEndSection": 579, 
                    "text": "Analysis of the liver histology was highly suggestive of an azathioprine-related, nodular regenerative hyperplasia"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17628557", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 725, 
                    "offsetInEndSection": 882, 
                    "text": "3 serious adverse events (SAEs) known to be associated with CD treatment (progressive multifocal leukoencephalopathy (PML), serious infections, and lymphoma)"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17667053", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 121, 
                    "text": "Severe pulmonary toxicity after azathioprine/6-mercaptopurine initiation for the treatment of inflammatory bowel disease"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18469440", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 81, 
                    "offsetInEndSection": 162, 
                    "text": "A severe side effect is acute pancreatitis, which is specific for Crohn's disease"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12603508", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 62, 
                    "text": "Recurrent myopericarditis in association with Crohn's disease"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11205659", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 91, 
                    "text": "Interstitial nephritis in patients with inflammatory bowel disease treated with mesalamine"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10981226", 
                    "endSection": "title", 
                    "offsetInBeginSection": 1, 
                    "offsetInEndSection": 89, 
                    "text": "Pancreatitis in a patient with Crohn disease treated with mesalazine and azathioprine"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9399771", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 174, 
                    "offsetInEndSection": 303, 
                    "text": "Leukopenia and thrombocytopenia are observed mostly as a side effect of therapy, particularly with use of immunosuppressive drugs"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9399771", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 305, 
                    "offsetInEndSection": 403, 
                    "text": "Immune thrombocytopenic purpura is rarely reported in association with inflammatory bowel disease."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9097825", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 500, 
                    "offsetInEndSection": 546, 
                    "text": "resulted to watery stools, vomiting, and fever"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9097825", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 640, 
                    "offsetInEndSection": 730, 
                    "text": "Eosionophilia was present and the lymphocyte stimulation test with mesalazine was positive"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9005529", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 149, 
                    "offsetInEndSection": 228, 
                    "text": "Pericarditis as a side effect induced by sulfasalazine or 5-aminosalicylic acid"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3069176", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 483, 
                    "offsetInEndSection": 602, 
                    "text": "The commonest side-effect was hyperaesthesia, but one patient developed nephrotoxicity and one developed hepatotoxicity"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6139796", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 336, 
                    "offsetInEndSection": 437, 
                    "text": "The only troublesome side effect is paresthesia, which apparently is dose-related and not progressive"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7084615", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1052, 
                    "offsetInEndSection": 1223, 
                    "text": "The only major side effect observed was paresthesias. These occurred in 50% of the patients and developed in the patients at a mean of 6.5 mo after the onset of treatment."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30666", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 690, 
                    "offsetInEndSection": 750, 
                    "text": "Hemolysis is not a rare side-effect of sulfasalazine therapy"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30666", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 79, 
                    "offsetInEndSection": 226, 
                    "text": "17 of 40 (43%) patients with inflammatory bowel disease receiving sulfasalazine had evidence of hemolysis as detected by starch gel electrophoresis"
                }
            ], 
            "type": "list"
        }, 
        {
            "body": "Is miR-21 related to carcinogenesis?", 
            "concepts": [
                "http://www.uniprot.org/uniprot/P21_BYVU"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23416953", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23335180", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23288924", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23239858", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23212265", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23175214", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22747440", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22703586", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22610076", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22550943", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22265967", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22168593", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21937590", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21882851", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21880514", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21406606", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21350005", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21081469", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20978195", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20952761", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20827319", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20702469", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20682703", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20380575", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20338946", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20309880", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19901002", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19789312", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19748927", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19737943", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19435529", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19175831", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18853072", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18596939", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18451233", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18230780", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18187804", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18089790", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17587821", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17475218", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23483606", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23466817", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23446999"
            ], 
            "id": "511a4ec01159fa8212000004", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23416953", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1460, 
                    "offsetInEndSection": 1553, 
                    "text": "miR-21* and miR-203 were significantly dysregulated (P < 0.05) in PTC tissues with BRAFV600E."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23416953", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 104, 
                    "text": "Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23335180", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1008, 
                    "offsetInEndSection": 1360, 
                    "text": "Levels of miRNA-21 (miR-21) and miR-106a in gastric cancer tissues were significantly higher compared with the levels in adjacent tissues (P = .006 and P = .001, respectively). Patients who had gastric cancer had significantly different levels of gastric juice miR-21 and miR-106a compared with patients who had benign gastric diseases (both P < .001)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23335180", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1448, 
                    "offsetInEndSection": 1591, 
                    "text": "miR-21 levels in intestinal type gastric cancer specimens were higher than that in diffuse (P = .003) or mixed (P < .001) gastric cancer types."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23288924", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 804, 
                    "offsetInEndSection": 1130, 
                    "text": "MiR-155 and miR-21 appeared significantly over-expressed in the colonic mucosa of IBD subjects without CRC, but also in neoplastic tissues of IBD patients compared to non-IBD controls (p<0.001). Importantly, in patients with IBD-CRCs, miR-155 and miR-21 over-expression extended to the distant non-neoplastic mucosa (p<0.001)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23288924", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 294, 
                    "offsetInEndSection": 495, 
                    "text": "Here we hypothesize that over-expression of miR-155 and miR-21, two inflammation-related miRNAs that target core MMR proteins, may constitute a pre-neoplastic event for the development of MSI IBD-CRCs."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23239858", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 285, 
                    "offsetInEndSection": 661, 
                    "text": "After administration, we determined the expressions of miR-21, miR-27a, miR-34a, miR-93, miR-143, miR-146a, miR-148a, miR-155, miR-196a, miR-203, miR-205, miR-221 and nuclear factor kappa-light-chain enhancer of activated B-cells-1 (Nf\u03bab1), mitogen-activated protein kinase-8 (Mapk8) and v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (K-ras) genes in the liver of mice."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23212265", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 88, 
                    "offsetInEndSection": 188, 
                    "text": "Programmed cell death 4 (PDCD4) is a tumor suppressor gene whose expression is controlled by miR-21."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23212265", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1250, 
                    "offsetInEndSection": 1375, 
                    "text": "Consistently with PDCD4 downregulation, miR-21 was upregulated in neoplastic by comparison with nonneoplastic tissue samples."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23175214", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 449, 
                    "offsetInEndSection": 632, 
                    "text": "Expression of miR-21 (p=0.027), miR-181b (p=0.002), and miR-146b (p=0.021) in tumor tissue and miR-21 (p=0.003) in noncancerous tissue were associated with patients' overall survival."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22747440", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 319, 
                    "offsetInEndSection": 575, 
                    "text": "We analyzed the expression of nine miRNAs (miR-21, miR-127, miR-154, miR-224, miR-323, miR-370, miR-9*, miR-183, and miR-375) by quantitative real-time-polymerase chain reaction in 34 cases of sMTC, 6 cases of hMTC, and 2 cases of C-cell hyperplasia (CCH)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22747440", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 886, 
                    "offsetInEndSection": 1206, 
                    "text": "MTC and CCH were both characterized by a significant overexpression of the whole set of miRNAs (the increase being 4.2-fold for miR-21, 6.7-fold for miR-127, 8.8-fold for miR-154, 6.6-fold for miR-224, 5.8-fold for miR-323, 6.1-fold for miR-370, 13-fold for miR-9*, 6.7-fold for miR-183, and 10.1 for miR-375, p<0.0001)."
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22703586", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 7144, 
                    "offsetInEndSection": 7426, 
                    "text": "As demonstrated in Figure 3A, the five miRNAs (mir-21, mir-223, mir-224, mir-29A and mir-29B) were significantly up-regulated in CRC tissues, except for mir-27a due to non-efficient amplification (CT value in most of the samples was either higher than 35 or even cannot be defined)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22610076", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 304, 
                    "offsetInEndSection": 585, 
                    "text": "The most frequent changes in miRNAs in CLL cells included downregulation of miR-126, miR-572, miR-494, miR-923, miR-638, miR-130a, miR-181a and miR-181b and up-regulation of miR-29a, miR-660, miR-20a, miR-106b, miR-142-5p, miR-101, miR-30b, miR-34a, miR-let-7f, miR-21 and miR-155."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22550943", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 839, 
                    "offsetInEndSection": 1170, 
                    "text": "Results: MTC and CCH were both characterized by a significant overexpression of the whole set of miRNAs (the increase being 4.2-fold for miR-21, 6.7-fold for miR-127, 8.8-fold for miR-154, 6.6-fold for miR-224, 5.8-fold for miR-323 and 6.1-fold for miR-370, 13-fold for miR-9*, 6.7-fold for miR-183 and 10.1 for miR-375, p<0.0001)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22265967", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 869, 
                    "offsetInEndSection": 1002, 
                    "text": "We found that the onco-miRNAs miR-21 and miR-221 displayed upregulated expression while the liver-specific miR-122 was downregulated."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22168593", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1007, 
                    "offsetInEndSection": 1313, 
                    "text": "The aim of the present review was to describe the mechanisms of several known miR, summarize recent studies on oncogenic miR (e.g. miR-21, miR-106a and miR-17), tumor suppressor miR (e.g. miR-101, miR-181, miR-449, miR-486, let-7a) and controversial roles of miR (e.g. miR-107, miR-126) for gastric cancer."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21937590", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 861, 
                    "offsetInEndSection": 1097, 
                    "text": "MiR-15b and miR-21 were differentially expressed in CSF samples from patients with gliomas, compared to control subjects with various neurologic disorders, including patients with primary CNS lymphoma and carcinomatous brain metastases."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21937590", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1268, 
                    "offsetInEndSection": 1526, 
                    "text": "Moreover, inclusion of miR-15b and miR-21 in combined expression analyses resulted in an increased diagnostic accuracy with 90% sensitivity and 100% specificity to distinguish patients with glioma from control subjects and patients with primary CNS lymphoma."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21882851", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 545, 
                    "offsetInEndSection": 971, 
                    "text": "Many aberrantly expressed miRNAs were related to various cancers (e.g., miR-125b, hepatocellular carcinoma; miR-21, leukemia; miR-16, chronic lymphocytic leukemia; miR-192, pituitary adenomas; miR-199a-3p, ovarian cancer; miR-34a, pancreatic cancer). Several miRNAs (e.g., miR-34a, miR-21) and proteins (e.g., TGM2, NDRG2) that play crucial roles in liver tumorigenesis were first found to be affected by MC-LR in mouse liver."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21880514", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1363, 
                    "offsetInEndSection": 1482, 
                    "text": "Except for miR-21 and miR-206, the expression levels of all miRNAs significantly changed during the progression of CaP."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21406606", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1392, 
                    "offsetInEndSection": 1578, 
                    "text": "In addition, diet and carcinogen exposure modulated a number of microRNAs (miR-16, miR-19b, miR-21, miR26b, miR27b, miR-93, and miR-203) linked to canonical oncogenic signaling pathways."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21350005", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 633, 
                    "offsetInEndSection": 817, 
                    "text": "RESULTS: Elevated miR-21 (HR 2.06, 1.13-3.75), miR-17 (HR 2.00, 1.10-3.61), and miR-155 (HR 2.37, 1.27-4.42) was associated with worse cancer-specific mortality in the Maryland cohort."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21081469", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 92, 
                    "text": "NF-\u03baB targets miR-16 and miR-21 in gastric cancer: involvement of prostaglandin E receptors."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20978195", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 377, 
                    "offsetInEndSection": 561, 
                    "text": "Expression of miR-21, miR-29b, miR-34a/b/c, miR-155, and let-7a was determined by quantitative real-time PCR in formalin-fixed paraffin-embedded tumor specimens from 639 IALT patients."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20952761", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 634, 
                    "offsetInEndSection": 831, 
                    "text": "hese two miRNAs have previously been identified as being overexpressed in MCF-7 breast cancer cells, with miR-21 specifically implicated in down-regulating the tumor suppressor gene, tropomyosin-1."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20827319", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 76, 
                    "text": "MicroRNA-21 is involved in ionizing radiation-promoted liver carcinogenesis."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20827319", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 452, 
                    "offsetInEndSection": 817, 
                    "text": "We showed here that among several hundred miRNAs, miR-21 was the only one that increased 6 folds in high-LET IR-promoted mouse liver tumors when compared with that in the non-irradiated liver tissues. We also showed that miR-21 was up-regulated in human or mouse hepatocytes after exposure to IR, as well as in liver tissues derived from whole body irradiated mice."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20827319", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 916, 
                    "offsetInEndSection": 1070, 
                    "text": "After the non-irradiated, low-LET or high-LET irradiated human hepatocytes were over-expressed with miR-21, these cells became tumorigenesis in nude mice."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20702469", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1300, 
                    "offsetInEndSection": 1457, 
                    "text": "Among others, the oncogenic microRNA miR-21 (hsa-miR-21) has been shown to specifically target the PDCD4 3\u2032-UTR, which negatively regulates PDCD4 expression."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20702469", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1628, 
                    "offsetInEndSection": 1956, 
                    "text": "19\u201324 PDCD4 protein levels have been found to be inversely correlated with miR-21 expression in oesophageal squamous cell carcinoma cell lines,18 and we have shown that PDCD4 expression is significantly downregulated in oesophageal cancers (adenocarcinoma and squamous cell carcinoma histotypes) and it predicts patient outcome."
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20702469", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 4667, 
                    "offsetInEndSection": 4783, 
                    "text": "Figure 4miR-21 is overexpressed in high-grade intraepithelial neoplasia (HG-IEN) and Barrett's adenocarcinoma (BAc)."
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20702469", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 2494, 
                    "offsetInEndSection": 2783, 
                    "text": "The nuclear-to-cytoplasm shift documented in preneoplastic/neoplastic lesions could theoretically result from epigenetic (and/or genetic) gene dysregulation.In oesophageal squamous carcinoma cell lines, Hiyoshi et al recently demonstrated that PDCD4 gene expression is regulated by miR-21."
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20702469", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 2854, 
                    "offsetInEndSection": 2975, 
                    "text": "miR-21 is overexpressed in different human cancers, being causally linked to cell proliferation, apoptosis and migration."
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20702469", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 2975, 
                    "offsetInEndSection": 3195, 
                    "text": "14\u201319 miR-21 was also found to be upregulated in both oesophageal adenocarcinoma and squamous cell carcinoma,18 40 41 suggesting a major oncogenic function for miR-21 (acquired early in both of these oncogenic pathways)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20682703", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 765, 
                    "offsetInEndSection": 1035, 
                    "text": "METHODS: We used this combined ISH/IHC assay to study a subset of cancer-associated miRNAs, including miRNAs frequently detected at low (miR-34a and miR-126) and high (miR-21 and miR-155) levels, in a panel of breast, colorectal, lung, pancreas, and prostate carcinomas."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20380575", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1915, 
                    "offsetInEndSection": 2080, 
                    "text": "The miR-15a, miR-16, miR-143, miR-155, and miR-21 were upregulated in M059K, and the modulation of these miRNAs fluctuated in M059J cells in a time-dependent manner."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20338946", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 91, 
                    "offsetInEndSection": 287, 
                    "text": "Aberrantly increased expression of miR-21 plays a significant role in lung carcinogenesis and is a potential therapeutic target in both epidermal growth factor receptor-mutant and wild-type cases."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19901002", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 963, 
                    "offsetInEndSection": 1174, 
                    "text": "Additionally, high miR-21 expression was associated with significantly decreased 5 year survival in patients (hazard ratio, 1.68; 95% CI: 1.04-2.77) in a model controlled for patient age, gender and tumor stage."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19789312", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 751, 
                    "offsetInEndSection": 936, 
                    "text": "ESULTS: In adenocarcinoma patients, miR-21, miR-223, miR-192, and miR-194 expression was elevated, whereas miR-203 expression was reduced in cancerous compared with noncancerous tissue."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19789312", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1211, 
                    "offsetInEndSection": 1430, 
                    "text": "Significantly, elevated miR-21 expression in noncancerous tissue of SCC patients and reduced levels of miR-375 in cancerous tissue of adenocarcinoma patients with Barrett's were strongly associated with worse prognosis."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19748927", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 723, 
                    "offsetInEndSection": 1071, 
                    "text": "miR-21, mir-31, miR-130a, miR-146b and miR-377 were consistently upregulated, whereas miR-1 and miR-143 were downregulated in lung tumors relative to normal lungs. In mice treated with VC and given I3C in the diet, levels of miR-21, mir-31, miR-130a, miR-146b and miR-377 were reduced relative to the level in mice treated with the carcinogen only."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19748927", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1243, 
                    "offsetInEndSection": 1474, 
                    "text": "Further studies with miR-21 indicated that phosphatase and tensin homolog, programmed cell death 4 and rich protein with Kazal motifs are potential targets for the oncogenic effect of miR-21 and the chemopreventive activity of I3C."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19737943", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 144, 
                    "offsetInEndSection": 336, 
                    "text": "This study examines the potential clinical utility of an inflammatory gene expression signature as a prognostic biomarker for colon cancer in addition to previously examined miR-21 expression."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19737943", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1616, 
                    "offsetInEndSection": 1780, 
                    "text": "CONCLUSIONS: IRS and miR-21 expression are independent predictors of colon cancer prognosis and may provide a clinically useful tool to identify high-risk patients."
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19435529", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 4927, 
                    "offsetInEndSection": 5014, 
                    "text": "Figure 4qRT-PCR analysis of miR-21 and miR-16 in three cancer and three normal tissues."
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19435529", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 1764, 
                    "offsetInEndSection": 1851, 
                    "text": "Correlation with cancersquamous cell carcinoma vs normal cheek pouch tissuehsa-miR-212."
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19435529", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 3050, 
                    "offsetInEndSection": 3518, 
                    "text": "Using miRNA microarray analysis, Chang et al. identified seven miRNAs that were up-regulated (mir-21, let-7, 18, 29c, 142-3p, 155, and 146b) and one miRNA that was down-regulated (mir-494) in HNSCC primary tissue and cell lines. Moreover, they demonstrated that cytochrome c release was decreased by mir-21 knockdown, which suggested mir-21 inhibited several mRNAs that then led to a cascade of events that prevented apoptosis and increased cellular proliferation [35]"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19175831", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1199, 
                    "offsetInEndSection": 1374, 
                    "text": "The most highly expressed miRNAs in gastric cancer tissues were miR-20b, miR-20a, miR-17, miR-106a, miR-18a, miR-21, miR-106b, miR-18b, miR-421, miR-340*, miR-19a and miR-658."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18853072", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 357, 
                    "offsetInEndSection": 959, 
                    "text": "Recent findings report their involvement in hair follicle morphogenesis (ablation of miRNAs from keratinocytes causes several defects, such as evagination instead of invagination), in psoriasis (skin-specific expression of miR-203 and psoriasisspecific expression of miR-146a, miR-21 and miR-125b in the skin), in autoimmune diseases affecting the skin, such as SLE and ITP, in wound healing (changes in the expression of specific miRNA at specific phases of the regeneration process), and in skin carcinogenesis (a novel miRNA signature that includes induction of miR-21, a candidate oncogenic miRNA)."
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18596939", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 6755, 
                    "offsetInEndSection": 7348, 
                    "text": "An expression abundance analysis, based on a signal density \u226520,000, showed that both normal and cancerous cervical tissues had abundant expression of miR-23a, miR-23b, let-7a, let-7c, and let-7d, whereas high expression of miR-26a, miR-29a, miR-99a, miR-100, miR-125b, miR-143, miR-145, miR195, and miR-199a was only observed in normal cervical tissues, and high expression of miR-16, miR-21, miR-205, and let-7f was only observed in cervical cancer tissues, despite that relatively low levels of miR-16 and miR-21 were noticed from a homogeneous cell population in some cell lines (Fig. 2B)."
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18596939", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 11983, 
                    "offsetInEndSection": 12282, 
                    "text": "Although upregulation of miR-15a and miR-223 and downregulation of miR-218 and miR-424 were observed both in the rafts (pre-neoplastic lesions) and in cervical cancer tissues, the majority of the miRNA expression signatures showed no correlation between the two tissues (compare Fig. 4A to Fig. 3A)."
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18596939", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 12555, 
                    "offsetInEndSection": 12780, 
                    "text": "In contrast, a slight increased expression of miR-21 and miR-26b was observed in both the pre-neoplastic lesions (HPV-infected rafts) and cervical cancer tissues and thus their expression appears not cancer-specific (Fig. 5)."
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18596939", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 152, 
                    "offsetInEndSection": 483, 
                    "text": "Although both cervical cancer tissues and HPV-infected raft tissues with pre-neoplastic lesions showed an upregulation of miR-15a and miR-223 and downregulation of miR-143, miR-145, miR-218, and miR-424, the majority of the miRNA expression showed no correlation between the two tissues and might delineate the disease progression."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18451233", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 597, 
                    "offsetInEndSection": 854, 
                    "text": "RESULTS: Several microRNAs were differentially expressed in serous ovarian carcinoma compared with normal ovarian tissues, including miR-21, miR-125a, miR-125b, miR-100, miR-145, miR-16, and miR-99a, which were each differentially expressed in >16 patients."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18230780", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1251, 
                    "offsetInEndSection": 1620, 
                    "text": "Selected for validation were miR-20a, miR-21, miR-106a, miR-181b, and miR-203, and all 5 were enriched in tumors from the validation cohort (P < .001). Higher miR-21 expression was present in adenomas (P = .006) and in tumors with more advanced TNM staging (P < .001). In situ hybridization demonstrated miR-21 to be expressed at high levels in colonic carcinoma cells."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18187804", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 235, 
                    "offsetInEndSection": 467, 
                    "text": "To test this hypothesis, we studied the pharmacologic roles of three microRNAs previously implicated in cancer biology (let-7i, mir-16, and mir-21) and also used in silico methods to test pharmacologic microRNA effects more broadly."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18187804", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 881, 
                    "offsetInEndSection": 1554, 
                    "text": "Changing the cellular levels of let-7i, mir-16, and mir-21 affected the potencies of a number of the anticancer agents by up to 4-fold. The effect was most prominent with mir-21, with 10 of 28 cell-compound pairs showing significant shifts in growth-inhibitory activity. Varying mir-21 levels changed potencies in opposite directions depending on compound class; indicating that different mechanisms determine toxic and protective effects. In silico comparison of drug potencies with microRNA expression profiles across the entire NCI-60 panel revealed that approximately 30 microRNAs, including mir-21, show highly significant correlations with numerous anticancer agents."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18089790", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 902, 
                    "offsetInEndSection": 1139, 
                    "text": "Conversely, expression of other miRNAs was detected at varying levels predominantly within luminal epithelial cells in normal tissue; expression of miR-21 was frequently increased, whereas that of let-7a was decreased in malignant cells."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17587821", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 447, 
                    "offsetInEndSection": 596, 
                    "text": "We describe a novel EMT-specific microRNA signature that includes induction of miR-21, a candidate oncogenic microRNA associated with carcinogenesis."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17475218", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 508, 
                    "offsetInEndSection": 562, 
                    "text": "Notable was the high expression of miR-21 and miR-205."
                }
            ], 
            "type": "yesno"
        }, 
        {
            "body": "Which is the most widely used anti-TNF drug?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D023201", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D044966", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000894", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D053199", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016756"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22379032", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21881980", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19854715", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21177290", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18420660"
            ], 
            "id": "512d0e635274a5fb07000005", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22379032", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 128, 
                    "offsetInEndSection": 249, 
                    "text": "higher rates are observed with anti-TNF Abs (e.g., infliximab) as compared with TNF receptor fusion protein (etanercept)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21881980", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 140, 
                    "offsetInEndSection": 201, 
                    "text": "Two of them received etanercept and the remainder adalimumab."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19854715", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 456, 
                    "offsetInEndSection": 633, 
                    "text": "with a possible differential risk between the three anti-TNF drugs: infliximab (INF) and adalimumab (ADA) (both monoclonal antibodies) having a higher risk than etanercept (ETA)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21177290", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 542, 
                    "offsetInEndSection": 661, 
                    "text": "45 cases were collected of non-TB OIs in 43 patients receiving infliximab (n=29), adalimumab (n=10) or etanercept (n=4)"
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18420660", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 805, 
                    "offsetInEndSection": 1016, 
                    "text": "During the period of recruitment, etanercept was administered as a subcutaneous injection either once (50 mg) or twice (25 mg) weekly and adalimumab was administered as a subcutaneous injection 40 mg fortnightly"
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18420660", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 1018, 
                    "offsetInEndSection": 1108, 
                    "text": "The suggested starting dose of infliximab was 3 mg/kg administered in conjunction with MTX"
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18420660", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 91, 
                    "offsetInEndSection": 208, 
                    "text": "Of these, 4458 (41%) started etanercept, 3956 (36%) infliximab and 2579 (23%) adalimumab as their first anti-TNF drug"
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18420660", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 1964, 
                    "offsetInEndSection": 2043, 
                    "text": "Second anti-TNF (n = 331)Etanercept (%)4445Infliximab (%)3717Adalimumab (%)1938"
                }
            ], 
            "type": "factoid"
        }, 
        {
            "body": "Is the H3K4me3 histone mark related to transcriptional initiation or elongation?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015533", 
                "http://www.biosemantics.org/jochem#4250488", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D048348", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D035165", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D035581", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D051697", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D035582", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D035181", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D050436", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D061805", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D051758", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020871", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D042925"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23355544", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23284292", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22904080", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22855832", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22768981", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22132139", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21435340", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18682226"
            ], 
            "id": "512d2fff5274a5fb07000006", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23355544", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 659, 
                    "offsetInEndSection": 782, 
                    "text": "The histone marks appeared mainly in generic regions and were enriched around the transcription start sites (TSSs) of genes"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23284292", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 150, 
                    "text": "Tri-methylated H3 lysine 4 (H3K4me3) is associated with transcriptionally active genes, but its function in the transcription process is still unclear"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23284292", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 623, 
                    "offsetInEndSection": 766, 
                    "text": "However, the catalytic function is critically required for transcription as H3K4me3 levels determine the efficiency of transcription elongation"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22904080", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 680, 
                    "offsetInEndSection": 827, 
                    "text": "In particular, tri-methyl H3K4 (H3K4me3) occurs at the transcription-start site (TSS) of active genes and is important for transcription activation"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22855832", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 86, 
                    "text": "Trimethylation of histone H3 Lys 4 (H3K4me3) is a mark of active and poised promoters."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22768981", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 128, 
                    "text": "Histone H3 lysine 4 trimethylation (H3K4me3) is well known to occur in the promoter region of genes for transcription activation"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22768981", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 348, 
                    "offsetInEndSection": 422, 
                    "text": "3'-H3K4me3 is associated with ~15% of protein-coding genes in both tissues"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22768981", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 697, 
                    "offsetInEndSection": 912, 
                    "text": "Furthermore, 3'-H3K4me3 modification levels correlate positively with the antisense expression levels of the associated sense genes, implying that 3'-H3K4me3 is involved in the activation of antisense transcription."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22132139", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 4198, 
                    "offsetInEndSection": 4372, 
                    "text": "indicated that H3K4me1, but not H3K4me3, was enriched around distal cis-elements for the E1A binding protein p300 (EP300), while both modifications were enriched at promoters"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21435340", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 654, 
                    "offsetInEndSection": 853, 
                    "text": "Among these are forms of histone 3 that are mono- or tri-methylated at lysine 4 (H3K4me1 or H3K4me3, respectively), which bind preferentially to promoter and enhancer elements in the mammalian genome"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21435340", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1066, 
                    "offsetInEndSection": 1156, 
                    "text": "we find that H3K4me1 and H3K4me3 are enriched at transcriptional start sites in the genome"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21435340", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1676, 
                    "offsetInEndSection": 1734, 
                    "text": "H3K4me1 and H3K4me3 generally mark cis regulatory elements"
                }
            ], 
            "type": "factoid"
        }, 
        {
            "body": "Which are the main histone modifications associated with enhancers?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D056545"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22270183", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20621055", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19021773"
            ], 
            "id": "5131bef65274a5fb07000008", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22270183", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 202, 
                    "offsetInEndSection": 246, 
                    "text": "Using H3K4me2 as a mark for active enhancers"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19021773", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 101, 
                    "offsetInEndSection": 257, 
                    "text": "Hyperacetylation of histones H3 and H4, a mark of active chromatin, is established broadly across target loci by enhancers that function over long distances"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19021773", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 881, 
                    "offsetInEndSection": 1018, 
                    "text": "The enhancer region itself was marked by mono-methylation at K4 and K9, distinguishing it from the methyl marks in the gene coding region"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20621055", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 300, 
                    "offsetInEndSection": 351, 
                    "text": "H3K4 methylation to monovalent and bivalent domains"
                }
            ], 
            "type": "list"
        }, 
        {
            "body": "Which are the main causes of fetal echogenic bowel?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D058535", 
                "http://www.disease-ontology.org/api/metadata/DOID:9779"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22990134", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22589170", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22378220", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21606744", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20932506", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20059439", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19921962", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18577682", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18417974", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18254450", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17364293", 
                "http://www.ncbi.nlm.nih.gov/pubmed/14663844", 
                "http://www.ncbi.nlm.nih.gov/pubmed/14626795", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12835583", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11717628", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11169342", 
                "http://www.ncbi.nlm.nih.gov/pubmed/10590441", 
                "http://www.ncbi.nlm.nih.gov/pubmed/10912967", 
                "http://www.ncbi.nlm.nih.gov/pubmed/10550877", 
                "http://www.ncbi.nlm.nih.gov/pubmed/10419606", 
                "http://www.ncbi.nlm.nih.gov/pubmed/10364670", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9664617", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8633653", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8538346", 
                "http://www.ncbi.nlm.nih.gov/pubmed/7474061", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8142051", 
                "http://www.ncbi.nlm.nih.gov/pubmed/1415421"
            ], 
            "id": "5131fa145274a5fb07000009", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22990134", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1054, 
                    "offsetInEndSection": 1156, 
                    "text": "In group 2 and 3, two anomalies, anorectal malformation and cystic fibrosis, were detected postnatally"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22589170", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 671, 
                    "offsetInEndSection": 774, 
                    "text": "Six had chromosomal/genetic abnormalities, two had congenital cytomegalovirus, none had cystic fibrosis"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22589170", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1325, 
                    "offsetInEndSection": 1385, 
                    "text": "Primary bowel pathology is rare following the finding of FEB"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22378220", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 899, 
                    "offsetInEndSection": 974, 
                    "text": "Maternal serology for cytomegalovirus (CMV) was performed in 49 (78%) cases"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22378220", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1066, 
                    "offsetInEndSection": 1181, 
                    "text": "Thirty-three pregnancies (53%) were tested for cystic fibrosis (CF) and 1 baby was confirmed to have CF postnatally"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22378220", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1446, 
                    "offsetInEndSection": 1618, 
                    "text": "This study reiterates the increased prevalence of aneuploidy, CMV, CF and fetal growth restriction in pregnancies complicated by the midtrimester sonographic finding of FEB"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21606744", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 453, 
                    "offsetInEndSection": 616, 
                    "text": "Primary outcomes were IUGR, defined as birth weight less than the 10th percentile for gestational age and intrauterine fetal demise at 20 weeks or more of gestatio"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21606744", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 780, 
                    "offsetInEndSection": 872, 
                    "text": "Analyses were repeated after excluding cases of aneuploidy, cytomegalovirus (CMV) infection,"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21606744", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1969, 
                    "offsetInEndSection": 2114, 
                    "text": "The presence of echogenic bowel on ultrasonography is independently associated with an increased risk for both IUGR and intrauterine fetal demise"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20932506", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1010, 
                    "offsetInEndSection": 1133, 
                    "text": "This study highlights the importance of pregnancy ultrasound examinations and their efficiency in detecting cystic fibrosis"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20932506", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 612, 
                    "offsetInEndSection": 836, 
                    "text": "A disorder was diagnosed in 32.2% of the fetuses, cystic fibrosis being the most commonly identified (7.6%). We also found digestive malformations (7.0%), chromosomal abnormalities (3.7%), and maternofetal infections (3.7%)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20059439", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 781, 
                    "offsetInEndSection": 887, 
                    "text": "A potential association with placental abnormalities and a low prevalence of viral infections was observed"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19921962", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1405, 
                    "offsetInEndSection": 1512, 
                    "text": "Our data suggests an inverse relationship between the maternal BMI and the detection of fetal EIF and/or EB"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18577682", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 125, 
                    "text": "Fetal echogenic bowel at 17 weeks' gestational age as the early and only sign of a very long segment of Hirschsprung disease."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18417974", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 17, 
                    "offsetInEndSection": 103, 
                    "text": "fetal ultrasound findings associated with intrauterine cytomegalovirus (CMV) infection"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18417974", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1109, 
                    "offsetInEndSection": 1235, 
                    "text": "the combination of hydrops fetalis, cerebral hemorrhage, and hyperechoic bowel should raise the possibility of a CMV infection"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18254450", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 706, 
                    "offsetInEndSection": 914, 
                    "text": "strongly associated with adverse pregnancy outcome due to utero-placental insufficiency, particularly in women with elevated maternal serum alpha-fetoprotein concentration due to severe feto-maternal bleeding"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17364293", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 89, 
                    "text": "Congenital cytomegalovirus infection presenting with echogenic bowel and oligohydramnios."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1415421", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 450, 
                    "offsetInEndSection": 515, 
                    "text": "Five cases of trisomy 21 and one case of trisomy 18 were detected"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1415421", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 809, 
                    "offsetInEndSection": 929, 
                    "text": "Brightly echogenic bowel in the second trimester was found to be associated with a significant risk of fetal aneuploidy."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8142051", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 922, 
                    "offsetInEndSection": 1126, 
                    "text": "echogenic bowel does not uniformly herald an abnormal outcome. Echogenic bowel coexistent with other abnormalities (such as growth deficiency or structural malformations) may be a comarker for aneuploidy."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7474061", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 101, 
                    "text": "Congenital cytomegalovirus infection with oligohydramnios and echogenic bowel at 14 weeks' gestation"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8538346", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1046, 
                    "offsetInEndSection": 1220, 
                    "text": "Parental CF carrier testing and amniocentesis to identify aneuploidy or fetal CF status has a high positive ascertainment rate in fetuses with echogenic bowel grades 2 and 3."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8633653", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1804, 
                    "offsetInEndSection": 1968, 
                    "text": "Swallowing of amniotic fluid after intraamniotic bleeding seems implicated in the etiology of second-trimester echogenic bowel in both euploid and aneuploid fetuses"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9664617", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 123, 
                    "text": "Fetal echogenic bowel and a dilated loop of bowel associated with cystic fibrosis (CF) mutations delta F508 and 2183AA-->G"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10364670", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 319, 
                    "offsetInEndSection": 385, 
                    "text": "Fifteen cases (19%) were associated with maternal vaginal bleeding"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10364670", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 613, 
                    "offsetInEndSection": 722, 
                    "text": "Five fetuses (6.3%) had evidence of bowel obstruction or perforation not associated with cystic fibrosis (CF)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10364670", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 724, 
                    "offsetInEndSection": 926, 
                    "text": "Chromosomal aberrations were found in 5 fetuses (6.3%). Intrauterine infection with cytomegalovirus, herpes simplex virus, varicella-zoster virus, or parvovirus B-19 was documented in 5 patients (6.3%)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10419606", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 175, 
                    "text": "Fetal echogenic bowel has been reported as a normal variant in the second trimester, and has also been associated with an adverse fetal outcome, including cystic fibrosis (CF)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10912967", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 918, 
                    "offsetInEndSection": 969, 
                    "text": "Intra-amniotic bleeding can lead to echogenic bowel"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12835583", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 549, 
                    "offsetInEndSection": 808, 
                    "text": "112 cases (57%) had a known etiology, which included chromosomal abnormality (7%), infection (4%), cystic fibrosis (1.5%), bowel abnormality (3%), bleeding or stained amniotic fluid (11%), Doppler abnormality (14%), malformation (16%) and miscellaneous (0.5%)"
                }
            ], 
            "type": "list"
        }, 
        {
            "body": "Are CpG islands located close to housekeeping genes?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006796", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018899", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020043"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/17591602", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16474211", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15784181", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15546139", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9990116", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9632720", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8128314", 
                "http://www.ncbi.nlm.nih.gov/pubmed/1505946", 
                "http://www.ncbi.nlm.nih.gov/pubmed/1968658", 
                "http://www.ncbi.nlm.nih.gov/pubmed/3186440", 
                "http://www.ncbi.nlm.nih.gov/pubmed/3656447"
            ], 
            "id": "5133b15e5274a5fb0700000b", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17591602", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1048, 
                    "offsetInEndSection": 1164, 
                    "text": "our analysis indicates that the association of CGIs with housekeeping genes is not as strong as previously estimated"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16474211", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 236, 
                    "offsetInEndSection": 372, 
                    "text": "CpG islands are preferentially located at the start of transcription of housekeeping genes and are associated with tissue-specific genes"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15784181", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 123, 
                    "text": "It has been envisaged that CpG islands are often observed near the transcriptional start sites (TSS) of housekeeping genes."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15546139", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 411, 
                    "offsetInEndSection": 528, 
                    "text": "These regions represent about 1% of genomic DNA and are generally found in the promoter region of housekeeping genes."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9990116", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 208, 
                    "text": "CpG islands are stretches of DNA sequence that are enriched in the (CpG)n repeat and are present in close association with all housekeeping genes as well as some tissue-specific genes in the mammalian genome."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9632720", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 225, 
                    "offsetInEndSection": 308, 
                    "text": "CpG islands, which are found almost exclusively at the 5'-end of housekeeping genes"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8128314", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 99, 
                    "text": "In housekeeping and many tissue-specific genes, the promoter is embedded in a so-called CpG island."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1505946", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 496, 
                    "offsetInEndSection": 689, 
                    "text": "All housekeeping and widely expressed genes have a CpG island covering the transcription start, whereas 40% of the genes with a tissue-specific or limited expression are associated with islands"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1968658", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 103, 
                    "offsetInEndSection": 319, 
                    "text": "Methylation-free CpG clusters, so-called HTF islands, are most often associated with the promoter regions of housekeeping genes, whereas genes expressed in a single-cell type are usually deficient in these sequences."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3186440", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 132, 
                    "text": "Unmethylated CpG rich islands are a feature of vertebrate DNA: they are associated with housekeeping and many tissue specific genes."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3656447", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 548, 
                    "offsetInEndSection": 702, 
                    "text": "CpG islands were associated with the 5' ends of all housekeeping genes and many tissue-specific genes, and with the 3' ends of some tissue-specific genes."
                }
            ], 
            "type": "yesno"
        }, 
        {
            "body": "Are nucleosomes positioned at DNA replication origins?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018741", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009707", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D051716", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004261", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D042522", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D051738"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20351051", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21148149", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19463783", 
                "http://www.ncbi.nlm.nih.gov/pubmed/1587867"
            ], 
            "id": "513596225274a5fb0700000d", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20351051", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 400, 
                    "offsetInEndSection": 663, 
                    "text": "yeast origins are characterized by an asymmetric pattern of positioned nucleosomes flanking the ACS. The origin sequences are sufficient to maintain a nucleosome-free origin; however, ORC is required for the precise positioning of nucleosomes flanking the origin."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21148149", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2984, 
                    "offsetInEndSection": 3170, 
                    "text": "ORC binds to Nucleosome free regions (NFRs) in both budding yeast and Drosophila (1,37,38), suggesting that nucleosome organization may be a defining feature of origins in all eukaryotes"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21148149", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 3231, 
                    "offsetInEndSection": 3388, 
                    "text": "the presence of a well-positioned nucleosome adjacent to the origin NFR was shown to be essential for ORC to nucleate pre-RC assembly and for origin activity"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21148149", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 5205, 
                    "offsetInEndSection": 5387, 
                    "text": "Together, our results demonstrate significant enrichment of pre-RC proteins at regions of generally low nucleosome occupancy that are found within a de-localized region of initiation"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19463783", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 258, 
                    "offsetInEndSection": 345, 
                    "text": "Here, we identify nucleosome occupancy as a likely candidate to set up ORI distribution"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19463783", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 442, 
                    "offsetInEndSection": 570, 
                    "text": "we demonstrate that open chromatin domains, characterized by nucleosome depletion, are preferentially permissive for replication"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1587867", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 294, 
                    "offsetInEndSection": 466, 
                    "text": "Nucleosome assembly of the template prevented DNA replication. Replication of chromosomes was severely inhibited at more than two-thirds of physiological nucleosome density"
                }
            ], 
            "type": "yesno"
        }, 
        {
            "body": "Which is the most widely used model for the study of multiple sclerosis (MS)?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009103", 
                "http://www.disease-ontology.org/api/metadata/DOID:2377", 
                "http://www.disease-ontology.org/api/metadata/DOID:2376"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23161666", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22530047", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22272832", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21255614", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21029240", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20829083", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20623621", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19894121", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19361871", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18950873", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18773082", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18673215", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17766043", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17463082", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17343922", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16440059", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16137612", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16126908", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16106061", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15949496", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15929040", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15898103", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15492125", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15288396", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15265674", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15039233", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11829341", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11391780", 
                "http://www.ncbi.nlm.nih.gov/pubmed/7739505", 
                "http://www.ncbi.nlm.nih.gov/pubmed/1793022"
            ], 
            "id": "5139b31dbee46bd34c000004", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23161666", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 241, 
                    "offsetInEndSection": 323, 
                    "text": "experimental autoimmune encephalomyelitis (EAE) animal model of multiple sclerosis"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22530047", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2260, 
                    "offsetInEndSection": 2441, 
                    "text": "Therefore, a well characterized homogeneous animal model, experimental autoimmune encephalomyelitis (EAE), was selected for this study to obtain a sample of the inflammatory lesions"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22272832", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2609, 
                    "offsetInEndSection": 2693, 
                    "text": "using experimental allergic encephalomyelitis (EAE) in rats as a disease model for M"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21255614", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 282, 
                    "offsetInEndSection": 427, 
                    "text": "Many aspects of MS can be mimicked in the animal model of myelin oligodendrocyte glycoprotein experimental autoimmune encephalomyelitis (MOG-EAE)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21029240", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 531, 
                    "offsetInEndSection": 608, 
                    "text": "the chronic experimental autoimmune encephalomyelitis (EAE) mouse model of MS"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20829083", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 343, 
                    "offsetInEndSection": 548, 
                    "text": "The aim of our study was to characterize the sensory abnormalities and in particular the clinical signs linked to persistent pain in two models of Experimental Autoimmune Encephalomyelitis (EAE) in the rat"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20623621", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 103, 
                    "text": "Experimental autoimmune encephalomyelitis (EAE) is an animal model for studying multiple sclerosis (MS)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19894121", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 118, 
                    "text": "Theiler's murine encephalomyelitis virus (TMEV) infection of mice is an experimental model for multiple sclerosis (MS)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19361871", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 508, 
                    "offsetInEndSection": 599, 
                    "text": "experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18950873", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 448, 
                    "offsetInEndSection": 593, 
                    "text": "In this study we investigated whether in an animal model for MS, namely in experimental autoimmune encephalomyelitis (EAE), similar changes occur"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18773082", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 722, 
                    "offsetInEndSection": 793, 
                    "text": "experimental autoimmune encephalomyelitis (EAE), the animal model of MS"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18673215", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 108, 
                    "text": "Experimental autoimmune encephalomyelitis (EAE), a widely recognized animal model of multiple sclerosis (MS)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17766043", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 196, 
                    "offsetInEndSection": 271, 
                    "text": "we utilized the Theiler's murine encephalomyelitis virus (TMEV) model of MS"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17463082", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 919, 
                    "offsetInEndSection": 1027, 
                    "text": "In a murine disease model, experimental autoimmune encephalomyelitis (EAE) mice lacking cyclophilin D (CyPD)"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17463082", 
                    "endSection": "title", 
                    "offsetInBeginSection": 45, 
                    "offsetInEndSection": 171, 
                    "text": "experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17343922", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 613, 
                    "offsetInEndSection": 660, 
                    "text": "Theiler's murine encephalomyelitis virus (TMEV)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16440059", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 69, 
                    "text": "Inflammatory diseases of the CNS, such as MS and its animal model EAE"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16137612", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 152, 
                    "offsetInEndSection": 243, 
                    "text": "the strong impact of the classical MS model experimental autoimmune encephalomyelitis (EAE)"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1793022", 
                    "endSection": "title", 
                    "offsetInBeginSection": 43, 
                    "offsetInEndSection": 234, 
                    "text": "an animal model of multiple sclerosis (MS): disease modifying activity on acute and chronic relapsing experimental allergic encephalomyelitis (EAE)."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7739505", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 99, 
                    "text": "The immunology of multiple sclerosis and its animal model, experimental allergic encephalomyelitis"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7739505", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 178, 
                    "offsetInEndSection": 286, 
                    "text": "EAE is the best available model for the inflammatory processes that occur in MS, and for the disease process"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11391780", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 455, 
                    "offsetInEndSection": 561, 
                    "text": "The present study addressed this question using the model of experimental allergic encephalomyelitis (EAE)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15039233", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 261, 
                    "offsetInEndSection": 345, 
                    "text": "The conventional animal model of MS, experimental autoimmune encephalomyelitis (EAE)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15265674", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 177, 
                    "text": "To assess neurological impairments quantitatively in an animal model of multiple sclerosis (MS), we have used a targeted model of experimental autoimmune encephalomyelitis (EAE)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15288396", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 155, 
                    "offsetInEndSection": 362, 
                    "text": "Experimental autoimmune encephalomyelitis (EAE) is a well-studied disease in rodents that mimics many clinical and pathological features of MS, including central nervous system inflammation and demyelination"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15492125", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1190, 
                    "offsetInEndSection": 1284, 
                    "text": "The neuropathology of MS and its animal model, experimental autoimmune encephalomyelitis (EAE)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15898103", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 172, 
                    "text": "Both multiple sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE), its animal model, involve inflammatory attack on central nervous system (CNS) white matter"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15929040", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 370, 
                    "offsetInEndSection": 459, 
                    "text": "both MS patients and the MS animal model, experimental autoimmune encephalomyelitis (EAE)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15949496", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 289, 
                    "offsetInEndSection": 359, 
                    "text": "In the MS animal model experimental autoimmune encephalomyelitis (EAE)"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16106061", 
                    "endSection": "title", 
                    "offsetInBeginSection": 20, 
                    "offsetInEndSection": 123, 
                    "text": "multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16126908", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 143, 
                    "offsetInEndSection": 256, 
                    "text": "inflammatory demyelination in multiple sclerosis (MS) lesions and experimental autoimmune encephalomyelitis (EAE)"
                }
            ], 
            "type": "factoid"
        }, 
        {
            "body": "Which human genes are more commonly related to craniosynostosis?", 
            "concepts": [
                "http://www.disease-ontology.org/api/metadata/DOID:2340", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003398", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018566"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20643727", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19530187", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18000908", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17955513", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17042739", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16258006", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15964893", 
                "http://www.ncbi.nlm.nih.gov/pubmed/14672347", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12407713", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11820058", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11746040", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11484208", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11428324", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11341328", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11197897", 
                "http://www.ncbi.nlm.nih.gov/pubmed/10951518", 
                "http://www.ncbi.nlm.nih.gov/pubmed/10914960", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9917362", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9600744", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9934984", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9042914", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8106171"
            ], 
            "id": "513ce3c8bee46bd34c000008", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20643727", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 635, 
                    "offsetInEndSection": 721, 
                    "text": "The FGFR3 P250R mutation was the single largest contributor (24%) to the genetic group"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20643727", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1416, 
                    "offsetInEndSection": 1521, 
                    "text": "FGFR3 P250R and FGFR2 exons IIIa/c) should be targeted to patients with coronal or multisuture synostoses"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19530187", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 602, 
                    "offsetInEndSection": 845, 
                    "text": "GNAS, the gene for guanine nucleotide-binding protein, alpha-stimulating activity polypeptide (gene for PHP1A), identified a de novo heterozygous 3 bp in frame deletion predicting a deletion of the asparagine residue at position 377 (deltaN377"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19530187", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 924, 
                    "offsetInEndSection": 961, 
                    "text": "craniosynostosis genes (FGFR2, FGFR3)"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18000908", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 96, 
                    "text": "Syndromic craniosynostosis due to complex chromosome 5 rearrangement and MSX2 gene triplication"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18000908", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 782, 
                    "offsetInEndSection": 898, 
                    "text": "early fusion of cranial sutures commonly observed in the dup(5q) syndrome is caused by triplication of the MSX2 gene"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17955513", 
                    "endSection": "title", 
                    "offsetInBeginSection": 52, 
                    "offsetInEndSection": 176, 
                    "text": "further evidence that extra copy of MSX2 gene leads to craniosynostosis"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17955513", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 737, 
                    "offsetInEndSection": 903, 
                    "text": "Our results support the previous finding that distal 5q-trisomy together with an extra copy of the MSX2 gene leads to abnormal closure of sutures and craniosynostosis"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17042739", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 62, 
                    "text": "Craniosynostosis-associated gene nell-1 is regulated by runx2"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17042739", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 96, 
                    "text": "We studied the transcriptional regulation of NELL-1, a craniosynostosis-related gene"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17042739", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2217, 
                    "offsetInEndSection": 2377, 
                    "text": "Runx2 directly binds to the OSE2 elements and transactivates the human NELL-1 promoter. These results suggest that Nell-1 is likely a downstream target of Runx2"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16258006", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 907, 
                    "offsetInEndSection": 1035, 
                    "text": "The breakpoint on chromosome 11p15 disrupts the SOX6 gene, known to be involved in skeletal growth and differentiation processes"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16258006", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1037, 
                    "offsetInEndSection": 1252, 
                    "text": "SOX6 mutation screening of another 104 craniosynostosis patients revealed one missense mutation leading to the exchange of a highly conserved amino acid (p.D68N) in a single patient and his reportedly healthy mother"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15964893", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 129, 
                    "text": "Revisiting the craniosynostosis-radial ray hypoplasia association: Baller-Gerold syndrome caused by mutations in the RECQL4 gene"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14672347", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 127, 
                    "text": "Overexpression of Nell-1, a craniosynostosis-associated gene"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12407713", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 139, 
                    "offsetInEndSection": 266, 
                    "text": "Mutations in five genes (FGFR1-, -2, -3, TWIST, and MSX2) causing craniosynostosis as the main clinical feature were described."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11820058", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 144, 
                    "text": "One of the genes involved in craniosynostosis syndromes is the fibroblast growth factor receptor 2 (FGFR2) gene, a tyrosine kinase receptor gene"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11484208", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 221, 
                    "text": "Most mutations in Crouzon, Pfeiffer, and Apert syndromes are in the extracellular, third immunoglobulin-like domain and adjacent linker regions (exons IIIa and IIIc) of the fibroblast growth factor receptor 2 (FGFR2) gene"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11428324", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 100, 
                    "text": "Familial craniosynostosis due to Pro250Arg mutation in the fibroblast growth factor receptor 3 gene."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11341328", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 142, 
                    "text": "Apert (Ap) syndrome is characterized by premature cranial suture ossification caused by fibroblast growth factor receptor 2 (FGFR-2) mutations"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11197897", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 212, 
                    "text": "Recently, the substitution of proline 250 by arginine in the fibroblast growth factor receptor 3 (FGFR3) gene, has been identified in patients with craniosynostosis and defines a new syndrome on a molecular basis"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10951518", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 164, 
                    "text": "Mutations in the fibroblast growth factor receptor 1, 2 and 3 (FGFR1, -2 and -3) and TWIST genes have been identified in several syndromic forms of craniosynostosis"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10951518", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 303, 
                    "offsetInEndSection": 472, 
                    "text": "We describe a novel heterozygous mutation of FGFR2 (943G --> T, encoding the amino acid substitution Ala315Ser) in a girl with non-syndromic unicoronal craniosynostosis."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10914960", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 141, 
                    "text": "A unique Pro250Arg mutation in fibroblast growth factor receptor 3 (FGFR3) was recently found in patients with non-syndromic craniosynostosis"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9917362", 
                    "endSection": "title", 
                    "offsetInBeginSection": 123, 
                    "offsetInEndSection": 312, 
                    "text": "a possible mechanism for MSX2-mediated craniosynostosis in humans"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9917362", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 532, 
                    "offsetInEndSection": 713, 
                    "text": "We found previously that a single amino acid substitution in the homeodomain of the human MSX2 gene is associated with the autosomal dominant disorder craniosynostosis, Boston type."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9600744", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 178, 
                    "text": "Recently, a unique Pro250Arg point mutation in fibroblast growth factor receptor 3 (FGFR3) was reported in 61 individuals with coronal craniosynostosis from 20 unrelated families"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9934984", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1240, 
                    "offsetInEndSection": 1409, 
                    "text": "We identified a novel TWIST gene mutation in this patient, a Glu181Stop mutation predicting a premature termination of the protein carboxy-terminal to the helix 2 domain"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9042914", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 120, 
                    "text": "A unique point mutation in the fibroblast growth factor receptor 3 gene (FGFR3) defines a new craniosynostosis syndrome"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8106171", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 115, 
                    "text": "A mutation in the homeodomain of the human MSX2 gene in a family affected with autosomal dominant craniosynostosis"
                }
            ], 
            "type": "list"
        }, 
        {
            "body": "Which is the most common disease attributed to malfunction or absence of primary cilia?", 
            "concepts": [
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0031514", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0031512", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0031513", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0035058"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21439862", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23124509", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19276629", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19273592", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19186246", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18694559", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18407555", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17429051", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15226261", 
                "http://www.ncbi.nlm.nih.gov/pubmed/14983006", 
                "http://www.ncbi.nlm.nih.gov/pubmed/14978161"
            ], 
            "id": "513ce494bee46bd34c000009", 
            "snippets": [
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21439862", 
                    "endSection": "title", 
                    "offsetInBeginSection": 81, 
                    "offsetInEndSection": 232, 
                    "text": "role of primary cilia in autosomal dominant polycystic kidney disease"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21439862", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 310, 
                    "offsetInEndSection": 424, 
                    "text": "Recent research has focused on defects in signaling mediated by the primary cilia as the causative factor in ADPKD"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23124509", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1038, 
                    "offsetInEndSection": 1377, 
                    "text": "Interestingly, primary cilia concentrate p75NTR receptors in their membranes and are abnormally structured/damaged in transgenic (Tg) AD\u2011model mice, which could impact on the adult neurogenesis occurring in the dentate gyrus's subgranular zone (SGZ) that is necessary for new memory encoding, thereby favouring typical AD cognitive decline"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19276629", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1041, 
                    "offsetInEndSection": 1207, 
                    "text": "malformation of primary cilia, and in the collecting ducts of kidney tubules this is accompanied by development of autosomal recessive polycystic kidney disease (PKD)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19276629", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1209, 
                    "offsetInEndSection": 1462, 
                    "text": "While PKD was one of the first diseases to be linked to dysfunctional primary cilia, defects in this organelle have subsequently been associated with many other phenotypes, including cancer, obesity, diabetes as well as a number of developmental defects"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19273592", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 147, 
                    "offsetInEndSection": 327, 
                    "text": "mice display abnormalities very similar to those of patients with neonatal diabetes and hypothyroidism syndrome, including the development of diabetes and polycystic kidney disease"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19273592", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 460, 
                    "offsetInEndSection": 578, 
                    "text": "Although Glis3(zf/zf) mice form normal primary cilia, renal cysts contain relatively fewer cells with a primary cilium"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19186246", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 470, 
                    "offsetInEndSection": 608, 
                    "text": "When ciliary function is perturbed, photoreceptors may die, kidney tubules develop cysts, limb digits multiply and brains form improperly."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18694559", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 306, 
                    "offsetInEndSection": 421, 
                    "text": "Here, we report that CP110 interacts with CEP290--a protein whose deficiency is implicated in human ciliary disease"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18407555", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 523, 
                    "offsetInEndSection": 640, 
                    "text": "The cholangiociliopathies include but are not limited to cystic and fibrotic liver diseases associated with mutations"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17429051", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 204, 
                    "text": "Cysts in the kidney are among the most common inherited human pathologies, and recent research has uncovered that a defect in cilia-mediated signaling activity is a key factor that leads to cyst formation"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17429051", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 301, 
                    "offsetInEndSection": 452, 
                    "text": "Multiple proteins whose functions are disrupted in cystic diseases have now been localized to the cilium or at the basal body at the base of the cilium"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15226261", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 691, 
                    "offsetInEndSection": 822, 
                    "text": "Polaris has been shown to co-localize with primary cilia, and these structures have been implicated in the formation of renal cysts"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15226261", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1112, 
                    "offsetInEndSection": 1245, 
                    "text": "hus, polaris and primary cilia function are required for the maturation and maintenance of proper tissue organization in the pancreas"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14983006", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 766, 
                    "offsetInEndSection": 948, 
                    "text": "In cultured renal cells, the PKHD1 gene product colocalized with polycystin-2, the gene product of autosomal dominant polycystic disease type 2, at the basal bodies of primary cilia."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14983006", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 69, 
                    "text": "Mutations of the polycystic kidney and hepatic disease 1 (PKHD1) gene"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14978161", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 131, 
                    "text": "The autosomal recessive polycystic kidney disease protein is localized to primary cilia"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14978161", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1082, 
                    "offsetInEndSection": 1213, 
                    "text": "It is proposed that the pathogenesis of autosomal recessive polycystic kidney disease is linked to the dysfunction of primary cilia"
                }
            ], 
            "type": "factoid"
        }, 
        {
            "body": "Which is the prevalence of cystic fibrosis in the human population?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003550", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005355", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015995", 
                "http://www.uniprot.org/uniprot/CFTR_MACMU", 
                "http://www.disease-ontology.org/api/metadata/DOID:1485", 
                "http://www.disease-ontology.org/api/metadata/DOID:2975", 
                "http://www.disease-ontology.org/api/metadata/DOID:10353"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22627569", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18442953", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18243066", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15970608", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15266396", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11336401"
            ], 
            "id": "513ce5f2bee46bd34c00000a", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22627569", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 688, 
                    "offsetInEndSection": 771, 
                    "text": "The allelic frequency of this variant was calculated to be 0.7% for this population"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18442953", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 111, 
                    "offsetInEndSection": 365, 
                    "text": "The results of literature reviews, surveys, and registry analyses revealed a mean prevalence of 0.737/10,000 in the 27 EU countries, which is similar to the value of 0.797 in the United States, and only one outlier, namely the Republic of Ireland at 2.98"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15970608", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 741, 
                    "offsetInEndSection": 942, 
                    "text": "The age related prevalence of CF among the South Asian and general populations was: 0-14 years, 1:9200 versus 1:6600; 15-24 years, 1:13,200 versus 1:7600; older than 25 years, 1:56,600 versus 1:12,400."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15266396", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 845, 
                    "offsetInEndSection": 1130, 
                    "text": "A theoretical estimate of the prevalence of cystic fibrosis based on anthropological data suggested a frequency of 25 affected individuals/100,000 inhabitants. However, our data indicated that the true prevalence in the population was considerably lower (6.9 cases/100,000 inhabitants)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11336401", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 856, 
                    "offsetInEndSection": 911, 
                    "text": "CF mutations were identified in 374 (4.0%) individuals."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11336401", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 110, 
                    "text": "The aim of this study was to evaluate the screening policies of cystic fibrosis (CF) in the Jewish population."
                }
            ], 
            "type": "factoid"
        }, 
        {
            "body": "What is the biological role of expansins in fungi?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005658"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20478643", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19479322", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18406638", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18400936", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15605243", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15195944"
            ], 
            "id": "513eec89bee46bd34c00000d", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20478643", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 88, 
                    "offsetInEndSection": 174, 
                    "text": "interactions with alpha-expansin in cell wall extension and polysaccharide degradation"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20478643", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1430, 
                    "offsetInEndSection": 1524, 
                    "text": "cell wall swelling may not be a significant event during the action of expansin and hydrolases"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19479322", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 442, 
                    "offsetInEndSection": 585, 
                    "text": "To evaluate a putative implication of three newly identified expansin/family 45 endoglucanase-like (EEL) proteins in lignocellulose degradation"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18406638", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1082, 
                    "offsetInEndSection": 1232, 
                    "text": "Our results show that EglD is a conidial cell wall localized expansin-like protein, which could be involved in cell wall remodeling during germination"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18400936", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 229, 
                    "text": "Swollenin, a protein first characterized in the saprophytic fungus Trichoderma reesei, contains an N-terminal carbohydrate-binding module family 1 domain (CBD) with cellulose-binding function and a C-terminal expansin-like domain"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15605243", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 86, 
                    "text": "alpha-Expansins are extracellular proteins that increase plant cell-wall extensibility"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15605243", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1448, 
                    "offsetInEndSection": 1561, 
                    "text": "these wall-loosening proteins are directly involved in the accommodation of the fungus by infected cortical cells"
                }
            ], 
            "type": "summary"
        }, 
        {
            "body": "Which are the major transcription factors regulating glycolysis in mammals?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006019", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D035165"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23388203", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22891351", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22886605", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21968997", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21810481", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21673794", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21625432", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21084727", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21042593", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20141841", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19861459", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19219035", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19056893", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18606808", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18391940", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17442734", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16627239", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16374431", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15838239", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15664996", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12200433", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12054621", 
                "http://www.ncbi.nlm.nih.gov/pubmed/10823814", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9371825", 
                "http://www.ncbi.nlm.nih.gov/pubmed/7649406"
            ], 
            "id": "514168ab23fec9037500000a", 
            "snippets": [
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7649406", 
                    "endSection": "title", 
                    "offsetInBeginSection": 35, 
                    "offsetInEndSection": 103, 
                    "text": "myc regulates hepatic glycolysis"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7649406", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1984, 
                    "offsetInEndSection": 2186, 
                    "text": "increase in c-Myc protein was able to induce liver glucose utilization and accumulation, and suggested that c-Myc transcription factor is involved in the control in vivo of liver carbohydrate metabolism"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23388203", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 639, 
                    "offsetInEndSection": 769, 
                    "text": "p53 regulates mitochondrial oxidative phosphorylation, glycolysis, glutamine metabolism, lipid metabolism, and antioxidant defense"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22891351", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1520, 
                    "offsetInEndSection": 1572, 
                    "text": "STAT3 is a negative regulator of aerobic glycolysis."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22886605", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 608, 
                    "offsetInEndSection": 702, 
                    "text": "HIF1 alpha-mediated switches in the energy production of tumor cells from OXPHOS to glycolysis"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21968997", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 453, 
                    "offsetInEndSection": 726, 
                    "text": "NF-\u03baB organizes energy metabolism networks by controlling the balance between the utilization of glycolysis and mitochondrial respiration. NF-\u03baB inhibition causes cellular reprogramming to aerobic glycolysis under basal conditions and induces necrosis on glucose starvation"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21810481", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 126, 
                    "text": "Hypoxia-inducible factor-1\u03b1 (HIF-1\u03b1), which is a transcription factor that enhances glycolysis in cells in response to hypoxia"
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21673794", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 11990, 
                    "offsetInEndSection": 12069, 
                    "text": "CRP plays a major role in switch control between glycolysis and gluconeogenesis"
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21625432", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 195, 
                    "offsetInEndSection": 428, 
                    "text": "the inhibition of PDK4 expression by NF-\u03baB is related to the shift towards increased glycolysis that is observed during cardiac pathological processes induced by pro-inflammatory stimuli, such as cardiac hypertrophy and heart failure"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21084727", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2844, 
                    "offsetInEndSection": 3029, 
                    "text": "The oxygen sensor HIF-1\u03b1 is a highly unstable protein that becomes stabilized under hypoxia, leading to the activation of glycolysis and the down-regulation of mitochondrial respiration"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21084727", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 3391, 
                    "offsetInEndSection": 3457, 
                    "text": "several reports have linked HIF-1\u03b1 induction with STAT3 activation"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21042593", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 3735, 
                    "offsetInEndSection": 3894, 
                    "text": "Functionally, we have shown that glycolysis, oxidative phosphorylation, and cellular respiratory systems are altered in response to changes in Ets-1 expression"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20141841", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 450, 
                    "offsetInEndSection": 581, 
                    "text": "SIRT6 appears to function as a corepressor of the transcription factor Hif1alpha, a critical regulator of nutrient stress responses"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20141841", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 612, 
                    "offsetInEndSection": 777, 
                    "text": "SIRT6-deficient cells exhibit increased Hif1alpha activity and show increased glucose uptake with upregulation of glycolysis and diminished mitochondrial respiration"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19861459", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 449, 
                    "offsetInEndSection": 579, 
                    "text": "c-Myc regulates genes involved in the biogenesis of ribosomes and mitochondria, and regulation of glucose and glutamine metabolism"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19861459", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 870, 
                    "offsetInEndSection": 982, 
                    "text": "Myc regulates gene expression either directly, such as glycolytic genes including lactate dehydrogenase A (LDHA)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19219035", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 259, 
                    "offsetInEndSection": 452, 
                    "text": "loss of the widely expressed transcription factor Oct1 induces a coordinated metabolic shift: mitochondrial activity and amino acid oxidation are increased, while glucose metabolism is reduced."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19056893", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 89, 
                    "text": "PVHL is a regulator of glucose metabolism"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18606808", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 224, 
                    "text": "Carbohydrate response element-binding protein (ChREBP) is a glucose-responsive transcription factor that plays a critical role in the glucose-mediated induction of gene products involved in hepatic glycolysis and lipogenesis"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18391940", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 375, 
                    "offsetInEndSection": 494, 
                    "text": "Activation of NF-kappaB, by loss of p53, caused an increase in the rate of aerobic glycolysis and upregulation of Glut3"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18391940", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 976, 
                    "offsetInEndSection": 1063, 
                    "text": "p53 restricts activation of the IKK-NF-kappaB pathway through suppression of glycolysis"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17442734", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 155, 
                    "offsetInEndSection": 287, 
                    "text": "cells express hypoxia-inducible factor (HIF)-1alpha, a transcription factor that responds to oxygen tension and regulates glycolysis"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16627239", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 590, 
                    "offsetInEndSection": 769, 
                    "text": "The HIF-1 dependent genic products are involved in tumoral angiogenesis, in the metabolic switch to anaerobic glycolysis and in prosurvival, proliferative and apoptotic mechanisms"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16374431", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 216, 
                    "offsetInEndSection": 353, 
                    "text": "he hypoxia-inducible transcription factor (HIF) regulates the expression of genes involved in angiogenesis, erythropoiesis and glycolysis"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15838239", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1437, 
                    "offsetInEndSection": 1558, 
                    "text": "hypoxia-inducible factor-1, which activates a gene program associated with angiogenesis, glycolysis, and adaptation to pH"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15664996", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 404, 
                    "offsetInEndSection": 551, 
                    "text": "ChREBP (carbohydrate response element-binding protein) was recently identified as a candidate transcription factor in the glucose-signaling pathway"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12200433", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 96, 
                    "text": "Hypoxia-inducible factor (HIF)-1 is a master transcription factor, which up-regulates glycolysis"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12200433", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 411, 
                    "offsetInEndSection": 528, 
                    "text": "(Src) express HIF-1alpha protein under normoxia, which results in the expression of multiple HIF-1alpha target genes."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12054621", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 397, 
                    "offsetInEndSection": 628, 
                    "text": "HIF-1 alpha can then translocate to the nucleus and facilitate transcription of numerous target genes, the majority of which are involved in glycolysis and angiogenesis via heterodimerisation with the beta subunit (HIF-1 beta/ARNT)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10823814", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 155, 
                    "offsetInEndSection": 393, 
                    "text": "We previously observed that the c-Myc oncogenic transcription factor regulates lactate dehydrogenase A and induces lactate overproduction. We, therefore, sought to determine whether c-Myc controls other genes regulating glucose metabolism"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10823814", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 899, 
                    "offsetInEndSection": 1039, 
                    "text": "overexpression of the c-Myc oncoprotein deregulates glycolysis through the activation of several components of the glucose metabolic pathway"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9371825", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1837, 
                    "offsetInEndSection": 1969, 
                    "text": "HNF4alpha is critical for regulating glucose transport and glycolysis and in doing so is crucial for maintaining glucose homeostasis"
                }
            ], 
            "type": "list"
        }, 
        {
            "body": "Which are the available biomedical text mining tools for the detection of protein-protein interactions?", 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22693219", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19234603", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18207462", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12689350", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18204916", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18834495", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22438567"
            ], 
            "id": "514217a6d24251bc05000005", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22693219", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 3161, 
                    "offsetInEndSection": 3369, 
                    "text": "In contrast, GeneView recognizes a broader set of entity types but not gene ontology terms, provides search facilities using unique database identifiers and also finds relationships between proteins in texts."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22693219", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1207, 
                    "offsetInEndSection": 1402, 
                    "text": "It uses a multitude of state-of-the-art text-mining tools optimized for recognizing mentions from 10 different entity classes and for automatically identifying protein\u2013protein interactions (PPI)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22693219", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 3518, 
                    "offsetInEndSection": 3728, 
                    "text": "GeneView offers all annotations as downloads to support the development of new applications by freeing developers of data analysis algorithms from the necessity to deal with a multitude of text-mining packages."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19234603", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 65, 
                    "text": "PPI finder: a mining tool for human protein-protein interactions."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19234603", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 370, 
                    "offsetInEndSection": 734, 
                    "text": "One of the most important applications is mining correlations or associations such as protein-protein interactions (PPIs) from the literature [4], [5]. Plenty of PPI text mining approaches have been categorized into two groups, one is statistical calculation of the co-occurrence of genes or proteins, and the other is the computational linguistic method [2], [4]."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19234603", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2363, 
                    "offsetInEndSection": 2704, 
                    "text": "In this study, we developed a novel algorithm by a frame-based approach for a web-based tool, PPI Finder, which can not only find the related genes of the gene of interest based on their co-occurrence frequencies but also extract the semantic descriptions of interactions from the co-occurring literature by computational linguistic methods."
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19234603", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 3757, 
                    "offsetInEndSection": 3877, 
                    "text": "The PPI Finder system consists of two modules: Information Retrieval (IR module) and Information Extraction (IE module)."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18207462", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 61, 
                    "text": "Extracting interactions between proteins from the literature."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18207462", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 308, 
                    "offsetInEndSection": 680, 
                    "text": "In the meantime, there has been a great interest with scientific communities in text mining tools to find knowledge such as protein-protein interactions, which is most relevant and useful for specific analysis tasks. This paper provides a outline of the various information extraction methods in biomedical domain, especially for discovery of protein-protein interactions."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12689350", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 118, 
                    "text": "PreBIND and Textomy--mining the biomedical literature for protein-protein interactions using a support vector machine."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12689350", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 408, 
                    "offsetInEndSection": 626, 
                    "text": "PreBIND and Textomy are two components of a literature-mining system designed to find protein-protein interaction information and present this to curators or public users for review and submission to the BIND database."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12689350", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2551, 
                    "offsetInEndSection": 2912, 
                    "text": "For the purposes of this paper and the initial population of the BIND database, we have chosen to focus on extracting information from the literature that is sufficient for defining a simple protein-protein interaction record in BIND. Subsequent text-mining modules can be added to PreBIND in future that will help fill out other aspects of the BIND data model."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12689350", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 3730, 
                    "offsetInEndSection": 3986, 
                    "text": "PreBIND and Textomy differ from these methods by a combination of five factors.1) Support Vector Machine (SVM) technology is used to identify articles about biomolecular interactions and confirm sentences that mention specific protein-protein interactions."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18204916", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 100, 
                    "text": "Discovering implicit protein-protein interactions in the cell cycle using bioinformatics approaches."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18204916", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 669, 
                    "offsetInEndSection": 875, 
                    "text": "In this paper we examine if P-P interactions in regenerating tissues and cells of the anuran Xenopus laevis can be discovered from biomedical literature using computational and literature mining techniques."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18204916", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1434, 
                    "offsetInEndSection": 1560, 
                    "text": "P-P interactions that are implicitly appearing in literature can be effectively discovered using literature mining techniques."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18204916", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1732, 
                    "offsetInEndSection": 1855, 
                    "text": "The developed BioMap system allows discovering implicit P-P interactions from large quantity of biomedical literature data."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18834495", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 653, 
                    "offsetInEndSection": 801, 
                    "text": "Also, bioinformatics techniques based on sequence, structural, or evolutionary information have been devised to predict binary protein interactions."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22438567", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 125, 
                    "text": "How to link ontologies and protein-protein interactions to literature: text-mining approaches and the BioCreative experience."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22438567", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 4279, 
                    "offsetInEndSection": 4492, 
                    "text": "In particular, we will focus on the attempts that have been made to automatically extract protein\u2013protein interaction (PPI) data taking advantage of ontologies, and to associate ontology terms to the interactions."
                }
            ], 
            "type": "list"
        }, 
        {
            "body": "What are the computational tools for the prediction of beta-barrel transmembrane proteins?", 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19421989", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18434251", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17958348", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16351738", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16225682", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15261149", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15215419", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15141026", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15070403", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12169530", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20952406", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16844989", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15647112", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15215418", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16542876", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23297037", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22987359", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22247276", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21426944", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21328706", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18467177", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18006547", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16844988", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15980452", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17557332"
            ], 
            "id": "51434c74d24251bc0500000c", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19421989", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 168, 
                    "offsetInEndSection": 332, 
                    "text": "In this work, we propose a method based on radial basis networks for predicting the number of beta-strands in OMPs and identifying their membrane spanning segments."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19421989", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 624, 
                    "offsetInEndSection": 806, 
                    "text": "We have developed a web server, TMBETAPRED-RBF for predicting the transmembrane beta-strands from amino acid sequence and it is available at http://rbf.bioinfo.tw/~sachen/tmrbf.html."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18434251", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1044, 
                    "offsetInEndSection": 1160, 
                    "text": "We have developed a prediction server, TMBETADISC-RBF, which is available at http://rbf.bioinfo.tw/~sachen/OMP.html."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17958348", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 102, 
                    "text": "TMB finding pipeline: novel approach for detecting beta-barrel membrane proteins in genomic sequences."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17958348", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1154, 
                    "offsetInEndSection": 1235, 
                    "text": "Interestingly, the present approach identified TMBs from all 15 families in TCDB."
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16351738", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 361, 
                    "offsetInEndSection": 505, 
                    "text": "Nevertheless, we show that when several concurring paths are present, as in the case of our beta-barrel HMM, PV performs better than the others."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16351738", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 120, 
                    "text": "A new decoding algorithm for hidden Markov models improves the prediction of the topology of all-beta membrane proteins."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15261149", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 331, 
                    "text": "A new method is presented for identification of beta-barrel membrane proteins. It is based on a hidden Markov model (HMM) with an architecture obeying these proteins' construction principles. Once the HMM is trained, log-odds score relative to a null model is used to discriminate beta-barrel membrane proteins from other proteins."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16225682", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 80, 
                    "text": "Prediction of beta-barrel membrane proteins by searching for restricted domains."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16225682", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2031, 
                    "offsetInEndSection": 2918, 
                    "text": "Now, four alternative directions are used in order to newly identify \u03b2-barrel proteins out of a genomic/proteomic data set. In the first approach, sequence profile based HMMs for predicting \u03b2-barrel membrane proteins were developed [10-12]. The second methodology is based on the alternating hydrophobicity as a measure for \u03b2-barrel transmembrane segments [13]. Thirdly, the structural data of the \u03b2-barrel membrane proteins were statistically analyzed and certain criteria developed for a linear prediction [14,15]. The fourth methodology is based on a modified k-nearest neighbor algorithm of the whole sequence amino acid composition [16,17]. Recently, the combination of several independent procedures for \u03b2-barrel membrane protein prediction [18,19] or their combination with other procedures, e.g. signal sequence prediction [15,19], was employed to improve the prediction quality."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15215419", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 91, 
                    "text": "PRED-TMBB: a web server for predicting the topology of beta-barrel outer membrane proteins."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15215419", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 91, 
                    "text": "PRED-TMBB: a web server for predicting the topology of beta-barrel outer membrane proteins."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15215419", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 346, 
                    "offsetInEndSection": 684, 
                    "text": "We present here a web server (PRED-TMBB, http://bioinformatics.biol.uoa.gr/PRED-TMBB) which is capable of predicting the transmembrane strands and the topology of beta-barrel outer membrane proteins of Gram-negative bacteria. The method is based on a Hidden Markov Model, trained according to the Conditional Maximum Likelihood criterion."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15141026", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 51, 
                    "text": "Predicting transmembrane beta-barrels in proteomes."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15141026", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 241, 
                    "offsetInEndSection": 386, 
                    "text": "Here we introduced the design, statistics and results of a novel profile-based hidden Markov model for the prediction and discrimination of TMBs."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15070403", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 107, 
                    "text": "A Hidden Markov Model method, capable of predicting and discriminating beta-barrel outer membrane proteins."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12169530", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 93, 
                    "text": "A sequence-profile-based HMM for predicting and discriminating beta barrel membrane proteins."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12169530", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 994, 
                    "offsetInEndSection": 1133, 
                    "text": "RESULTS: We develop a HMM model, which can predict the topology of beta barrel membrane proteins using, as input, evolutionary information."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15070403", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2261, 
                    "offsetInEndSection": 2502, 
                    "text": ". For the reasons mentioned above, there is clearly a need to develop computational tools for predicting the membrane spanning strands of those proteins, and also discriminating them from water-soluble proteins when searching entire genomes."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20952406", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 87, 
                    "text": "OMPdb: a database of {beta}-barrel outer membrane proteins from Gram-negative bacteria."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20952406", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 957, 
                    "offsetInEndSection": 1602, 
                    "text": "Given these facts, and because many \u03b2-barrel OMPs nowadays attract an increased medical interest, several approaches have been made towards the development of predictive algorithms for this type of proteins. These methods are based grossly on hydrophobicity (10) and statistical analysis (11,12), remote homology detection (13), Hidden Markov Models (HMMs) (14\u201318), feed-forward Neural Networks (19\u201321), radial basis function Neural Networks (22,23) and Support Vector Machines (24), whereas others like BOMP (25), TMB-Hunt (26,27) and the TMB-finding pipeline (28) are oriented towards genome scale discrimination of \u03b2-barrel membrane proteins."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16844989", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 104, 
                    "text": "transFold: a web server for predicting the structure and residue contacts of transmembrane beta-barrels."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16844989", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 687, 
                    "offsetInEndSection": 780, 
                    "text": "In the last few years, various methods have addressed TM \u03b2-barrel structure prediction (1\u20136)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16844989", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1152, 
                    "offsetInEndSection": 1347, 
                    "text": "The transFold program extends a method introduced previously by Waldisp\u00fchl and Steyaert (8) for TM \u03b1-bundle proteins, and employs statistical potentials developed for the program BETAWRAP (9,10)."
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16844989", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 144, 
                    "offsetInEndSection": 330, 
                    "text": "Our software, named transFold, applies grammars to describe all potential \u03b2-barrel supersecondary structures and then computes the global minimum energy structure by dynamic programming."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15647112", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 123, 
                    "text": "Evaluation of methods for predicting the topology of beta-barrel outer membrane proteins and a consensus prediction method."
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15647112", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 11, 
                    "offsetInEndSection": 484, 
                    "text": "We have evaluated the currently available methods, for predicting the topology of \u03b2-barrel outer membrane proteins, using a non-redundant dataset of 20 proteins with structures known at atomic resolution. By using multivariate and univariate analysis of variance, we conclude that the HMM-based methods HMM-B2TMR, ProfTMB and PRED-TMBB perform significantly better than the other (mostly NN-based) methods, in both terms of per-residue and per-segment measures of accuracy."
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15647112", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 1156, 
                    "offsetInEndSection": 1306, 
                    "text": "A consensus prediction method is for the first time been applied for the prediction of the transmembrane strands, of \u03b2-barrel outer membrane proteins."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15215418", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 121, 
                    "text": "BOMP: a program to predict integral beta-barrel outer membrane proteins encoded within genomes of Gram-negative bacteria."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15215418", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 339, 
                    "text": "This work describes the development of a program that predicts whether or not a polypeptide sequence from a Gram-negative bacterium is an integral beta-barrel outer membrane protein. The program, called the beta-barrel Outer Membrane protein Predictor (BOMP), is based on two separate components to recognize integral beta-barrel proteins."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15215418", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 339, 
                    "text": "This work describes the development of a program that predicts whether or not a polypeptide sequence from a Gram-negative bacterium is an integral beta-barrel outer membrane protein. The program, called the beta-barrel Outer Membrane protein Predictor (BOMP), is based on two separate components to recognize integral beta-barrel proteins."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16542876", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 139, 
                    "offsetInEndSection": 432, 
                    "text": "On the basis of existing knowledge of beta-barrel outer-membrane proteins, several state of the art prediction methods, as well as a new in-house program (PROB) were employed for the systematic exploration of Mycobacterium tuberculosis predicted proteomes for potential beta-barrel structures."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16542876", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 149, 
                    "text": "Computational identification of beta-barrel outer-membrane proteins in Mycobacterium tuberculosis predicted proteomes as putative vaccine candidates."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23297037", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 106, 
                    "text": "BETAWARE: a machine-learning tool to detect and predict transmembrane beta-barrel proteins in prokaryotes."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23297037", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 684, 
                    "offsetInEndSection": 866, 
                    "text": "Recently, we developed two top-performing methods based on machine-learning approaches to tackle both the detection of TMBBs in sets of proteins and the prediction of their topology."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22987359", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 74, 
                    "text": "Supersecondary structure prediction of transmembrane beta-barrel proteins."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22987359", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 265, 
                    "text": "We introduce a graph-theoretic model for predicting the supersecondary structure of transmembrane \u03b2-barrel proteins--a particular class of proteins that performs diverse important functions but it is difficult to determine their structure with experimental methods."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22247276", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 74, 
                    "text": "BOCTOPUS: improved topology prediction of transmembrane \u03b2 barrel proteins."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22247276", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 480, 
                    "offsetInEndSection": 655, 
                    "text": "Here, we present BOCTOPUS; an improved method for the topology prediction of TMBs by employing a combination of support vector machines (SVMs) and Hidden Markov Models (HMMs)."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21426944", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 154, 
                    "text": "TMBHMM: a frequency profile based HMM for predicting the topology of transmembrane beta barrel proteins and the exposure status of transmembrane residues."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21426944", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 332, 
                    "offsetInEndSection": 838, 
                    "text": "We present here TMBHMM, a computational method based on a hidden Markov model for predicting the structural topology of putative TMBs from sequence. In addition to predicting transmembrane strands, TMBHMM also predicts the exposure status (i.e., exposed to the membrane or hidden in the protein structure) of the residues in the transmembrane region, which is a novel feature of the TMBHMM method. Furthermore, TMBHMM can also predict the membrane residues that are not part of beta barrel forming strands."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21328706", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 398, 
                    "text": "We present BTMX (Beta barrel TransMembrane eXposure), a computational method to predict the exposure status (i.e. exposed to the bilayer or hidden in the protein structure) of transmembrane residues in transmembrane beta barrel proteins (TMBs). BTMX predicts the exposure status of known TM residues with an accuracy of 84.2% over 2,225 residues and provides a confidence score for all predictions."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18467177", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 97, 
                    "text": "A method for discovering transmembrane beta-barrel proteins in Gram-negative bacterial proteomes."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18467177", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 570, 
                    "offsetInEndSection": 682, 
                    "text": "A web server based on the proposed method is available at http://yanbioinformatics.cs.usu.edu:8080/TMBKNNsubmit."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18467177", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 100, 
                    "offsetInEndSection": 199, 
                    "text": "This paper presents a k-nearest neighbor (K-NN) method for discriminating TMB and non-TMB proteins."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18006547", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 114, 
                    "text": "TMBpro: secondary structure, beta-contact and tertiary structure prediction of transmembrane beta-barrel proteins."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18006547", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 732, 
                    "offsetInEndSection": 1102, 
                    "text": "We develop a suite (TMBpro) of specialized predictors for predicting secondary structure (TMBpro-SS), beta-contacts (TMBpro-CON) and tertiary structure (TMBpro-3D) of transmembrane beta-barrel proteins. We compare our results to the recent state-of-the-art predictors transFold and PRED-TMBB using their respective benchmark datasets, and leave-one-out cross-validation."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16844988", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 82, 
                    "text": "PROFtmb: a web server for predicting bacterial transmembrane beta barrel proteins."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16844988", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 835, 
                    "offsetInEndSection": 890, 
                    "text": "PROFtmb predicts TMBs from Gram-negative bacteria only."
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16844988", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 88, 
                    "offsetInEndSection": 268, 
                    "text": "For each sequence, PROFtmb builds a PSI-BLAST profile and runs the prediction, attempting to find the best fit of the protein to its TMB-based architecture, indicated as a Z-value."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17557332", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 97, 
                    "text": "A consensus algorithm to screen genomes for novel families of transmembrane beta barrel proteins."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17557332", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 554, 
                    "offsetInEndSection": 769, 
                    "text": "Here we describe a new algorithm combining composition and hidden Markov model topology based classifiers (called TMB-Hunt2), which achieves a crossvalidation accuracy of >95%, with 96.7% precision and 94.2% recall."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17557332", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1347, 
                    "offsetInEndSection": 1476, 
                    "text": "Tools and datasets are made available through a website called TMB-Web (http://www.bioinformatics.leeds.ac.uk/TMB-Web/TMB-Hunt2)."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15980452", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 86, 
                    "text": "TMB-Hunt: a web server to screen sequence sets for transmembrane beta-barrel proteins."
                }, 
                {
                    "beginSection": "sections.5", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15980452", 
                    "endSection": "sections.5", 
                    "offsetInBeginSection": 10, 
                    "offsetInEndSection": 129, 
                    "text": "TMB-Hunt is a program that uses whole sequence amino acid composition to discriminate between TMB and non-TMB proteins."
                }, 
                {
                    "beginSection": "sections.5", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15980452", 
                    "endSection": "sections.5", 
                    "offsetInBeginSection": 477, 
                    "offsetInEndSection": 589, 
                    "text": "TMB-Hunt is extremely quick, and so the web server allows screening of up to 10\u2009000 sequences in a single query."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15980452", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1714, 
                    "offsetInEndSection": 1815, 
                    "text": "TMB-Hunt uses whole sequence amino acid composition to discriminate between TMB and non-TMB proteins."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15980452", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2080, 
                    "offsetInEndSection": 2489, 
                    "text": "However, although studies of TMB protein composition have been made, whole sequence amino acid composition has not yet been applied to the discrimination problem.Because TMB-Hunt puts no emphasis on identification of TM \u03b2-strands, we were not dependent on sequences with resolved structures, thus allowing the use of training sets that were larger and more representative than those used for other predictors."
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15980452", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 547, 
                    "offsetInEndSection": 834, 
                    "text": "sing the \u2018leave homologues out\u2019 cross-validation, without inclusion of evolutionary information and without differential amino acid weightings, the program was able to discriminate between TMB and NTM proteins with 85% accuracy, 83% sensitivity and 86.5% positive predictive value (PPV)."
                }
            ], 
            "type": "list"
        }, 
        {
            "body": "Which type of lung cancer is the most strongly associated with Lambert-Eaton syndrome?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015624", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008175"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/7731034", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8009147", 
                "http://www.ncbi.nlm.nih.gov/pubmed/1470196", 
                "http://www.ncbi.nlm.nih.gov/pubmed/1318636", 
                "http://www.ncbi.nlm.nih.gov/pubmed/1448671", 
                "http://www.ncbi.nlm.nih.gov/pubmed/1339000", 
                "http://www.ncbi.nlm.nih.gov/pubmed/2189179", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18506722", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17395141", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15767964", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15000529", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20979723", 
                "http://www.ncbi.nlm.nih.gov/pubmed/10486838", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9538660", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8568672", 
                "http://www.ncbi.nlm.nih.gov/pubmed/2833535"
            ], 
            "id": "5147c088d24251bc05000026", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7731034", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1592, 
                    "offsetInEndSection": 1792, 
                    "text": "The autoantibodies implicated in the Lambert-Eaton myasthenic syndrome (LES), which are known to inhibit ICa and INa in bovine adrenal chromaffin cells, also significantly inhibited INa in SCLC cells."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7731034", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1793, 
                    "offsetInEndSection": 2211, 
                    "text": "These results indicate that (i) action potentials in human SCLC cells result from the regenerative increase in voltage-gated Na+ channel conductance; (ii) fundamental characteristics of SCLC Na+ channels are the same as the classical sodium channels found in a variety of excitable cells; and (iii) in some LES patients, SCLC Na+ channels are an additional target of the pathological IgG present in the patients' sera."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8009147", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 110, 
                    "offsetInEndSection": 369, 
                    "text": "Clinical features were those of LES and occurred insidiously in this 68-year old man: proximal weakness predominant in the lower limbs, generalized areflexia, dryness of the mouth and partial right eye palsy. Investigations disclosed a small cell lung cancer."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1318636", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 964, 
                    "offsetInEndSection": 1240, 
                    "text": "Voltage-gated Ca2+ channels may be important to the secretion of ectopic hormones and the etiology and pathogenesis of Lambert-Eaton syndrome, an autoimmune disorder of the motor nerve terminal in which autoantibodies directed against voltage-gated Ca2+ channels are produced."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1339000", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 143, 
                    "text": "Lambert-Eaton syndrome is a myasthenia-like syndrome of paraneoplastic origin which is often associated with anaplastic small-cell lung cancer."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18506722", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 185, 
                    "offsetInEndSection": 247, 
                    "text": "Small-cell lung cancer (SCLC) is the most common cause of LES."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18506722", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 248, 
                    "offsetInEndSection": 353, 
                    "text": "We report an unusual case of LES associated with large-cell neuroendocrine carcinoma (LCNEC) of the lung."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17395141", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 406, 
                    "offsetInEndSection": 553, 
                    "text": "The Lambert-Eaton syndrome is caused by antibodies against voltage-gated calcium channels and often occurs in patients with small cell lung cancer."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15767964", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 214, 
                    "offsetInEndSection": 560, 
                    "text": "A 53 year-old heavy smoker presented with a Lambert-Eaton myasthenic syndrome (LEMS). Bronchoscopy was normal but radiological examinations revealed a lymph node in site 4R. The pathological diagnosis after mediastinoscopy was negative. Twenty-five months later, an opacity on chest X-ray led to a biopsy which revealed a squamous cell carcinoma."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15767964", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 926, 
                    "offsetInEndSection": 1019, 
                    "text": "LEMS is generally associated with small cell lung cancer occurring in three percent of cases."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15767964", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1020, 
                    "offsetInEndSection": 1202, 
                    "text": "However, the case that we report shows the unusual association of LEMS with non small-cell lung cancer and highlights the difficulties associated in the management of this condition."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15000529", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1672, 
                    "offsetInEndSection": 1824, 
                    "text": "LEMS has a high degree of coincidence (approximately 60%) with small cell lung cancer; the remaining 40% of patients with LEMS have no detectable tumor."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20979723", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 109, 
                    "text": "BACKGROUND: To enhance the acknowledgement of Lambert-Eaton syndrome in patients with small cell lung cancer."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20979723", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 455, 
                    "offsetInEndSection": 555, 
                    "text": "There were 10 cases of Lambert-Eaton syndrome in 332 pathologically diagnosed small cell lung cancer"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20979723", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 800, 
                    "offsetInEndSection": 886, 
                    "text": "Treatment of small cell lung cancer may improve the symptoms of Lambert-Eaton syndrome"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20979723", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 901, 
                    "offsetInEndSection": 1140, 
                    "text": "Improving the recognition of Lambert-Eaton syndrome may be helpful to identify early small cell lung cancer and improve the prognosis,as the symptom of muscular weakness usually appears early before the diagnosis of small cell lung cancer."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10486838", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 799, 
                    "offsetInEndSection": 1001, 
                    "text": "The Lambert Eaton syndrome is a paraneoplastic manifestation of small-cell lung cancer in 50% of the cases unlike generalized myasthenia which apparently is never associated with small-cell lung cancer."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9538660", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 103, 
                    "text": "Paraneoplastic Lambert-Eaton myasthenia syndrome is presented in two cases with small cell lung cancer."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8568672", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 3, 
                    "offsetInEndSection": 280, 
                    "text": "Human small-cell lung cancer (SCLC) cells are believed to express the antigens responsible for the production of pathological antibodies in the Lambert-Eaton syndrome (LES), a Ca2+ channel disorder in which quantal transmitter release from the motor nerve terminal is impaired."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2833535", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 318, 
                    "text": "Lambert-Eaton myasthenic syndrome (LEMS) is a paraneoplastic autoimmune disorder caused by an IgG-mediated reduction in number of presynaptic voltage-gated calcium channels (VGCC) at the neuromuscular junction. In at least 50% of cases, the stimulus for antibody production may be VGCC on small cell lung cancer (SCLC)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1470196", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 691, 
                    "offsetInEndSection": 804, 
                    "text": "Also, there was no obvious band pattern distinguishing patients with LES from those with LES and concurrent SCLC."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1448671", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 157, 
                    "offsetInEndSection": 279, 
                    "text": "The cancer associated with LEMS was small-cell lung carcinoma (SCLC) in 15 cases and epidermoid lung carcinoma in 3 cases."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2189179", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 501, 
                    "offsetInEndSection": 698, 
                    "text": "Etiology of this disease is uncertain but in view of its frequent association with small cell lung cancer, this specific type of neoplasm may be implicated in the initiation of autoimmune response."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2189179", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 699, 
                    "offsetInEndSection": 881, 
                    "text": "Recent studies indeed support the possibility that the antigenic stimulus in the neoplastic form of LES may arise from voltage-dependent Ca2+ channels found in the lung cancer cells."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15000529", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2007, 
                    "offsetInEndSection": 2220, 
                    "text": "In the majority of LEMS patients, those having detectable tumor, the disease is thought to occur as a result of immune response directed initially against voltage-gated Ca2+ channels found on the lung tumor cells."
                }
            ], 
            "type": "factoid"
        }, 
        {
            "body": "Which enzyme is deficient in Krabbe disease?", 
            "concepts": [
                "http://www.disease-ontology.org/api/metadata/DOID:10587", 
                "http://www.disease-ontology.org/api/metadata/DOID:3211", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007965", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003677", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004798"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23438514", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20301416", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19439584", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17072020", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16645197", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16498763", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11978730", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11814461", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11493025", 
                "http://www.ncbi.nlm.nih.gov/pubmed/10448809", 
                "http://www.ncbi.nlm.nih.gov/pubmed/10090061", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9875712", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9441867", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8940268", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8577041", 
                "http://www.ncbi.nlm.nih.gov/pubmed/7581365", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8297359", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8281145", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8399327", 
                "http://www.ncbi.nlm.nih.gov/pubmed/1521344", 
                "http://www.ncbi.nlm.nih.gov/pubmed/2079710", 
                "http://www.ncbi.nlm.nih.gov/pubmed/85413"
            ], 
            "id": "5147c8a6d24251bc05000027", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23438514", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 239, 
                    "text": "Krabbe disease is a lethal, demyelinating condition caused by genetic deficiency of galactocerebrosidase (GALC) and resultant accumulation of its cytotoxic substrate, psychosine (galactosylsphingosine), primarily in oligodendrocytes (OLs)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23438514", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 692, 
                    "offsetInEndSection": 946, 
                    "text": "In this study, we report that accumulation of endogenous psychosine under GALC deficient Krabbe conditions impedes OL differentiation process both by decreasing the expression of myelin lipids and protein and by inducing the cell death of maturating OLs."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20301416", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 808, 
                    "offsetInEndSection": 1023, 
                    "text": "In almost all individuals with Krabbe disease, galactocerebrosidase (GALC) enzyme activity is deficient (0%-5% of normal activity) in leukocytes isolated from whole heparinized blood or in cultured skin fibroblasts."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17072020", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 239, 
                    "text": "This chapter describes in detail a practical procedure for the preparation of radiolabeled galactocerebroside and its use in the assay of galactocerebrosidase (GalCase), the enzyme deficient in globoid cell leukodystrophy (Krabbe disease)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16645197", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 237, 
                    "text": "Globoid cell leukodystrophy (Krabbe disease) is an inherited neurological disorder caused by the pathogenomic accumulation of psychosine (galactosylsphingosine), a substrate for the deficient enzyme galactocerebroside beta-galactosidase."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16498763", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 194, 
                    "text": "Krabbe disease is an extremely rare condition with an incidence of 1 in 1,00,000 live births. It is caused by deficient activity of the Iysosomal hydrolase galactosylceramide beta-galactosidase."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11978730", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 227, 
                    "text": "Globoid cell leukodystrophy (Krabbe disease) is characterized by the accumulation of a toxic metabolite, psychosine (galactosylsphingosine), which is a substrate for the deficient enzyme (galactocerebroside beta-galactosidase)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11814461", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 195, 
                    "text": "Krabbe disease (globoid-cell leukodystrophy; GLD) is caused by mutations in the GALC gene. Beta-galactocerebrosidase (GALC) is a specific beta-galactosidase which is defective in GLD."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11814461", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 807, 
                    "offsetInEndSection": 970, 
                    "text": "Both galactosylceramide beta-galactosidase (GALC-GC) and GALC-PS activities were reduced by at least 85% of the normal in all but 2 of the 10 GLD patients studied."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10448809", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 160, 
                    "text": "Krabbe disease, or globoid cell leukodystrophy, is an autosomal recessive disorder caused by the deficiency of galactocerebrosidase (GALC) activity."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10448809", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 392, 
                    "offsetInEndSection": 522, 
                    "text": "The disease can be diagnosed by detecting the deficiency of GALC activity (less than 5% of normal) in any available tissue sample."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10090061", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 178, 
                    "text": "Globoid cell leukodystrophy, or Krabbe disease, is a severe disorder of the peripheral and central nervous system myelin caused by deficient galactocerebrosidase (GALC) activity."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9875712", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 187, 
                    "text": "Globoid cell leukodystrophy (GCL or Krabbe disease) is a recessive disease caused by mutations of the lysosomal enzyme galactocerebrosidase (GALC) and twitcher is the murine model of GCL."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9441867", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 155, 
                    "text": "Galactocerebrosidase (GALC) is the lysosomal enzyme deficient in human and certain animal species with globoid cell leukodystrophy (GLD) or Krabbe disease."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8940268", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 226, 
                    "text": "Globoid-cell leukodystrophy (GLD) is an autosomal recessive inherited disorder caused by the deficiency of galactocerebrosidase, the lysosomal enzyme responsible for the degradation of the myelin glycolipid galactocerebroside."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8577041", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 135, 
                    "text": "Krabbe disease is an autosomal recessive inherited demyelinating disease, which is deficient in lysosomal enzyme, galactocerebrosidase."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7581365", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 105, 
                    "text": "Galactocerebrosidase (GALC) activity is deficient in all patients with globoid cell leukodystrophy (GLD)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8297359", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 177, 
                    "text": "Human galactocerebrosidase, the enzyme deficient in Krabbe disease, was purified, through several hydrophobic column steps and gel filtration, 22,650-fold from human lymphocytes"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8281145", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 150, 
                    "text": "Globoid cell leukodystrophy (Krabbe disease) is an autosomal recessive disorder resulting from the deficiency of galactocerebrosidase (GALC) activity."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1521344", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 258, 
                    "text": "6-Hexadecanoylamino-4-methylumbelliferyl-beta-D-galactopyranoside (HMGal) has been shown to be a specific fluorogenic substrate of galactocerebrosidase and to facilitate the simple enzymatic diagnosis of Krabbe disease in human patients and in twitcher mice."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2079710", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 209, 
                    "text": "The inherited deficiency of galactosylceramide beta-galactosidase (E.C. 3.2.1.46: galactocerebrosidase) activity results in globoid cell leukodystrophy in humans (Krabbe disease) and in mice (twitcher mutant)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2079710", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 997, 
                    "offsetInEndSection": 1316, 
                    "text": "The lack of complementation between Krabbe disease patient and twitcher mutant mouse cells provides further evidence that the twitcher mouse is an authentic murine model for Krabbe disease and supports the hypothesis that the mutations in both species are within the structural gene for the galactocerebrosidase enzyme."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/85413", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 151, 
                    "text": "Galactosylceramide beta-galactosidase cross reacting material was demonstrated in brain, liver, and skin fibroblasts from patients with Krabbe disease."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19439584", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 385, 
                    "offsetInEndSection": 718, 
                    "text": ". In this study, LRs in the brain of the twitcher (TWI) mouse, a bona-fide model for infant variants of human globoid cell leukodystrophy or Krabbe disease, were investigated. This mouse has deficient activity of GALC (beta-galactosylceramidase) that leads to a progressive accumulation of some galactosyl-sphingolipids in the brain."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11814461", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1615, 
                    "offsetInEndSection": 1792, 
                    "text": "A GALC genotype with one deleted and one polymorphic GALC activity-reducing allele can lead to enzymatic and clinical signs of LOGLD in the absence of marked GALC-PS deficiency."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11493025", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 151, 
                    "text": "Galactocerebrosidase (GALC) is deficient in all tissues from human patients and animal models with globoid cell leukodystrophy (GLD) or Krabbe disease."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8399327", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1530, 
                    "offsetInEndSection": 1739, 
                    "text": "The purification of GALC and the securing of amino acid sequence information will aid in the cloning of the GALC gene. This enzyme is deficient in human patients with Krabbe disease and several animal species."
                }
            ], 
            "type": "factoid"
        }, 
        {
            "body": "Which scales are recommended by the American Heart Association for depression screening in cardiovascular patients? ", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000572", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003863", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008403"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23283084", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21862720", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21505152", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20435186", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19840561", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19261139", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18824640"
            ], 
            "id": "51486f7dd24251bc0500002e", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21862720", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 274, 
                    "text": "In 2008, the American Heart Association (AHA) recommended a 2-step screening method, consisting of the 2-item Patient Health Questionnaire (PHQ-2) followed by the 9-item Patient Health Questionnaire (PHQ-9), for identifying depression in cardiovascular patients."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21505152", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 207, 
                    "text": "The American Heart Association (AHA) statement has recommended routine screening for depression in coronary artery disease with a 2-stage implementation of the Patient Health Questionnaire (PHQ)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20435186", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 309, 
                    "text": "A recent American Heart Association (AHA) Prevention Committee report recommended depression screening of all coronary heart disease patients using 2- and 9-item instruments from the Patient Health Questionnaire (PHQ-2 and PHQ-9) to identify patients who may need further assessment and treatment."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19840561", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 348, 
                    "offsetInEndSection": 572, 
                    "text": "Patients were screened for depression using a protocol identical to the one endorsed by the AHA in a cardiology community clinic in Elmhurst (Queens, New York). Depression was assessed using the Patient Health Questionnaire."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23283084", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 467, 
                    "text": "Depression screening in cardiac patients has been recommended by the American Heart Association, but the best approach remains unclear. OBJECTIVE: To evaluate nurse-administered versions of the Patient Health Questionnaire for depression screening in patients hospitalized for acute coronary syndrome. METHODS: Staff nurses in an urban cardiac care unit administered versions 2, 9, and 10 of the questionnaire to 100 patients with acute coronary syndrome."
                }
            ], 
            "type": "list"
        }, 
        {
            "body": "Which two catechol-O-methyl transferase (COMT) inhibitors can be used for treatment of Parkinson disease?", 
            "concepts": [
                "http://www.uniprot.org/uniprot/COMT_PIG", 
                "http://www.uniprot.org/uniprot/COMT_BOVIN", 
                "http://www.uniprot.org/uniprot/COMT_RAT", 
                "http://www.uniprot.org/uniprot/COMT_HORSE", 
                "http://www.uniprot.org/uniprot/COMT_MOUSE", 
                "http://www.uniprot.org/uniprot/COMT_HUMAN", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0016206", 
                "http://www.disease-ontology.org/api/metadata/DOID:14330", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D010300"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21164341", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19589043", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19198095", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15853578", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15372589", 
                "http://www.ncbi.nlm.nih.gov/pubmed/14741081", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12952501", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12588639", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11147512", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11147511", 
                "http://www.ncbi.nlm.nih.gov/pubmed/10733264", 
                "http://www.ncbi.nlm.nih.gov/pubmed/10651109", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8784230", 
                "http://www.ncbi.nlm.nih.gov/pubmed/1933685"
            ], 
            "id": "51487ef9d24251bc05000031", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21164341", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 11, 
                    "offsetInEndSection": 215, 
                    "text": "Entacapone is a highly potent, reversible, peripherally acting catechol-O-methyl transferase (COMT) inhibitor that is used as an adjunct to L-dopa in the treatment of patients with Parkinson disease (PD)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19589043", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1251, 
                    "offsetInEndSection": 1614, 
                    "text": "Stalevo is a combination tablet comprised of levodopa, carbidopa, and the COMT inhibitor entacapone. It is available in fixed-dose combinations of levodopa/carbidopa/entacapone, 50/12.5/200, 75/18.75/200, 100/25/200, 125/31.25/200, 150/37.5/200 and 200/50/200 mg. Stalevo is currently approved for use in Parkinson's disease patients with end-of-dose wearing off."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19198095", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 306, 
                    "offsetInEndSection": 637, 
                    "text": "Good news were marketing of ropinirole, a new non-ergot agonist, in December 2006 and entacapone, the first catechol-O-methyl transferase (COMT) inhibitor in Japan in April 2007. Having faced these new situations, Japanese Neurological Association has started revising \"the Guideline 2002 for the treatment of Parkinson's disease\"."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15853578", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 620, 
                    "offsetInEndSection": 776, 
                    "text": "Stalevo (Orion) combines levodopa, the dopa-decarboxylase inhibitor carbidopa and the catechol-O-methyl transferase inhibitor entacapone in a single tablet."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15372589", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 250, 
                    "text": "We investigated whether administration of the catechol-O-methyl transferase (COMT) inhibitor entacapone, at doses of 200 mg and 400 mg, alters the pharmacokinetics of apomorphine in Parkinson's disease patients experiencing severe motor fluctuations."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14741081", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 197, 
                    "text": "The catechol-O-methyl transferase inhibitor entacapone is given in combination with levodopa/dopa decarboxylase inhibitor for Parkinson's disease (PD) patients experiencing end-of-dose wearing-off."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12952501", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 325, 
                    "text": "Entacapone (Comtess/Comtan) is Orion Pharma's original proprietary catechol-O-methyl transferase (COMT) inhibitor. Entacapone is able to slow down degradation of levodopa and improve the availability and efficacy of each levodopa dose, hence its use as a complement to levodopa/carbidopa in patients with Parkinson's disease."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12588639", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 77, 
                    "text": "Sleep attacks in Parkinson's disease induced by Entacapone, a COMT-inhibitor."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12588639", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 266, 
                    "text": "We present a patient who suffered from sleep attacks after starting entacapone in addition to levodopa. Entacapone, a catechol-O-methyl transferase inhibitor, alters the pharmacokinetics of levodopa, leading to increase of levodopa concentration in plasma and brain."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11147512", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 160, 
                    "offsetInEndSection": 273, 
                    "text": "Two COMT inhibitors, tolcapone and entacapone, have recently been made available as adjunctive agents to levodopa"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11147511", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 185, 
                    "text": "Two inhibitors of catechol-O-methyl transferase (COMT), tolcapone and entacapone, have recently been introduced as adjuncts to levodopa in the treatment of Parkinson's disease patients."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10733264", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1446, 
                    "offsetInEndSection": 1569, 
                    "text": "Tolcapone, a peripheral and central COMT inhibitor, appears to be quite effective, producing a 47% reduction in 'off' time."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10733264", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1761, 
                    "offsetInEndSection": 1957, 
                    "text": ". Entacapone, a purely peripheral COMT inhibitor with a lower potency than tolcapone, has also proved to be effective and has not been associated with liver damage, obviating the need for testing."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10651109", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 316, 
                    "offsetInEndSection": 524, 
                    "text": "Here we report that a treatment of the cerebral tissue with tolcapone, a central and peripheral inhibitor of COMT, does not change the membrane responses of midbrain dopamine neurons to dopamine and levodopa."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10651109", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 721, 
                    "offsetInEndSection": 873, 
                    "text": "Therefore, the therapeutic action of tolcapone in Parkinson's disease, might be dependent on the reduction of COMT activity in the extracerebral tissue."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8784230", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 294, 
                    "offsetInEndSection": 568, 
                    "text": "Pretreatment with entacapone (OR-611), a peripheral catechol O-methyl-transferase (COMT) inhibitor, greatly reduces the plasma 3OMFD fraction and provides an ideal situation to evaluate the contribution of the plasma 3OMFD fraction in several kinetic models of FDOPA uptake."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1933685", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 87, 
                    "offsetInEndSection": 356, 
                    "text": "The novel and reversible inhibitors are the catechol-O-methyl-transferase (COMT) inhibitors, Ro 40-7592 (3,4-dihydroxy-4'-methyl-5-nitrobenzophenone), and the monoamine oxidase type-B (MAO-B) inhibitor, Ro 19-6327 (N-(2-aminoethyl)-5-chloro-2-pyridine carboxamide HC1)."
                }
            ], 
            "type": "list"
        }, 
        {
            "body": "What pharmacological and non-pharmacological interventions can be considered as prophylactic therapies in Cluster Headache patients?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003027", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D055502"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21284609", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20352587", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17901920", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16041199", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16628535", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15651299", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12390644", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11252143", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11026146", 
                "http://www.ncbi.nlm.nih.gov/pubmed/2520442"
            ], 
            "id": "5148a2f6d24251bc05000035", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21284609", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 563, 
                    "offsetInEndSection": 767, 
                    "text": "The calcium channel blocker verapamil is the drug of choice for CH prevention. Other drugs that may be used for this purpose include lithium carbonate, topiramate, valproic acid, gabapentin, and baclofen."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21284609", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 967, 
                    "offsetInEndSection": 1149, 
                    "text": "Recently, the therapeutic options for refractory CH patients have expanded with the emergence of both peripheral (mostly occipital nerve) and central (hypothalamic) neurostimulation."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21284609", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1150, 
                    "offsetInEndSection": 1244, 
                    "text": "With the emergence of these novel treatments, the role of ablative surgery in CH has declined."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20352587", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1102, 
                    "offsetInEndSection": 1338, 
                    "text": "The mainstay of prophylactic therapy is verapamil. Yet, other medications, including lithium, divalproex sodium, topiramate, methysergide, gabapentin, and even indomethacin, may be useful when the headache fails to respond to verapamil."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20352587", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1339, 
                    "offsetInEndSection": 1471, 
                    "text": "For medically refractory patients, surgical interventions, occipital nerve stimulation, and deep brain stimulation remain an option."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17901920", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 192, 
                    "text": "The objective of this open single-centre study was to evaluate the efficacy and tolerability of botulinum toxin type-A (BTX-A) as add-on in the prophylactic treatment of cluster headache (CH)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17901920", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 829, 
                    "offsetInEndSection": 973, 
                    "text": "These findings provide evidence that BTX-A may be beneficial as an add-on prophylactic therapy for a limited number of patients with chronic CH."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16041199", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1253, 
                    "offsetInEndSection": 1397, 
                    "text": "There are a variety of different medications for abortive and prophylactic therapy, accompanied by a variable amount of evidence-based medicine."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16041199", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1503, 
                    "offsetInEndSection": 1639, 
                    "text": "Most procedures are directed against the sensory trigeminal nerve and associated ganglia, eg, anesthetizing the sphenopalatine ganglion."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16628535", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1060, 
                    "offsetInEndSection": 1172, 
                    "text": "The mainstay of prophylactic therapy is verapamil. Lithium, divalproex sodium, or topiramate may also be useful."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15651299", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1154, 
                    "offsetInEndSection": 1299, 
                    "text": "Based on our clinical experience, we recommended the combination of nasal sumatriptan for acute attacks and verapamil 240 mg/day for prophylaxis."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12390644", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 3204, 
                    "offsetInEndSection": 3308, 
                    "text": "Topiramate also appears to be well tolerated and useful in the adjunctive treatment of cluster headache."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11252143", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1071, 
                    "offsetInEndSection": 1276, 
                    "text": "The cornerstone of maintenance prophylaxis is verapamil, yet methysergide, lithium, and divalproex sodium may also be employed. In some patients, melatonin or topiramate may be useful adjunctive therapies."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11026146", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 600, 
                    "offsetInEndSection": 685, 
                    "text": "Prophylactic therapy in most cases consisted of verapamil, also with a good response."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2520442", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 913, 
                    "offsetInEndSection": 1079, 
                    "text": "Patients with chronic cluster headache may achieve good results from long-term treatment with other therapies, including lithium carbonate, verapamil, and ketoprofen."
                }
            ], 
            "type": "summary"
        }, 
        {
            "body": "What is the mechanism of action of abiraterone?", 
            "concepts": [
                "http://www.biosemantics.org/jochem#4266316", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D045504"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23344012", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23199349", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22672122", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22291466", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21860772", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9876107"
            ], 
            "id": "5148b466d24251bc05000037", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23344012", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 664, 
                    "offsetInEndSection": 897, 
                    "text": "The recognition of sustained androgen dependence of CRPC has led to the identification of more potent and selective inhibitors of androgen synthesis and androgen-receptor signaling, such as abiraterone and enzalutamide, respectively."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23199349", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 566, 
                    "offsetInEndSection": 743, 
                    "text": "This review summarizes the rationale, mechanism of action and relevant clinical data of abiraterone acetate , an oral androgen biosynthesis inhibitor, in the management of CRPC."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22672122", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 350, 
                    "offsetInEndSection": 637, 
                    "text": "Sipuleucel-T, an immunotherapeutic vaccine, is now available in the US for patients with non-metastatic CRPC and abiraterone, an oral enzyme inhibitor of androgen biosynthesis, as well as cabazitaxel, a cytotoxic chemotherapeutic, have been approved for the treatment of metastatic CRPC."
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22291466", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 566, 
                    "offsetInEndSection": 662, 
                    "text": "Abiraterone acetate was identified to be a potent and selective irreversible inhibitor of CYP17."
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22291466", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 663, 
                    "offsetInEndSection": 863, 
                    "text": "Preclinical studies with abiraterone demonstrated reduction in androgen production downstream of CYP17 which resulted in decreased weight of the ventral prostate, testis, and seminal vesicles in mice."
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22291466", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 6887, 
                    "offsetInEndSection": 7108, 
                    "text": "This could potentially be explained by the fact that although abiraterone blocks androgen synthesis at the CYP17 level, androgens upstream continue to accumulate and can potentially stimulate an altered androgen receptor."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21860772", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1064, 
                    "offsetInEndSection": 1227, 
                    "text": "Recently, abiraterone acetate, which is a potent inhibitor of cytochrome P450 17\u03b1-hydroxylase/17,20-lyase (CYP17A1), has been focused on for the treatment of CRPC."
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21860772", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 10, 
                    "offsetInEndSection": 110, 
                    "text": "Abiraterone acetate is a potent, selective, and irreversible inhibitor of CYP17A1 (IC50, 2-4 nmol/l)"
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21860772", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 1518, 
                    "offsetInEndSection": 1699, 
                    "text": "Thus, the original rationale for the use of abiraterone acetate in CRPC is that a complete blockade of not only testicular but also adrenal androgen may beneficial in CRPC patients."
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21860772", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 2956, 
                    "offsetInEndSection": 3103, 
                    "text": "Thus, abiraterone acetate has been expected to block not only testicular and adrenal androgenesis but also intratumoral de novo androgen synthesis."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9876107", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 141, 
                    "text": "Abiraterone (17-(3-pyridyl)androsta-5,16-dien-3beta-ol, 1) is a potent inhibitor (IC50 4 nM for hydroxylase) of human cytochrome P45017alpha."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22291466", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 112, 
                    "text": "Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer."
                }
            ], 
            "type": "summary"
        }, 
        {
            "body": "Mutation of which gene and which chromosome cause Neurofibromatosis type I?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009456", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016514", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0005694"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22312371", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20860891", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16830335", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16459992", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16377376", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12696059", 
                "http://www.ncbi.nlm.nih.gov/pubmed/10787042", 
                "http://www.ncbi.nlm.nih.gov/pubmed/10633134", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8768681", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8630973", 
                "http://www.ncbi.nlm.nih.gov/pubmed/7522538", 
                "http://www.ncbi.nlm.nih.gov/pubmed/7519874", 
                "http://www.ncbi.nlm.nih.gov/pubmed/2562822", 
                "http://www.ncbi.nlm.nih.gov/pubmed/2491784", 
                "http://www.ncbi.nlm.nih.gov/pubmed/2491782", 
                "http://www.ncbi.nlm.nih.gov/pubmed/2491780", 
                "http://www.ncbi.nlm.nih.gov/pubmed/2491777"
            ], 
            "id": "5148e1d6d24251bc0500003a", 
            "snippets": [
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22312371", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 337, 
                    "offsetInEndSection": 409, 
                    "text": "NF-1 is caused by loss of function mutations in the NF1 gene in 17q11.2."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2491777", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 118, 
                    "text": "The von Recklinghausen neurofibromatosis (NF1) gene has been localized to the pericentromeric region of chromosome 17."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2491780", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 155, 
                    "text": "Nine markers from the pericentromeric region of chromosome 17 were typed in 16 British and five South African families with neurofibromatosis type 1 (NF1)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2491780", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 305, 
                    "offsetInEndSection": 521, 
                    "text": "Inspection of recombinant events in families informative for several markers suggests that the NF1 gene is located between the markers EW301 (cen-p11.2) and EW206 (cen-q12) and possibly distal to pHHH202 (q11.2-q12)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2491782", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 141, 
                    "text": "The gene for von Recklinghausen neurofibromatosis type 1 (NF1) has recently been mapped to the pericentromeric region of human chromosome 17."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2491784", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 441, 
                    "text": "In addition to reporting, in accompanying papers, their individual analyses of mapping the neurofibromatosis type 1 (NF1) gene on chromosome 17, members of the International Consortium for NF1 Linkage contributed their data for our joint analysis to determine the exact sequence of flanking markers and to obtain precise estimates and confidence limits of the recombination fractions for the closest markers, in anticipation of clinical use."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2562822", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 304, 
                    "text": "To better map the location of the von Recklinghausen neurofibromatosis (NF1) gene, we have characterized a somatic cell hybrid designated 7AE-11. This microcell-mediated, chromosome-transfer construct harbors a centromeric segment and a neo-marked segment from the distal long arm of human chromosome 17."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2562822", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1057, 
                    "offsetInEndSection": 1310, 
                    "text": "The cosmids in the NF1 region will be an important resource for testing DNA blots of large-fragment restriction-enzyme digests from NF1 patient cell lines, to detect rearrangements in patients' DNA and to identify the 17;22 NF1 translocation breakpoint."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7519874", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 740, 
                    "offsetInEndSection": 950, 
                    "text": "The frequent LOH surrounding the NF1 locus and lack of neurofibromin expression in these tumors suggest that NF1 gene mutations may contribute to the development of adrenal gland neoplasms in patients with NF1."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8630973", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 676, 
                    "offsetInEndSection": 813, 
                    "text": "In the latter, the breakpoint in 17q occurred below the centromere and is at or in the region of the Neurofibromatosis Type 1 (NF1) gene."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10787042", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 158, 
                    "offsetInEndSection": 362, 
                    "text": "Neurofibromatosis type I (NF1) is an autosomal dominant condition associated with mutations in the long arm of chromosome 17, and characterised by neurofibromas, caf\u00e9-au-lait spots and axillary freckling."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10787042", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 964, 
                    "offsetInEndSection": 1159, 
                    "text": "In addition, the mother's and maternal grandmother's genetic analysis showed identical mutations in the neurofibromatosis I gene on the long arm of chromosome 17, confirming the diagnosis of NF1."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12696059", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 254, 
                    "text": "Duplicon-mediated microdeletions around the NF1 gene are frequently associated with a severe form of neurofibromatosis type I in a subgroup of patients who show an earlier onset of cutaneous neurofibromas, dysmorphic facial features, and lower IQ values."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16377376", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 238, 
                    "offsetInEndSection": 405, 
                    "text": "Neurofibromatosis had been diagnosed in infancy, and genetic testing showed that the patient had a mutation in chromosome 17, consistent with neurofibromatosis type I."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16459992", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 233, 
                    "text": "Neurofibromatosis Type 1 (NF1) is one of the most common inherited diseases in humans. It is caused by a mutation in the NF1 gene on chromosome 17, and is associated with numerous central and peripheral nervous system manifestations."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16830335", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 144, 
                    "offsetInEndSection": 339, 
                    "text": "In 95% of NF1 individuals, a mutation is found in the NF1 gene, and in 5% of the patients, the germline mutation consists of a microdeletion that includes the NF1 gene and several flanking genes."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20860891", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 493, 
                    "offsetInEndSection": 986, 
                    "text": "Herein, we describe a unique case of anaplastic de novo astroblastoma-sarcoma, in essence a variant of gliosarcoma, occurring in a 50-year-old female with documented NF1. Genetic study (fluorescence in situ hybridization) demonstrated no chromosomal losses or gains. Testing for abnormalities of chromosomes 7, 9, 10, 12, 17, 19 and 20, including the EGFR, p16, PTEN, MDM2 and NF1 gene regions, we found the tumor to exhibit a deletion of PTEN, monosomy 17 and gains of chromosomes 19 and 20q."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10633134", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 191, 
                    "text": "Neurofibromatosis type I (NF1) is an autosomal dominant disorder affecting 1 in 3000 people. The NF1 gene is located on chromosome 17q11.2, spans 350 kb of genomic DNA, and contains 60 exons."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8768681", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 476, 
                    "text": "A patient with recurrent-remittent multiple sclerosis associated with neurofibromatosis type I is described. The case is interesting for two reasons: 1) the difficulty of evaluating MRI findings, since both entities involve similar anomalies and 2) the relation between the two entities, according to evidence from recent genetic studies showing that the myelin protein gene associated to oligodendrocytes is part of an intron of the neurofibromatosis-1 gene of chromosome 17."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7522538", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 241, 
                    "text": "Neurofibromatosis type I (NFI) is a common autosomal dominant disorder with an increased risk for developing benign and malignant tumors. The NFI gene has been cloned and maps to 17q11.2, and the gene product acts as a tumor suppressor gene."
                }
            ], 
            "type": "list"
        }, 
        {
            "body": "Is nimodipine recommended for prevention of vasospasm in aneurysmal subarachnoid hemorrhage patients?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013345", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009553", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000783", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020301", 
                "http://www.disease-ontology.org/api/metadata/DOID:13100", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011322", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011315", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002532", 
                "http://www.disease-ontology.org/api/metadata/DOID:10941"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22543491", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22152574", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22027241", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21608279", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19108757", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19066110", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18847340", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18842226", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17705883", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17479073", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17029347", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16998274", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15846536", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9706722", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9164696", 
                "http://www.ncbi.nlm.nih.gov/pubmed/7785750", 
                "http://www.ncbi.nlm.nih.gov/pubmed/3521193"
            ], 
            "id": "51490275d24251bc0500003d", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22543491", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 643, 
                    "offsetInEndSection": 900, 
                    "text": "This article discusses some of these unresolved issues, including the use of medications such as nimodipine, antifibrinolytics, statins, and magnesium; coiling or clipping for aneurysm securement; and the prevention and treatment of potential complications."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22152574", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 914, 
                    "offsetInEndSection": 1342, 
                    "text": "The results of this study were as follows: nimodipine demonstrated benefit following aneurysmal SAH; other calcium channel blockers, including nicardipine, do not provide unequivocal benefit; triple-H therapy, fasudil, transluminal balloon angioplasty, thrombolytics, endothelin receptor antagonists, magnesium, statins, and miscellaneous therapies such as free radical scavengers and antifibrinolytics require additional study."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22027241", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1119, 
                    "offsetInEndSection": 1316, 
                    "text": "The present results suggest that fasudil is equally or more effective than nimodipine for the prevention of cerebral vasospasm and subsequent ischemic injury in patients undergoing surgery for SAH."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21608279", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1700, 
                    "offsetInEndSection": 1905, 
                    "text": "Three studies (2 meta-analyses and 1 randomized controlled trial) demonstrated that nimodipine use confers benefits (reduced morbidity and mortality) for patients with aneurysmatic subarachnoid hemorrhage."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21608279", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2246, 
                    "offsetInEndSection": 2316, 
                    "text": "Nimodipine is the only preventative treatment that can be recommended."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19108757", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 698, 
                    "offsetInEndSection": 961, 
                    "text": "Nimodipine (Nimotop), HMG Co-A reductase inhibitor (statins) and enoxaparin (Lovenox) were the only drugs with level-1 evidence available for the treatment of vasospasm from aneurysmal subarachnoid hemorrhage as defined by the US Preventative Services Task Force."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18847340", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 11, 
                    "offsetInEndSection": 161, 
                    "text": "The calcium antagonist nimodipine has been shown to reduce the incidence of ischemic complications following aneurysmal subarachnoid hemorrhage (SAH)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18847340", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1165, 
                    "offsetInEndSection": 1382, 
                    "text": "There was no significant difference in the incidence of DINDs (28 vs 30% in the peroral and intravenous groups, respectively) or middle cerebral artery blood flow velocities (> 120 cm/second, 50 vs 45%, respectively)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18847340", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1383, 
                    "offsetInEndSection": 1557, 
                    "text": "Clinical outcome according to the Glasgow Outcome Scale was the same in both groups, and there was no difference in the number of patients with new infarctions on MR imaging."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18847340", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1571, 
                    "offsetInEndSection": 1768, 
                    "text": "The results suggest that there is no clinically relevant difference in efficacy between peroral and intravenous administration of nimodipine in preventing DINDs or cerebral vasospasm following SAH."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18842226", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 969, 
                    "offsetInEndSection": 1058, 
                    "text": "the risk of delayed cerebral ischemia is reduced with nimodipine and avoiding hypovolemia"
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17705883", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 708, 
                    "offsetInEndSection": 912, 
                    "text": "A major randomized controlled trial, the British aneurysm oral nimodipine trial, showed a significant reduction in the incidence of cerebral infarction and poor outcome at three months compared to placebo"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15846536", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 470, 
                    "offsetInEndSection": 599, 
                    "text": "A recommendations (standard) for the prophylaxis and treatment of cerebral vasospasm with oral Nimodipine in good grade patients."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9706722", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 678, 
                    "offsetInEndSection": 1007, 
                    "text": "Of the 75 patients initially considered for active treatment, 83% underwent surgery within 48 hours of rupture, all received nimodipine, 16% received tissue plasminogen activator to lyse subarachnoid or intraventricular clots, 40% underwent hypertensive treatment, and 7% underwent transluminal balloon angioplasty for vasospasm."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9164696", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1690, 
                    "offsetInEndSection": 1850, 
                    "text": "All patients with aneurysmal SAH should be treated with the calcium antagonist nimodipine, and in certain circumstances patients should receive anticonvulsants."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7785750", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 262, 
                    "offsetInEndSection": 499, 
                    "text": "The following review gives an account of pathophysiological mechanisms; the importance of treatment with calcium antagonists, hypervolaemic haemodilution, and induced arterial hypertension is discussed in light of the current literature."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7785750", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1433, 
                    "offsetInEndSection": 1593, 
                    "text": "Seven placebo-controlled clinical studies have shown that nimodipine improves the outcome of patients with severe neurological damage due to cerebral vasospasm."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3521193", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 527, 
                    "offsetInEndSection": 805, 
                    "text": "In a series of 100 individuals with a ruptured supratentorial aneurysm, who were subjected to aneurysm operation in the acute stage and who subsequently received intravenous treatment with the calcium channel blocker nimodipine, the occurrence of DID with FND was reduced to 5%."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22152574", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1382, 
                    "offsetInEndSection": 1784, 
                    "text": "There are many possible successful treatment options for preventing vasospasm, delayed ischemic neurologic deficits, and poor neurologic outcome following aneurysmal subarachnoid hemorrhage; however, further multicenter RCTs need to be performed to determine if there is a significant benefit from their use. Nimodipine is the only treatment that provided a significant benefit across multiple studies."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22027241", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 641, 
                    "offsetInEndSection": 1050, 
                    "text": "Absence of symptomatic vasospasm, occurrence of low density areas associated with vasospasm on CT, and occurrence of adverse events were similar between the two groups. The clinical outcomes were more favorable in the fasudil group than in the nimodipine group (p = 0.040). The proportion of patients with good clinical outcome was 74.5% (41/55) in the fasudil group and 61.7% (37/60) in the nimodipine group."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19066110", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 459, 
                    "text": "Cerebral vasospasm is the classic cause of delayed neurological deterioration leading to cerebral ischemia and infarction, and thus, poor outcome and occasionally death, after aneurysmal subarachnoid hemorrhage (SAH). Advances in diagnosis and treatment, principally nimodipine, intensive care management, hemodynamic manipulations, and endovascular neuroradiology procedures, have improved the prospects for these patients, but outcomes remain disappointing. <a class=\"btn btn-mini annotationText\" href=\"#\" data-id=\"15\" rel=\"tooltip\" title=\"Remove annotation\"><i class=\"icon-remove\"></i></a>"
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17705883", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 328, 
                    "offsetInEndSection": 707, 
                    "text": "Nimodipine is a dihydropyridine that blocks calcium influx through the L-type calcium channels. It is the most rigorously studied and only drug approved by the US Food and Drug Administration for use in treatment of vasospasm. It is safe [12,59], cost-effective [60], and most importantly reduces the risk of poor outcome and secondary ischemia after aneurysmal SAH [7,10-12,61]. <a class=\"btn btn-mini annotationText\" href=\"#\" data-id=\"27\" rel=\"tooltip\" title=\"Remove annotation\"><i class=\"icon-remove\"></i></a>"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17479073", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 463, 
                    "text": "Cerebral vasospasm is the classic cause of delayed neurological deterioration after aneurysmal subarachnoid hemorrhage, leading to cerebral ischemia and infarction, and thus to poor outcome and occasionally death. Advances in diagnosis and treatment-principally the use of nimodipine, intensive care management, hemodynamic manipulations and endovascular neuroradiology procedures-have improved the prospects for these patients, but outcomes remain disappointing."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17029347", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 296, 
                    "text": "Cerebral vasospasm and delayed cerebral ischemia remain common complications of aneurysmal subarachnoid hemorrhage (SAH), and yet therapies for cerebral vasospasm are limited. Despite a large number of clinical trials, only calcium antagonists have strong evidence supporting their effectiveness."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17029347", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 821, 
                    "offsetInEndSection": 873, 
                    "text": "The only proven therapy for vasospasm is nimodipine."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17029347", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1152, 
                    "offsetInEndSection": 1217, 
                    "text": "nimodipine is indicated after SAH and tirilazad is not effective."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16998274", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 643, 
                    "offsetInEndSection": 1199, 
                    "text": "Fasudil hydrochloride and nimodipine both showed inhibitory effects on cerebral vasospasm. The incidence of symptomatic vasospasm was five of 33 patients in the fasudil group and nine of 32 patients in the nimodipine group. Good recovery evaluated by the Glasgow Outcome Scale was achieved by 23 of 33 patients in the fasudil group and 19 of 34 patients in the nimodipine group. Both drugs significantly improved consciousness levels and neurological deficits such as aphasia. However, fasudil hydrochloride improved motor disturbance more than nimodipine."
                }
            ], 
            "type": "yesno"
        }, 
        {
            "body": "Which depression rating scales were shown to have acceptable psychometric properties for screening of poststroke depression?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003863", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008403", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003866", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003865", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011569", 
                "http://www.disease-ontology.org/api/metadata/DOID:3455", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020521"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23385849", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23167974", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19074478", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18648195", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18039246", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15387399", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12297607", 
                "http://www.ncbi.nlm.nih.gov/pubmed/1410202"
            ], 
            "id": "51492168d24251bc05000041", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23385849", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 704, 
                    "offsetInEndSection": 1157, 
                    "text": "The Center of Epidemiological Studies-Depression Scale (CESD) (sensitivity: 0.75; 95% CI 0.60 to 0.85; specificity: 0.88; 95% CI 0.71 to 0.95), the Hamilton Depression Rating Scale (HDRS) (sensitivity: 0.84; 95% CI 0.75 to 0.90; specificity:0.83; 95% CI 0.72 to 0.90) and the Patient Health Questionnaire (PHQ)-9 (sensitivity: 0.86; 95% CI 0.70 to 0.94; specificity: 0.79; 95% CI 0.60 to 0.90) appeared to be the optimal measures for screening measures."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23385849", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1246, 
                    "offsetInEndSection": 1385, 
                    "text": "There are a number of possible instruments that may help in screening for poststroke depression but none are satisfactory for case-finding."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23385849", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1386, 
                    "offsetInEndSection": 1470, 
                    "text": "Preliminary data suggests the CESD, HDRS or the PHQ-9 as the most promising options."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23167974", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 424, 
                    "offsetInEndSection": 956, 
                    "text": "The Beck Depression Inventory (BDI), Hospital Anxiety and Depression Scale-depression subscale (HADS-D), Hamilton Rating Scale for Depression (HAMD), and Montgomery-Asberg Depression Rating Scale (MADRS) were administered. The balance of sensitivity and specificity was assessed using receiver operating characteristics (ROC) analysis. RESULTS: Discriminating abilities of all the scales for major and all PSD were good (area under ROC values 0.88-0.93 and 0.88-0.92 at 2 weeks; and 0.93-0.96 and 0.89-0.91 at 1 year, respectively)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19074478", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 277, 
                    "offsetInEndSection": 646, 
                    "text": "We compared the Beck Depression Inventory, Hamilton Rating Scale for Depression, Visual Analogue Mood Scale, proxy assessment, and Clinical Global Impression of the nursing and study personnel, together with Diagnostic and Statistical Manual of Mental Disorders, 3rd Edition, Revised diagnosis, in assessing depression after stroke in a follow-up study of 100 patients."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19074478", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1060, 
                    "offsetInEndSection": 1325, 
                    "text": "The sensitivity and specificity against the Diagnostic and Statistical Manual of Mental Disorders criteria were acceptable with the Clinical Global Impression, Beck Depression Inventory, and Hamilton Rating Scale for Depression, mostly in the range of 0.70 to 1.00."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19074478", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1486, 
                    "offsetInEndSection": 1668, 
                    "text": "The Visual Analogue Mood Scale was not a sensitive instrument (sensitivity, 0.20 to 0.60) and did not correlate with the Beck Depression Inventory during the first year after stroke."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19074478", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1682, 
                    "offsetInEndSection": 2015, 
                    "text": "Beck Depression Inventory, Hamilton Rating Scale for Depression, and Clinical Global Impression assessment by professionals, in addition to the Diagnostic and Statistical Manual of Mental Disorders, 3rd Edition, Revised diagnosis, are useful in assessing depression, but none of these instruments clearly stood apart from the others."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19074478", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2016, 
                    "offsetInEndSection": 2187, 
                    "text": "Proxy ratings should be used with caution, and the use of the Visual Analogue Mood Scale among patients with aphasia and other cognitive impairments cannot be recommended."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18648195", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 358, 
                    "offsetInEndSection": 590, 
                    "text": "This study evaluated the diagnostic accuracy of the Poststroke Depression Rating Scale (PSDRS), a diagnostic tool specifically devised to assess depression after stroke, in comparison to the Hamilton Depression Rating Scale (Ham-D)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18648195", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 989, 
                    "offsetInEndSection": 1199, 
                    "text": "At their optimum cut-off points, the Ham-D and PSDRS showed good sensitivity and specificity for MDL or MDL + MDDM; the PSDRS had a higher positive predictive value for MDL in respect of the Ham-D (78 vs. 59%)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18648195", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1200, 
                    "offsetInEndSection": 1305, 
                    "text": "Furthermore, the diagnostic accuracy of the PSDRS was higher in respect of the Ham-D in aphasic patients."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18648195", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1534, 
                    "offsetInEndSection": 1614, 
                    "text": "The Ham-D and PSDRS are both reliable diagnostic tools for the diagnosis of PSD."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18648195", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1852, 
                    "offsetInEndSection": 1948, 
                    "text": "We suggest that the PSDRS could be a useful tool in clinical practice and in therapeutic trials."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18039246", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1036, 
                    "offsetInEndSection": 1573, 
                    "text": "The psychiatrist classified 25/71 (35.2%) patients as depressed. Using the recommended cut-point of 2 or more on the Signs of Depression Scale, the nurse and carer respectively rated 27/71 (38.0%) and 18/30 (60.0%) patients as potentially depressed. The proportion of patients correctly identified as depressed by the test (sensitivity) when rated by nurses was 64%, and the proportion of patients not depressed who were correctly identified by the test (specificity) was 61%, whereas carers achieved sensitivity 90% and specificity 35%."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18039246", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1768, 
                    "offsetInEndSection": 2180, 
                    "text": "The Signs of Depression Scale is easily completed by clinical staff, although we found the sensitivity when completed by nurses to be low. Information from carers shows potential to improve screening and it is important for nurses to value the knowledge and skills of carers in detecting depression following a stroke. Further refinement of the Signs of Depression Scale, with accompanying research, is required."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15387399", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 743, 
                    "offsetInEndSection": 940, 
                    "text": "The VAMS was not useful in screening for depression in Chinese stroke patients while both the HADS and the GDS demonstrated satisfactory accuracy in detecting depression in Chinese stroke patients."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12297607", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 315, 
                    "offsetInEndSection": 578, 
                    "text": "At their respective optimum cutoff values, the sensitivity of the self-rated scales varied between 80% and 90%, while the specificity was about 60%. For the observer-rated scale (Hamilton Depression Rating Scale), sensitivity was 78.1%, and specificity was 74.6%."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1410202", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 329, 
                    "offsetInEndSection": 593, 
                    "text": "The hypothesis was supported: in contrast to psychiatric interview (68% depressed) and self-report (Beck Depression Inventory, 50% depressed), none of the patients were described as depressed in chart notes by the rehabilitation team (excluding the psychiatrists)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23167974", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1280, 
                    "offsetInEndSection": 1571, 
                    "text": "Although there were no marked differences in the screening abilities for PSD between the scales, differences were found in factors influencing misclassification. Assessment scales with less somatic items may be recommended for the screening of PSD, particularly at the acute phase of stroke."
                }
            ], 
            "type": "summary"
        }, 
        {
            "body": "Is marijuana use associated with increased risk for stroke?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002188", 
                "http://www.disease-ontology.org/api/metadata/DOID:3455", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020521", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012306", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008385", 
                "http://www.disease-ontology.org/api/metadata/DOID:9505", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002189", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012307"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23299821", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23160887", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22150621", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22107013", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18025032", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17432216", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16832776", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15801396", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15716544", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15297005", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15060269", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12412838", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11811864", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11462796", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8944217", 
                "http://www.ncbi.nlm.nih.gov/pubmed/1992832"
            ], 
            "id": "5149e23dd24251bc0500004b", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23299821", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 305, 
                    "offsetInEndSection": 504, 
                    "text": "The illicit drugs more commonly associated with stroke are psychomotor stimulants, such as amphetamine and cocaine. Less commonly implicated are opioids and psychotomimetic drugs, including cannabis."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22107013", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 565, 
                    "offsetInEndSection": 805, 
                    "text": "Among 326 patients (184 males), the most frequent stroke risk factors overall were dyslipidaemia (187), smoking (161), hypertension (105) and obesity (92). Fifty-one patients used illicit drugs, mostly comprising marijuana and amphetamines."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22107013", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1386, 
                    "offsetInEndSection": 1611, 
                    "text": "Patients in Adelaide are more likely to be obese, to be misusing marijuana and amphetamines, to suffer a cardioembolic event and to have a stroke that concurrently affects both the anterior and posterior cerebral circulation."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18025032", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 511, 
                    "offsetInEndSection": 741, 
                    "text": "RCVS was spontaneous in 37% of patients and secondary in the 63% others, to postpartum in 5 and to exposure to various vasoactive substances in 37, mainly cannabis, selective serotonin-recapture inhibitors and nasal decongestants."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17432216", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 219, 
                    "offsetInEndSection": 463, 
                    "text": "We reported two cases of young stroke associated with drug misuse. Case 1 used amphetamine, cocaine, marijuana and LSD for few yaers, and developed occlusion of a middle cerebral artery. Case 2 presented aphasia shortly after marijuana smoking."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17432216", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 558, 
                    "offsetInEndSection": 673, 
                    "text": "Marijuana may have accelerated stroke onset, but essential cause of stroke in this case must be protein S mutation."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16832776", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 93, 
                    "offsetInEndSection": 238, 
                    "text": "Cannabis is the most widely consumed among the illicit drugs worldwide, but it has only exceptionally been associated to cerebrovascular disease."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16832776", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 248, 
                    "offsetInEndSection": 395, 
                    "text": "We here describe 2 young patients (26 and 29 years, respectively) who suffered from ischemic stroke in temporal relation with cannabis consumption."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16832776", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 409, 
                    "offsetInEndSection": 523, 
                    "text": "The review of the literature on this topic reveals another 18 patients with stroke in association to cannabis use."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16832776", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 573, 
                    "offsetInEndSection": 725, 
                    "text": "Although a causal relationship is difficult to establish due to the widespread use of cannabis, this drug may play an etiologic role in ischemic stroke."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15801396", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 243, 
                    "offsetInEndSection": 319, 
                    "text": "Marijuana may trigger a myocardial infarction and have a vasospastic effect."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15716544", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 97, 
                    "offsetInEndSection": 244, 
                    "text": "Despite the fact that cannabis is the most widely used illicit drug, there are only a few reports associating its use with cerebrovascular disease."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15716544", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 245, 
                    "offsetInEndSection": 343, 
                    "text": "We describe a patient who suffered three ischaemic strokes immediately after cannabis consumption."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15716544", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 596, 
                    "offsetInEndSection": 697, 
                    "text": "Cannabis use may be associated with ischaemic stroke in young patients, but its mechanism is unclear."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15297005", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 95, 
                    "offsetInEndSection": 292, 
                    "text": "A right occipital ischemic stroke occurred in a 37-year-old Albanese man with a previously uneventful medical history, 15 min after having smoked a cigarette with approximately 250 mg of marijuana."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15297005", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 716, 
                    "offsetInEndSection": 1019, 
                    "text": "Therefore, as the family history for cerebrovascular events, blood pressure, clotting tests, examinations for thrombophilia, vasculitis, extracranial and intracranial arteries and cardiac investigations were normal or respectively negative, the stroke was attributed to the chronic cannabis consumption."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15060269", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 734, 
                    "offsetInEndSection": 923, 
                    "text": "Three adolescent males had similar presentations of headache, fluctuating level of consciousness or lethargy, visual disturbance, and variable ataxia after self-administration of marijuana."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15060269", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1132, 
                    "offsetInEndSection": 1250, 
                    "text": "Episodic marijuana use may represent a risk factor for stroke in childhood, particularly in the posterior circulation."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12412838", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 904, 
                    "offsetInEndSection": 1159, 
                    "text": "Although several mechanisms exist by which marijuana use might contribute to the development of chronic cardiovascular conditions or acutely trigger cardiovascular events, there are few data regarding marijuana/THC use and cardiovascular disease outcomes."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11811864", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 282, 
                    "offsetInEndSection": 466, 
                    "text": "Reported here is the case of a previously healthy young man who smoked marijuana on a daily basis and had an occipital lobe stroke; he was found to be heterozygous for factor V Leiden."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11811864", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 467, 
                    "offsetInEndSection": 628, 
                    "text": "This case suggests that marijuana smoking may increase the risk of arterial thrombosis in otherwise healthy individuals who are heterozygous for factor V Leiden."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11462796", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 587, 
                    "offsetInEndSection": 654, 
                    "text": "Thus, chronic abuse of marijuana might be a risk factor for stroke."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8944217", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 279, 
                    "text": "A 22-year-old man with a five-year history of drug and alcohol abuse presented with a left hemiparesis preceded by three transient ischaemic attacks, two of which occurred whilst smoking cannabis. Substance abuse was the only identifiable risk factor for cerebrovascular disease."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1992832", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 928, 
                    "offsetInEndSection": 984, 
                    "text": "Chronic marijuana smoking, however, seems to reduce CBF."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12412838", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1687, 
                    "offsetInEndSection": 2185, 
                    "text": "Research directions might include more studies of cardiovascular disease outcomes and relationships of marijuana with cardiovascular risk factors, studies of metabolic and physiologic effects of chronic marijuana use that may affect cardiovascular disease risk, increased understanding of the role of the cannabinoid receptor system in cardiovascular regulation, and studies to determine if there is a therapeutic role for cannabinoids in blood pressure control or for neuroprotection after stroke."
                }
            ], 
            "type": "yesno"
        }, 
        {
            "body": "Which drug should be used as an antidote in benzodiazepine overdose?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000931", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001569", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D062787"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21785147", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19500521", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18175099", 
                "http://www.ncbi.nlm.nih.gov/pubmed/14620397", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11349753", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11383664", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9306053", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8905360", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8644960", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8605789", 
                "http://www.ncbi.nlm.nih.gov/pubmed/7629986", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8306565", 
                "http://www.ncbi.nlm.nih.gov/pubmed/1286503", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8438687", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8239101", 
                "http://www.ncbi.nlm.nih.gov/pubmed/1354979", 
                "http://www.ncbi.nlm.nih.gov/pubmed/1996802", 
                "http://www.ncbi.nlm.nih.gov/pubmed/1672103", 
                "http://www.ncbi.nlm.nih.gov/pubmed/2231833", 
                "http://www.ncbi.nlm.nih.gov/pubmed/2113543", 
                "http://www.ncbi.nlm.nih.gov/pubmed/2575692", 
                "http://www.ncbi.nlm.nih.gov/pubmed/3132054", 
                "http://www.ncbi.nlm.nih.gov/pubmed/2899985", 
                "http://www.ncbi.nlm.nih.gov/pubmed/2893240"
            ], 
            "id": "514a0a57d24251bc05000051", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21785147", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 11, 
                    "offsetInEndSection": 250, 
                    "text": "Benzodiazepine (BZD) overdose (OD) continues to cause significant morbidity and mortality in the UK. Flumazenil is an effective antidote but there is a risk of seizures, particularly in those who have co-ingested tricyclic antidepressants."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21785147", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 530, 
                    "offsetInEndSection": 698, 
                    "text": "Flumazenil was administered to 80 patients in 4504 BZD-related enquiries, 68 of whom did not have ventilatory failure or had recognised contraindications to flumazenil."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21785147", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1366, 
                    "offsetInEndSection": 1436, 
                    "text": "Flumazenil is used infrequently in the management of BZD OD in the UK."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19500521", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 152, 
                    "text": "Flumazenil is a benzodiazepine antagonist. It is widely used as an antidote in comatose patients suspected of having ingested a benzodiazepine overdose."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18175099", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2100, 
                    "offsetInEndSection": 2227, 
                    "text": "Flumazenil is very useful in reversing benzodiazepine-induced sedation as well as to diagnose or treat benzodiazepine overdose."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14620397", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 225, 
                    "text": "Flumazenil is indicated for reversal of sedation from benzodiazepines administered during therapeutic or diagnostic procedures and during induction or maintenance of general anesthesia, as well as for benzodiazepine overdose."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14620397", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 766, 
                    "offsetInEndSection": 990, 
                    "text": "When measures are required to ensure adequate recovery of a patient's respiratory function and mental awareness, such as in patients with benzodiazepine toxicity, consideration of continuous-infusion flumazenil is warranted."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11349753", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 439, 
                    "offsetInEndSection": 695, 
                    "text": "Flumazenil is a potent benzodiazepine antagonist that competitively blocks the central effects of benzodiazepines. It can reverse the sedative effects of benzodiazepines occurring after diagnostic or therapeutic procedures or after benzodiazepine overdose."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11383664", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 139, 
                    "text": "A 54-y-old man ingested 2 g of bulk laboratory diazepam and was treated with activated charcoal, enhanced diuresis and flumazenil infusion."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9306053", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 200, 
                    "offsetInEndSection": 390, 
                    "text": "Flumazenil is a specific and competitive antagonist at the central benzodiazepine receptor, reversing all effects of benzodiazepine agonists without tranquillising or anticonvulsant actions."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9306053", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 391, 
                    "offsetInEndSection": 676, 
                    "text": "Incremental intravenous bolus injections of flumazenil 0.1 to 0.3 mg are the most effective and well tolerated in the diagnosis and treatment of pure benzodiazepine overdose; additional boluses or an infusion (0.3 to 0.5 mg/h) can be given to prevent patients from relapsing into coma."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8905360", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 277, 
                    "text": "Flumazenil is a competitive benzodiazepine antagonist that acts to reverse their sedative and hypnotic effects. It is indicated in the management of benzodiazepine overdose, but its role in the routine reversal of endoscopic conscious sedation has not been defined."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8644960", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 11, 
                    "offsetInEndSection": 119, 
                    "text": "To develop clinical rules for the safe and effective use of flumazenil in suspected benzodiazepine overdose."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8605789", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 438, 
                    "offsetInEndSection": 637, 
                    "text": "Unconscious patients (n = 110) suspected of benzodiazepine overdose, graded 2 to 4 on the Matthew and Lawson coma scale, were treated with flumazenil, the specific benzodiazepine receptor antagonist."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8605789", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1685, 
                    "offsetInEndSection": 2084, 
                    "text": "Fourteen of 17 double-blind, flumazenil-treated patients woke after a mean of 0.8 +/- 0.3 (SD) mg vs. one of 14 placebo patients (p < .001). Seventy-five percent of the aggregated controlled and uncontrolled patients awoke from coma scores of 3.1 +/- 0.6 to 0.4 +/- 0.5 (p < .01) after the injection of 0.7 +/- 0.3 mg of flumazenil. These patients had high benzodiazepine serum blood concentrations."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8605789", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 3379, 
                    "offsetInEndSection": 3459, 
                    "text": "Flumazenil is effective in preventing recurrence of benzodiazepine-induced coma."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7629986", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1430, 
                    "offsetInEndSection": 1550, 
                    "text": "Flumazenil is best left for reversal of therapeutic conscious sedation and rare select cases of benzodiazepine overdose."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8306565", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 161, 
                    "offsetInEndSection": 353, 
                    "text": "Flumazenil interacts at the central benzodiazepine receptor to antagonize or reverse the behavioral, neurologic, and electrophysiologic effects of benzodiazepine agonists and inverse agonists."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8306565", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 613, 
                    "offsetInEndSection": 862, 
                    "text": "It improves the level of consciousness in patients with benzodiazepine overdose; however, resedation may occur within one to two hours after administration, so repeated doses or a continuous infusion may be required to maintain therapeutic efficacy."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8306565", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1841, 
                    "offsetInEndSection": 2069, 
                    "text": "Flumazenil has been shown to reverse sedation caused by intoxication with benzodiazepines alone or benzodiazepines in combination with other agents, but it should not be used when cyclic antidepressant intoxication is suspected."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1286503", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 131, 
                    "text": "Flumazenil, a specific benzodiazepine antagonist, was evaluated as adjunctive therapy in the management of benzodiazepine overdose."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1286503", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 831, 
                    "offsetInEndSection": 971, 
                    "text": "The mean CGIS score at 10 minutes for benzodiazepine-positive patients treated with flumazenil was 1.95 versus 3.58 for those given placebo."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1286503", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1346, 
                    "offsetInEndSection": 1539, 
                    "text": "Among the benzodiazepine-positive patients, 9 (53%) of 17 patients from the flumazenil group responded to the additional flumazenil, and 58 (81%) of patients previously given placebo responded."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1286503", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2286, 
                    "offsetInEndSection": 2454, 
                    "text": "The results of this study confirm published reports of the efficacy of flumazenil in reversing benzodiazepine-induced sedation in patients with benzodiazepine overdose."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8438687", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 269, 
                    "text": "Flumazenil, a specific benzodiazepine antagonist, is useful in reversing the sedation and respiratory depression that often occur when benzodiazepines are administered to patients undergoing anesthesia or when patients have taken an intentional benzodiazepine overdose."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8239101", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2414, 
                    "offsetInEndSection": 2508, 
                    "text": "Flumazenil rapidly and effectively reverses the clinical signs and symptoms of a BDZ overdose."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1354979", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 146, 
                    "offsetInEndSection": 288, 
                    "text": "Flumazenil is a benzodiazepine antagonist that is highly effective in reversing the central nervous system effects of benzodiazepine overdose."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1996802", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 645, 
                    "offsetInEndSection": 827, 
                    "text": "In the setting of isolated benzodiazepine overdose, flumazenil is capable of completely reversing coma within one to two minutes, with this effect lasting between one and five hours."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1672103", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 319, 
                    "offsetInEndSection": 682, 
                    "text": "Fifteen comatous patients with suspected sedatives/hypnotics overdose were included in this study and flumazenil 0.25 mg per dose was administrated intravenously. The average score of Glasgow Coma Scale increased from 7.13 +/- 2.92 to 10.93 +/- 3.67 after one dose of flumazenil. Clear consciousness was restored after multiple doses of flumazenil administration."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1672103", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 908, 
                    "offsetInEndSection": 1048, 
                    "text": "We concluded that flumazenil is an excellent antidote for benzodiazepine overdose and valuable for differentiating the patients in comatose."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2231833", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1176, 
                    "offsetInEndSection": 1307, 
                    "text": "Patients with benzodiazepine overdose who received 5 mg flumazenil regained consciousness about 1-2 min after the end of injection."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2113543", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1383, 
                    "offsetInEndSection": 1485, 
                    "text": "We conclude that flumazenil is an effective and safe drug in the treatment of benzodiazepine overdose."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2575692", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 235, 
                    "offsetInEndSection": 380, 
                    "text": "Flumazenil is the first benzodiazepine antagonist which can be used in humans and is a well established for treatment of benzodiazepine overdose."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2893240", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 420, 
                    "offsetInEndSection": 631, 
                    "text": "Flumazenil, a 1,4-imidazobenzodiazepine, is a highly effective, specific benzodiazepine antagonist which is indicated for use when the effect of a benzodiazepine must be attenuated or terminated at short notice."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2893240", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2200, 
                    "offsetInEndSection": 2509, 
                    "text": "Thus, flumazenil provides a safe and effective means of attenuating or reversing the CNS-depressant effects of benzodiazepines whenever indicated, e.g. following benzodiazepine-induced general anaesthesia, conscious sedation, or after benzodiazepine overdose, either alone or in combination with other agents."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8605789", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 3524, 
                    "offsetInEndSection": 3676, 
                    "text": "Flumazenil is safe when administered cautiously, even in patients with coma caused by a mixed overdose of benzodiazepine plus tricyclic antidepressants."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8239101", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1222, 
                    "offsetInEndSection": 1648, 
                    "text": "The mean +/- SD CGIS score at ten minutes for BDZ-positive patients was 1.41 +/- 0.72 for patients who received flumazenil and 3.41 +/- 0.91 for the placebo group (P < .01). There was no difference in the mean CGIS score between the flumazenil (3.25 +/- 1.15) and placebo (3.75 +/- 0.69) groups in BDZ-negative patients. The GCS and NAS were also significantly better in patients who were BDZ-positive and received flumazenil."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2113543", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 145, 
                    "offsetInEndSection": 665, 
                    "text": "In 23 patients admitted to the Intensive Care Unit with coma due to overdose with benzodiazepines or other sedatives, flumazenil i.v. (up to 2 mg or placebo) was given. In 13 patients given flumazenil the Glasgow Coma Scale (GCS) increased significantly from 4.9 to 7.8 (p less than 0.05). Six of these 13 patients, including mainly benzodiazepine mono-intoxications, needed only one series of injections (up to 1.0 mg flumazenil); the GCS increased thereby from 4.5 to 10.7 within a maximum of 5 min (p less than 0.01)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3132054", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 416, 
                    "text": "The efficacy and safety of flumazenil were assessed in comparison to placebo in a double-blind randomised study of 31 adults intoxicated with benzodiazepines. The criteria of efficacy were the degree of sedation, and orientation in time and space. Patients who received flumazenil awoke within minutes but central depression returned partly one hour later, which reflects the short elimination half-life of the drug."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3132054", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 417, 
                    "offsetInEndSection": 615, 
                    "text": "Side effects were few and the results indicate that flumazenil is effective in the primary management of benzodiazepine overdose and in states where benzodiazepines have been taken with other drugs."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2899985", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 222, 
                    "text": "Flumazenil (Ro 15-1788) proved to be a very efficacious competitive antagonist of benzodiazepines that reliably counteracts their pharmacological actions within 1-2 min as could be demonstrated in clinical and EEG studies."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2899985", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1243, 
                    "offsetInEndSection": 1411, 
                    "text": "In intensive care medicine, the antagonist may be used in the treatment of benzodiazepine overdose as well as in the differential diagnosis of a coma of unknown origin."
                }
            ], 
            "type": "factoid"
        }, 
        {
            "body": "What are the polymorphisms in hypertrophic cardiomyopathy in Caucasians?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002312", 
                "http://www.disease-ontology.org/api/metadata/DOID:11984", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D024741", 
                "http://www.disease-ontology.org/api/metadata/DOID:11986", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009202", 
                "http://www.disease-ontology.org/api/metadata/DOID:0050700", 
                "http://www.uniprot.org/uniprot/XIRP1_HUMAN", 
                "http://www.uniprot.org/uniprot/MYOME_HUMAN", 
                "http://www.uniprot.org/uniprot/XIRP2_HUMAN", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011110"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22718505", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19659763", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18591919", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18497553", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16313983", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12404107", 
                "http://www.ncbi.nlm.nih.gov/pubmed/7959583", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20044516", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18505755", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16716659"
            ], 
            "id": "5150b029d24251bc05000068", 
            "snippets": [
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22718505", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 91, 
                    "text": "New polymorphisms in human MEF2C gene as potential modifier of hypertrophic cardiomyopathy."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22718505", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1350, 
                    "offsetInEndSection": 1608, 
                    "text": "15 bp-deletion and C-insertion in the 5'UTR region of MEF2C could affect hypertrophic cardiomyopathy, potentially by affecting expression of MEF2C and therefore, the expression of their target cardiac proteins that are implicated in the hypertrophic process."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19659763", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 383, 
                    "offsetInEndSection": 444, 
                    "text": "We screened patients for sarcomeric genes associated with HCM"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19659763", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 563, 
                    "offsetInEndSection": 975, 
                    "text": "We recruited 39 families with HCM from southern Italy and found mutations in 41% of families (12 with familial HCM and 4 with sporadic HCM). The remaining 23 families (59%) were negative for myofilament gene mutations. Of the 12 mutations identified, 8 were novel. Screening of the other family members available revealed that 27 had mutations; 11 of these individuals had no signs or symptoms suggestive of HCM."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18591919", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 99, 
                    "text": "Sequence analysis of myozenin 2 in 438 European patients with familial hypertrophic cardiomyopathy."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18591919", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 477, 
                    "offsetInEndSection": 548, 
                    "text": "To assess the prevalence of MYOZ2 mutations among European HCM patients"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18591919", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 625, 
                    "offsetInEndSection": 1339, 
                    "text": "Four hundred thirty-eight patients with HCM in four European cardiovascular centers were recruited. The coding region of MYOZ2 was directly sequenced in all the HCM subjects. RESULTS: Two non-synonymous polymorphisms in exon 2 (rs17851524) and exon 5 (rs7687613) of MYOZ2 were identified in eight and twenty-two patients, respectively. However, no disease-causing mutations could be identified in this large cohort of HCM patients. CONCLUSIONS: Although a large cohort of more than 400 patients with familial HCM was screened, a disease-associated mutation in MYOZ2 was not identified. When these results are combined with previous reports, it can be concluded that MYOZ2 mutations are rare causes of familial HCM."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18497553", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 304, 
                    "offsetInEndSection": 432, 
                    "text": "In this study, we aimed to investigate a possible association between mutations in the Irx4 gene and hypertrophic cardiomyopathy"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18497553", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1542, 
                    "offsetInEndSection": 1793, 
                    "text": "This is the first human study investigating the association between the Irx4 gene and HC. Polymorphism A381>G of the Irx4 gene may have a modifier effect on septal thickness, resulting in increased corrected QT dispersion and higher outflow gradients."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16313983", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 366, 
                    "offsetInEndSection": 447, 
                    "text": "We analysed the association between the nine common European haplogroups and HCM."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16313983", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 789, 
                    "offsetInEndSection": 1071, 
                    "text": "Haplogroup T, specifically defined by 13368A, was significantly involved in the risk of developing HCM in our population (p=0.007; OR=2.42; 95% CI=1.25-4.67). Our data suggest that the genetic variation at the mitochondrial genome could significantly contribute to the risk for HCM."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12404107", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1387, 
                    "offsetInEndSection": 1578, 
                    "text": "In conclusion, myosin light chain mutations are a very rare cause of HCM responsible for about 1% of cases. Mutations in MYL2 could be associated with both benign and malignant HCM phenotype."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7959583", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 185, 
                    "text": "Familial hypertrophic cardiomyopathy (FHCM) is thought to be caused by missense mutations in cardiac beta-myosin heavy chain (beta-MHC) gene in 30-40% of affected Caucasian individuals."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20044516", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1092, 
                    "offsetInEndSection": 1267, 
                    "text": "Given the well-known high frequency of this mutation in Caucasians of up to 1%, our data suggest that (W4R-MLP) might contribute significantly to human cardiovascular disease."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18505755", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 459, 
                    "offsetInEndSection": 1124, 
                    "text": "We used linkage analysis and identified a CSRP3 missense mutation in a large German family affected by HCM. We confirmed CSRP3 as an HCM disease gene. Furthermore, CSRP3 missense mutations segregating with HCM were identified in four other families. We used a newly designed monoclonal antibody to show that muscle LIM protein (MLP), the protein encoded by CSRP3, is mainly a cytosolic component of cardiomyocytes and not tightly anchored to sarcomeric structures. Our functional data from both in vitro and in vivo analyses suggest that at least one of MLP's mutated forms seems to be destabilized in the heart of HCM patients harbouring a CSRP3 missense mutation."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16716659", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 966, 
                    "offsetInEndSection": 1353, 
                    "text": "Coexistence of unexplained ventricular hypertrophy and pre-excitation should prompt the diagnosis of PRKAG2 mutations and these patients should be referred for genetic analysis. The possible alteration of AMP-activated protein kinase activity due to genetic defects in PRKAG2 may serve as a template for developing more specific therapies in the treatment of patients with this mutation."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12404107", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 947, 
                    "offsetInEndSection": 1385, 
                    "text": "Two MYL2 missense mutations were identified in two Caucasian families while no mutation was found in MYL3. The mutation Glu22Lys was associated with moderate septal hypertrophy, a late onset of clinical manifestation, and benign disease course and prognosis. The mutation Arg58Gln showed also moderate septal hypertrophy, but, in contrast, it was associated with an early onset of clinical manifestation and premature sudden cardiac death"
                }
            ], 
            "type": "list"
        }, 
        {
            "body": "How many clinical trials for off-label drugs in neonates are cited in the literature.", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D056687", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002986", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016032", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018849", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007231", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017326"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20821198"
            ], 
            "id": "5150b807d24251bc05000072", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20821198", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 459, 
                    "offsetInEndSection": 1195, 
                    "text": "Of the 17 Paediatric Investigation Plans submitted, 14 have resulted in an EMA Decision, 3 were withdrawn by the applicants, 8 were granted a full waiver from development, and 1 resulted in a negative opinion. Decisions as issued included 15 clinical trials, with at least 1,282 children to be recruited into studies across five different products. Neonates were included in four of the products. CONCLUSIONS: The small number of submissions indicates a lack of new drugs being developed for the management of pain. Ethical concerns that too many vulnerable children will be recruited into clinical trials must be balanced against limiting the number of off-label prescribing and obtaining age-appropriate information on paediatric use."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20821198", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 298, 
                    "offsetInEndSection": 449, 
                    "text": "Paediatric Investigations Plans (PIPs) submitted with a Decision (outcome) reached between September 2007 and March 2010 were included in the analysis."
                }
            ], 
            "type": "factoid"
        }, 
        {
            "body": "Which population has a high frequency of the HLA-B*1502 allele?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011153", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005787", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D044382", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005828", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D044469", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005805"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22211527", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21424386", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21306565", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21169036", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20345939", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19915237", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19694795", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18855540", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18637831", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16415921", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15057820"
            ], 
            "id": "51542e6fd24251bc05000082", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22211527", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 229, 
                    "offsetInEndSection": 438, 
                    "text": "A strong association between human leukocyte antigen (HLA)-B*1502 and CBZ-induced SJS/TEN has been reported in Han Chinese, Thai, Malaysian and Indian populations, but not in Caucasian or Japanese populations."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21424386", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 802, 
                    "offsetInEndSection": 1129, 
                    "text": "found a strong association between HLA-B*1502 and CBZ-induced SJS/TEN in the Han Chinese population from central and northern China. Combined with previous studies of the southern Han Chinese subpopulation, our results suggest that HLA-B*1502 is strongly associated with CBZ-induced SJS/TEN in the whole Han Chinese population."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21306565", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 274, 
                    "offsetInEndSection": 388, 
                    "text": "A strong association between HLA-B*1502 and carbamazepine-induced SJS/TEN has been identified in Chinese and Thai."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21169036", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 321, 
                    "offsetInEndSection": 487, 
                    "text": "In the present study, we conducted a pilot study to detect a possible association of oxcarbazepine (OXC)-induced MPE with HLA-B*1502 allele in Chinese Han population."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21169036", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1263, 
                    "offsetInEndSection": 1591, 
                    "text": "observed an increased frequency of HLA-B*1502 allele in patients (44.44%) compared with tolerant controls (11.11%), although it failed to reach statistical significance (P=0.294). CONCLUSIONS: Our findings indicate that HLA-B*1502 allele may contribute to the genetic susceptibility to OXC-induced MPE in Chinese Han population."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20345939", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 189, 
                    "offsetInEndSection": 479, 
                    "text": "A strong association between HLA-B*1502 and CBZ-induced SJS/TEN has been reported in Han Chinese but not in Caucasian and Japanese populations. A case-control study was conducted to determine whether HLA-B*1502 is a valid pharmacogenetic test for SJS/TEN caused by CBZ in a Thai population."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20345939", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1120, 
                    "offsetInEndSection": 1283, 
                    "text": "Results from this study suggest that HLA-B*1502 may be a useful pharmacogenetic test for screening Thai individuals who may be at risk for CBZ-induced SJS and TEN."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19915237", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 169, 
                    "offsetInEndSection": 414, 
                    "text": "A strong association has been reported between human leucocyte antigen (HLA)-B*1502 and carbamazepine-induced SJS in Han Chinese patients. European studies suggested that HLA-B*1502 is not a universal marker but is ethnicity-specific for Asians."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19694795", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 189, 
                    "offsetInEndSection": 308, 
                    "text": "the human leukocyte antigen HLA-B*1502 is associated with Stevens-Johnson syndrome (SJS) induced by CBZ in Han Chinese."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18855540", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 134, 
                    "offsetInEndSection": 265, 
                    "text": "the HLA allele B*1502 as a marker for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese,"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18855540", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 323, 
                    "offsetInEndSection": 525, 
                    "text": "This allele is seen in high frequency in many Asian populations other than Han Chinese, but there are few data on whether the allele is a marker for this severe outcome in anyone other than Han Chinese."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18637831", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 34, 
                    "offsetInEndSection": 186, 
                    "text": "a strong association between HLA-B*1502 and carbamazepine (CBZ)-induced Stevens-Johnson syndrome (SJS) in Han Chinese, but not in Caucasian populations."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16415921", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 234, 
                    "offsetInEndSection": 363, 
                    "text": "A very strong association of carbamazepine-induced SJS with HLA-B*1502 has recently been described in the Han Chinese population."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15057820", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 172, 
                    "offsetInEndSection": 394, 
                    "text": "there is a strong association in Han Chinese between a genetic marker, the human leukocyte antigen HLA-B*1502, and Stevens-Johnson syndrome induced by carbamazepine, a drug commonly prescribed for the treatment of seizures"
                }
            ], 
            "triples": [
                {
                    "o": "http://www.w3.org/2008/05/skos-xl#Label", 
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A18289792"
                }, 
                {
                    "o": "http://www.w3.org/2008/05/skos-xl#Label", 
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A7573122"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A7573122", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1257890"
                }, 
                {
                    "o": "Population", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A0103552"
                }, 
                {
                    "o": "http://www.w3.org/2008/05/skos-xl#Label", 
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A0103553"
                }, 
                {
                    "o": "http://www.w3.org/2008/05/skos-xl#Label", 
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A0103554"
                }, 
                {
                    "o": "POPULATIONS", 
                    "p": "http://www.w3.org/2000/01/rdf-schema#label", 
                    "s": "http://linkedlifedata.com/resource/pubmed/keyword/POPULATIONS"
                }, 
                {
                    "o": "Population", 
                    "p": "http://www.w3.org/2000/01/rdf-schema#label", 
                    "s": "http://linkedlifedata.com/resource/pubmed/mesh/Population"
                }
            ], 
            "type": "factoid"
        }, 
        {
            "body": "Is imatinib an antidepressant drug?", 
            "concepts": [
                "http://www.biosemantics.org/jochem#4275840", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007202"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22678007", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22593820", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22484890", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22460758", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22135725", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22110503", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22035758", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21938530", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21087500", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21073206", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20726677", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20676553", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20442314", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20407930", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19628568", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19110398", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18506179", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17554495", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16566359", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16403813", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15966213", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23394826", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21607924", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22831984", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22487918"
            ], 
            "id": "51542e84d24251bc05000083", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22487918", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 11, 
                    "offsetInEndSection": 325, 
                    "text": "Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract. Surgery remains the elective treatment. We retrospectively compared two group of patients, who underwent surgery for GIST before and after Imatinib advent in order to analyze the recurrence and survival rate."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22831984", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1206, 
                    "offsetInEndSection": 1368, 
                    "text": "Adjuvant imatinib 400 mg/day for 3 years duration is a standard treatment in all patients with significant risk of recurrence following resection of primary GISTs"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22831984", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1496, 
                    "offsetInEndSection": 1585, 
                    "text": "R1 surgery (versus R0) alone is not an indication for adjuvant imatinib in low-risk GIST."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22831984", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1931, 
                    "offsetInEndSection": 2005, 
                    "text": "Treatment is not recommended in an imatinib-insensitive D842V-mutated GIST"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22678007", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 310, 
                    "offsetInEndSection": 701, 
                    "text": "Prognostic factors such as tumor size, mitotic rate and presence of metastases may provide an indication for adjuvant imatinib mesylate (IM) treatment. Here we present a young patient with a large GIST with high-risk features who is in complete remission after surgical excision and adjuvant IM treatment. This patient is the only colon-located CD117-positive case where IM was administered."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22593820", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 447, 
                    "offsetInEndSection": 575, 
                    "text": "Imatinib is the first tyrosine kinase inhibitor to have achieved long term disease control in the majority of patients with CML."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22460758", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 154, 
                    "text": "Imatinib mesylate is the sole BCR-ABL tyrosine kinase inhibitor approved as first-line treatment of accelerated-phase (AP) chronic myeloid leukemia (CML)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22135725", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1596, 
                    "offsetInEndSection": 1686, 
                    "text": "imatinib mesylate could be a therapeutic target of strategies against osteosarcoma tumors."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22110503", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1224, 
                    "offsetInEndSection": 1539, 
                    "text": "Following the success of the tyrosine kinase inhibitor (TKI) imatinib in chronic myeloid leukemia (CML), research focused on targeted therapy strategies for Ph-positive ALL and other ALL subtypes [9\u201313]. Imatinib has since become part of pre- and posttransplant treatment for patients with Ph-positive ALL [13, 14]."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22035758", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 300, 
                    "text": "Allogeneic hematopoietic stem cell transplantation (HSCT) is well-established as a potentially curative treatment for patients who have chronic myeloid leukemia. The success of imatinib and other tyrosine kinase inhibitors (TKI) as initial therapy has changed the treatment paradigm for this disease."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21938530", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1089, 
                    "offsetInEndSection": 1219, 
                    "text": "Imatinib plus hydroxyurea is well tolerated among patients with meningioma but has modest anti-tumor activity for this indication."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21607924", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1272, 
                    "offsetInEndSection": 1440, 
                    "text": "Ki67 correlated with time to recurrence (p=0.022). Ki67 >11% was taken as the indication to start imatinib chemotherapy (sensitivity 61.5%, specificity 92.0%, p=0.022)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23394826", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 410, 
                    "offsetInEndSection": 554, 
                    "text": "Significant pharmacokinetic interactions have already been shown between St. John's Wort (SJW) and the anticancer drugs imatinib and irinotecan."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21087500", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1061, 
                    "offsetInEndSection": 1522, 
                    "text": "The search for a specific inhibitor of the BCR-ABL tyrosine kinase have resulted in the identification of the specific inhibitor imatinib mesylate (STI571), which has now become the standard first-line therapy in patients with CP-CML [10,11]. Imatinib, also known as Gleevec\u00ae (Novartis, Basel, Switzerland), is a selective inhibitor not only of ABL but also for Kit and PDGFR kinases and exerts significant antileukemic activity in the majority of CML patients."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21073206", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1386, 
                    "offsetInEndSection": 1440, 
                    "text": "for CML we analysed imatinib, dasatinib and nilotinib."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20726677", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 253, 
                    "text": "Imatinib mesylate, an orally administered kinase inhibitor that targets the Kit (CD117) protein, currently has 10 approved indications including treatment of chronic myelogenous leukemia and metastatic gastrointestinal stromal tumors (GIST)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20676553", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 539, 
                    "offsetInEndSection": 903, 
                    "text": "The drugs were assessed according to clinical evidence on efficacy and safety, based on Micromedex categorization, on systematic reviews and meta-analyses. Indications present in the legal documentation were compared to the indications approved by regulatory agencies. RESULTS: Bevacizumab, capecitabine, cetuximab, erlotinib, rituximab, imatinib, and temozolomide"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20442314", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 540, 
                    "offsetInEndSection": 580, 
                    "text": "Bcr-Abl, an oncogene responsible for CML"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20442314", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1442, 
                    "offsetInEndSection": 1545, 
                    "text": "Bcr-Abl-expressing cells showed resistance to death activated by spindle defects, reversed by imatinib."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20407930", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 275, 
                    "offsetInEndSection": 399, 
                    "text": "Imatinib, an oral tyrosine kinase inhibitor (TKI), is first-line treatment in patients with metastatic or unresectable GIST."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19628568", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 130, 
                    "text": "Surgical indication for metastatic gastrointestinal stromal tumor (GIST) treated with imatinib is not yet established."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19628568", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1097, 
                    "offsetInEndSection": 1285, 
                    "text": "Surgery of residual disease upon best clinical response seems associated with survival benefit compared with historical controls in similar patient collectives treated with imatinib alone."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19110398", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 11, 
                    "offsetInEndSection": 167, 
                    "text": "To explore the effect of preoperative imatinib mesylate (IM) in patients with unresectable or locally advanced primary gastrointestinal stromal tumor (GIST)"
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18506179", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 301, 
                    "offsetInEndSection": 636, 
                    "text": "In 2004, imatinib was approved for use as a first-line treatment for GIST after phase II and III clinical trials yielded overall response rates of approximately 50%, a 1-year survival rate greater than 80%, and a 2-year survival rate around 70% (Joensuu et al, 2001; Dagher et al, 2002; Demetri et al, 2002, 2005; Verweij et al, 2004)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17554495", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 725, 
                    "offsetInEndSection": 1054, 
                    "text": "The patient had been diagnosed 14 months earlier and had been submitted to surgery, followed by adjuvant radiotherapy and temozolomide-based chemotherapy. On clinical suspicion of recurrence 5 months later, magnetic resonance imaging (MRI) revealed a lesion at the site of preceded surgery, which was treated by imatinib mesylate"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16566359", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1512, 
                    "offsetInEndSection": 1678, 
                    "text": "Radical surgery remains the most effective method of GIST treatment. In inoperable/metastatic lesion the treatment of choice is tyrosinase kinase inhibitor--imatinib."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16403813", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 162, 
                    "text": "Imatinib mesylate (STI571), a specific Bcr-Abl inhibitor, has shown a potent antileukemic activity in clinical studies of chronic myeloid leukemia (CML) patients."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15966213", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 195, 
                    "text": "Imatinib, an inhibitor of the tyrosine kinase activity of c-kit, was used as an adjuvant chemotherapy in two patients who underwent curative surgery for recurrent gastrointestinal stromal tumors."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22487918", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 11, 
                    "offsetInEndSection": 325, 
                    "text": "Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract. Surgery remains the elective treatment. We retrospectively compared two group of patients, who underwent surgery for GIST before and after Imatinib advent in order to analyze the recurrence and survival rate."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22831984", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1206, 
                    "offsetInEndSection": 1369, 
                    "text": "Adjuvant imatinib 400 mg/day for 3 years duration is a standard treatment in all patients with significant risk of recurrence following resection of primary GISTs."
                }
            ], 
            "triples": [
                {
                    "o": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00619", 
                    "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/possibleDrug", 
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/724"
                }, 
                {
                    "o": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00619", 
                    "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/possibleDrug", 
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3066"
                }, 
                {
                    "o": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00619", 
                    "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/possibleDrug", 
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/541"
                }, 
                {
                    "o": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00619", 
                    "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/possibleDrug", 
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2610"
                }, 
                {
                    "o": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00619", 
                    "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/possibleDrug", 
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/513"
                }, 
                {
                    "o": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00619", 
                    "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/possibleDrug", 
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/612"
                }, 
                {
                    "o": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00619", 
                    "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/possibleDrug", 
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/441"
                }, 
                {
                    "o": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00619", 
                    "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/possibleDrug", 
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/251"
                }, 
                {
                    "o": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00619", 
                    "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/possibleDrug", 
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/795"
                }, 
                {
                    "o": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00619", 
                    "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/possibleDrug", 
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3277"
                }, 
                {
                    "o": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00619", 
                    "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/possibleDrug", 
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/782"
                }, 
                {
                    "o": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00619", 
                    "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/possibleDrug", 
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2806"
                }, 
                {
                    "o": "Imatinib", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A12798671"
                }, 
                {
                    "o": "http://www.w3.org/2008/05/skos-xl#Label", 
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A17885052"
                }, 
                {
                    "o": "IMATINIB", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A12790183"
                }, 
                {
                    "o": "MeSH", 
                    "p": "http://www.w3.org/2004/02/skos/core#note", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A1989038"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/pubmed/mesh/Anxiety", 
                    "p": "http://linkedlifedata.com/resource/relationontology/hasSideEffect", 
                    "s": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00619"
                }
            ], 
            "type": "yesno"
        }, 
        {
            "body": "What gene test is recommended for clopidogrel?", 
            "concepts": [
                "http://www.biosemantics.org/jochem#4260620", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005796", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005820", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003955"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22974536", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22674970", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22624833", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22464343", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22154242", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22088980", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21803320", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20435227", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20083681", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19706858", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18577829", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18004210", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17681590"
            ], 
            "id": "5156be04d24251bc05000085", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22674970", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 607, 
                    "offsetInEndSection": 677, 
                    "text": "polymorphisms in the CYP2C19 gene affect clopidogrel pharmacokinetics."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22624833", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 11, 
                    "offsetInEndSection": 212, 
                    "text": "This study sought to evaluate the influence of single nucleotide polymorphisms (SNPs) on the pharmacodynamic effect of high- or standard-dose clopidogrel after percutaneous coronary intervention (PCI)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22624833", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1621, 
                    "offsetInEndSection": 2056, 
                    "text": "CYP2C19, but not PON1 or ABCB1, is a significant determinant of the pharmacodynamic effects of clopidogrel, both early and late after PCI. In patients with high OTR identified by platelet function testing, the CYP2C19 genotype provides limited incremental information regarding the risk of persistently high reactivity with clopidogrel 150-mg maintenance dosing. (Genotype Information and Functional Testing Study [GIFT]; NCT00992420)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22088980", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 324, 
                    "text": "Variants in the CYP2C19 gene influence the pharmacologic and clinical response to the standard 75-mg daily maintenance dose of the antiplatelet drug clopidogrel. OBJECTIVE: To test whether higher doses (up to 300 mg daily) improve the response to clopidogrel in the setting of loss-of-function CYP2C19 genotypes."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22674970", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 607, 
                    "offsetInEndSection": 920, 
                    "text": "polymorphisms in the CYP2C19 gene affect clopidogrel pharmacokinetics. These polymorphisms may be useful to identify clopidogrel nonresponders who may benefit from taking an alternative antiplatelet agent such as prasugrel and ticagrelor. Although both drugs have pharmacogenomic tests available for clinical use,"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22624833", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 11, 
                    "offsetInEndSection": 212, 
                    "text": "This study sought to evaluate the influence of single nucleotide polymorphisms (SNPs) on the pharmacodynamic effect of high- or standard-dose clopidogrel after percutaneous coronary intervention (PCI)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22624833", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1621, 
                    "offsetInEndSection": 2056, 
                    "text": "CYP2C19, but not PON1 or ABCB1, is a significant determinant of the pharmacodynamic effects of clopidogrel, both early and late after PCI. In patients with high OTR identified by platelet function testing, the CYP2C19 genotype provides limited incremental information regarding the risk of persistently high reactivity with clopidogrel 150-mg maintenance dosing. (Genotype Information and Functional Testing Study [GIFT]; NCT00992420)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22464343", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 136, 
                    "offsetInEndSection": 497, 
                    "text": "The CYP2C19*2 allele is a common genetic variant associated with increased rates of major adverse events in individuals given clopidogrel after percutaneous coronary intervention (PCI). We used a novel point-of-care genetic test to identify carriers of the CYP2C19*2 allele and aimed to assess a pharmacogenetic approach to dual antiplatelet treatment after PCI"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22154242", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 401, 
                    "text": "The antiplatelet effect of clopidogrel has been linked to cytochrome P450 2C19 (CYP2C19) carrier status. The presence of loss of function and gain of function variants were found to have a gene-dose effect on clopidogrel metabolism. However, genotyping is only one aspect of predicting response to clopidogrel and several platelet function tests are available to measure platelet response."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22088980", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 324, 
                    "text": "Variants in the CYP2C19 gene influence the pharmacologic and clinical response to the standard 75-mg daily maintenance dose of the antiplatelet drug clopidogrel. OBJECTIVE: To test whether higher doses (up to 300 mg daily) improve the response to clopidogrel in the setting of loss-of-function CYP2C19 genotypes."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21803320", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 164, 
                    "text": "The cytochrome P450 (CYP) 2C19*2 loss-of-function allele has been associated with impaired clopidogrel response and worse prognosis in clopidogrel-treated patients."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21803320", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 357, 
                    "offsetInEndSection": 637, 
                    "text": "The present study was designed to evaluate the benefit of tailored therapy with a higher maintenance dose according to CYP2C19 genotypes in patients identified as nonresponders who underwent percutaneous coronary intervention for non-ST-segment elevation acute coronary syndromes."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20435227", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 893, 
                    "offsetInEndSection": 977, 
                    "text": "identify genes and mutations with known associations with disease and drug response."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20435227", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1654, 
                    "offsetInEndSection": 1753, 
                    "text": "The patient had a heterozygous null mutation in CYP2C19 suggesting probable clopidogrel resistance,"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20083681", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 344, 
                    "text": "The cytochrome P450 (CYP) 2C19 isoenzyme plays an important role in clopidogrel metabolization. A recently explored CYP2C19*17 allelic variant has been linked to increased transcriptional activity, resulting in extensive metabolization of CYP2C19 substrates, which may lead to an enhanced platelet response to clopidogrel treatment."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19706858", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 333, 
                    "offsetInEndSection": 395, 
                    "text": "To identify gene variants that influence clopidogrel response."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19706858", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 608, 
                    "offsetInEndSection": 973, 
                    "text": "A genome-wide association study was performed followed by genotyping the loss-of-function cytochrome P450 (CYP) 2C19*2 variant (rs4244285). Findings in the PAPI Study were extended by examining the relation of CYP2C19*2 genotype to platelet function and cardiovascular outcomes in an independent sample of 227 patients undergoing percutaneous coronary intervention."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18577829", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 116, 
                    "text": "Coexisting polymorphisms of the genes affecting clopiogrel resistance may influence platelet activation."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18577829", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 439, 
                    "offsetInEndSection": 754, 
                    "text": "Genotyping revealed 7 carriers of both the C allele of P2Y12 and A allele of CYP2C19 (group 1), 14 carriers of the T allele of P2Y12 and A allele of CYP2C19 (group 2), 17 carriers of the C allele of P2Y12 and G allele of CYP2C19 (group 3) and 67 carriers of the T allele of P2Y12 and G allele of CYP2C19 (controls)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18004210", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 37, 
                    "offsetInEndSection": 285, 
                    "text": "to evaluate the effect of polymorphisms affecting the clopidogrel metabolism (CYP3A4 IVS10+12G/A and CYP2C19*2) and the P2Y12 receptor (P2Y12 T744C) on modulating platelet function in acute coronary syndrome patients on dual antiplatelet treatment."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17681590", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 260, 
                    "offsetInEndSection": 337, 
                    "text": "to test the influence of the CYP 2C19*2 allele on clopidogrel responsiveness."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22674970", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 84, 
                    "text": "Genetic polymorphisms significantly influence responses to warfarin and clopidogrel."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22974536", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 286, 
                    "text": "A recent clinical trial has demonstrated that patients with acute coronary syndromes (ACS) and the reduced function allele CYP2C19*2 (*2 allele), who are treated with thienopyridines, have an increased risk of adverse cardiac events with clopidogrel, but not with prasugrel."
                }
            ], 
            "triples": [
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A0173515", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C0070166"
                }, 
                {
                    "o": "clopidogrel", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A0173515"
                }, 
                {
                    "o": "http://www.w3.org/2008/05/skos-xl#Label", 
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A12101557"
                }, 
                {
                    "o": "Clopidogrel", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A12785306"
                }, 
                {
                    "o": "MeSH", 
                    "p": "http://www.w3.org/2004/02/skos/core#note", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A0173516"
                }, 
                {
                    "o": "http://www.w3.org/2008/05/skos-xl#Label", 
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A10928568"
                }
            ], 
            "type": "factoid"
        }, 
        {
            "body": "What disease is mirtazapine predominantly used for?", 
            "concepts": [
                "http://www.biosemantics.org/jochem#4191931", 
                "http://www.biosemantics.org/jochem#4134182", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007202"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21810886", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21071407", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19034656", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19016570", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17440145", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19412502", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16280409", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15520364", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15052512", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12908614", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21810375", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23018612"
            ], 
            "id": "5156be17d24251bc05000086", 
            "snippets": [
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21810886", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 4461, 
                    "offsetInEndSection": 5111, 
                    "text": "The 10 most commonly prescribed antidepressant drugs (citalopram hydrobromide (selective serotonin reuptake inhibitor), fluoxetine hydrochloride (selective serotonin reuptake inhibitor), amitriptyline hydrochloride (tricyclic antidepressant), dosulepin hydrochloride (tricyclic antidepressant), paroxetine hydrochloride (selective serotonin reuptake inhibitor), venlafaxine hydrochloride (other), sertraline hydrochloride (selective serotonin reuptake inhibitor), mirtazapine (other), lofepramine (tricyclic antidepressant), and escitalopram (selective serotonin reuptake inhibitor)) comprised 93.6% (n=1\u2009309\u2009056) of all antidepressant prescriptions."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19034656", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1475, 
                    "offsetInEndSection": 1565, 
                    "text": "mirtazapine will make it the first-choice drug in depressive patients with gastric ulcers."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19016570", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1695, 
                    "offsetInEndSection": 2460, 
                    "text": "If antidepressants are used to treat insomnia, sedating ones should be preferred over activating agents such as serotonin reuptake inhibitors. In general, drugs lacking strong cholinergic activity should be preferred. Drugs blocking serotonin 5-HT2A or 5-HT2C receptors should be preferred over those whose sedative property is caused by histamine receptor blockade only. The dose should be as low as possible (e.g. as an initial dose: doxepin 25 mg, mirtazapine 15 mg, trazodone 50 mg, trimipramine 25 mg). Regarding the lack of substantial data allowing for evidence-based recommendations, we are facing a clear need for well designed, long-term, comparative studies to further define the role of antidepressants versus other agents in the management of insomnia."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17440145", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 770, 
                    "offsetInEndSection": 970, 
                    "text": "second-generation antidepressants (selective serotonin reuptake inhibitors, nefazodone, venlafaxine, and mirtazapine) in participants younger than 19 years with MDD, OCD, or non-OCD anxiety disorders."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15520364", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 731, 
                    "offsetInEndSection": 897, 
                    "text": "patients 65 years or older with major depression. METHODS: Antidepressant therapy with 15 to 45 mg/d of mirtazapine (n = 124) or 20 to 40 mg/d of paroxetine (n = 122)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16280409", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 521, 
                    "offsetInEndSection": 710, 
                    "text": "A case report involving linezolid with citalopram and mirtazepine in the precipitation of serotonin syndrome in a critically ill bone marrow transplant patient is described in this article."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21810375", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2266, 
                    "offsetInEndSection": 2885, 
                    "text": "other antidepressants was associated with the highest HRs for all-cause mortality (1.66, 95% CI 1.56 to 1.77), attempted suicide/self-harm (5.16, 95% CI 3.90 to 6.83), stroke/TIA (1.37, 95% CI 1.22 to 1.55), fracture (1.63, 95% CI 1.45 to 1.83) and epilepsy/seizures (2.24, 95% CI 1.60 to 3.15) compared with when antidepressants were not being used. TCAs did not have the highest HR for any of the outcomes. There were also significantly different associations between the individual drugs for seven outcomes, with trazodone, mirtazapine and venlafaxine associated with the highest rates for several of these outcomes."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23018612", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2237, 
                    "offsetInEndSection": 2569, 
                    "text": "But when trazodone, amitriptyline or mirtazapine were used to treat depression, respectively, 92.3, 55.5 and 44.5 % of prescribed dosages were below the MED. In the indication of insomnia, most of the time, trazodone (90.5 %) or mirtazapine (5.4 %) were used, and in lower dosages than those required for depression treatment (<MED)"
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21071407", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 1599, 
                    "offsetInEndSection": 1687, 
                    "text": "Mirtazapine is an antidepressant for which 184 side-effects are detailed in PROMISCUOUS."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15052512", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 997, 
                    "offsetInEndSection": 1089, 
                    "text": "Mirtazapine was the most common AD in 2001, followed by citalopram, sertraline, and doxepin."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12908614", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 350, 
                    "offsetInEndSection": 391, 
                    "text": "antidepressant treatment with mirtazapine"
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19412502", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 14548, 
                    "offsetInEndSection": 15093, 
                    "text": "Other dual-acting compoundsMirtazapineMirtazapine acts primarily as a \u03b12-adrenergic receptor antagonist and as such has indirect effects on both serotonergic and noradrenergic neurotransmission (Szegedi and Schwertfeger 2005). It is thus considered to be a dual acting antidepressant albeit by a mechanism different from the SNRIs. In 26 patients with FMS who completed a 6-week open study with mirtazapine, 10 (38%) responded with a reduction of at least 40% of the initial levels of pain, fatigue and sleep disturbances (Samborski et al 2004)."
                }
            ], 
            "triples": [
                {
                    "o": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00370", 
                    "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/possibleDrug", 
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/852"
                }, 
                {
                    "o": "http://www.w3.org/2008/05/skos-xl#Label", 
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A11577558"
                }, 
                {
                    "o": "mirtazapine", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A0600233"
                }, 
                {
                    "o": "http://www.w3.org/2008/05/skos-xl#Label", 
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A18168147"
                }, 
                {
                    "o": "http://www.w3.org/2008/05/skos-xl#Label", 
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A17928971"
                }, 
                {
                    "o": "Mirtazapine", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A11898470"
                }, 
                {
                    "o": "mirtazapine", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A17977028"
                }, 
                {
                    "o": "mirtazapine", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A11575491"
                }
            ], 
            "type": "factoid"
        }, 
        {
            "body": "Which diseases is microRNA 132 (miR-132) implicated in?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004194", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002908", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D030342", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005128", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007905", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D010300", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000544", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006816", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020734"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23560086", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23485811", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23269581", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23001356", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22659469", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22518321", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22315408", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21807765", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21035445", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20949564", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21136867", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17314675"
            ], 
            "id": "5156be75d24251bc05000088", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23560086", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 302, 
                    "text": "Chronic lymphocytic leukemia (CLL) is a disease with variable clinical outcome. Several prognostic factors such as the immunoglobulin heavy chain variable genes (IGHV) mutation status are linked to the B-cell receptor (BCR) complex, supporting a role for triggering the BCR in vivo in the pathogenesis."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23560086", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 502, 
                    "offsetInEndSection": 967, 
                    "text": "miRNA and mRNA expression was measured using hybridization arrays and qPCR. We found both IGHV mutated and unmutated CLL cells to respond with increased expression of MYC and other genes associated with BCR activation, and a phenotype of cell cycle progression. Genome-wide expression studies showed hsa-miR-132-3p/hsa-miR-212 miRNA cluster induction associated with a set of downregulated genes, enriched for genes modulated by BCR activation and amplified by Myc."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23269581", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 588, 
                    "offsetInEndSection": 901, 
                    "text": "Levels of six candidate miRNAs (miR-21, miR-199a-3p, miR-143, miR-34, miR-140, and miR-132) that were previously demonstrated to be regulated in osteosarcoma were examined in plasma of 40 osteosarcoma patients and 40 matched healthy controls by quantitative reverse-transcription polymerase chain reaction assays."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23001356", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 204, 
                    "text": "Early stages of many neurodegenerative diseases, such as Alzheimer's disease, vascular and frontotemporal dementia, and Parkinson's disease, are frequently associated with Mild Cognitive Impairment (MCI)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23485811", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1538, 
                    "offsetInEndSection": 2044, 
                    "text": "Functional studies employing antagomirs have identified contributions from miR-34a and miR-132 to seizure-induced neuronal death whereas silencing miR-134 potently reduced status epilepticus, seizure-damage and the later occurrence of spontaneous seizures. Efforts to identify the in vivo target(s) of epilepsy-regulated miRNAs, is now a priority. Last, miRNA are stable, information-carrying (paracrine) signals. Profiling miRNA in biofluids may represent a novel source of disease biomarkers in epilepsy."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23485811", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1172, 
                    "offsetInEndSection": 1265, 
                    "text": "Inflammation, stress signalling and neuronal excitation are among the pathways most impacted."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23001356", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1040, 
                    "offsetInEndSection": 1321, 
                    "text": "sensitivity and specificity at 79%-100% (miR-132 family) and 79%-95% (miR-134 family), and p\u30080.001. In a separate longitudinal study, the identified miRNA biomarker pairs successfully detected MCI in majority of patients at asymptomatic stage 1-5 years prior to clinical diagnosis."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22659469", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 119, 
                    "offsetInEndSection": 469, 
                    "text": "Herpes simplex virus (HSV) causes a chronic immuno-inflammatory response in the eye that may result in corneal neovascularization during blinding immunopathological lesion stromal keratitis (SK). miR-132 is a highly conserved miRNA that is induced in endothelial cells in response to growth factors, such as vascular endothelial growth factor (VEGF)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22659469", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 498, 
                    "offsetInEndSection": 647, 
                    "text": "miR-132 expression was up-regulated (10- to 20-fold) after ocular infection with HSV, an event that involved the production of both VEGF-A and IL-17."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22659469", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1091, 
                    "offsetInEndSection": 1526, 
                    "text": "The anti-angiogenic effect of antagomir-132 was reflected by a reduction in angiogenic Ras activity in corneal CD31-enriched cells (presumably blood vessel endothelial cells) during SK. To our knowledge, this is one of the first reports of miRNA involvement in an infectious ocular disease. Manipulating miRNA expression holds promise as a therapeutic approach to control an ocular lesion that is an important cause of human blindness."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22659469", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 81, 
                    "text": "Role of miR-132 in angiogenesis"
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22518321", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 40, 
                    "offsetInEndSection": 264, 
                    "text": "Alcoholic Liver Disease (ALD)Alcoholic liver disease (ALD) is a global health-related problem, which contributes significantly to liver-related mortality. Increased inflammation and fat accumulation are the hallmarks of ALD."
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22518321", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 7672, 
                    "offsetInEndSection": 8001, 
                    "text": "MiR-132 was shown to play a role in neuroinflammation [39] and also regulates innate antiviral immunity, where it targets the p300 transcriptional coactivator [40]. However, the role of miR-132 in the alcohol-mediated TLR response is yet to be elucidated; therefore, in this study, we determined the effect of alcohol on miR-132."
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22518321", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 8216, 
                    "offsetInEndSection": 8328, 
                    "text": "Among the miRNAs tested, we found significant induction of miR-132 in the livers of alcohol-fed mice (Figure 1)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22315408", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 459, 
                    "offsetInEndSection": 818, 
                    "text": "The cyclic AMP-responsive element binding- and NMDA-regulated microRNA miR-132 was significantly down-regulated in both the schizophrenic discovery cohort and a second, independent set of schizophrenic subjects. Analysis of miR-132 target gene expression in schizophrenia gene-expression microarrays identified 26 genes up-regulated in schizophrenia subjects."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22315408", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1545, 
                    "offsetInEndSection": 1740, 
                    "text": "Our data suggest miR-132 dysregulation and subsequent abnormal expression of miR-132 target genes contribute to the neurodevelopmental and neuromorphological pathologies present in schizophrenia."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21807765", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 768, 
                    "offsetInEndSection": 1630, 
                    "text": "Analysis of miRNA expression profiles from sporadic progressive supranuclear palsy (PSP) patients, a major 4R-tau tauopathy, showed that miR-132 is specifically down-regulated in disease. We demonstrate that miR-132 directly targets the neuronal splicing factor polypyrimidine tract-binding protein 2 (PTBP2), which protein levels were increased in PSP patients. miR-132 overexpression or PTBP2 knockdown similarly affected endogenous 4R:3R-tau ratios in neuronal cells. Finally, we provide evidence that miR-132 is inversely correlated with PTBP2 during post-natal brain development at the time when 4R-tau becomes expressed. Taken together, these results suggest that changes in the miR-132/PTBP2 pathway could contribute to the abnormal splicing of tau exon 10 in the brain, and sheds light into the potential role played by miRNAs in a subset of tauopathies."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21035445", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 227, 
                    "text": "Huntington's disease (HD) is a genetic neurodegenerative disease caused by abnormal CAG expansion. MicroRNAs (miRNAs) are short RNA molecules regulating gene expression, and are implicated in a variety of diseases including HD."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21035445", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1117, 
                    "offsetInEndSection": 1302, 
                    "text": "Nine miRNAs (miR-22, miR-29c, miR-128, miR-132, miR-138, miR-218, miR-222, miR-344, and miR-674*) were commonly down-regulated in both the 12-month-old YAC128 and 10-week-old R6/2 mice."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20949564", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 103, 
                    "offsetInEndSection": 236, 
                    "text": "Osteosarcoma is the first primary malignant bone tumor, characterized by a complex genetic and resistance to conventional treatments."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20949564", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1014, 
                    "offsetInEndSection": 1306, 
                    "text": "Osteosarcoma of rat and human origins showed a miRNA signature, which could discriminate good from bad responders. In particular, we identified five discriminating miRNAs (miR-92a, miR-99b, miR-132, miR-193a-5p and miR-422a) in patient tumors, which could be easily transferable to diagnosis."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21136867", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1097, 
                    "offsetInEndSection": 1576, 
                    "text": "Levels of several microRNA (miR-10a, -10b, -212, -132, -495) were significantly altered. One of them (miR-132) has been reported to be highly inducible by growth factors and to be a key regulator of neurite outgrowth. Moreover, miR-132-recognition sequences were detected in the mRNA transcripts of two differentially expressed proteins. MicroRNA may thus represent novel biomarkers for neuronal malfunction and potential therapeutic targets for human neurodegenerative diseases."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17314675", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 407, 
                    "offsetInEndSection": 889, 
                    "text": "The data indicate that micro-RNAs encoding miR-9, miR-124a, miR-125b, miR-128, miR-132 and miR-219 are abundantly represented in fetal hippocampus, are differentially regulated in aged brain, and an alteration in specific micro-RNA complexity occurs in Alzheimer hippocampus. These data are consistent with the idea that altered micro-RNA-mediated processing of messenger RNA populations may contribute to atypical mRNA abundance and neural dysfunction in Alzheimer's disease brain."
                }
            ], 
            "triples": [
                {
                    "o": "http://www.w3.org/2008/05/skos-xl#Label", 
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A18453276"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A0015570", 
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C0012634"
                }, 
                {
                    "o": "MeSH", 
                    "p": "http://www.w3.org/2004/02/skos/core#note", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A0015570"
                }, 
                {
                    "o": "http://www.w3.org/2008/05/skos-xl#Label", 
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A17694181"
                }, 
                {
                    "o": "http://www.w3.org/2008/05/skos-xl#Label", 
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A7568412"
                }
            ], 
            "type": "list"
        }, 
        {
            "body": "Is TREM2 associated with Alzheimer's disease in humans?", 
            "concepts": [
                "http://www.uniprot.org/uniprot/TREM2_HUMAN", 
                "http://www.disease-ontology.org/api/metadata/DOID:10652", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000544"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23462268", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23407992", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23391427", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23380991", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23150934", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23150908", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17088018"
            ], 
            "id": "51588c34d24251bc05000095", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23462268", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 331, 
                    "text": "Genetic deficits and loss of function for the triggering receptor expressed in myeloid cells 2 (TREM2; encoded at chr6p21.1), a transmembrane spanning stimulatory receptor of the immunoglobulin/lectin-like gene superfamily, have been associated with deficiencies in phagocytosis and the innate immune system in Alzheimer's disease."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23407992", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 216, 
                    "text": "Recent works have demonstrated a rare functional variant (R47H) in triggering receptor expressed on myeloid cells (TREM) 2 gene, encoding TREM2 protein, increase susceptibility to late-onset Alzheimer's disease (AD),"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23407992", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 588, 
                    "offsetInEndSection": 637, 
                    "text": "possible involvement of TREM2 in AD pathogenesis."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23391427", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 79, 
                    "text": "TREM2 is associated with the risk of Alzheimer's disease in Spanish population."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23391427", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 126, 
                    "text": "Two recent studies have reported the association of rs75932628-T in the TREM2 gene with the risk for Alzheimer's disease (AD)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23391427", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 902, 
                    "offsetInEndSection": 1044, 
                    "text": "we report the first positive replication study in a Spanish population and confirm that TREM2 rs75932628-T is associated with the risk for AD."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23380991", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 99, 
                    "offsetInEndSection": 198, 
                    "text": "(TREM2) has recently been identified as a rare risk factor for late-onset Alzheimer's disease (AD)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23380991", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 199, 
                    "offsetInEndSection": 409, 
                    "text": "In this study we examined the association between TREM2 exon 2 variants and early-onset AD in a sample of Caucasian subjects of French origin including 726 patients with age of onset \u226465 years and 783 controls."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23150934", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 947, 
                    "offsetInEndSection": 1077, 
                    "text": "We found significantly more variants in exon 2 of TREM2 in patients with Alzheimer's disease than in controls in the discovery set"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23150934", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1210, 
                    "offsetInEndSection": 1349, 
                    "text": "The most commonly associated variant, rs75932628 (encoding R47H), showed highly significant association with Alzheimer's disease (P<0.001)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23150908", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1542, 
                    "offsetInEndSection": 1780, 
                    "text": "Our findings strongly implicate variant TREM2 in the pathogenesis of Alzheimer's disease. Given the reported antiinflammatory role of TREM2 in the brain, the R47H substitution may lead to an increased predisposition to Alzheimer's disease"
                }
            ], 
            "triples": [
                {
                    "o": "http://purl.uniprot.org/core/Gene", 
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
                    "s": "http://linkedlifedata.com/resource/#_45325250343700D"
                }
            ], 
            "type": "yesno"
        }, 
        {
            "body": "Is cocaine use associated with increased risk for intracerebral hemorrhage?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002543", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003042", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019970", 
                "http://www.disease-ontology.org/api/metadata/DOID:809", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016578", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020300", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013345"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20645024", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20456585", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20444626", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20185779", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12764233", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11456006", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9122836", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8754572", 
                "http://www.ncbi.nlm.nih.gov/pubmed/7482637", 
                "http://www.ncbi.nlm.nih.gov/pubmed/7774897", 
                "http://www.ncbi.nlm.nih.gov/pubmed/2742464", 
                "http://www.ncbi.nlm.nih.gov/pubmed/2492650", 
                "http://www.ncbi.nlm.nih.gov/pubmed/2909100"
            ], 
            "id": "5159b990d24251bc050000a3", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20645024", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 71, 
                    "text": "Stroke in crack-cocaine abusers is increasingly recognized."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20645024", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 533, 
                    "offsetInEndSection": 1137, 
                    "text": "There were significant differences between crack-cocaine cases and controls in age (48.7 years vs. 55 years) (P = 0.0001), male gender (65.6% vs. 40.9%) (odds ratios, OR = 1.64, 95% CI 1.22-2.21), arterial hypertension (61.1% vs. 83.9%) (OR = 0.30, 95% CI 0.15-0.60), hypercholesterolemia (18.7% vs. 68.5%) (OR = 0.10, 95% CI 0.05-0.21), diabetes (20.9% vs. 41.9%) (OR = 0.36, 95% CI 0.19-0.70), cigarette smoking (70.6% vs. 29%) (OR = 5.86, 95% CI 3.07-11.20), ischemic stroke (61.3% vs. 79.6%) (OR = 0.40, 95% CI 0.21-0.78), and intracerebral hemorrhage (33.3% vs. 17.2%) (OR = 3.03, 95% CI 1.53-6.00)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20456585", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 93, 
                    "text": "Intracerebral hemorrhage (ICH) is a well-recognized complication of recreational cocaine use."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20444626", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1616, 
                    "offsetInEndSection": 1718, 
                    "text": "ICH is more common in those currently using cocaine perhaps because of acute spikes in blood pressure."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20185779", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 42, 
                    "text": "Intracerebral hemorrhage in cocaine users."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20185779", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 11, 
                    "offsetInEndSection": 196, 
                    "text": "Cocaine is a cause of intracerebral hemorrhage (ICH), but there are no large studies that have characterized the location, pathology, and outcome of patients with cocaine-associated ICH"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12764233", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1542, 
                    "offsetInEndSection": 1772, 
                    "text": "Aneurysmal SAH may be largely a preventable disease among the young and middle-aged because several prevalent risk factors can be modified by medication (eg, hypertension) or behavioral change (eg, cigarette smoking, cocaine use)."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11456006", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 108, 
                    "text": "Cocaine use and hypertension are major risk factors for intracerebral hemorrhage in young African Americans."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11456006", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 851, 
                    "offsetInEndSection": 1026, 
                    "text": "Cocaine use (OR 6.1, 95% CI 3.3-11.8), hypertension (OR 5.2, 95% CI 3.2-8.7) and alcohol use (OR 1.9, 95% CI 1.1-3.3) were independently associated with increased risk for ICH"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9122836", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 138, 
                    "text": "Cocaine use has been temporally associated with neurovascular complications, including the rupture of intracerebral aneurysms."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9122836", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1892, 
                    "offsetInEndSection": 2076, 
                    "text": "Chronic cocaine use appears to predispose patients who harbor incidental neurovascular anomalies to present at an earlier point in their natural history than similar non-cocaine users."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8754572", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 168, 
                    "text": "Acute intoxication with either cocaine or methamphetamine may contribute to formation and rupture of a berry aneurysm by causing transient hypertension and tachycardia."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8754572", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1096, 
                    "offsetInEndSection": 1364, 
                    "text": "Although the exact mechanism by which berry aneurysms form remains undetermined, research indicates that propagation and rupture of the aneurysm are aggravated by hypertension and tachycardia, both of which are pharmacologic side effects of cocaine and methamphetamine"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7482637", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1101, 
                    "offsetInEndSection": 1336, 
                    "text": "The high frequency of hypertension, hypertensive intracerebral hemorrhage, and lacunar infarction among young black patients with stroke suggests accelerated hypertensive arteriolar damage, possibly due to poor control of hypertension."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7774897", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 118, 
                    "text": "Cocaine induced intracerebral hemorrhage: analysis of predisposing factors and mechanisms causing hemorrhagic strokes."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7774897", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 195, 
                    "offsetInEndSection": 427, 
                    "text": "hypertensive cardiovascular disease (HCVD) was significantly higher in persons with intracerebral hemorrhage than in those with aneurysm rupture. Our findings suggest that HCVD predisposes to cocaine induced intracerebral hemorrhage"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2742464", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 55, 
                    "text": "Intracerebral hemorrhage associated with cocaine abuse."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2742464", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 383, 
                    "offsetInEndSection": 527, 
                    "text": "n view of the present epidemic of cocaine abuse, cocaine toxicity should be considered in the differential diagnosis of intracerebral hemorrhage"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2492650", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 205, 
                    "text": "An increase in cocaine abuse by pregnant women has been associated with a range of maternal/fetal cardiovascular complications. Intracerebral hemorrhage has been reported as a cocaine-related complication,"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2909100", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 50, 
                    "offsetInEndSection": 348, 
                    "text": "13 patients were identified with neurologic deficits attributable to the use of cocaine. Ischemic manifestations were the most frequent, occurring in seven (54%) patients, with a mean age of 34.2 years. Three (23%) patients had subarachnoid hemorrhage, and three (23%) had intracerebral hemorrhage."
                }
            ], 
            "type": "yesno"
        }, 
        {
            "body": "How does exercise affect thyroid hormone receptors expression in the heart?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011988", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0004887", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0010861", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D037021", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D037042", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0046966", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013963", 
                "http://www.uniprot.org/uniprot/THB_CAIMO", 
                "http://www.uniprot.org/uniprot/THB_HUMAN", 
                "http://www.uniprot.org/uniprot/THB_PAROL", 
                "http://www.uniprot.org/uniprot/THB_MOUSE", 
                "http://www.uniprot.org/uniprot/THB_DANRE", 
                "http://www.uniprot.org/uniprot/THB_RAT", 
                "http://www.uniprot.org/uniprot/THA_PIG", 
                "http://www.uniprot.org/uniprot/THA_CAIMO", 
                "http://www.uniprot.org/uniprot/THB_CHICK", 
                "http://www.uniprot.org/uniprot/THBA_XENLA", 
                "http://www.uniprot.org/uniprot/THB_LITCT", 
                "http://www.uniprot.org/uniprot/THB_SHEEP", 
                "http://www.uniprot.org/uniprot/THA_MOUSE", 
                "http://www.uniprot.org/uniprot/THA_SALSA", 
                "http://www.uniprot.org/uniprot/THA_HIPHI", 
                "http://www.uniprot.org/uniprot/THAA_DANRE", 
                "http://www.uniprot.org/uniprot/THAA_PAROL", 
                "http://www.uniprot.org/uniprot/THA_APTPA", 
                "http://www.uniprot.org/uniprot/THAA_XENLA", 
                "http://www.uniprot.org/uniprot/THA_LITCT", 
                "http://www.uniprot.org/uniprot/THA_SPAAU", 
                "http://www.uniprot.org/uniprot/THA_HUMAN", 
                "http://www.uniprot.org/uniprot/THA_SHEEP", 
                "http://www.uniprot.org/uniprot/THA_CHICK", 
                "http://www.uniprot.org/uniprot/THA_PYGAD", 
                "http://www.uniprot.org/uniprot/THA_ELECQ", 
                "http://www.uniprot.org/uniprot/THA_ONCMY", 
                "http://www.uniprot.org/uniprot/THA_NECMA", 
                "http://www.uniprot.org/uniprot/THA_RAT", 
                "http://www.uniprot.org/uniprot/THBB_XENLA", 
                "http://www.uniprot.org/uniprot/THAB_XENLA", 
                "http://www.uniprot.org/uniprot/THAB_PAROL", 
                "http://www.uniprot.org/uniprot/TR150_RAT", 
                "http://www.uniprot.org/uniprot/TR150_MOUSE", 
                "http://www.uniprot.org/uniprot/TR150_HUMAN", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0030375"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21625820", 
                "http://www.ncbi.nlm.nih.gov/pubmed/14704232", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11577024"
            ], 
            "id": "5159cc88d24251bc050000a4", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21625820", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1107, 
                    "offsetInEndSection": 1162, 
                    "text": "Exercise increased the TR\u03b21 receptor, L-channel and NCX"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14704232", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 878, 
                    "offsetInEndSection": 1093, 
                    "text": "Expression of TR-alpha1 and TR-beta1 proteins in the heart were significantly lower in sedentary aged rats than in sedentary young rats and were significantly higher in trained aged rats than in sedentary aged rats."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11577024", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 903, 
                    "offsetInEndSection": 1040, 
                    "text": "Myocyte TRbeta1 was upregulated in models with a hyperthyroid-like phenotype, TH (triiodothyronine, T3), in culture and exercise in vivo."
                }
            ], 
            "type": "summary"
        }, 
        {
            "body": "Does thyroid hormone regulate calcium transient in the myocardium? ", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013963", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0070327", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0070324", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011988", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0004887", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0010861", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D037021", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D037042", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014284", 
                "http://www.uniprot.org/uniprot/THB_RAT", 
                "http://www.uniprot.org/uniprot/THB_DANRE", 
                "http://www.uniprot.org/uniprot/THB_MOUSE", 
                "http://www.uniprot.org/uniprot/THB_HUMAN", 
                "http://www.uniprot.org/uniprot/THB_PAROL", 
                "http://www.uniprot.org/uniprot/THB_SHEEP", 
                "http://www.uniprot.org/uniprot/THB_CAIMO", 
                "http://www.uniprot.org/uniprot/THB_CHICK", 
                "http://www.uniprot.org/uniprot/THA_MOUSE", 
                "http://www.uniprot.org/uniprot/THA_APTPA", 
                "http://www.uniprot.org/uniprot/THAA_DANRE", 
                "http://www.uniprot.org/uniprot/THAA_PAROL", 
                "http://www.uniprot.org/uniprot/THA_ONCMY", 
                "http://www.uniprot.org/uniprot/THA_HUMAN", 
                "http://www.uniprot.org/uniprot/THA_LITCT", 
                "http://www.uniprot.org/uniprot/THA_SPAAU", 
                "http://www.uniprot.org/uniprot/THB_LITCT", 
                "http://www.uniprot.org/uniprot/THBA_XENLA", 
                "http://www.uniprot.org/uniprot/THA_CHICK", 
                "http://www.uniprot.org/uniprot/THA_ELECQ", 
                "http://www.uniprot.org/uniprot/THAA_XENLA", 
                "http://www.uniprot.org/uniprot/THA_CAIMO", 
                "http://www.uniprot.org/uniprot/THA_NECMA", 
                "http://www.uniprot.org/uniprot/THA_PIG", 
                "http://www.uniprot.org/uniprot/THA_RAT", 
                "http://www.uniprot.org/uniprot/THA_SALSA", 
                "http://www.uniprot.org/uniprot/THA_HIPHI", 
                "http://www.uniprot.org/uniprot/THA_PYGAD"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19298522", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9875761", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9773867", 
                "http://www.ncbi.nlm.nih.gov/pubmed/2428004"
            ], 
            "id": "515ac533d24251bc050000a9", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19298522", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 249, 
                    "text": "3-iodothyronamine (T(1)AM) is a novel endogenous relative of thyroid hormone, able to interact with trace amine-associated receptors, a class of plasma membrane G protein-coupled receptors, and to produce a negative inotropic and chronotropic effect"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19298522", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 455, 
                    "offsetInEndSection": 580, 
                    "text": "In adult rat cardiomyocytes acute exposure to 20 microM T(1)AM decreased the amplitude and duration of the calcium transient."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9875761", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1520, 
                    "offsetInEndSection": 1869, 
                    "text": "In normal porcine myocardium T3 had no effect on the extent of isometric force generation but accelerated the time course of force development (p < 0.05) and increased the calcium transient (p < 0.001). After induction of myocardial depression by epinephrine exposure T3 accelerated the intracellular calcium transients and reduced diastolic calcium"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9773867", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2162, 
                    "offsetInEndSection": 2428, 
                    "text": "The experimental data showing increased force amplitudes at unaltered amplitudes of the intracellular calcium transient and an even-reduced calcium time integral provide strong evidence for a sensitization of the contractile apparatus for calcium by triiodothyronine"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2428004", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1313, 
                    "offsetInEndSection": 1525, 
                    "text": "hese results indicate that the thyroid state influences the time course of the calcium transient and are consistent with the abbreviation in the duration of contraction that is observed in the hyperthyroid state."
                }
            ], 
            "type": "yesno"
        }, 
        {
            "body": "Is Rheumatoid Arthritis related to myopathy?", 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23171360", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19642078", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17296665", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15909088", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12682624", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12652413", 
                "http://www.ncbi.nlm.nih.gov/pubmed/10555889"
            ], 
            "id": "515ae990d24251bc050000ad", 
            "snippets": [
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23171360", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 87, 
                    "text": "Minocycline-associated rimmed vacuolar myopathy in a patient with rheumatoid arthritis"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19642078", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 88, 
                    "text": "Prevalence of risk factors for statin-induced myopathy in rheumatoid arthritis patients"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17296665", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 353, 
                    "offsetInEndSection": 475, 
                    "text": "we describe a patient with rheumatoid arthritis and respiratory failure associated with proximal myopathy secondary to HCQ"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15909088", 
                    "endSection": "title", 
                    "offsetInBeginSection": 1, 
                    "offsetInEndSection": 111, 
                    "text": "Occurrence of chloroquine-induced myopathy after low-dose treatment of rheumatoid arthritis for seven years"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12652413", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 488, 
                    "offsetInEndSection": 720, 
                    "text": "a 75 year old female with rheumatoid arthritis treated with daily doses of 250 mg of chloroquine for four years. The patient visited because of several months history of predominantly proximal progressive tetraparesis with areflexia"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10555889", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 99, 
                    "text": "Myopathy and neuropathy in rheumatoid arthritis"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10555889", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 48, 
                    "offsetInEndSection": 153, 
                    "text": "with rheumatoid arthritis (RA) have clinical or subclinical evidence of peripheral neuropathy or myopathy"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10555889", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1321, 
                    "offsetInEndSection": 1444, 
                    "text": "The study reveals an increased prevalence of neurogenic but not myogenic changes in patients with RA compared with controls"
                }
            ], 
            "type": "yesno"
        }, 
        {
            "body": "Which genes does thyroid hormone receptor alpha1 regulate in the heart?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011988", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0004887", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0010861", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0046966", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D037021", 
                "http://www.uniprot.org/uniprot/THA_PYGAD", 
                "http://www.uniprot.org/uniprot/THA_NECMA", 
                "http://www.uniprot.org/uniprot/THA_LITCT", 
                "http://www.uniprot.org/uniprot/THAA_XENLA", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013963"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23532677", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20228172", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19832729", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19629520", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19171649", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18622044", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17317766", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16155104", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15831522", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15808842", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15687816", 
                "http://www.ncbi.nlm.nih.gov/pubmed/14704232", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11577024"
            ], 
            "id": "515c4f05298dcd4e51000006", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23532677", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 547, 
                    "offsetInEndSection": 643, 
                    "text": "A group of mice was treated with debutyl-dronedarone (DBD), a selective TR\u03b11 inhibitor (AMI-DBD)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23532677", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1223, 
                    "offsetInEndSection": 1435, 
                    "text": "Furthermore, AMI resulted in \u03b2-myosin heavy chain overexpression and reduction in the ratio of SR(Ca)ATPase to phospholamban (PLB). The latter further declined in AMI-DBD mainly due to increased expression of PLB"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20228172", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 501, 
                    "offsetInEndSection": 774, 
                    "text": "We identified that mice expressing the mutant TRalpha1R384C (TRalpha1+m mice) displayed a mild bradycardia, which becomes more pronounced during night activity or on stress and is accompanied by a reduced expression of nucleotide-gated potassium channel 2 mRNA in the heart"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19832729", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 794, 
                    "offsetInEndSection": 863, 
                    "text": "KCNE1 was four to 10-fold overexpressed in mice deficient in TRalpha1"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19832729", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1361, 
                    "offsetInEndSection": 1542, 
                    "text": "The bradycardia and prolonged QT(end) time in hypothyroid states can be explained by altered K(+) channel function due to decreased TRalpha1-dependent repression of KCNE1 expression"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19629520", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 965, 
                    "offsetInEndSection": 1107, 
                    "text": "Consistently, TR alpha 1-infected myocytes exhibited larger I(f) current densities along with increased HCN2 and HCN4 mRNA and protein levels."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19171649", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 530, 
                    "offsetInEndSection": 649, 
                    "text": "T3 stimulation enhanced KCND2 and KCND3 expression and decreased KCNA4 transcription, while KCNIP2 remained unaffected."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19171649", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 824, 
                    "offsetInEndSection": 1010, 
                    "text": "TRalpha1 increased I(to), while TRbeta1 significantly reduced I(to) in size, which was associated with TRalpha1-mediated increase and TRbeta1-mediated reduction of KCND2/3 transcription."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19171649", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1280, 
                    "offsetInEndSection": 1474, 
                    "text": "While the TRalpha1 aporeceptor enhanced KCND3 transcription, the TRbeta1 aporeceptor suppressed KCND3 expression, with both effects exhibiting ligand-dependent amplification upon T3 stimulation."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18622044", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 791, 
                    "offsetInEndSection": 1097, 
                    "text": "PE, in the absence of T3, resulted in 5.0 fold increase in TRalpha1 expression in nucleus and 2.0 fold decrease in TRalpha1 expression in cytosol, P<0.05. As a result, a fetal pattern of myosin isoform expression with marked expression of beta-MHC was observed in PE treated vs the untreated cells, P<0.05."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16155104", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1597, 
                    "offsetInEndSection": 2002, 
                    "text": "PKC alpha overexpression in cardiomyocytes caused marked repression of triiodothyronine (T3)-responsive genes, alpha-myosin heavy chain, and the sarcoplasmic reticulum calcium-activated adenosinetriphosphatase SERCA2. Treatment with T3 for 4 h resulted in significant reductions of PKC alpha in nuclear and cytosolic compartments, and decreased TR alpha1 mRNA and protein, with normalization of phenotype."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15831522", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 444, 
                    "offsetInEndSection": 618, 
                    "text": "The mechanism of TH and TRalpha1-specific hypertrophy is novel for a nuclear hormone receptor and involves the transforming growth factor beta-activated kinase (TAK1) and p38"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15808842", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1301, 
                    "offsetInEndSection": 1383, 
                    "text": "Excised TRalpha(1)+/m hearts showed an increased expression of phospholamban (PLB)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15687816", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 112, 
                    "offsetInEndSection": 290, 
                    "text": "administration of dronedarone, an amiodarone-like compound that has been shown to preferentially antagonize thyroid hormone binding to thyroid hormone receptor alpha1 (TRalpha1),"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15687816", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 776, 
                    "offsetInEndSection": 976, 
                    "text": "lpha-Myosin heavy chain (alpha-MHC) decreased in DRON while beta-myosin heavy chain (beta-MHC) and sarcoplasmic reticulum Ca2+ adenosine triphosphatase (ATPase) expression (SERCA) was similar to CONT."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14704232", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1094, 
                    "offsetInEndSection": 1424, 
                    "text": "The activity of TR DNA binding to the transcriptional regulatory region in the alpha-MHC and SR Ca(2+)-ATPase genes and the mRNA and protein expression of alpha-MHC and SR Ca(2+)-ATPase in the heart and plasma 3,3'-triiodothyronine and thyroxine levels were altered in association with changes in the myocardial TR protein levels."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11577024", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1173, 
                    "offsetInEndSection": 1441, 
                    "text": "addition, TR cotransfection and treatment with the TRbeta1-selective agonist GC-1 suggested different functional coupling of the TR isoforms, TRbeta1 to transcription of beta-MyHC, SERCA, and TRbeta1, and TRalpha1 to alpha-MyHC transcription and increased myocyte size"
                }
            ], 
            "type": "list"
        }, 
        {
            "body": "Which genes does thyroid hormone receptor beta1 regulate in the heart?", 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21149577", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19629520", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19171649", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17317766", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11577024", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9927321"
            ], 
            "id": "515c4f1f298dcd4e51000007", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21149577", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 959, 
                    "offsetInEndSection": 1079, 
                    "text": "we identified thyroid hormone receptor \u03b21 (TR\u03b21), which negatively regulates \u03b2-MHC transcription, as a target of miR-27a"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19629520", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1121, 
                    "offsetInEndSection": 1239, 
                    "text": "HCN2 gene expression was not significantly affected by TR beta 1. TR beta 1 exclusively suppressed HCN4 transcription."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19171649", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 824, 
                    "offsetInEndSection": 1010, 
                    "text": "TRalpha1 increased I(to), while TRbeta1 significantly reduced I(to) in size, which was associated with TRalpha1-mediated increase and TRbeta1-mediated reduction of KCND2/3 transcription."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19171649", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1342, 
                    "offsetInEndSection": 1392, 
                    "text": "he TRbeta1 aporeceptor suppressed KCND3 expression"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17317766", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1651, 
                    "offsetInEndSection": 1792, 
                    "text": "increasing TR expression in the hypertrophied heart is associated with an improvement in contractile function and increased SERCA expression."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11577024", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1315, 
                    "offsetInEndSection": 1373, 
                    "text": "TRbeta1 to transcription of beta-MyHC, SERCA, and TRbeta1,"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9927321", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 75, 
                    "offsetInEndSection": 288, 
                    "text": "Our study investigates both the regulation of cardiac-specific genes and contractile behavior of the heart in the presence of a mutant thyroid hormone receptor beta1 (T3Rbeta1-delta337T) derived from the S kindred"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9927321", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 698, 
                    "offsetInEndSection": 939, 
                    "text": "The messenger RNA levels for MHC alpha and SERCA2 were markedly down-regulated, MHC beta messenger RNA was up-regulated. Although T3 levels were normal in these animals, this pattern of cardiac gene expression mimics a hypothyroid phenotype."
                }
            ], 
            "type": "list"
        }, 
        {
            "body": "Which cellular processes are regulated by Nanog?", 
            "concepts": [
                "http://www.uniprot.org/uniprot/NANOG_MOUSE", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0065007"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22934707", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22493428", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22421047", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22378194", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22315219", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20962578", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20581802", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20578184", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19544407", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19415763", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19139263", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16518401", 
                "http://www.ncbi.nlm.nih.gov/pubmed/14728807"
            ], 
            "id": "515d1ff7298dcd4e51000009", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22934707", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 487, 
                    "offsetInEndSection": 536, 
                    "text": "critical for the regulation of cancer stem cells."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22493428", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1525, 
                    "offsetInEndSection": 1665, 
                    "text": "the effect of FAK and Nanog cross-regulation on cancer cell morphology, invasion, and growth that plays a significant role in carcinogenesis"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22421047", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 72, 
                    "text": "Nanog-like regulates endoderm formation"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22421047", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 88, 
                    "text": "In mammalian embryonic stem cells, the acquisition of pluripotency is dependent on Nanog"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22421047", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 241, 
                    "offsetInEndSection": 338, 
                    "text": "we identified a zebrafish Nanog ortholog and found that its\u00a0knockdown impaired endoderm formation"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22421047", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 925, 
                    "offsetInEndSection": 1047, 
                    "text": "establishes a role for Nanog-like in regulating the formation of the extraembryonic tissue required for endoderm induction"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22378194", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 150, 
                    "text": "Nanog regulates molecules involved in stemness and cell cycle-signaling pathway for maintenance of pluripotency"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22378194", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 44, 
                    "offsetInEndSection": 170, 
                    "text": "Nanog, a key transcription factor in the maintenance of pluripotency of embryonic stem (ES) and embryonal carcinoma (EC) cells"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22315219", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 947, 
                    "offsetInEndSection": 1015, 
                    "text": "Nanog, a positive regulator of ESC proliferation and G1/S transition"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20962578", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 100, 
                    "text": "Nanog is a stem cell transcription factor required for self-renewal and for maintaining pluripotency"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20581802", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 114, 
                    "text": "NANOG regulates glioma stem cells"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20581802", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 519, 
                    "offsetInEndSection": 626, 
                    "text": "We find that NANOG modulates gliomasphere clonogenicity, CD133(+) stem cell cell behavior and proliferation"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20581802", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 789, 
                    "offsetInEndSection": 831, 
                    "text": "NANOG is essential for GBM tumourigenicity"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20578184", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 62, 
                    "text": "Nanog regulates primordial germ cell migration"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20578184", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1274, 
                    "offsetInEndSection": 1334, 
                    "text": "Nanog mediates PGC migration by regulating Cxcr4b expression"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19544407", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 60, 
                    "text": "Nanog regulates proliferation during early fish development."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19544407", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 693, 
                    "offsetInEndSection": 777, 
                    "text": "Nanog is necessary for S-phase transition and proliferation in the developing embryo"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19415763", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1137, 
                    "offsetInEndSection": 1293, 
                    "text": "our results demonstrate that NANOG, a cell-fate regulatory molecule known to be important for ESC self-renewal, also plays a novel role in tumor development"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19415763", 
                    "endSection": "title", 
                    "offsetInBeginSection": 25, 
                    "offsetInEndSection": 112, 
                    "text": "the self-renewal gene NANOG regulates human tumor development"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19139263", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 111, 
                    "text": "A role for NANOG in G1 to S transition in human embryonic stem cells"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19139263", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1145, 
                    "offsetInEndSection": 1241, 
                    "text": "Elevated expression of Nanog has also been reported to result in clonal expansion of murine ESCs"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19139263", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1746, 
                    "offsetInEndSection": 1951, 
                    "text": "Not surprisingly, transfection of OCT4, SOX2, NANOG, and LIN28 in human fibroblasts induces pluripotency, suggesting an important role for each of these factors in reprogramming the genome of somatic cells"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19139263", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2744, 
                    "offsetInEndSection": 2837, 
                    "text": "NANOG is able to enhance hESC proliferation while still maintaining the pluripotent phenotype"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16518401", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 936, 
                    "offsetInEndSection": 1134, 
                    "text": "The emerging picture is one in which Oct4 and Nanog control a cascade of pathways that are intricately connected to govern pluripotency, self-renewal, genome surveillance and cell fate determination"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14728807", 
                    "endSection": "title", 
                    "offsetInBeginSection": 58, 
                    "offsetInEndSection": 157, 
                    "text": "the pluripotency sustaining factor nanog"
                }
            ], 
            "type": "list"
        }, 
        {
            "body": "What is known about Vancomycin dosing in neonates?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014640", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007231", 
                "http://www.biosemantics.org/jochem#4272290", 
                "http://www.biosemantics.org/jochem#4272288", 
                "http://www.biosemantics.org/jochem#4022642", 
                "http://www.biosemantics.org/jochem#4145076", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007234"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22892931", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22488303", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21862473", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21455009", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21378399", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11378679", 
                "http://www.ncbi.nlm.nih.gov/pubmed/10801244", 
                "http://www.ncbi.nlm.nih.gov/pubmed/10103340", 
                "http://www.ncbi.nlm.nih.gov/pubmed/2630235", 
                "http://www.ncbi.nlm.nih.gov/pubmed/3991250"
            ], 
            "id": "515d71ee298dcd4e5100000b", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22892931", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 643, 
                    "offsetInEndSection": 819, 
                    "text": "Vancomycin is active against gram-positive bacteria. Staphylococcus epidermis, including methicillin-resistant strains, are inhibited by vancomycin concentrations of 1-4 \u00b5g/ml."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22892931", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 820, 
                    "offsetInEndSection": 1062, 
                    "text": "Staphylococcus pyogenes, Streptococcus pneumonia, and Streptococcus viridans are susceptible to 2 \u00b5g/ml vancomycin. Bacillus spp. are inhibited by 2 \u00b5g/ml, Corynebacterium spp. by 0.04-3.1 \u00b5g/ml and Clostridium spp. by 0.39-6 \u00b5g/ml vancomycin"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22892931", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1068, 
                    "offsetInEndSection": 1565, 
                    "text": "Peak and trough concentrations of vancomycin should be <40 \u03bcg/ml and <10 \u03bcg/ml, respectively, to both be effective and avoid oto- or nephrotoxicity in adults (6,7,8). Because vancomycin activity is primarily time-dependent, the 24-h area under the curve (AUC0-24h) divided by the minimum inhibitor concentration (MIC) value (AUC0-24h/MIC) is a better predictor of efficacy. In adults with MIC values less than 1 \u03bcg/ml, trough concentrations greater than 10 \u00b5g/ml result in AUC0-24h/MIC values >400"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22892931", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1566, 
                    "offsetInEndSection": 2131, 
                    "text": "In subsequent analyses addressing clinical pharmacology, it is important to note that vancomycin is water-soluble, has a limited plasma protein binding capacity (i.e., IgA and albumin) and is mainly eliminated renally by glomerular filtration, although its elimination is further modulated by renal tubular transport (4). Compared with adults, neonates have a higher extracellular fluid volume and a limited renal elimination capacity (4,9). Consequently, vancomycin pharmacokinetics are different in neonates and undergo significant alterations as neonates mature."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22488303", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2117, 
                    "offsetInEndSection": 2534, 
                    "text": "Monte Carlo simulations based on our population pharmacokinetic model suggest that vancomycin dosing guidelines based on serum creatinine concentration have a greater likelihood of achieving trough concentrations in the 5-15-mg/L range compared with other evaluated dosing regimens. None of the four dosing regimens is suitable to produce target trough concentration of 15-20 mg/L in an acceptable number of patients."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21862473", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 827, 
                    "offsetInEndSection": 1039, 
                    "text": "There is significant variation in gentamicin and vancomycin dosing regimens and TDM guidance across a UK network of neonatal units. The development of standardized, evidence-based protocols should be prioritized."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21455009", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1323, 
                    "offsetInEndSection": 1380, 
                    "text": "Vancomycin, by contrast, was associated with ototoxicity."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21378399", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 85, 
                    "text": "There is no consensus on vancomycin dosing in newborns and young infants."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21378399", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1244, 
                    "offsetInEndSection": 1391, 
                    "text": "The modified regimen for a target vancomycin concentration of 25 mg/l consisted of a bolus of 20 mg/kg followed by continuous infusion of 30 mg/kg."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11378679", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1767, 
                    "offsetInEndSection": 1857, 
                    "text": "There is no ideal pattern of vancomycin dosing; vancomycin dosages must be individualized."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11378679", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1598, 
                    "offsetInEndSection": 1775, 
                    "text": "Recommended vancomycin schedules for term newborn infants with neonatal sepsis should be based on the weight and postconceptual age only to start antimicrobial therapy. There is"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10801244", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 927, 
                    "offsetInEndSection": 1879, 
                    "text": "Targets were a trough concentration between 5 and 15 mg/L and a peak below 40 mg/L. In the prospective study, the optimal scheme was tested in 22 patients. RESULTS: Of the 108 patients, 34.3% of measured trough concentrations and 17.6% of peak concentrations were outside the desired therapeutic range. The model that best fitted the data included clearance and volume per kilogram and was independent of gestational age. Simulation of various dosing schemes showed that a dosing schedule of 30 mg/kg/day, irrespective of gestational age, in three doses was optimal, and this scheme was prospectively tested. Mean trough concentrations before the second dose were 8.2 +/- 2.2 mg/L versus a predicted trough of 8.9 +/- 2.5 mg/L. No peak levels higher than 40 mg/L were found. CONCLUSIONS: The use of the proposed schedule leads to adequate vancomycin trough serum concentrations, and there is no need for routine monitoring of peak serum concentrations."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10103340", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2578, 
                    "offsetInEndSection": 2686, 
                    "text": "Vancomycin-associated nephrotoxicity is rare in neonates, even with serum peak concentrations >40 microg/mL."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3991250", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 68, 
                    "offsetInEndSection": 760, 
                    "text": "Infants weighing less than 1,000 gm had significantly larger volumes of drug distribution and consequently longer drug half-lives than larger premature infants, regardless of postconceptual or actual age. These differences alter the vancomycin dosing recommendations in these two groups of premature infants. We recommend initial dosage regimens consisting of a loading dose of vancomycin of 25 mg/kg followed by doses of 15 mg/kg every 12 hours for infants with weights less than 1,000 gm. Infants weighing over 1,000 gm should receive 10 mg/kg every 12 hours, with a loading dose of 12.5 mg/kg. Serum vancomycin concentration should be monitored, however, for final optimization of therapy."
                }
            ], 
            "type": "summary"
        }, 
        {
            "body": "Is Propofol used for short-term sedation?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015742", 
                "http://www.biosemantics.org/jochem#4277106", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016292"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22577917", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21257635", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19589243", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19448211", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19189080", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19046459", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16741692", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15960715", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15959548", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15891317", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15774043", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12500519", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12392590", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11575340", 
                "http://www.ncbi.nlm.nih.gov/pubmed/10853884", 
                "http://www.ncbi.nlm.nih.gov/pubmed/10757567", 
                "http://www.ncbi.nlm.nih.gov/pubmed/10502909", 
                "http://www.ncbi.nlm.nih.gov/pubmed/10150552", 
                "http://www.ncbi.nlm.nih.gov/pubmed/1636917", 
                "http://www.ncbi.nlm.nih.gov/pubmed/2212256"
            ], 
            "id": "515d9a42298dcd4e5100000d", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22577917", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 144, 
                    "offsetInEndSection": 263, 
                    "text": "The current study explores the incidence and content of dreaming during short-term sedation with sevoflurane or propofo"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21257635", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1060, 
                    "offsetInEndSection": 1241, 
                    "text": "Propofol is the sedative most frequently used for short-term sedation and the weaning phase, whereas benzodiazepines are the preferred substances for medium- and long-term sedation."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19589243", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 155, 
                    "text": "Performance of the A-line Autoregressive Index (AAI) and of the Bispectral Index (BIS) at assessing depth of short-term sedation following cardiac surgery."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19589243", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 275, 
                    "offsetInEndSection": 352, 
                    "text": "All patients received sedation with propofol according to the study protocol."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19448211", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1881, 
                    "offsetInEndSection": 2004, 
                    "text": "Short-term sedation with either sevoflurane using ACD or propofol did not negatively affect renal function postoperatively."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19189080", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 11, 
                    "offsetInEndSection": 197, 
                    "text": "Assessing feasibility and physiological effects of sedation with sevoflurane, administered with the anesthetic conserving device (AnaConDa), in comparison with propofol and remifentanil."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19189080", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 964, 
                    "offsetInEndSection": 1086, 
                    "text": "Sevoflurane can be effectively and safely used for short-term sedation of ICU patients with stable hemodynamic conditions."
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19046459", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 4468, 
                    "offsetInEndSection": 4591, 
                    "text": "Propofol is the most frequently used sedating agent for patients with expected duration of ICU admission less than 24 hours"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16741692", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 754, 
                    "offsetInEndSection": 855, 
                    "text": "Propofol was used for most of the patients during short-term sedation (57%) and during weaning (48%)."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15960715", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 104, 
                    "text": "Effects of short-term propofol administration on pancreatic enzymes and triglyceride levels in children."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15960715", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 208, 
                    "text": "This prospective, clinical trial evaluated the effects of short-term propofol administration on triglyceride levels and serum pancreatic enzymes in children undergoing sedation for magnetic resonance imaging."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15959548", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 103, 
                    "text": "Dexmedetomidine vs. propofol for short-term sedation of postoperative mechanically ventilated patients."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15959548", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 76, 
                    "offsetInEndSection": 299, 
                    "text": "The aim of this study was to compare the efficacy and endocrine response of propofol vs. the new alpha2-agonist dexmedetomidine for sedation in surgical intensive care patients who need postoperative short-term ventilation."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15891317", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 504, 
                    "offsetInEndSection": 685, 
                    "text": "A total of 89 adult, nonemergent, coronary artery bypass graft patients with an expected length of intubation of <24 hrs. METHODS: Patients were randomized to either DEX or propofol"
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15774043", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 1603, 
                    "offsetInEndSection": 1749, 
                    "text": "Sedative agentsFor sedation up to 24 hours, propofol was used significantly more often (81%) as a continuous agent than midazolam (45%, P < 0.05)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12500519", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 499, 
                    "offsetInEndSection": 661, 
                    "text": "The majority of practitioners (82%) use propofol infusion in children in PICU, the main indication being for short-term sedation in children requiring procedures."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12392590", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 117, 
                    "text": "Pharmacokinetics and effects of propofol 6% for short-term sedation in paediatric patients following cardiac surgery."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12392590", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 11, 
                    "offsetInEndSection": 119, 
                    "text": "This paper describes the pharmacokinetics and effects of propofol in short-term sedated paediatric patients."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11575340", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 194, 
                    "offsetInEndSection": 418, 
                    "text": "Twenty patients who were expected to require 8 h of post-operative sedation and ventilation were allocated randomly to receive either an infusion of dexmedetomidine 0.2-2.5 microg kg(-1) h(-1) or propofol 1-3 mg kg(-1) h(-1)"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10853884", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 163, 
                    "text": "Pharmacokinetics and pharmacodynamics of propofol 6% SAZN versus propofol 1% SAZN and Diprivan-10 for short-term sedation following coronary artery bypass surgery."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10853884", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 217, 
                    "offsetInEndSection": 723, 
                    "text": "The pharmacokinetics, pharmacodynamics and safety characteristics of propofol 6% SAZN were investigated during a short-term infusion and compared with the commercially available product propofol 1% in Intralipid 10% (Diprivan-10) and propofol 1% in Lipofundin MCT/LCT 10% (propofol 1% SAZN). METHODS: In a randomised double-blind study, 24 male patients received a 5-h infusion of propofol at the rate of 1 mg/kg/h for sedation in the immediate postoperative period following coronary artery bypass surgery"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10757567", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1210, 
                    "offsetInEndSection": 1702, 
                    "text": "Propofol infusion and oxycodone-thiopental bolus dosages, titrated to the same sedation end point, resulted in similar time from admission to extubation, although the weaning period was shorter in the propofol group. In terms of breathing pattern, gas exchange, blood gases and haemodynamics, the methods were similar. Propofol, despite its attractive pharmacological profile, may offer no clinical benefit in short-term sedation after a moderate dose fentanyl anaesthesia in cardiac surgery."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10502909", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 67, 
                    "text": "Postoperative short-term sedation with propofol in cardiac surgery."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10502909", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 173, 
                    "text": "We conducted a randomized double-blind study to assess the safety and effectiveness of short-term sedation with propofol in adult patients immediately after cardiac surgery."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10150552", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 828, 
                    "offsetInEndSection": 1049, 
                    "text": "The use of propofol for short-term sedation in ICUs has allowed the maintenance of sedation to continue until just a few hours before extubation but the benefits of propofol for longer-term indications are more debatable."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1636917", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 363, 
                    "offsetInEndSection": 470, 
                    "text": "Midazolam and propofol are available as hypnotics for short-term sedation during the post-operative period."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2212256", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 103, 
                    "text": "The use of midazolam versus propofol for short-term sedation following coronary artery bypass grafting."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2212256", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 186, 
                    "text": "Midazolam and propofol were compared in an open randomized study for postoperative sedation during 12 h of mechanical ventilation in 40 patients following coronary artery bypass grafting"
                }
            ], 
            "type": "yesno"
        }, 
        {
            "body": "Are there randomised controlled trials on sevoflurane?", 
            "concepts": [
                "http://www.biosemantics.org/jochem#4252326"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23452265", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22577917", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22103571", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21733178", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21675061", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20683334", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16867087", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15310345", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12693995", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11966554"
            ], 
            "id": "515d9e5c298dcd4e5100000e", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23452265", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 459, 
                    "offsetInEndSection": 641, 
                    "text": "After Ethics Review Board approval, 44 ASA I-III patients undergoing elective gynaecological surgery were randomised after surgery to either hypercapnic hyperpnoea or control groups."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23452265", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1471, 
                    "offsetInEndSection": 1617, 
                    "text": "Hypercapnic hyperpnoea in spontaneously breathing patients halves the time of recovery from sevoflurane-induced anaesthesia in the operating room."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22577917", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 329, 
                    "offsetInEndSection": 569, 
                    "text": "A total of 200 women undergoing first trimester abortion (American Society of Anesthesiologists physical status I) participated in the study. Patients were randomly assigned to receive either sevoflurane or propofol for short-term sedation."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22577917", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 650, 
                    "offsetInEndSection": 841, 
                    "text": "The results showed the incidence of dreaming was significantly different between anaesthesia groups with 60% (60/100) of the sevoflurane group and 33% (33/100) of the propofol group (P=0.000)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22577917", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1269, 
                    "offsetInEndSection": 1569, 
                    "text": "Anaesthesia administered had no effect on patient satisfaction. The results suggest that the incidence of dreaming was not affected by recovery time. Patient satisfaction was not influenced by choice of sedative and/or by the occurrence of dreaming during sevoflurane or propofol short-term sedation."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22577917", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 142, 
                    "text": "Prior reports suggest that dreaming during anaesthesia is dependent on recovery time. Dreaming during sedation may impact patient satisfaction"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22103571", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 105, 
                    "text": "Sevoflurane vs. propofol in patients with coronary disease undergoing mitral surgery: a randomised study."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22103571", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 197, 
                    "offsetInEndSection": 373, 
                    "text": "We therefore performed a randomised controlled trial (sevoflurane vs. propofol) to compare cardiac troponin release in patients with coronary disease undergoing mitral surgery."
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21733178", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 7, 
                    "offsetInEndSection": 297, 
                    "text": "The PINOCCHIO study is a multicentre, double-blind, phase II, prospective, randomized, controlled clinical trial, designed to evaluate postoperative delirium rate after general anaesthesia with various hypnotics in patients undergoing surgical procedures other than cardiac or brain surgery"
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21733178", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 542, 
                    "offsetInEndSection": 800, 
                    "text": "After obtaining institutional board approval (IRB), each centre will recruit and randomly assign (with a computerized randomization procedure) patients to one of three treatment arms to receive desflurane, sevoflurane or propofol for anaesthesia maintenance."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21675061", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 147, 
                    "text": "Myocardial injury in remifentanil-based anaesthesia for off-pump coronary artery bypass surgery: an equipotent dose of sevoflurane versus propofol"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21675061", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 340, 
                    "text": "This randomised controlled trial compared the effect of equipotent anaesthetic doses of sevoflurane (S group) versus propofol (P group), during remifentanil-based anaesthesia for off-pump coronary artery bypass surgery, on myocardial injury. Either sevoflurane or propofol was titrated to maintain bispectral index values between 40 and 50."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20683334", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 365, 
                    "offsetInEndSection": 545, 
                    "text": "This randomised, multicentre, parallel-group trial included 98 adult patients. Patients received intravenous propofol for induction followed by sevoflurane maintenance anaesthesia."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20683334", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 654, 
                    "offsetInEndSection": 747, 
                    "text": "Patients were randomly allocated to receive sugammadex 2.0 mg kg(-1) or neostigmine 50 microg"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16867087", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 269, 
                    "text": "We compared the haemodynamics, emergence and recovery characteristics of total intravenous anaesthesia using propofol/remifentanil with sevoflurane/remifentanil anaesthesia, under bispectral index guidance, in 103 patients undergoing surgical procedures lasting > 3.5 h"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15310345", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 177, 
                    "text": "A randomised controlled trial of paediatric conscious sedation for dental treatment using intravenous midazolam combined with inhaled nitrous oxide or nitrous oxide/sevoflurane"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15310345", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1403, 
                    "offsetInEndSection": 1643, 
                    "text": "Intravenous midazolam, especially in combination with inhaled nitrous oxide or sevoflurane and nitrous oxide, are effective techniques, with the combination of midazolam and sevoflurane the one most likely to result in successful treatment."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12693995", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 114, 
                    "offsetInEndSection": 244, 
                    "text": "We randomly assigned 1063 adult and 322 paediatric elective patients to one of four (adult) or two (paediatric) anaesthesia groups"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12693995", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 842, 
                    "offsetInEndSection": 1174, 
                    "text": "In both studies, there was no difference in postdischarge outcomes at Day 7. Sevoflurane/sevoflurane was more costly with higher PONV rates in both studies. In adults, the cost per extra episode of PONV avoided was pound 296 (propofol/propofol vs. propofol/ sevoflurane) and pound 333 (propofol/sevoflurane vs. propofol/isoflurane)."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11966554", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 178, 
                    "text": "Comparison of sevoflurane and nitrous oxide mixture with nitrous oxide alone for inhalation conscious sedation in children having dental treatment: a randomised controlled trial."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11966554", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 215, 
                    "text": "We studied 411 children aged 3-10 years who were referred for dental treatment. They were randomly allocated to have inhalation conscious sedation with either sevoflurane/nitrous oxide mixture or nitrous oxide alone"
                }
            ], 
            "type": "yesno"
        }, 
        {
            "body": "What is the catalytic mechanism of DNA (cytosine-5) methyltransferases? ", 
            "concepts": [
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0009008", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0003886", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004248", 
                "http://www.uniprot.org/uniprot/DCM_ECOLI"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/3558369", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18567810", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12787669", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11087417", 
                "http://www.ncbi.nlm.nih.gov/pubmed/7473738", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23528166", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16606828", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16472822", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8441637"
            ], 
            "id": "515da5b5298dcd4e5100000f", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8441637", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 223, 
                    "text": "All DNA (cytosine-5)-methyltransferases contain a single conserved cysteine. It has been proposed that this cysteine initiates catalysis by attacking the C6 of cytosine and thereby activating the normally inert C5 position."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3558369", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 58, 
                    "text": "Kinetic and catalytic mechanism of HhaI methyltransferase."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3558369", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 383, 
                    "text": "Kinetic and catalytic properties of the DNA (cytosine-5)-methyltransferase HhaI are described. With poly(dG-dC) as substrate, the reaction proceeds by an equilibrium (or processive) ordered Bi-Bi mechanism in which DNA binds to the enzyme first, followed by S-adenosylmethionine (AdoMet). After methyl transfer, S-adenosylhomocysteine (AdoHcy) dissociates followed by methylated DNA."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3558369", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1062, 
                    "offsetInEndSection": 1268, 
                    "text": "Our studies reveal that the catalytic mechanism of DNA (cytosine-5)-methyltransferases involves attack of the C6 of substrate cytosines by an enzyme nucleophile and formation of a transient covalent adduct."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12787669", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 174, 
                    "text": "Catalytic mechanism of DNA-(cytosine-C5)-methyltransferases revisited: covalent intermediate formation is not essential for methyl group transfer by the murine Dnmt3a enzyme."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12787669", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1116, 
                    "offsetInEndSection": 1348, 
                    "text": "We propose that correct positioning of the flipped base and the cofactor and binding to the transition state of methyl group transfer are the most important roles of the Dnmt3a enzyme in the catalytic cycle of methyl group transfer."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12787669", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 367, 
                    "text": "Co-transfections of reporter plasmids and plasmids encoding the catalytic domain of the murine Dnmt3a DNA methyltransferase lead to inhibition of reporter gene expression. As Dnmt3a mutants with C-->A and E-->A exchanges in the conserved PCQ and ENV motifs in the catalytic center of the enzyme also cause repression, we checked for their catalytic activity in vitro."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12787669", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 536, 
                    "offsetInEndSection": 730, 
                    "text": "In contrast, enzyme variants carrying E-->A, E-->D or E-->Q exchanges of the ENV glutamate are catalytically almost inactive, demonstrating that this residue has a central function in catalysis."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12787669", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1024, 
                    "offsetInEndSection": 1348, 
                    "text": "Therefore, covalent complex formation is not essential in the reaction mechanism of Dnmt3a. We propose that correct positioning of the flipped base and the cofactor and binding to the transition state of methyl group transfer are the most important roles of the Dnmt3a enzyme in the catalytic cycle of methyl group transfer."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11087417", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1331, 
                    "offsetInEndSection": 1482, 
                    "text": "Our results point to a possible connection between the catalytic mechanism of C5 Mtases and of enzymes that transfer methyl groups to N(4) of cytosine."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7473738", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 230, 
                    "text": "Previous X-ray crystallographic studies have revealed that the catalytic domain of a DNA methyltransferase (Mtase) generating C5-methylcytosine bears a striking structural similarity to that of a Mtase generating N6-methyladenine."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23528166", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 985, 
                    "offsetInEndSection": 1228, 
                    "text": "Spontaneous and reversible proton transfer between a conserved Glu in the active site and cytosine N3 at the transition state was observed in our simulations, revealing the chemical participation of this Glu residue in the catalytic mechanism."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16606828", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 301, 
                    "text": "The mechanism of DNA cytosine-5-methylation catalyzed by the bacterial M.HhaI enzyme has been considered as a stepwise nucleophilic addition of Cys-81-S- to cytosine C6 followed by C5 nucleophilic replacement of the methyl of S-adenosyl-L-methionine to produce 5-methyl-6-Cys-81-S-5,6-dihydrocytosine."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16606828", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 797, 
                    "offsetInEndSection": 893, 
                    "text": "Hydroxide at 10(-7) mole fraction (pH = 7) is shown to be sufficient for the required catalysis."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16472822", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 234, 
                    "text": "On the basis of amino acid sequence alignments and structural data of related enzymes, we have performed a mutational analysis of 14 amino acid residues in the catalytic domain of the murine Dnmt3a DNA-(cytosine C5)-methyltransferase."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16472822", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 616, 
                    "offsetInEndSection": 938, 
                    "text": "We demonstrate that Phe50 (motif I) and Glu74 (motif II) are important for AdoMet binding and catalysis. D96A (motif III) showed reduced AdoMet binding but increased activity under conditions of saturation with S-adenosyl-L-methionine (AdoMet), indicating that the contact of Asp96 to AdoMet is not required for catalysis."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16472822", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1077, 
                    "offsetInEndSection": 1268, 
                    "text": "R130A displayed a strong reduction in catalytic activity and a complete change in flanking sequence preferences, indicating that Arg130 has an important role in the DNA interaction of Dnmt3a."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16472822", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1546, 
                    "offsetInEndSection": 1840, 
                    "text": "While Asn167 might contribute to the positioning of residues from motif VI, according to structural data Arg202 has a role in catalysis of cytosine-C5 methyltransferases. The R295A variant was catalytically inactive most likely because of destabilization of the hinge sub-domain of the protein."
                }
            ], 
            "triples": [
                {
                    "o": "Cytosine-C5 specific DNA methyltransferase", 
                    "p": "http://purl.uniprot.org/core/fullName", 
                    "s": "http://linkedlifedata.com/resource/#_413849585033007"
                }
            ], 
            "type": "summary"
        }, 
        {
            "body": "What is the treatment of neuropathic pain in children?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013812", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D010146", 
                "http://www.disease-ontology.org/api/metadata/DOID:0060164"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22735246", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22401313", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22147611", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21332246", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18820538", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18363625", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15265351", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12712053", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11902308", 
                "http://www.ncbi.nlm.nih.gov/pubmed/7561230"
            ], 
            "id": "515da6e2298dcd4e51000010", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22735246", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 336, 
                    "text": "Oxcarbazepine, a metabolite of carbamazepine, is used as an antiepileptic, analgesic for neuropathic pain and in the treatment of affective disorders. It has been approved by the Food and Drug Administration for partial seizures in adults as both adjunctive and monotherapy, and as adjunctive therapy in children aged from 2 to 16 years"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22401313", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 100, 
                    "text": "For difficult to treat neuropathic pain from cancer, adjuvant analgesics are often used with opioids"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22401313", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 448, 
                    "offsetInEndSection": 593, 
                    "text": "Ketamine and lidocaine can be safely infused together with concomitant opioids for the treatment of refractory neuropathic pain caused by cancer."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22147611", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1245, 
                    "offsetInEndSection": 1417, 
                    "text": "Patient-controlled analgesia with morphine as continuous subcutaneous or intravenous infusions and the possibility of a bolus injection is suited for children aged 6 years."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22147611", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1773, 
                    "offsetInEndSection": 1881, 
                    "text": "In neuropathic pain or phantom pain coanalgetics should be used to effectively treat pain in young patients."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21332246", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 236, 
                    "text": "Pregabalin is one of the first drugs registered for the treatment of neuropathic pain. It is also indicated as adjuvant therapy in the treatment of epilepsy and for generalized anxiety disorder. Pregabalin is a GABA analogue"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18820538", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 694, 
                    "offsetInEndSection": 1166, 
                    "text": "Treatment was typically initiated with a tricyclic antidepressant, and 5 of the 6 girls noted improvement in their symptoms, including 2 who had marked improvement, and another 3 with substantial improvement who were able to discontinue therapy without a recurrence. CONCLUSIONS: Vulvodynia does occur among young girls and, when treated as a neuropathic pain disorder, was found to dramatically improve or remit in the majority of those treated in this small case series."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18363625", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 288, 
                    "text": "We describe a case series of five adolescents who were managed with lidocaine 5% patches for chronic localized neuropathic pain from a variety of causes with minimal adverse effects. Treatment was effective in four of five patients with only one patient complaining of minimal pain relief"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15265351", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 317, 
                    "offsetInEndSection": 1022, 
                    "text": "Twenty-two children or 14% of children on opioid therapy underwent 30 opioid rotations. Mucositis was the cause of pain in 19 (70%) children, bone pain in 3 (11%) children, and postoperative, visceral, or neuropathic pain in the remainder. The opioid was rotated either for excessive side effects with adequate analgesia (70%), excessive side effects with inadequate analgesia (16.7%), or tolerance (6.7%). Five (23%) children required two rotations, 3 during the same admission. The favored rotations were morphine to fentanyl in 20 (67%) children and fentanyl to hydromorphone in 6 (20%). Adverse opioid effects were resolved in 90% of cases, all failures occurred when morphine was rotated to fentanyl."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12712053", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 11, 
                    "offsetInEndSection": 268, 
                    "text": "To test the hypothesis that children with terminal cancer and neuropathic pain require rapid increases of opioids and benzodiazepines immediately before death, we compared drug usage in the last 72 hours of life in children with and without neuropathic pain"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12712053", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1164, 
                    "offsetInEndSection": 1394, 
                    "text": "Dying children with cancer and neuropathic pain have higher baseline requirements of morphine and benzodiazepines and require rapid increases of both drugs in the last 72 hours of life than dying children without neuropathic pain."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11902308", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1299, 
                    "offsetInEndSection": 1580, 
                    "text": "ketamine treatment may be effective in children with severe neuropathic pain not responsive to other analgesics. This patient also demonstrates the feasibility of long-term ketamine treatment in pediatric oncology and that such treatment can be administered in a home care setting."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7561230", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 734, 
                    "text": "Oral amitriptyline has been used as an analgesic in a wide range of pain settings. Despite long-term availability of a parenteral form, the few reports about this formulation have been limited to pharmacokinetic studies in normal volunteers, trials in depressed patients, and analyses of electroencephalogram (EEG) activation. We retrospectively reviewed our experience using intravenous (IV) amitriptyline at Children's Hospital, Boston and at Children's Hospital at Stanford. Eight children (aged 5-16.6 years), who were unable to tolerate medications by the oral route, received IV amitriptyline for a variety of indications, including neuropathic pain, depression, sleep disturbance, and as an adjuvant agent for opioid analgesia."
                }
            ], 
            "type": "list"
        }, 
        {
            "body": "List all clinical trials of the polypill.", 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23038750", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22162939", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21647425", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21777702", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19339045"
            ], 
            "id": "515db020298dcd4e51000011", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23038750", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 404, 
                    "offsetInEndSection": 987, 
                    "text": "The 'Use of a Multidrug Pill In Reducing cardiovascular Events' (UMPIRE) trial assesses whether a polypill strategy (by combining aspirin, a statin and two blood pressure lowering agents) would improve adherence to guideline-indicated therapies and would lower both blood pressure and cholesterol, in people with established cardiovascular disease. UMPIRE, running in India and three European countries (England, Ireland and the Netherlands), is an open, randomised, controlled trial designed to include 1000 participants in India and 1000 in Europe, with a followup of 12-24 months."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23038750", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1520, 
                    "offsetInEndSection": 1923, 
                    "text": "UMPIRE is registered with the European Clinical Trials database, as EudraCT: 2009-016278-34 and the Clinical Trials Registry, India as CTRI/2010/091/000250. The trial was part of the 'Single Pill Against Cardiovascular Events (SPACE)' collaboration, which encompasses the 'IMProving Adherence using Combination Therapy (IMPACT)' and 'Kanyini Guidelines Adherence with the Polypill (Kanyini-GAP)' trials."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22162939", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1136, 
                    "offsetInEndSection": 1409, 
                    "text": "various pilot studies and Phase II trials of other single-pill combinations of antihypertensives, lipid-lowering medications, and aspirin (eg, the Polycap, which contains low doses of thiazide, atenolol, ramipril, simvastatin, and aspirin) have been completed and published"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22162939", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1426, 
                    "offsetInEndSection": 1521, 
                    "text": "results of some of these studies have been promising, such as the Phase II study of the Polycap"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22162939", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2473, 
                    "offsetInEndSection": 2722, 
                    "text": "A single-pill combination of the antihypertensive amlodipine besylate and the lipid-lowering agent atorvastatin calcium (single-pill amlodipine/atorvastatin [SPAA]), has been available in the USA since 2004 and in other parts of the world since 2005"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22162939", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2996, 
                    "offsetInEndSection": 3272, 
                    "text": "The Cluster Randomized Usual Care vs Caduet Investigation Assessing Long-term-risk (CRUCIAL trial) will be discussed in detail (Figure 1). This trial is the most recent and longest clinical study of SPAA.21 Earlier SPAA studies have been discussed in detail in earlier reviews"
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22162939", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 8020, 
                    "offsetInEndSection": 8152, 
                    "text": "small pilot study indicated that patients were satisfied with SPAA treatment in relation to their previous treatment of HTN and DYS."
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22162939", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 38, 
                    "offsetInEndSection": 201, 
                    "text": "Single-pill amlodipine/atorvastatin studiesThe AVALON41 and Respond42 studies outlined above both used co-administered amlodipine and atorvastatin rather than SPAA"
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22162939", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 340, 
                    "offsetInEndSection": 581, 
                    "text": "The first of these was the GEMINI trial, which was a 14-week, open-label trial conducted in 1220 patients from the USA, which demonstrated that SPAA was well tolerated and could help patients with HTN and DYS achieve their BP and LDL-C goals"
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22162939", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 585, 
                    "offsetInEndSection": 837, 
                    "text": "The subsequent GEMINI-Australia, Asia, Latin America, Africa/Middle East (AALA) study, which was a very similar study design, confirmed the findings of GEMINI among 1649 patients residing across Asia Pacific, the Middle East, Africa, and Latin America."
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22162939", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 840, 
                    "offsetInEndSection": 1034, 
                    "text": "The findings of these two studies were confirmed in the JEWEL study program, with JEWEL 1 conducted among 1138 patients from the UK and Canada and JEWEL 2 conducted in 1107 patients from Europe."
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22162939", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 1037, 
                    "offsetInEndSection": 1327, 
                    "text": "A further study on the use of SPAA in the USA, the Clinical Utility of Caduet in Simultaneously Achieving Blood Pressure and Lipid End Points (CAPABLE54), was conducted in 499 African American patients. CAPABLE examined the efficacy and safety of SPAA in a population that is rarely studied"
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22162939", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 3219, 
                    "offsetInEndSection": 3503, 
                    "text": "two randomized, double-blind, placebo-controlled trials have also been conducted to evaluate the efficacy of SPAA. The first of these studies, CUSP (The Caduet\u00ae in an Untreated Subject Population trial),60 compared SPAA plus therapeutic lifestyle changes (TLC) with placebo plus TLC i"
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22162939", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 3781, 
                    "offsetInEndSection": 4091, 
                    "text": "The second of these studies, the TOGETHER trial, evaluated whether targeting multiple CV risk factors with SPAA (5/20\u201310/20 mg) and TLC resulted in greater BP/lipid control and additional reduction in CVD risk in comparison with amlodipine (5\u201310 mg) plus TLC in patients with HTN and additional CV risk factors"
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22162939", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 4386, 
                    "offsetInEndSection": 4747, 
                    "text": "The CRUCIAL study is the only long-term randomized comparative trial of SPAA.21 CRUCIAL was a 12-month, international, multicenter, prospective, open-label, parallel design, cluster-randomized trial conducted in 19 countries in four geographical regions, including Asia, the Middle East, Europe, and Latin America, between March 2007 and October 2009 (Figure 1)"
                }, 
                {
                    "beginSection": "sections.4", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22162939", 
                    "endSection": "sections.4", 
                    "offsetInBeginSection": 5748, 
                    "offsetInEndSection": 6207, 
                    "text": "The Caduet Adherence Research Program and Education (CARPE) retrospective cohort studies were designed to evaluate potential adherence benefits of SPAA vs co-administered antihypertensive and lipid-lowering therapy in real-world settings (Table 1).The first of these studies, CARPE-Patient Benefits Management (CARPE-PBM), was a retrospective database study of pharmacy claims data that identified patients who were newly initiated on SPAA, or a CCB or statin"
                }, 
                {
                    "beginSection": "sections.4", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22162939", 
                    "endSection": "sections.4", 
                    "offsetInBeginSection": 6504, 
                    "offsetInEndSection": 6671, 
                    "text": "The CARPE-M study provided further insight into the potential adherence benefits of SPAA, by investigating the impact of prior CCB and statin use on adherence to SPAA."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21777702", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 711, 
                    "offsetInEndSection": 897, 
                    "text": "IMProving Adherence using Combination Therapy (IMPACT) is an open-label randomised controlled trial comparing a once-daily polypill containing four preventive medications with usual care"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21777702", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1701, 
                    "offsetInEndSection": 1803, 
                    "text": "The trial is registered with the Australian New Zealand Clinical Trial Registry (ACTRN12606000067572)."
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21647425", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 142, 
                    "offsetInEndSection": 606, 
                    "text": "We conducted a randomised controlled trial in seven countries \u2013 Australia (n\u200a=\u200a21), Brazil (n\u200a=\u200a8), India (n\u200a=\u200a109), Netherlands (n\u200a=\u200a102), New Zealand (n\u200a=\u200a12), United Kingdom (n\u200a=\u200a113) and United States (n\u200a=\u200a13). Approval for the trial was obtained from the institutional ethics committee of each centre and all participants provided written informed consent. The trial is registered with the Australian New Zealand Clinical Trials Registry (ACTRN 12607000099426"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19339045", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 157, 
                    "text": "Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19339045", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1284, 
                    "offsetInEndSection": 1352, 
                    "text": "This study is registered with ClinicalTrials.gov, number NCT00443794"
                }
            ], 
            "type": "list"
        }, 
        {
            "body": "What are the current treatments for generalised anxiety disorder in teenagers?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001008", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000293", 
                "http://www.disease-ontology.org/api/metadata/DOID:2030", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001007", 
                "http://www.disease-ontology.org/api/metadata/DOID:14320"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23404595", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12108800", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20429947", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18341545", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16675030"
            ], 
            "id": "515db20e298dcd4e51000014", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23404595", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 632, 
                    "offsetInEndSection": 729, 
                    "text": "49.3% of the youths with depression had comorbid conditions: anxiety disorders in 23.37% of cases"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12108800", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 11, 
                    "offsetInEndSection": 334, 
                    "text": "To evaluate the feasibility and effectiveness of a school-based group cognitive-behavioral treatment (CBT) for anxiety disorders with African-American adolescents. METHODS: Twelve adolescents (mean age = 15.6 years) with anxiety disorders were randomly assigned to CBT (n = 6) or a group attention-support control condition"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12108800", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 721, 
                    "offsetInEndSection": 1073, 
                    "text": "At posttreatment and among those who attended more than one treatment session, 3/4 adolescents in CBT no longer met diagnostic criteria for their primary anxiety disorder, compared with 1/5 in AS-Control. Clinician ratings of impairment and self-report levels of overall anxiety were significantly lower at posttreatment in CBT compared with AS-Control"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20429947", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1675, 
                    "offsetInEndSection": 1930, 
                    "text": "Sertraline, along with the SSRIs escitalopram and paroxetine, is seen as a first-line pharmacologic treatment for GAD [12]. Randomised, placebo controlled trials have found sertraline efficacious for GAD in adults [13,14], children and adolescents [15,16]"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20429947", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2327, 
                    "offsetInEndSection": 2439, 
                    "text": "While both CBT and SSRIs are beneficial, some evidence suggests that the effects of CBT may be more long lasting"
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20429947", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 10, 
                    "offsetInEndSection": 358, 
                    "text": "As of February 2010, there were no registered randomised controlled trials examining the effectiveness of online CBT treatments for GAD in young adults. This trial will be one of the first to assess the use of an internet-based CBT program in the treatment of GAD, and to date, the first to compare it with a gold standard pharmacological treatment"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18341545", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 443, 
                    "text": "The present study compares an individual versus a group format in the delivery of manualised cognitive-behavioural therapy (FRIENDS) for children with anxiety disorders. Clinically referred children (aged 8 to 12) diagnosed with Separation Anxiety Disorder (n = 52), Generalised Anxiety Disorder (n = 37), Social Phobia (n = 22) or Specific Phobia (n = 16) were randomly assigned to individual (n = 65) or group (n = 62) treatment."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18341545", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 683, 
                    "offsetInEndSection": 986, 
                    "text": "Forty-eight percent of the children in the individual versus 41% in the group treatment were free of any anxiety disorder at post-treatment; 62% versus 54% were free of their primary anxiety disorder. Regression analyses showed no significant difference in outcome between individual and group treatment"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18341545", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1001, 
                    "offsetInEndSection": 1203, 
                    "text": "Children improved in both conditions. Choice between treatments could be based on pragmatic considerations such as therapeutic resources, referral rates, and the preference of the parents and the child."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16675030", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1257, 
                    "offsetInEndSection": 1563, 
                    "text": "All child anxiety disorders were associated with several forms of anxiety disorder in the mother. Some specificity in the form of anxiety disorder in the child and the mother was apparent for social phobia and separation anxiety disorder. The findings have implications for the management of child anxiety."
                }
            ], 
            "type": "list"
        }, 
        {
            "body": "What is the average diameter of intermediate filaments?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007382"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/2264817", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22848616", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22126386", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19656809", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21669844", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19559031", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18726512", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18523546", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17289402", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16458019", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15373777"
            ], 
            "id": "515db3d8298dcd4e51000015", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2264817", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 553, 
                    "offsetInEndSection": 801, 
                    "text": "Negative staining showed that supernatants from the centrifugation assays contained protofilaments, protofibrils and short particles (less than 300 nm), but pellets contained long filaments (greater than 1 micron) with an average diameter of 10 nm."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22848616", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 811, 
                    "offsetInEndSection": 1018, 
                    "text": "The building blocks of the cortex are trichocyte keratins intermediate filaments (IFs) with a 7.5 nm diameter embedded in a sulfur-rich protein matrix and arranged in a paracrystalline hexagonal lattice [4]."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22126386", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1072, 
                    "offsetInEndSection": 1197, 
                    "text": "Ultrastructurally, rhabdoid cells showed paranuclear aggregates and whorls of intermediate filaments with a 9-10 nm diameter."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19656809", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 437, 
                    "offsetInEndSection": 650, 
                    "text": "After removing IFs by calcination, electron microscopy revealed hollow silica nanotubes several micrometers long, with outer diameters of 35-55 nm and an average inner diameter of 10 nm (comparable to that of IFs)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21669844", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 133, 
                    "text": "Intermediate filaments are filaments 10\u2009nm in diameter that make up an important component of the cytoskeleton in most metazoan taxa."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19559031", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 259, 
                    "text": "Neurofilaments (NFs) are essential cytoskeletal filaments that impart mechanical integrity to nerve cells. They are assembled from three distinct molecular mass proteins that bind to each other to form a 10-nm-diameter filamentous rod with sidearm extensions."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18726512", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 108, 
                    "offsetInEndSection": 312, 
                    "text": "Scanning tunneling microscope (STM) and transmission electron microscope (TEM) micrographs showed that acidic keratins and basic keratins can assemble into dimers and further into 10 nm filamentsin vitro."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18523546", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1, 
                    "offsetInEndSection": 137, 
                    "text": "ntroductionIntermediate filaments are a diverse family of cytoskeletal proteins that assemble into 10 nm diameter filaments in cells[1]."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17289402", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 151, 
                    "offsetInEndSection": 289, 
                    "text": "Intermediate in diameter between microtubules and microfilaments, IFs constitute the third cytoskeletal filament system of metazoan cells."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16458019", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 613, 
                    "offsetInEndSection": 720, 
                    "text": "Just above the bulb, the filaments are characterized by a diameter of 100 Angstroms and a low-density core."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15373777", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1656, 
                    "offsetInEndSection": 2023, 
                    "text": "Further, using cryo-transmission electron microscopy on native, fully hydrated, vitreous epidermis we show that the subfilametous keratin electron density pattern consists, both in corneocytes and in viable keratinocytes, of one axial subfilament surrounded by an undetermined number of peripheral subfilaments forming filaments with a diameter of approximately 8 nm."
                }
            ], 
            "triples": [
                {
                    "o": "Filaments, Intermediate", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A0059267"
                }
            ], 
            "type": "factoid"
        }, 
        {
            "body": "What are the reported adverse effects of gabapentin used in children?", 
            "concepts": [
                "http://www.biosemantics.org/jochem#4258191", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002648", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004362"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23112238", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22134010", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19193587", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16490100", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15072101", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12199723", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12022084", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11361047", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11305405", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11274308", 
                "http://www.ncbi.nlm.nih.gov/pubmed/10030434", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9120226", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8648543", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8617181", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8603631", 
                "http://www.ncbi.nlm.nih.gov/pubmed/7489697"
            ], 
            "id": "515db70c298dcd4e51000017", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23112238", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 156, 
                    "offsetInEndSection": 288, 
                    "text": "he purpose of our study was to review our experience with using gabapentin to treat insomnia in children. We identified 23 children,"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23112238", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 839, 
                    "offsetInEndSection": 880, 
                    "text": "Adverse effects were noted in 6 children."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22134010", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 11, 
                    "offsetInEndSection": 129, 
                    "text": "To determine the effectiveness of gabapentin as an add-on therapy in children presenting with overactive bladder (OAB)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22134010", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 651, 
                    "offsetInEndSection": 741, 
                    "text": "Data were analyzed in 30 patients as treatment was terminated in 1 due to adverse effects."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22134010", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1307, 
                    "offsetInEndSection": 1473, 
                    "text": "Gabapentin gives moderate results in children with OAB refractory to conventional anticholinergics. In general, the drug is well tolerated with fewer adverse effects."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19193587", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 11, 
                    "offsetInEndSection": 159, 
                    "text": "To describe a child who developed a skin reaction during gabapentin therapy and discuss how we evaluated the probability of an adverse drug reaction"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19193587", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 725, 
                    "offsetInEndSection": 1093, 
                    "text": "In contrast to other antiepileptic drugs, skin reactions to gabapentin are considered uncommon. In adults, reported prevalence of rash possibly related to gabapentin range from 1% to 10%. A postmarketing surveillance study reported gabapentin treatment failure as a consequence of rash in 0.4% of 3000 patients. The product monograph does not mention rash in children."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19193587", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1227, 
                    "offsetInEndSection": 1514, 
                    "text": "This case, and limited literature data, suggest that gabapentin may cause rash that is severe enough to necessitate discontinuation in a small percentage of children. Further research is needed to determine the actual incidence and severity of gabapentin-related rash in this population."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16490100", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 285, 
                    "offsetInEndSection": 425, 
                    "text": "Five patients treated in the Children's Hospital Pain Control Service for intractable neuropathic pain were included in gabapentin treatment"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16490100", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 614, 
                    "offsetInEndSection": 738, 
                    "text": "We noticed a rapid improvement, in 1 week, of our patients' VAS scores (from 9 or 10 to 4 or 3) with minimal adverse effects"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15072101", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 206, 
                    "offsetInEndSection": 277, 
                    "text": "The charts of all children given gabapentin for seizures were reviewed."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15072101", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 906, 
                    "offsetInEndSection": 990, 
                    "text": "Only 8 children (7%) reported adverse effects, and the drug was discontinued in two."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12199723", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 97, 
                    "text": "A postmarketing surveillance study of gabapentin as add-on therapy for 3,100 patients in England."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12199723", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 880, 
                    "offsetInEndSection": 948, 
                    "text": "The cohort comprised 3,100 patients, of whom 136 (4%) were children."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12199723", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 998, 
                    "offsetInEndSection": 1252, 
                    "text": "The most frequently reported adverse events reported during the first month of treatment, drowsiness/sedation, dizziness, and malaise/lassitude, also were the commonest reasons for discontinuing GBP and reported as suspected adverse drug reactions (ADRs)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12199723", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1495, 
                    "offsetInEndSection": 1667, 
                    "text": "Neurologic-related events were the most frequently reported adverse events. They also were the commonest reasons for discontinuing treatment and reported as suspected ADRs."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12022084", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 144, 
                    "offsetInEndSection": 391, 
                    "text": "We reviewed the reports in the literature on the safety, adverse effects and tolerance of GBP as treatment, used as monotherapy or associated with other drugs, in epilepsies in patients of all age groups, including children, adults and the elderly"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12022084", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 437, 
                    "offsetInEndSection": 815, 
                    "text": "GBP is a well tolerated drug when used for monotherapy or associated with other antiepileptic drugs. The commonest adverse effects seen were somnolence, fainting, ataxia, nystagmus, tremor and headache. However, their incidence was low and intensity mild. There was no clear relationship between the dose given and appearance of side effects, except for fainting and somnolence."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12022084", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 829, 
                    "offsetInEndSection": 1049, 
                    "text": "GBP is a drug which is free of unwanted side effects. Its safety and tolerability profile is excellent for treatment of simple and complex partial crises, with or without generalization in epileptic patients of all ages."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11361047", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 168, 
                    "offsetInEndSection": 378, 
                    "text": "Two studies were conducted to determine the single-dose pharmacokinetics of gabapentin in healthy subjects age 1 month to 12 years and to guide dose selection in safety and efficacy trials in pediatric patients"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11361047", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 612, 
                    "offsetInEndSection": 689, 
                    "text": "Single doses of gabapentin were well tolerated by healthy pediatric subjects."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11305405", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 161, 
                    "text": "The efficacy and safety of gabapentin as add-on therapy for refractory partial seizures in 237 children, aged 3 to 12 years were evaluated over a 6-month period."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11305405", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 655, 
                    "offsetInEndSection": 739, 
                    "text": "Thirteen patients (5%) withdrew during the 6-month period because of adverse events."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11274308", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 457, 
                    "offsetInEndSection": 626, 
                    "text": "Male or female patients, at least 12 years old, with a recent history of partial seizures with or without secondary generalization, were randomized to receive gabapentin"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11274308", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1045, 
                    "offsetInEndSection": 1256, 
                    "text": "Of the four most common adverse events (somnolence, dizziness, ataxia, fatigue), only one, dizziness, occurred more often in the nontitrated (Rapid initiation) group than in the titrated (Slow initiation) group."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10030434", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 276, 
                    "text": "Twenty-six children with intellectual disability and six normal children, all suffering from refractory partial seizures, received open-label gabapentin (range = 10-50 mg kg(-1) day(-1); mean = 26.7 mg kg(-1) day(-1) as an add-on medication to their antiepileptic drug regimen"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10030434", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 768, 
                    "offsetInEndSection": 1371, 
                    "text": "In the present patient population, patients younger than 10 years of age, all of whom had intellectual disability, were more likely to have side-effects than those older than 10 years of age. Observed adverse effects, which were generally mild, occurred in patients with baseline intellectual disability, attention deficit disorder and behavioural problems. Behavioural adverse effects warranted discontinuation of the medication in only three patients. The severity of intellectual disability (mild versus moderate or severe) did not affect the extent of the response or the occurrence of side-effects."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10030434", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1527, 
                    "offsetInEndSection": 1703, 
                    "text": "However, children with intellectual disability who also are less than 10 years of age with baseline attention deficit appear to be at a higher risk of behavioural side-effects."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9120226", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 113, 
                    "text": "Efficacy and safety of gabapentin monotherapy were evaluated in 33 children with newly diagnosed absence epilepsy"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9120226", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 712, 
                    "offsetInEndSection": 928, 
                    "text": "Somnolence and dizziness were the only adverse events reported by at least two patients during gabapentin treatment. No clinically important changes in laboratory assessments or other safety parameters were observed."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8648543", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 147, 
                    "text": "Thirty-two children with refractory partial epilepsy received open-label gabapentin as an additional medication to their antiepileptic drug regimen"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8648543", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 757, 
                    "offsetInEndSection": 950, 
                    "text": "The major reported side effects were behavioral. These consisted of hyperactivity, irritability, and agitation that occurred in patients with baseline mental retardation with attention deficit."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8617181", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 176, 
                    "offsetInEndSection": 454, 
                    "text": "We report 2 children who received GBP for intractable seizures and who developed intolerable aggressive behavior requiring dose reduction or drug discontinuation. Behavioral changes should be recognized as a possible side effect of GBP, especially in mentally retarded children."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8603631", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 564, 
                    "text": "We report 7 children who received gabapentin (GBP) as adjunctive medic ation and subsequently developed behavioral side effects. These behavioral changes consisted of intensification of baseline behaviors as well as new behavioral problems. Behaviors that parents considered most troublesome were tantrums, aggression directed toward others, hyperactivity, and defiance. All behavioral changes were reversible and were managed by dose reduction or discontinuation of GBP. All children had baseline attention deficit hyperactivity disorder and developmental delays."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7489697", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 88, 
                    "offsetInEndSection": 511, 
                    "text": "We described 3 learning disabled children, 1 aged 7 and 2 aged 10 years, with intractable partial seizures who developed severe behavioral problems while receiving modest doses of GBP. The children became hyperactive and had explosive outburst consisting of aggressive and oppositional behavior. The behavioral problems were sufficiently severe to require discontinuation of GBP despite moderately improved seizure control."
                }
            ], 
            "type": "list"
        }, 
        {
            "body": "How histone deacetylation causes transcriptional gene silencing?", 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/11134508", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15172996", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23114751", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22990449", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22684523", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22504884", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22472323", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22357272", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22222205", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22102827", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22042362", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21947282", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21913088", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21622623", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21325281", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21211723", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21186298", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21130077", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20811718", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20516197", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20504333", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20053684", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19782027", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19745053", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19259094", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18683042", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18632628"
            ], 
            "id": "515dbb3b298dcd4e51000018", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21913088", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 497, 
                    "text": "Lysine acetylation of histones is one of the major epigenetic regulators of chromatin conformation and gene expression. The dynamic nature of histone acetylation is determined by the counterbalancing activity of histone acetyltransferase and histone deacetylase (HDAC) enzymes. Acetylation of histones is generally associated with open and transcriptionally active chromatin, whereas the activity of HDACs leads to histone deacetylation, condensation of chromatin, and inhibition of transcription."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21913088", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 599, 
                    "offsetInEndSection": 861, 
                    "text": "Abnormal activity of HDACs has been implicated in tumorigenesis and therefore considerable effort has been put into the development of HDAC inhibitors as a means of modifying histone acetylation status and reexpressing aberrantly silenced tumor suppressor genes."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11134508", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 360, 
                    "text": "Histone acetylation and deacetylation play essential roles in eukaryotic gene regulation. Reversible modifications of core histones are catalyzed by two intrinsic enzymes, histone acetyltransferase and histone deacetylase (HD). In general, histone deacetylation is related to transcriptional gene silencing, whereas acetylation correlates with gene activation."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23114751", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 810, 
                    "offsetInEndSection": 1045, 
                    "text": "The reversible nature of deregulated chromatin structure by DNA methylation and histone deacetylation inhibitors, leading to re-expression of tumor suppressor genes, makes chromatin-remodeling pathways as promising therapeutic targets."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22990449", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1151, 
                    "offsetInEndSection": 1392, 
                    "text": "Furthermore, the histone deacetylase inhibitor, trichostatin A (TSA), recovered the expression and function of NEO1 in the silenced lines, suggesting that histone deacetylation is essential for the direct suppression of target genes by DNAi."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22684523", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 169, 
                    "offsetInEndSection": 558, 
                    "text": "We had previously shown that in anergic CD4(+) T cells, Ikaros participates in the transcriptional repression of the Il2 gene by recruiting histone deacetylases that cause core histone deacetylation at the Il2 promoter. Here we show that deacetylation at the Il2 promoter is the initial step in a process that leads to the stable silencing of the Il2 gene transcription in anergic T cells."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22504884", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 831, 
                    "offsetInEndSection": 986, 
                    "text": "We demonstrate that HP1 forms distinct DNA methylation and histone deacetylation complexes that work in parallel to assemble silent chromatin in N. crassa."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22472323", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1569, 
                    "offsetInEndSection": 1704, 
                    "text": "These results indicated that histone deacetylation is a silencing mechanism for GATA4 expression in AFP-producing gastric cancer cells."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22222205", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 146, 
                    "offsetInEndSection": 290, 
                    "text": "We found that histone deacetylase 1 (HDAC1) increases the expression levels of mature miRNAs despite repressing the transcription of host genes."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22102827", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1719, 
                    "offsetInEndSection": 1929, 
                    "text": "siRNAs not only direct DNA methylation, but also trigger repressive histone modifications at RdDM target loci, including histone deacetylation, H3K9 dimethylation (H3K9me2) and H3K27 monomethylation (H3K27me1)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22102827", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 3089, 
                    "offsetInEndSection": 3266, 
                    "text": "The histone deacetylase HDA6 deacetylates lysines of core histones including H3 and H4, and is required for cytosine methylation in transgenes and silenced rRNA genes [11]\u2013[13]."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22042362", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 564, 
                    "offsetInEndSection": 668, 
                    "text": "Promoter methylation and histone deacetylation were studied as possible mechanisms for klotho silencing."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22042362", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1450, 
                    "offsetInEndSection": 1645, 
                    "text": "Taken together, these data indicate loss of klotho expression as an early event in breast cancer development, and suggest a role for DNA methylation and histone deacetylation in klotho silencing."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21947282", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 319, 
                    "text": "DNA methylation and histone acetylation/deacetylation are distinct biochemical processes that control gene expression. While DNA methylation is a common epigenetic signal that inhibits gene transcription, histone deacetylation similarly represses transcription but can be both an epigenetic and nonepigenetic phenomenon"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21947282", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 320, 
                    "text": "DNA methylation and histone acetylation/deacetylation are distinct biochemical processes that control gene expression. While DNA methylation is a common epigenetic signal that inhibits gene transcription, histone deacetylation similarly represses transcription but can be both an epigenetic and nonepigenetic phenomenon."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21622623", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1497, 
                    "offsetInEndSection": 1724, 
                    "text": "Because DNA hypermethylation-based silencing may couple with and depend on histone deacetylation, our study suggests that endogenous HDAC inhibition by maspin may prevent pathologic gene silencing in prostate tumor progression."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21325281", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 119, 
                    "text": "Epigenetic regulation of the IL-13-induced human eotaxin-3 gene by CREB-binding protein-mediated histone 3 acetylation."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21211723", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 338, 
                    "text": "Heterochromatin impacts various nuclear processes by providing a recruiting platform for diverse chromosomal proteins. In fission yeast, HP1 proteins Chp2 and Swi6, which bind to methylated histone H3 lysine 9, associate with SHREC (Snf2/HDAC repressor complex) and Clr6 histone deacetylases (HDACs) involved in heterochromatic silencing."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21186298", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 836, 
                    "offsetInEndSection": 1180, 
                    "text": "We established that the silencing of these genes in UVB-exposed epidermis and UVB-induced skin tumors is associated with a network of epigenetic modifications, including hypoacetylation of histone H3 and H4 and increased histone deacetylation, as well as recruitment of methyl-binding proteins, including MeCP2 and MBD1, to the methylated CpGs."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21130077", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 73, 
                    "text": "Histone deacetylation directs DNA methylation in survivin gene silencing."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21130077", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 624, 
                    "offsetInEndSection": 787, 
                    "text": "Next, we investigated the roles of histone acetylation and DNA methylation in survivin silencing after blockade of histone deacetylation with Trichostatin A (TSA)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21130077", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1322, 
                    "offsetInEndSection": 1474, 
                    "text": "The results showed that histone deacetylation blocked by TSA reversed the increasing effect of histone deacetylation on the expression of survivin mRNA."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20811718", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 206, 
                    "text": "Aberrant hypermethylation at CpG sites within the CDKN2A gene is associated with silencing and has been proposed as a target for reactivation using both DNA methylation and histone deacetylation inhibitors."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20811718", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 206, 
                    "text": "Aberrant hypermethylation at CpG sites within the CDKN2A gene is associated with silencing and has been proposed as a target for reactivation using both DNA methylation and histone deacetylation inhibitors."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20516197", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 179, 
                    "text": "Mechanisms of HDA6-mediated rRNA gene silencing: suppression of intergenic Pol II transcription and differential effects on maintenance versus siRNA-directed cytosine methylation."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20516197", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 172, 
                    "text": "The Arabidopsis histone deacetylase HDA6 is required to silence transgenes, transposons, and ribosomal RNA (rRNA) genes subjected to nucleolar dominance in genetic hybrids."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20504333", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 97, 
                    "text": "Histone H4 deacetylation plays a critical role in early gene silencing during neuronal apoptosis."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20504333", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2474, 
                    "offsetInEndSection": 2797, 
                    "text": "Acetylated histones are typically found in transcriptionally active euchromatic chromatin, whereas transcriptionally inactive heterochromatic chromatin is rich in deacetylated histones. Theoretically, deacetylation is thought to lead to a more compact chromatin structure, which limits access of transcription factors [24]."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20504333", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 3030, 
                    "offsetInEndSection": 3193, 
                    "text": "The acetylation and deacetylation of histones is controlled by opposing protein families called histone acetyltransferases (HATs) and histone deacetylases (HDACs)."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20053684", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 116, 
                    "text": "Distinct and temporal roles of nucleosomal remodeling and histone deacetylation in the repression of the hTERT gene."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20053684", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1022, 
                    "offsetInEndSection": 1478, 
                    "text": "Surprisingly, inhibition of histone deacetylation at the hTERT promoter did not prevent hTERT repression or nucleosomal deposition, indicating that nucleosomal deposition at the core promoter, but not histone deacetylation, was the cause of transcriptional repression. Our data also suggested that succeeding nucleosomal remodeling and histone deacetylation worked in parallel to establish the stable repressive status of hTERT gene in human somatic cells."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19782027", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 75, 
                    "text": "Reconstitution of heterochromatin-dependent transcriptional gene silencing."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19782027", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 746, 
                    "offsetInEndSection": 1108, 
                    "text": "Silencing requires all three Sir proteins, even with fully deacetylated chromatin, and involves the specific association of Sir3 with deacetylated H4K16. These results define a minimal set of components that mediate heterochromatic gene silencing and demonstrate distinct contributions for histone deacetylation and nucleosome binding in the silencing mechanism."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19782027", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 746, 
                    "offsetInEndSection": 1107, 
                    "text": "Silencing requires all three Sir proteins, even with fully deacetylated chromatin, and involves the specific association of Sir3 with deacetylated H4K16. These results define a minimal set of components that mediate heterochromatic gene silencing and demonstrate distinct contributions for histone deacetylation and nucleosome binding in the silencing mechanism"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19745053", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1651, 
                    "offsetInEndSection": 1876, 
                    "text": "In the enzymatic model, MeCP2 specifically targets mCpGs and determines repressive heterochromatin by interacting with the co-repressor mSin3A, which is part of a large complex containing histone deacetylases (HDACs) (24,25)."
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19745053", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 332, 
                    "offsetInEndSection": 564, 
                    "text": "Furthermore, we show that either in non-expressing or in IL-6-expressing cell lines DAC, but not TSA, is able to induce IL-6, indicating that DNA methylation, but not histone deacetylation, plays an essential role in IL-6 silencing."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19259094", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 120, 
                    "text": "Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo."
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19259094", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 290, 
                    "text": "Baylin and co-workers have shown that the combination of the histone deacetylase (HDAC) inhibitor trichostatin A with decitabine is more effective in reactivating transcription of epigenetically silenced genes such as hMLH1 in tumour cell lines than either drug alone (Cameron et al, 1999)."
                }, 
                {
                    "beginSection": "sections.6", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19259094", 
                    "endSection": "sections.6", 
                    "offsetInBeginSection": 1268, 
                    "offsetInEndSection": 1494, 
                    "text": "Belinostat alone has no effect on MLH1 expression and this is consistent with the observation that histone deacetylase inhibitors cannot induce the expression of genes silenced due to promoter methylation (Suzuki et al, 2002)."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18683042", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 136, 
                    "text": "Inhibition of histone deacetylase suppresses EGF signaling pathways by destabilizing EGFR mRNA in ER-negative human breast cancer cells."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18683042", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 170, 
                    "offsetInEndSection": 387, 
                    "text": "Our previous studies demonstrate that histone deacetylation plays a key role in ER gene silencing, and ER expression can be restored with histone deacetylase (HDAC) inhibitors in ER-negative human breast cancer cells."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18632628", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 871, 
                    "offsetInEndSection": 1056, 
                    "text": "This chromatin pattern, and particularly H3K4me2 levels, crisply separates DNA-hypermethylated genes from those where histone deacetylation is responsible for transcriptional silencing."
                }
            ], 
            "type": "summary"
        }, 
        {
            "body": "What do studies show about the effect of Induced hypothermia in premature babies?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007036", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007234", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D047928", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007752", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007235"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22320395", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20470651", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20100756", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19020525"
            ], 
            "id": "515dc066298dcd4e5100001a", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22320395", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 245, 
                    "text": "Therapeutic hypothermia is a recognized treatment for term infants with hypoxic-ischemic encephalopathy (HIE) in reducing rate of death or neurodevelopmental disabilities. Little is known about applications of this treatment to preterm newborns."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20470651", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 179, 
                    "text": "Randomised studies have demonstrated the efficacy of hypothermia for the treatment of perinatal hypoxic-ischaemic encephalopathy (HIE) in term or late preterm infants."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20100756", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 263, 
                    "offsetInEndSection": 679, 
                    "text": "We aimed to establish the feasibility and safety of mild hypothermia in preterm neonates with NEC and MODS as a prelude to a randomized trial. METHODS: This was a prospective, nonrandomized pilot study of 15 preterm infants who were referred for surgical intervention of advanced NEC and failure of at least 3 organs. Whole-body cooling was achieved by ambient temperature adjustment with or without cooling mattress"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20100756", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1915, 
                    "offsetInEndSection": 2117, 
                    "text": "Mild hypothermia for 48 hours in preterm neonates with severe NEC seems both feasible and safe. Additional investigation of the efficacy of this therapeutic intervention in this population is warranted."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19020525", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 622, 
                    "offsetInEndSection": 1200, 
                    "text": "The National Institute of Child Health and Human Development (NICHD) whole-body hypothermia trial9, demonstrated a 28% relative reduction in death or moderate or severe disability at 18 to 22 months in hypothermia-treated infants compared with control infants. Although how hypothermia confers neuroprotection is not fully understood, hypothermia reduces cerebral metabolism, inhibits glutamate release, preserves high energy phosphates, reduces neuronal nitric oxide production, preserves endogenous antioxidants, and ameliorates apoptotic neuronal death in experimental models"
                }
            ], 
            "type": "summary"
        }, 
        {
            "body": "What are the clinical trial outcomes of metformin use in polycystic ovary disease?", 
            "concepts": [
                "http://www.disease-ontology.org/api/metadata/DOID:11612", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011085", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008687", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D010053"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23412023", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21631446", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20517830", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19342396", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15802325", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15117902", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12364442", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11836287", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11473953"
            ], 
            "id": "515dd9a0298dcd4e5100001e", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23412023", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 302, 
                    "offsetInEndSection": 510, 
                    "text": "It has been demonstrated that by reducing hyperinsulinemia, in particular with the administration of metformin, insulin-lowering agents might improve endocrine and reproductive abnormalities in PCOS patients."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21631446", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 788, 
                    "text": "Metformin has failed to gain wide acceptance as a first-line treatment option for women with anovulatory infertility related to polycystic ovary syndrome. This study aimed to ascertain factors that predict fertility success with treatment that included metformin compared to standard (non-metformin) treatment. METHODS: Randomised trial data analysis by logistic regression of factors likely to have a differential influence on the likelihood of success of metformin versus non-metformin treatment amongst women with ovulation dysfunction related to polycystic ovary syndrome. RESULTS: metformin versus those receiving placebo and those with lower BMI who received metformin were more likely to become pregnant than their lower BMI counterparts who received placebo (P=0.039)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21631446", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1264, 
                    "offsetInEndSection": 1581, 
                    "text": "This study provides preliminary evidence that BMI may be an important prognostic factor in response to metformin for women with ovulation dysfunction related to polycystic ovary syndrome, suggesting that women with a lower BMI may respond better to metformin treatment versus placebo amongst women with BMI>32 kg/m(2)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20517830", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 842, 
                    "offsetInEndSection": 1159, 
                    "text": "A prospective comparative study including 63 patients with PCOS has been done during 2 years. Women were randomly allocated to clomifene + Metformin (Metformin group, Metformin took during 8 weeks, 850 mg twice a day, plus Clomifene 100 mg per day during five days) or Clomifene only (100 mg per day during five days)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20517830", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1854, 
                    "offsetInEndSection": 2033, 
                    "text": "Our conclusion is that Metformin is an effective addition to Clomifene Citrate in term of reestablishment of ovulation and full-term pregnancies achievement, excluding ART cycles."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19342396", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 442, 
                    "offsetInEndSection": 628, 
                    "text": "A prospective, randomized, double-blind 26 week long study was undertaken in 50 women with PCOS. They all received diet and lifestyle counselling, and metformin 850 mg three times daily."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19342396", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 155, 
                    "offsetInEndSection": 275, 
                    "text": "nti-M\u00fcllerian hormone (AMH) levels reflect the number of small antral follicles in the ovaries and are elevated in PCOS."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19342396", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1602, 
                    "offsetInEndSection": 1736, 
                    "text": "Six months of androgen suppression by either metformin or low-dose dexamethasone treatment failed to influence circulating AMH levels."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15802325", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 971, 
                    "offsetInEndSection": 1139, 
                    "text": "The effect of metformin on serum AMH concentrations, follicle number and ovarian volume was studied in 26 women (aged 20-41 years) with PCOS after 6 months of treatment"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15802325", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1735, 
                    "offsetInEndSection": 1854, 
                    "text": "Serum AMH levels, the number of antral follicles and ovarian volume decreased significantly during metfromin treatment."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15117902", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 123, 
                    "text": "Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15117902", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 27, 
                    "offsetInEndSection": 159, 
                    "text": "investigate the effect of pre-treatment with metformin in women with polycystic ovary syndrome (PCOS) scheduled for IVF stimulation."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15117902", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1521, 
                    "offsetInEndSection": 1753, 
                    "text": "Pre-treatment with metformin prior to conventional IVF/ICSI in women with PCOS does not improve stimulation or clinical outcome. However, among normal weight PCOS women, pre-treatment with metformin tends to improve pregnancy rates."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12364442", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1092, 
                    "offsetInEndSection": 1218, 
                    "text": "Treatment of 10 insulin-resistant PCOS women with metformin significantly increased circulating fasting ghrelin concentrations"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11836287", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 407, 
                    "offsetInEndSection": 493, 
                    "text": "double-blind, placebo-controlled approach with detailed assessment of ovarian activity"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11836287", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1443, 
                    "offsetInEndSection": 2185, 
                    "text": "The effect of metformin on follicular maturation was rapid, because the E2 circulating concentration increased over the first week of treatment only in the metformin group. Significant (P < 0.01) weight loss (and leptin reduction) was recorded in the metformin group, whereas the placebo group actually increased weight (P < 0.05). A significant increase in circulating high-density lipoprotein was observed only in the metformin-treated group. Metabolic risk factor benefits of metformin treatment were not observed in the morbidly obese subgroup of patients (body mass index > 37). No change in fasting glucose concentrations, fasting insulin, or insulin responses to glucose challenge was recorded after 14-wk metformin or placebo therapy."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11836287", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2262, 
                    "offsetInEndSection": 2669, 
                    "text": "We show in a large randomized placebo-controlled trial that metformin treatment improves ovulation frequency in women with abnormal ovarian function and polycystic ovaries significantly but to a modest degree, and protracted treatment improves cardiovascular risk factors. These data support a beneficial effect of metformin in improving ovarian function in women with oligomenorrhea and polycystic ovaries."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11473953", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 193, 
                    "offsetInEndSection": 304, 
                    "text": "studies evaluating metformin treatment in women with clomiphene citrate (CC)-resistant polycystic ovaries (PCO)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11473953", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1098, 
                    "offsetInEndSection": 1273, 
                    "text": "There was no improvement in the ovulation rate despite a significant reduction of body mass index, serum testosterone and fasting leptin concentrations in the metformin group."
                }
            ], 
            "type": "summary"
        }, 
        {
            "body": "List all approved indications for Glivec", 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22929880", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22789835", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22363762", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21464883", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21073206", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20726677", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20099379", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20032453", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19584824", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22793867", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17033447", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17024483", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16444286", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15671523", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12401900", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11831069"
            ], 
            "id": "515de748298dcd4e51000023", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22929880", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 35, 
                    "offsetInEndSection": 73, 
                    "text": "gastrointestinal stromal tumour (GIST)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22789835", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1459, 
                    "offsetInEndSection": 1739, 
                    "text": "The limited available experience suggests that imatinib could be considered as an individualized treatment approach in severe SSc and underscores the need to identify markers for selecting particular patients, who will safely respond to therapeutic inhibition of tyrosine kinases."
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22363762", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 4392, 
                    "offsetInEndSection": 4548, 
                    "text": "Imatinib (Gleevec)Chronic myelogenous leukemia (CML)May 2001Y42,000205.1, 208.1, 758.89Gastrointestinal stromal tumor (GIST)February 2002Y15,000238.1, 238.9"
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22363762", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 5324, 
                    "offsetInEndSection": 5571, 
                    "text": "In the case of imatinib, approved for a second orphan indication in 2002 (gastrointestinal stromal tumor, GIST), we assigned uses associated with the supplemental orphan indication to the \u201cFDA-approved orphan use\u201d category after February 2002."
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22363762", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 284, 
                    "offsetInEndSection": 368, 
                    "text": "By contrast, imatinib use was mostly related to its FDA-approved orphan indications."
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22363762", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 1636, 
                    "offsetInEndSection": 1733, 
                    "text": "Unlike the other three drugs studied, imatinib was approved for distinct conditions (CML and GIST"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21464883", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 72, 
                    "text": "Dermatofibrosarcoma protuberans (DFSP) is an uncommon cutaneous neoplasm"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21464883", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 516, 
                    "offsetInEndSection": 819, 
                    "text": "Moreover, even when surgery is utilized, there are cases where positive margins remain, in which case imatinib would be an option, often in combination with surgery. Imatinib can decrease tumor size preoperatively and help to improve postsurgical aesthetic appearance and minimize functional impairment."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21073206", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1386, 
                    "offsetInEndSection": 1619, 
                    "text": "for CML we analysed imatinib, dasatinib and nilotinib. RESULTS: Most drugs included in this study had received market authorization in all countries, but the range of indications for which they had been authorized differed by country"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20726677", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 514, 
                    "text": "Imatinib mesylate, an orally administered kinase inhibitor that targets the Kit (CD117) protein, currently has 10 approved indications including treatment of chronic myelogenous leukemia and metastatic gastrointestinal stromal tumors (GIST). Treatment with adjuvant imatinib following surgical resection of localized Kit-positive GIST, the most recent FDA-approved indication (December 2008), has been shown to significantly improve recurrence-free survival (RFS) compared with surgical resection alone"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20099379", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 458, 
                    "offsetInEndSection": 696, 
                    "text": "Currently, there are no clinical recommendations regarding how to incorporate imatinib drug plasma monitoring in patients with either chronic myeloid leukemia or gastrointestinal stromal tumors, indications for which imatinib is approved."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20032453", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2125, 
                    "offsetInEndSection": 2195, 
                    "text": "Imatinib was effective against GIST that were positive for KIT protein"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19584824", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 759, 
                    "offsetInEndSection": 872, 
                    "text": "The introduction of alternative therapies, such as imatinib for CML, has challenged well-established indications."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22793867", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 249, 
                    "offsetInEndSection": 481, 
                    "text": "More micro-GIST are discovered with the development of investigations, rising the question of wait and see policy for some of them. In locally advanced inoperable patients and metastatic patients, Imatinib is the standard treatment."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16444286", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 742, 
                    "offsetInEndSection": 875, 
                    "text": "The introduction of alternative therapies has challenged well-established indications such as imatinib for chronic myeloid leukaemia."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15671523", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 284, 
                    "text": "Imatinib mesylate (Gleevec, Novartis Pharmaceuticals East Manruer, NJ) received accelerated approval on May 10, 2001 for the treatment of patients with chronic myeloid leukemia (CML) in (a) chronic phase after failure of IFN-alpha therapy, (b) accelerated phase, and (c) blast crisis."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12401900", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 430, 
                    "text": "Gleevec (imatinib mesylate), a highly promising new drug for the treatment of chronic myelogenous leukemia in blast crisis, in accelerated phase, and in chronic phase after interferon failure or intolerance, received orphan drug status from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development on January 31, 2001, and accelerated approval from the FDA for the above three indications on May 10, 2001."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11831069", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1482, 
                    "offsetInEndSection": 1549, 
                    "text": "Imatinib is the first effective systemic therapy for advanced GIST."
                }
            ], 
            "type": "list"
        }, 
        {
            "body": "What is the INSURE procedure in premature babies.", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007234"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22430447", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22266202", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21506654", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20642659", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20545934", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20180736", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19679893", 
                "http://www.ncbi.nlm.nih.gov/pubmed/10218338", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17069738"
            ], 
            "id": "515e078e298dcd4e51000031", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22430447", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 11, 
                    "offsetInEndSection": 311, 
                    "text": "Nasal continuous positive airway pressure (NCPAP) plus intubation, surfactant, and extubation (InSurE) with the option of back-up ventilation for those infants for whom noninvasive ventilatory support failed resulted in a significant increase in survival in extremely low birth weight (ELBW) infants."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22266202", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 281, 
                    "text": "The INSURE method, which consists of an intubation-surfactant-extubation sequence, is effective in reducing the need for mechanical ventilation (MV), the duration of respiratory support, and the need for surfactant replacement in preterm infants with respiratory distress syndrome."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21506654", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 11, 
                    "offsetInEndSection": 260, 
                    "text": "Our aim was to evaluate whether single and multiple intubation-surfactant-extubation (INSURE) procedures have similar effects on the need of mechanical ventilation (MV) and occurrence of bronchopulmonary dysplasia (BPD) in extremely preterm infants."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20642659", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 237, 
                    "offsetInEndSection": 374, 
                    "text": "Propofol seemed to be efficient, safe and ideally suited for the INSURE (Intubation SURfactant Extubation) procedure in preterm neonates."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20545934", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 11, 
                    "offsetInEndSection": 242, 
                    "text": "Surfactant given during brief intubation followed by immediate extubation on nasal continuous positive airway pressure [Intubation-Surfactant-Extubation (InSurE) approach] is used to treat respiratory distress syndrome in newborns."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20180736", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 11, 
                    "offsetInEndSection": 261, 
                    "text": "Our aim was to identify the clinical characteristics which could distinguish infants who can be managed with INSURE (intubatio-surfactant-extubation) method for preventing mechanical ventilation (MV) and which could predict INSURE success or failure."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19679893", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 208, 
                    "text": "In preterm infants with respiratory distress syndrome (RDS) nasal continuous positive airway pressure (nCPAP) with the \"InSurE\" procedure (intubation, surfactant, extubation) is increasingly used."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10218338", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 251, 
                    "offsetInEndSection": 574, 
                    "text": "In the Stockholm area, 12 VLBW infants born after 27-30 gestational weeks and suffering from RDS were recently treated using the INSURE (Intubation-SURfactant-Extubation) approach--i.e., surfactant therapy during brief intubation, immediately followed by extubation and continuous positive airway pressure (CPAP) treatment."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17069738", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 202, 
                    "offsetInEndSection": 392, 
                    "text": "Curosurf was given as early rescue therapy during a brief intubation (INSURE method: INtubation-SURfactant-Extubation) during treatment with nasal Continuous Positive Airway Pressure (CPAP)."
                }
            ], 
            "type": "summary"
        }, 
        {
            "body": "What is the function of the yeast protein Aft1?", 
            "concepts": [
                "http://www.uniprot.org/uniprot/AFT1_YEAST"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22157760", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21542867", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21361388", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20439772", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19469713", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17096368", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16648636", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16024809", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15649888", 
                "http://www.ncbi.nlm.nih.gov/pubmed/14739928", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11877447", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11223939", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9200812", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8670839", 
                "http://www.ncbi.nlm.nih.gov/pubmed/7720713"
            ], 
            "id": "51600ca2298dcd4e51000037", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7720713", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 177, 
                    "text": "Using a scheme for selecting mutants of Saccharomyces cerevisiae with abnormalities of iron metabolism, we have identified a gene, AFT1, that mediates the control of iron uptake"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7720713", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1216, 
                    "offsetInEndSection": 1358, 
                    "text": "AFT1 functions to activate transcription of target genes in response to iron deprivation and thereby plays a central role in iron homeostasis."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8670839", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 82, 
                    "text": "Iron-regulated DNA binding by the AFT1 protein controls the iron regulon in yeast"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8670839", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 159, 
                    "text": "Iron deprivation of Saccharomyces cerevisiae induces transcription of genes required for high-affinity iron uptake. AFT1 mediates this transcriptional control."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9200812", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 137, 
                    "text": "The AFT1 transcriptional factor is differentially required for expression of high-affinity iron uptake genes in Saccharomyces cerevisiae."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9200812", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1260, 
                    "offsetInEndSection": 1461, 
                    "text": "Aft1 displays phosphorylation modifications depending on the growth stage of the cells, and it might link induction of genes for iron uptake to other metabolically dominant requirement for cell growth."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11223939", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 352, 
                    "offsetInEndSection": 431, 
                    "text": "an aft1 mutation in S. cerevisiae that makes cells dependent on iron for growth"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11877447", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 106, 
                    "text": "Subcellular localization of Aft1 transcription factor responds to iron status in Saccharomyces cerevisiae."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11877447", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 275, 
                    "text": "The Aft1 transcription factor regulates the iron regulon in response to iron availability in Saccharomyces cerevisiae. Aft1 activates a battery of genes required for iron uptake under iron-starved conditions, whereas Aft1 function is inactivated under iron-replete conditions"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11877447", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 965, 
                    "offsetInEndSection": 1177, 
                    "text": "the nuclear export of Aft1 is critical for ensuring iron-responsive transcriptional activation of the Aft1 regulon and that the nuclear import/export systems are involved in iron sensing by Aft1 in S. cerevisiae."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14739928", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1154, 
                    "offsetInEndSection": 1197, 
                    "text": "the Aft1 iron-responsive DNA-binding factor"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15649888", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 101, 
                    "text": "Two transcriptional activators, Aft1 and Aft2, regulate iron homeostasis in Saccharomyces cerevisiae."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15649888", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1158, 
                    "offsetInEndSection": 1250, 
                    "text": "iron sensing by Aft1/Aft2 is not linked to the maturation of cytosolic/nuclear Fe-S proteins"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16024809", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 192, 
                    "text": "The yeast Saccharomyces cerevisiae contains a pair of paralogous iron-responsive transcription activators, Aft1 and Aft2. Aft1 activates the cell surface iron uptake systems in iron depletion,"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16024809", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1138, 
                    "offsetInEndSection": 1245, 
                    "text": "the absence of either Aft1 or Aft2 showed an iron-dependent increase in the amount of the remaining paralog"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16648636", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 132, 
                    "text": "The transcription factors Aft1 and Aft2 from Saccharomyces cerevisiae regulate the expression of genes involved in iron homeostasis."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17096368", 
                    "endSection": "title", 
                    "offsetInBeginSection": 108, 
                    "offsetInEndSection": 272, 
                    "text": "iron insufficiency-responsive transcription factor Aft1"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17096368", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 225, 
                    "offsetInEndSection": 472, 
                    "text": "The mRNA levels of 14 proteins involved in iron homeostasis were shown to be increased by cisplatin. Interestingly, the expression of all 14 genes is known to be regulated by Aft1, a transcription factor activated in response to iron insufficiency"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19469713", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 156, 
                    "text": "Aft1 is a transcriptional activator in Saccharomyces cerevisiae that responds to iron availability and regulates the expression of genes in the iron regulon"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19469713", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 224, 
                    "offsetInEndSection": 310, 
                    "text": "we found that Aft1 physically interacts with the FOB (ferrioxamine B) transporter Arn3"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19469713", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 787, 
                    "offsetInEndSection": 911, 
                    "text": "These results suggest that Aft1 interacts with Arn3 and may regulate the ubiquitination of Arn3 in the cytosolic compartment"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20439772", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 247, 
                    "text": "The Saccharomyces cerevisiae transcription factor Aft1 is activated in iron-deficient cells to induce the expression of iron regulon genes, which coordinate the increase of iron uptake and remodel cellular metabolism to survive low-iron conditions"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20439772", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 262, 
                    "offsetInEndSection": 375, 
                    "text": "Aft1 has been implicated in numerous cellular processes including cell-cycle progression and chromosome stability"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20439772", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1093, 
                    "offsetInEndSection": 1485, 
                    "text": "We demonstrate that Aft1 works in parallel with the RIM101 pH pathway and the role of Aft1 in DNA damage repair is mediated by iron. In contrast, through both directed studies and microarray transcriptional profiling, we show that the role of Aft1 in chromosome maintenance and benomyl resistance is independent of its iron regulatory role, potentially through a nontranscriptional mechanism."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21361388", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 175, 
                    "text": "Aft1p is a major iron regulator in budding yeast Saccharomyces cerevisiae. It indirectly senses cytosolic Fe status and responds by activating or repressing iron regulon genes"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21542867", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 175, 
                    "offsetInEndSection": 276, 
                    "text": "Expression of components of the high-affinity system is controlled by the Aft1 transcriptional factor"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22157760", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 119, 
                    "text": "Iron-responsive transcription factor Aft1 interacts with kinetochore protein Iml3 and promotes pericentromeric cohesin"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22157760", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 191, 
                    "text": "The Saccharomyces cerevisiae iron-responsive transcription factor, Aft1, has a well established role in regulating iron homeostasis through the transcriptional induction of iron-regulon genes"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22157760", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 202, 
                    "offsetInEndSection": 325, 
                    "text": "recent studies have implicated Aft1 in other cellular processes independent of iron regulation such as chromosome stability"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22157760", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 392, 
                    "offsetInEndSection": 454, 
                    "text": "Aft1 interacts with and co-localizes with kinetochore proteins"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22157760", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 837, 
                    "offsetInEndSection": 915, 
                    "text": "Our work defines a new role for Aft1 in chromosome stability and transmission."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20439772", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 693, 
                    "offsetInEndSection": 912, 
                    "text": "Our genetic network reveals that Aft1 affects a diverse range of cellular processes, including the RIM101 pH pathway, cell-wall stability, DNA damage, protein transport, chromosome stability, and mitochondrial function."
                }
            ], 
            "type": "summary"
        }, 
        {
            "body": "Have microRNAs been implicated in pharmacogenomics? ", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D010597", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D035683"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23376192", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23189953", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22630332", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22445829", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21499217", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21412770", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21047203", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20585341", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18187804", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17483436", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16854228", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22909203"
            ], 
            "id": "5162a089298dcd4e51000043", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23376192", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 156, 
                    "offsetInEndSection": 435, 
                    "text": "A major discovery is the ability of miRNAs to determine the efficacy of drugs, which has given rise to the field of 'miRNA pharmacogenomics' through 'Pharmaco-miRs'. miRNAs play a significant role in pharmacogenomics by down-regulating genes that are important for drug function."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23189953", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 878, 
                    "offsetInEndSection": 1199, 
                    "text": "The potential modulation of toxicology-related changes in miRNA expression, the role of miRNA in immune-mediated drug-induced liver injuries, the use of circulating miRNAs in body fluids as potential toxicological biomarkers, and the link between miRNA-related pharmacogenomics and adverse drug reactions are highlighted."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22445829", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 232, 
                    "offsetInEndSection": 531, 
                    "text": "Single nucleotide polymorphisms (SNPs) in the miRNA target sequences may affect or impair the binding of miRNAs. Studies have shown that SNPs in miRNA target sites (miR-TS-SNPs) have a great influence on diverse biological functions, including pharmacogenomics and disease susceptibilities in human."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22630332", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 407, 
                    "text": "Regulatory elements play an important role in the variability of individual responses to drug treatment. This has been established through studies on three classes of elements that regulate RNA and protein abundance: promoters, enhancers and microRNAs. Each of these elements, and genetic variants within them, are being characterized at an exponential pace by next-generation sequencing (NGS) technologies."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22630332", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1081, 
                    "offsetInEndSection": 1471, 
                    "text": "there is no doubt that these approaches will bring about a systems-level understanding of the interplay between genetic variants and drug response. An understanding of the importance of regulatory variants in pharmacogenomics will facilitate the identification of responders versus non-responders, the prevention of adverse effects and the optimization of therapies for individual patients."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21499217", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 454, 
                    "offsetInEndSection": 782, 
                    "text": "Pharmacogenomics genes can be divided into drug target genes termed as pharmacodynamics genes (PD) and genes involved in drug transport and metabolism termed as pharmacokinetics genes (PK). To clarify the regulatory potential of miRNAs in pharmacogenomics, we have examined the potential regulation by miRNAs of PK and PD genes."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21499217", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1284, 
                    "offsetInEndSection": 1786, 
                    "text": "Our analysis identify a striking difference in the level of miRNA regulation between PK and PD genes, with the former having less than half predicted conserved miRNA binding sites compared with the latter. Importantly, this finding is reflected in a highly significant difference in the shift in expression levels of PD versus PK genes after depletion of miRNAs. CONCLUSIONS: Our study emphasizes an intrinsic difference between PK and PD genes and helps clarify the role of miRNAs in pharmacogenomics."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21412770", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 419, 
                    "text": "Pharmacogenomics, toxicogenomics, and small RNA expression analysis are three of the most active research topics in the biological, biomedical, pharmaceutical, and toxicological fields. All of these studies are based on gene expression analysis, which requires reference genes to reduce the variations derived from different amounts of starting materials and different efficiencies of RNA extraction and cDNA synthesis."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21412770", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2269, 
                    "offsetInEndSection": 2426, 
                    "text": "In contrast, hTBCA and small RNAs are more stable during drug treatment, and they are better reference genes for pharmacogenomics and toxicogenomics studies."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21047203", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 11, 
                    "offsetInEndSection": 152, 
                    "text": "Polymorphisms of genes involved in the pharmacokinetic and pharmacodynamic processes underlie the divergent drug responses among individuals."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21047203", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1036, 
                    "offsetInEndSection": 1167, 
                    "text": "A panel of drug-response genes was constructed, which contains 923 pharmacokinetic genes, 703 pharmacodynamic genes and 720 miRNAs."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20585341", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 123, 
                    "offsetInEndSection": 243, 
                    "text": "miRNA variations can affect drug resistance, efficacy, and metabolism, opening new avenues of pharmacogenomics research."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18187804", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 260, 
                    "offsetInEndSection": 467, 
                    "text": "we studied the pharmacologic roles of three microRNAs previously implicated in cancer biology (let-7i, mir-16, and mir-21) and also used in silico methods to test pharmacologic microRNA effects more broadly."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18187804", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1322, 
                    "offsetInEndSection": 1781, 
                    "text": "n silico comparison of drug potencies with microRNA expression profiles across the entire NCI-60 panel revealed that approximately 30 microRNAs, including mir-21, show highly significant correlations with numerous anticancer agents. Ten of those microRNAs have already been implicated in cancer biology. Our results support a substantial role for microRNAs in anticancer drug response, suggesting novel potential approaches to the improvement of chemotherapy."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17483436", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 392, 
                    "offsetInEndSection": 603, 
                    "text": "The NCI-60 has also been profiled for mRNA and protein expression, mutational status, chromosomal aberrations, and DNA copy number, generating an unparalleled public resource for integrated chemogenomic studies."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17483436", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 738, 
                    "offsetInEndSection": 941, 
                    "text": "To complement the existing NCI-60 data sets, we have measured expression levels of microRNAs in the NCI-60 and incorporated the resulting data into the CellMiner program package for integrative analysis."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17483436", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1375, 
                    "offsetInEndSection": 1765, 
                    "text": ". Comparison of microRNA expression patterns and compound potency patterns showed significant correlations, suggesting that microRNAs may play a role in chemoresistance. Combined with gene expression and other biological data using multivariate analysis, microRNA expression profiles may provide a critical link for understanding mechanisms involved in chemosensitivity and chemoresistance."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22909203", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 296, 
                    "offsetInEndSection": 364, 
                    "text": "This study reports on miRNAs implicated in SSRI sensitivity of LCLs."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22909203", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 949, 
                    "offsetInEndSection": 1071, 
                    "text": "these miRNAs as tentative SSRI response biomarkers awaits validation with lymphocyte samples of major depression patients."
                }
            ], 
            "triples": [
                {
                    "o": "http://purl.uniprot.org/pubmed/12052143", 
                    "p": "http://www.w3.org/2004/02/skos/core#exactMatch", 
                    "s": "http://purl.uniprot.org/pubmed/12052143"
                }, 
                {
                    "o": "Pharmacogenomics", 
                    "p": "http://purl.uniprot.org/core/name", 
                    "s": "http://purl.uniprot.org/pubmed/15584875"
                }, 
                {
                    "o": "http://purl.uniprot.org/pubmed/16886893", 
                    "p": "http://www.w3.org/2004/02/skos/core#exactMatch", 
                    "s": "http://purl.uniprot.org/pubmed/16886893"
                }, 
                {
                    "o": "Pharmacogenomics", 
                    "p": "http://purl.uniprot.org/core/name", 
                    "s": "http://purl.uniprot.org/pubmed/16981842"
                }, 
                {
                    "o": "Pharmacogenomics", 
                    "p": "http://purl.uniprot.org/core/name", 
                    "s": "http://purl.uniprot.org/pubmed/17638511"
                }, 
                {
                    "o": "http://purl.uniprot.org/pubmed/17391071", 
                    "p": "http://www.w3.org/2004/02/skos/core#exactMatch", 
                    "s": "http://purl.uniprot.org/pubmed/17391071"
                }, 
                {
                    "o": "http://purl.uniprot.org/pubmed/17716225", 
                    "p": "http://www.w3.org/2004/02/skos/core#exactMatch", 
                    "s": "http://purl.uniprot.org/pubmed/17716225"
                }, 
                {
                    "o": "Pharmacogenomics", 
                    "p": "http://purl.uniprot.org/core/name", 
                    "s": "http://purl.uniprot.org/pubmed/17979512"
                }
            ], 
            "type": "yesno"
        }, 
        {
            "body": "What are the known families of deadenylases?", 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23388391", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21965533", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21245038", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19605561", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19276069", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12590136", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11747467", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22073225", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20628353", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15769875", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15044470", 
                "http://www.ncbi.nlm.nih.gov/pubmed/14618157", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11889047"
            ], 
            "id": "5162c8a8298dcd4e51000047", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21245038", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2737, 
                    "offsetInEndSection": 2869, 
                    "text": "All deadenylases characterized to date belong to either the DEDD or the exonuclease\u2013endonuclease\u2013phosphatase (EEP) superfamily (17)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21245038", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 3024, 
                    "offsetInEndSection": 3105, 
                    "text": "In humans, members of this group include the POP2, CAF1Z, PARN and PAN2 proteins."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21245038", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 3271, 
                    "offsetInEndSection": 3674, 
                    "text": "This group comprises enzymes active on both DNA and RNA, and includes the CCR4, Nocturnin and ANGEL proteins.Here we show that human 2\u2032-PDE, unlike other components constituting the 2\u20135A system (24\u201329), is located in the mitochondrial matrix compartment, and comprises a general 3\u2032\u20135\u2032 exoribonuclease exhibiting a preference for oligo-adenosine RNA like canonical cytoplasmic deadenylases (21,22,30\u201333)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23388391", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 157, 
                    "offsetInEndSection": 377, 
                    "text": "Among the deadenylase family, poly(A)-specific ribonuclease (PARN) is unique in its domain composition, which contains three potential RNA-binding domains: the catalytic nuclease domain, the R3H domain and the RRM domain"
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21965533", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 8908, 
                    "offsetInEndSection": 9101, 
                    "text": "Finally, as many members of the EEP family are also active on DNA, we tested if Ngl3p would be able to degrade a deoxy nucleotide substrate with a sequence identical to RNA-polyA10 (Figure 2D)."
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21965533", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 14294, 
                    "offsetInEndSection": 14488, 
                    "text": "As several members of the EEP family are known endonucleases, we wanted to investigate whether Ngl3p, in addition to functioning as a 3\u2032\u20135\u2032 exonuclease, could also cleave RNA by endonucleolysis."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19605561", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 813, 
                    "offsetInEndSection": 1090, 
                    "text": "On the other hand, the interaction between CNOT7 and BTG2, a member of the antiproliferative BTG/Tob family involved in transcription and mRNA decay appears less important for proliferation of MCF7 cells, suggesting that CNOT7 does not function solely in conjunction with BTG2."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19276069", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 310, 
                    "text": "The Tob/BTG family is a group of antiproliferative proteins containing two highly homologous regions, Box A and Box B. These proteins all associate with CCR4-associated factor 1 (Caf1), which belongs to the ribonuclease D (RNase D) family of deadenylases and is a component of the CCR4-Not deadenylase complex."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12590136", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 115, 
                    "text": "The CCR4 family proteins are 3'-5'-deadenylases that function in the first step of the degradation of poly(A) mRNA."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22073225", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2334, 
                    "offsetInEndSection": 3159, 
                    "text": "Nocturnin is a member of the CCR4 family of deadenylases, of which there are 5 in mice and humans [11], [12]. A single Ccr4p protein exists in yeast and interacts with Caf1p/Pop2p proteins as part of the Ccr4-Not complex \u2013 the major deadenylase in yeast [13], [14], [15]. In mammals, the members of this family all contain a conserved Mg++-dependent nuclease domain similar to that found in yeast Ccr4p and typified by the apurinic/apyrimidinic endonuclease (APE) family of proteins [11], but only two of the members of this family (called \u201cCcr4a\u201d and \u201cCcr4b\u201d in humans) have N-terminal extensions that contain leucine-rich repeats like those necessary for the Caf1p/Pop2p interaction in yeast. The other three members, including Nocturnin (also known as \u201chCcr4c\u201d in humans) are shorter, lacking these N-terminal domains."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20628353", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 226, 
                    "text": "CCR4, an evolutionarily conserved member of the CCR4-NOT complex, is the main cytoplasmic deadenylase. It contains a C-terminal nuclease domain with homology to the endonuclease-exonuclease-phosphatase (EEP) family of enzymes."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15769875", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 108, 
                    "text": "The yeast Pop2 protein, belonging to the eukaryotic Caf1 family, is required for mRNA deadenylation in vivo."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15044470", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 178, 
                    "offsetInEndSection": 308, 
                    "text": "Although CAF1 protein belongs to the DEDDh family of RNases, CCR4 appears to be the principle deadenylase of the CCR4-NOT complex."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15044470", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 417, 
                    "offsetInEndSection": 630, 
                    "text": "Like CCR4, increased length of RNA substrates converted mCAF1 into a processive enzyme. In contrast to two other DEDD family members, PAN2 and PARN, mCAF1 was not activated either by PAB1 or capped RNA substrates."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14618157", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 346, 
                    "offsetInEndSection": 462, 
                    "text": "The domain has the fold of the DnaQ family and represents the first structure of an RNase from the DEDD superfamily."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11889047", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 253, 
                    "offsetInEndSection": 452, 
                    "text": "The evolutionarily conserved CCR4 protein, which is part of the cytoplasmic deadenylase, contains a C-terminal domain that displays homology to an Mg2+-dependent DNase/phosphatase family of proteins."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11889047", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1051, 
                    "offsetInEndSection": 1219, 
                    "text": "These results establish that CCR4 and most probably other members of a widely distributed CCR4-like family of proteins constitute a novel class of RNA-DNA exonucleases."
                }
            ], 
            "triples": [
                {
                    "o": "Cytoplasmic deadenylase", 
                    "p": "http://purl.uniprot.org/core/fullName", 
                    "s": "http://linkedlifedata.com/resource/#_51354137363100D"
                }, 
                {
                    "o": "mRNA deadenylase", 
                    "p": "http://purl.uniprot.org/core/fullName", 
                    "s": "http://linkedlifedata.com/resource/#_443256444B36007"
                }
            ], 
            "type": "list"
        }, 
        {
            "body": "Could DNA (cytosine-5-)-methyltransferases serve as tumour markers?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004248"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23100393", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22330137", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21629434", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21150312", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20454457", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17965599", 
                "http://www.ncbi.nlm.nih.gov/pubmed/1684097", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21458988", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20460473", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19468253"
            ], 
            "id": "5162e9df298dcd4e5100004b", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23100393", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 385, 
                    "offsetInEndSection": 611, 
                    "text": "Here, we provide evidence that the expression of de novo DNA methyltransferases (DNMTs) is deregulated in MM cells. Moreover, we show that miR-29b targets DNMT3A and DNMT3B mRNAs and reduces global DNA methylation in MM cells."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22330137", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 226, 
                    "offsetInEndSection": 398, 
                    "text": "Here, we report evidence of the overexpression of DNA methyltransferases 3B (DNMT3B) in invasive cervical cancer and of the inhibition of metastasis by DNMT3B interference."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21629434", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 45, 
                    "text": "Cytosine methyltransferases as tumor markers."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21629434", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1105, 
                    "offsetInEndSection": 1339, 
                    "text": "The aberrant CpG methylation patterns in human cancer cells are inscribed by the de novo DNA cytosine-5 methyltransferases (DNMTs), DNMT3a and DNMT3b, and transmitted in the subsequent cell generations by the maintenance DNMT1 [4, 6]."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21629434", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1473, 
                    "offsetInEndSection": 1585, 
                    "text": "In the current paper, a comprehensive review of CpG methylation, DNA methyltransferases and cancer is presented."
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21629434", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 2387, 
                    "offsetInEndSection": 2796, 
                    "text": "It has been demonstrated that DNMT1 accounts for the majority of de novo methyltransferase activity in protein extracts from human colon cancer cells [86]. Taking into account the low intrinsic de novo methyltransferase ability of DNMT1 cases [6, 77], this protein may also be capable of initiating aberrant CpG island methylation patterns, replacing the conventional de novo DNMT3s, at least in cancer cells."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21150312", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 238, 
                    "text": "This study was designed to determine the significance of DNA methyltransferases (DNMTs) in DNA hypermethylation in esophageal squamous cell carcinoma (ESCC) and to identify DNA methylation markers in serum for the early diagnosis of ESCC."
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20454457", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 761, 
                    "offsetInEndSection": 881, 
                    "text": "DNA methyltransferases, expressed at relatively low levels in somatic cells, are frequently upregulated in cancer cells."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21458988", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 118, 
                    "text": "DNA methyltransferase 1 as a predictive biomarker and potential therapeutic target for chemotherapy in gastric cancer."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21458988", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 178, 
                    "offsetInEndSection": 342, 
                    "text": "We examined the prognostic and predictive impact of DNA methyltransferase (DNMT) 1 and 3b expression in gastric carcinomas (GC) treated by neoadjuvant chemotherapy."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21458988", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 970, 
                    "offsetInEndSection": 1072, 
                    "text": "High DNMT1 and DNMT3b expression was found in 105/127 (83%) and 79/127 (62%) carcinomas, respectively."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21150312", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1005, 
                    "offsetInEndSection": 1132, 
                    "text": "Tumoral DNMT3b mRNA up-regulation was significantly correlated with hypermethylation of multiple tumor-related genes (P=0.021)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17965599", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 932, 
                    "offsetInEndSection": 1406, 
                    "text": "A regulator of de novo DNA methyltransferases DNMT3A and DNMT3B, DNMT3L promoter was found to have lost DNA methylation to varying levels in 14 out of 15 cancer cervix samples analysed. The present study highlights the importance of DNA methylation profile at DNMT3L promoter not only as a promising biomarker for cervical cancer, which is the second most common cancer among women worldwide, but also provides insight into the possible role of DNMT3L in cancer development."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20460473", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 86, 
                    "text": "DNMT3L is a novel marker and is essential for the growth of human embryonal carcinoma."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20460473", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 753, 
                    "offsetInEndSection": 1040, 
                    "text": "Among the DNMT genes, we found that mRNA for DNMT3L was specifically expressed in TGCTs, but neither in normal testicular tissues nor in cancer cells of somatic tissue origin. DNMT3L protein was strongly expressed in two EC cell lines, but not in the cell lines of somatic tissue origin."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19468253", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 970, 
                    "offsetInEndSection": 1297, 
                    "text": "Positive nuclear labeling for DNMT3a was found only in few neoplasms: 1 pleomorphic adenoma (9.0%), 2 adenoid cystic carcinoma (16.6%) and 1 mucoepidermoid (9.0%) cases. CONCLUSIONS: Our results were not able to demonstrate a clear correlation between DNMT1 and DNMT3a immunoexpression and salivary gland neoplasms development."
                }
            ], 
            "type": "yesno"
        }, 
        {
            "body": "Do DNA double-strand breaks play a causal role in carcinogenesis?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D053903"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23469115", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23450137", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23393345", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22979979", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22366412", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22170030", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22034884", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21511815", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21421565", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21281740", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20663777", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20373286", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19027772", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17985346", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17919494", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17494053", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16650867", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16596281", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11285192", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11178982", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9111196"
            ], 
            "id": "5162f5b6298dcd4e5100004c", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23469115", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 201, 
                    "offsetInEndSection": 375, 
                    "text": "Densely ionizing radiation induces complex damage consisting of different types of DNA lesions in close proximity that are difficult to repair and may promote carcinogenesis."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23450137", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 509, 
                    "offsetInEndSection": 722, 
                    "text": "It is well-known that the extremely large localized energy deposition can lead to complex types of DNA double strand breaks. These effects can lead to cell death, mutations, genomic instability, or carcinogenesis."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23393345", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 127, 
                    "offsetInEndSection": 410, 
                    "text": "The DNA non-homologous end-joining repair gene XRCC6/Ku70 plays an important role in the repair of DNA double-strand breaks (DSBs) induced by both exogenous and endogenous DNA-damaging agents. Defects in overall DSB repair capacity can lead to genomic instability and carcinogenesis."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22979979", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 4613, 
                    "offsetInEndSection": 4732, 
                    "text": "The latter targets might be suitable to sensitize carcinomas to DSBs-inducing therapeutics by promoting apoptosis [21]."
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22979979", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 7190, 
                    "offsetInEndSection": 7316, 
                    "text": "This is in agreement with the reported potentiation of SSBs-induced cell death by ATR inactivation in carcinoma cells [35,36]."
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22979979", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 34827, 
                    "offsetInEndSection": 34935, 
                    "text": "Moreover, breast cancer 1, early onset (BRCA1) is essential for homologous recombination repair of DSBs [1]."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22979979", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 10, 
                    "offsetInEndSection": 123, 
                    "text": "DNA damage is of profound biomedical interest, as this type of lesions largely contributes to cancerogenesis [1]."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22170030", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 364, 
                    "text": "The tumor suppressor breast cancer susceptibility protein 1 (BRCA1) protects our cells from genomic instability in part by facilitating the efficient repair of DNA double-strand breaks (DSBs). BRCA1 promotes the error-free repair of DSBs through homologous recombination and is also implicated in the regulation of nonhomologous end joining (NHEJ) repair fidelity."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22170030", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1258, 
                    "offsetInEndSection": 1391, 
                    "text": "The increased frequency of DSB mutagenesis and MMEJ repair in the absence of BRCA1 suggests a potential mechanism for carcinogenesis."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21511815", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 223, 
                    "text": "DNA double-strand breaks (DSBs) represent one of the most serious forms of DNA damage that can occur in the genome and their correct repair is critical for the avoidance of chromosomal translocations and cancer."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21421565", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 140, 
                    "text": "Irreparable complex DNA double-strand breaks induce chromosome breakage in organotypic three-dimensional human lung epithelial cell culture."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21421565", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 92, 
                    "text": "DNA damage and consequent mutations initiate the multistep carcinogenic process."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21421565", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1510, 
                    "offsetInEndSection": 1704, 
                    "text": "Most of the work on induction and repair of DNA damage and signaling pathways involved in DNA repair and carcinogenesis has been performed in proliferating, two-dimensional (2D) culture systems."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21421565", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 4333, 
                    "offsetInEndSection": 4511, 
                    "text": "However, in certain circumstances, such as when tissue must be repaired, these cells can re-enter the cell cycle and DNA damage might initiate the multistep carcinogenic process."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21421565", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 5644, 
                    "offsetInEndSection": 5830, 
                    "text": "Thus, downregulation of multiple DNA repair pathway genes in differentiated cells renders them vulnerable to complex DSBs that might promote genome instability leading to carcinogenesis."
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21421565", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 21469, 
                    "offsetInEndSection": 21662, 
                    "text": "To investigate how impaired DSB repair may lead to the initiation of carcinogenesis, we evaluated chromosomal aberrations in metaphase cells derived from the monolayer and organotypic cultures."
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21421565", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 23318, 
                    "offsetInEndSection": 23434, 
                    "text": "The genomic instability that results from these aberrations presumably facilitates the initiation of carcinogenesis."
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21421565", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 1304, 
                    "offsetInEndSection": 1515, 
                    "text": "Thus, our data suggest that downregulation of multiple DNA repair pathway genes in differentiated cells renders them vulnerable to chromosomal damage and may promote genome instability leading to carcinogenesis."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21281740", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 153, 
                    "text": "Comet assay under neutral conditions allows detection of DNA double-strand breaks (DSBs), which has consequence to genome instability and carcinogenesis."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20663777", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 90, 
                    "text": "Loss of p15/Ink4b accompanies tumorigenesis triggered by complex DNA double-strand breaks."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20663777", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 97, 
                    "offsetInEndSection": 341, 
                    "text": "Although DSBs are potentially carcinogenic, it is not clear whether complex DSBs that are refractory to repair are more potently tumorigenic compared with simple breaks that can be rapidly repaired, correctly or incorrectly, by mammalian cells."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20373286", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 133, 
                    "text": "Aurora-A expressing tumour cells are deficient for homology-directed DNA double strand-break repair and sensitive to PARP inhibition."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20373286", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2187, 
                    "offsetInEndSection": 2483, 
                    "text": "Deficiency in the DNA repair processes that normally deal with DSBs is associated with cancer susceptibility as illustrated by the tumour suppressor activity of breast and ovarian cancer susceptibility genes BRCA1 and BRCA2 which both are part of the DSB repair machinery (Kastan & Bartek, 2004)."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19027772", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 94, 
                    "text": "Zinc chromate induces chromosome instability and DNA double strand breaks in human lung cells."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19027772", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 356, 
                    "offsetInEndSection": 517, 
                    "text": "Our study shows that zinc chromate induced concentration-dependent increases in cytotoxicity, chromosome damage and DNA double strand breaks in human lung cells."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17985346", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 123, 
                    "text": "Foci formation of P53-binding protein 1 in thyroid tumors: activation of genomic instability during thyroid carcinogenesis."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17919494", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 116, 
                    "text": "Nitric oxide and acid induce double-strand DNA breaks in Barrett's esophagus carcinogenesis via distinct mechanisms."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17494053", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 66, 
                    "text": "DNA double-strand break repair capacity and risk of breast cancer."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17494053", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 292, 
                    "text": "A tumorigenic role of the non-homologous end-joining (NHEJ) pathway for the repair of DNA double-strand breaks (DSBs) has been suggested by our finding of a significant association between increased breast cancer risk and a cooperative effect of single-nucleotide polymorphisms in NHEJ genes."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16650867", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 76, 
                    "text": "Carcinogen-induced DNA double strand break repair in sporadic breast cancer."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16650867", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 473, 
                    "text": "Induction of DNA double strand breaks and alterations in the repair of these breaks is implicated in breast carcinogenesis. Prior studies have demonstrated that peripheral blood mononuclear cells (PBMC) from breast cancer patients exhibit increased numbers of DNA strand breaks after exposure to ionizing radiation, but these studies did not specifically measure DNA double strand breaks and it is not known whether chemical carcinogens produce similar effects."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16596281", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 64, 
                    "text": "Abnormal DNA end-joining activity in human head and neck cancer."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16596281", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 475, 
                    "text": "In human cells, DNA double-strand breaks (DSBs) are repaired primarily by the DNA end-joining (EJ) process and thus, abnormal DNA EJ activities lead to an accumulation of mutations and/or aneuploidy, resulting in genetic instability of cells. Since genetic instability is the hallmark of cancer cells, we studied the DNA EJ activities of normal, non-malignant immortalized and malignant human epithelial cells to investigate the association between DNA EJ and carcinogenesis."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11178982", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 95, 
                    "offsetInEndSection": 485, 
                    "text": "Homologous recombination repair plays an important role in DSB repair and impairment of this repair mechanism may lead to loss of genomic integrity, which is one of the hallmarks of cancer. Recent research has shown that the tumor suppressor genes p53 and BRCA1 and -2 are involved in the proper control of homologous recombination, suggesting a role of this type of repair in human cancer."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9111196", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 325, 
                    "text": "In order to study the role of DNA damage processing in the development of cutaneous squamous cell carcinoma (SCC), we assessed the ability of six keratinocyte cell lines from a multistage-tumor progression model to repair three types of DNA damage: pyrimidine dimers, oxidative DNA lesions and DNA double strand breaks (DSB)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9111196", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1822, 
                    "offsetInEndSection": 2004, 
                    "text": "However, an acquired deficiency in repairing DNA double strand breaks can be one mechanism promoting progression towards malignancy, possibly through impairing chromosomal stability."
                }
            ], 
            "type": "yesno"
        }, 
        {
            "body": "What disease is Velcade (bortezomib) mainly used for?", 
            "concepts": [
                "http://www.biosemantics.org/jochem#4241338", 
                "http://www.disease-ontology.org/api/metadata/DOID:4", 
                "http://www.disease-ontology.org/api/metadata/DOID:9974", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0042493", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0008144", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0017144", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0042737", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=2001023", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=2001025", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=2001040", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=2001039"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23176720", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22699304", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22381702", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22353937", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22189222", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22087865", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22028144", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21839906", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21751810", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21634429", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21501555", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21223249", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20685499", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20079210", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19190249", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18410447", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18381602", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18327587", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17133426", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16470606", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15985470", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15626743"
            ], 
            "id": "51631154298dcd4e5100004e", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23176720", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 5, 
                    "offsetInEndSection": 40, 
                    "text": "patients with multiple myeloma (MM)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23176720", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 166, 
                    "offsetInEndSection": 242, 
                    "text": "bortezomib, and lenalidomide have shown improved outcomes in these patients."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22699304", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 11, 
                    "offsetInEndSection": 212, 
                    "text": "Bortezomib, a proteasome inhibitor drug very effective against multiple myeloma, may induce the so-called bortezomib-induced peripheral neuropathy (BIPN), hardly manageable with common analgesic drugs."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22381702", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 714, 
                    "offsetInEndSection": 800, 
                    "text": "bortezomib have emerged as effective treatment in patients with multiple myeloma (MM)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22189222", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 275, 
                    "offsetInEndSection": 481, 
                    "text": "the use of thalidomide to treat multiple myeloma, and describe problems arising in the Thaled\u00ae outpatient department. METHODS: Multiple myeloma patients treated with thalidomide at Hitachi General Hospital."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22189222", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1363, 
                    "offsetInEndSection": 1676, 
                    "text": "Thalidomide showed some success in treating multiple myeloma either after auto-PBSCT or following treatment with bortezomib. In the case demonstrating hematotoxicity Grade 3 (in addition to neutropenia), grave complications could have very easily developed, thus underscoring the importance of careful monitoring."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22087865", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 525, 
                    "offsetInEndSection": 731, 
                    "text": "Patients aged \u226518 years with relapsed or refractory multiple myeloma or non-Hodgkin's lymphoma received intravenous bortezomib 1.3\u2009mg/m2, administered on days 1, 4, 8 and 11 of a 21-day cycle, for 3 cycles."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22087865", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2100, 
                    "offsetInEndSection": 2414, 
                    "text": "In patients with multiple myeloma or non-Hodgkin's lymphoma, co-administration of rifampicin decreased the exposure to bortezomib but did not affect the proteasome inhibition or safety profiles; co-administration of dexamethasone did not affect the exposure to bortezomib, proteasome inhibition or safety profiles."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22028144", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 615, 
                    "offsetInEndSection": 818, 
                    "text": "we provide data comparing sFLC with M protein as biomarkers of response in newly diagnosed patients with MM undergoing induction therapy with the novel agents thalidomide, lenalidomide and/or bortezomib."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21839906", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 96, 
                    "offsetInEndSection": 245, 
                    "text": "Bortezomib, indicated for multiple myeloma (MM) treatment, is available in 3.5-mg vials, a quantity higher than the average dose commonly prescribed."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21634429", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 165, 
                    "text": "Bortezomib, a dipeptidyl boronic acid and potent inhibitor of the 26S proteasome, is remarkably effective against multiple myeloma (MM) but not against solid tumors."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21501555", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 26, 
                    "offsetInEndSection": 257, 
                    "text": "efficacy and safety of bortezomib (BOR) for treatment of multiple myeloma in comparison with thalidomide (THAL) by reference to adverse events, and searched for laboratory markers that could be used for prognostication of patients."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21501555", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 607, 
                    "offsetInEndSection": 907, 
                    "text": "BOR showed a higher rate of effectiveness than THAL for refractory multiple myeloma, and its effects were rapid. BOR treatment prolonged the survival time of THAL-resistant patients. The efficacy of BOR was unrelated to patient age, the number of previous therapeutic regimens, or the disease period."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21501555", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1236, 
                    "offsetInEndSection": 1547, 
                    "text": "It is suggested that BOR has therapeutic efficacy for multiple myeloma as a first-line medical treatment and/or for patients with THAL resistance, and can improve prognosis and survival. Since serum ALP elevation was observed in many patients for whom BOR was effective, this may be a predictor of BOR efficacy."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21223249", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1065, 
                    "offsetInEndSection": 1404, 
                    "text": "Bortezomib-treated MM patients whose tumours had high baseline expression of genes suppressed by LCQ195 had significantly shorter progression-free and overall survival than those with low levels of these transcripts in their MM cells. These observations provide insight into the biological relevance of multi-targeted CDK inhibition in MM."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20685499", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 57, 
                    "offsetInEndSection": 294, 
                    "text": "bortezomib is the only effective agent in the treatment of plasma cell leukemia (PCL), a type of plasma cell dyscrasia characterized by poor prognosis despite conventional chemotherapy including autologous and allogeneic transplantation."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20685499", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2518, 
                    "offsetInEndSection": 2655, 
                    "text": "These 3 patients with primary or secondary PCL who received a bortezomib-based regimen as rescue medication did not respond to treatment."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20079210", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 11, 
                    "offsetInEndSection": 162, 
                    "text": "To evaluate the effects and safety of the regimen of bortezomib combined with dexamethasone (VD) in the treatment of primary systemic (AL) amyloidosis."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20079210", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 923, 
                    "offsetInEndSection": 1025, 
                    "text": "VD regimen might be an efficient, rapid effective and safe regimen in the treatment of AL amyloidosis."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19190249", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 240, 
                    "offsetInEndSection": 496, 
                    "text": "Bortezomib (BZM) is a proteasome inhibitor in clinical use for multiple myeloma. Here, we investigated whether the combination of these compounds would yield increased antitumor efficacy in multiple myeloma and glioblastoma cell lines in vitro and in vivo."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19190249", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1170, 
                    "offsetInEndSection": 1404, 
                    "text": "Taken together, our results indicate that green tea polyphenols may have the potential to negate the therapeutic efficacy of BZM and suggest that consumption of green tea products may be contraindicated during cancer therapy with BZM."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18410447", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 154, 
                    "text": "Relapsed/refractory myeloma has a poor outcome because of multi-drug resistance, patient low-performance status and toxicity of conventional chemotherapy."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18410447", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 273, 
                    "offsetInEndSection": 607, 
                    "text": "Bortezomib, by inhibiting proteasome function, may enhance chemosensitivity to other drugs and overcome drug-resistance. Notably, doxorubicin and bortezomib may reciprocally increase their efficacy. Thus, to improve outcome whilst minimizing therapy-related toxicity, liposomal doxorubicin was added to a bortezomib-based combination."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18381602", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 371, 
                    "offsetInEndSection": 703, 
                    "text": "the growth inhibitory and pro-apoptotic effects of the proteasome inhibitor bortezomib in combination with anti-EGFR drugs, such as gefitinib, vandetanib, and cetuximab in EGFR-expressing human cancer cell lines. Bortezomib determined dose-dependent growth inhibition in a nine cancer cell line panel (IC(50) values, range 6-42 nM)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18381602", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1280, 
                    "offsetInEndSection": 1727, 
                    "text": "overexpression of a constitutively active P-Akt protected A549 cells by cell growth inhibition and apoptosis following treatment with bortezomib and EGFR inhibitors. The combined treatment with bortezomib and EGFR inhibitors has a synergistic growth inhibitory and pro-apoptotic activity in different human cancer cells which possess a functional EGFR-dependent autocrine growth pathway through to a more efficient and sustained inhibition of Akt."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18327587", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1353, 
                    "offsetInEndSection": 1431, 
                    "text": "Among 19 patients with breast cancer, four had evidence of a clinical benefit."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18327587", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 11, 
                    "offsetInEndSection": 265, 
                    "text": "Pre-clinical studies combining the proteasome inhibitor bortezomib with anthracyclines have shown enhanced anti-tumor activity. We conducted a phase I trial of bortezomib and pegylated liposomal doxorubicin (PLD) in patients with refractory solid tumors."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18327587", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1554, 
                    "offsetInEndSection": 1722, 
                    "text": "A regimen of bortezomib, 1.3 mg/m(2) on days 1, 4, 8, and 11 with PLD, 30 mg/m(2), on day 4 of a 21-day cycle, was safe in this study, and merits further investigation."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17133426", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 132, 
                    "text": "Bortezomib, a proteasome inhibitor, has been used for patients with refractory and relapsed multiple myeloma, lymphoma and leukemia."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16470606", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 168, 
                    "text": "Bortezomib, a first-in-class proteasome inhibitor, has shown clinical activity in relapsed, refractory multiple myeloma in a pivotal Phase II trial, SUMMIT."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16470606", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1535, 
                    "offsetInEndSection": 1651, 
                    "text": "treatment with bortezomib results in meaningful long-term benefit for patients with relapsed and refractory myeloma."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15985470", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 205, 
                    "text": "The proteasome inhibitor bortezomib (BTZ), used in antineoplastic chemotherapy, must be diluted in NaCl 0.9% for injection and stored for no more than 3 hours in a syringe or 8 hours in a vial."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15626743", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 444, 
                    "text": "Proteasome inhibitors, a novel class of chemotherapeutic agents, enhance the antitumor efficacy of anthracyclines in vitro and in vivo. We therefore sought to determine the maximum tolerated dose (MTD) and dose-limiting toxicities of bortezomib and pegylated liposomal doxorubicin (PegLD). Bortezomib was given on days 1, 4, 8, and 11 from 0.90 to 1.50 mg/m2 and PegLD on day 4 at 30 mg/m2 to 42 patients with advanced hematologic malignancies."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15626743", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 943, 
                    "offsetInEndSection": 1471, 
                    "text": "Antitumor activity was seen against multiple myeloma, with 8 of 22 evaluable patients having a complete response (CR) or near-CR, including several with anthracycline-refractory disease, and another 8 having partial responses (PRs). One patient with relapsed/refractory T-cell non-Hodgkin lymphoma (NHL) achieved a CR, whereas 2 patients each with acute myeloid leukemia and B-cell NHL had PRs. Bortezomib/PegLD was safely administered in this study with promising antitumor activity, supporting further testing of this regimen."
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21751810", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 152, 
                    "offsetInEndSection": 501, 
                    "text": "BTZ is a dipeptide boronic acid analogue that inhibits cancer cell proteasome through direct binding between its boronic acid group and threonine residues in the active sites of several proteases.7,8 This drug is currently marketed as Velcade (Millenium Pharmaceuticals) and has been approved for multiple myeloma and mantle cell lymphoma treatment;"
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21751810", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 511, 
                    "offsetInEndSection": 599, 
                    "text": "BTZ is less active against many solid tumors and has significant dose-limiting toxicity."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20685499", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 694, 
                    "offsetInEndSection": 801, 
                    "text": "These patients were treated with bortezomib variously combined with other drugs outside of clinical trials."
                }
            ], 
            "triples": [
                {
                    "o": "http://www.w3.org/2008/05/skos-xl#Label", 
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A15661541"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A4368130", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1174739"
                }, 
                {
                    "o": "http://www.w3.org/2008/05/skos-xl#Label", 
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A4368130"
                }, 
                {
                    "o": "http://www.w3.org/2008/05/skos-xl#Label", 
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A7589426"
                }, 
                {
                    "o": "http://www.w3.org/2008/05/skos-xl#Label", 
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A10483519"
                }, 
                {
                    "o": "http://www.w3.org/2008/05/skos-xl#Label", 
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A4361967"
                }, 
                {
                    "o": "http://www.w3.org/2008/05/skos-xl#Label", 
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A7827139"
                }
            ], 
            "type": "factoid"
        }, 
        {
            "body": "How is myotonic dystrophy inherited?", 
            "concepts": [
                "http://www.disease-ontology.org/api/metadata/DOID:11722", 
                "http://www.disease-ontology.org/api/metadata/DOID:450", 
                "http://www.disease-ontology.org/api/metadata/DOID:655", 
                "http://www.disease-ontology.org/api/metadata/DOID:9884"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22332444", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18228241", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12970845", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12577208", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8154209"
            ], 
            "id": "51635202298dcd4e5100004f", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22332444", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 229, 
                    "text": "Myotonic dystrophy type 2 (DM2) is an autosomal dominant, multisystem disorder caused by a CCTG tetranucleotide repeat expansion located in intron 1 of the zinc finger protein 9 gene (ZNF9 gene) on chromosome 3q 21.3."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18228241", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 131, 
                    "text": "Myotonic dystrophy type 1 (DM1) is an autosomal dominant disorder, caused by an expansion of a CTG triplet repeat in the DMPK gene."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12970845", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 362, 
                    "text": "Myotonic dystrophy (DM), the most common form of muscular dystrophy in adults, is a clinically and genetically heterogeneous neuromuscular disorder. DM is characterized by autosomal dominant inheritance, muscular dystrophy, myotonia, and multisystem involvement. Type 1 DM (DM1) is caused by a (CTG)(n) expansion in the 3' untranslated region of DMPK in 19q13.3."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12970845", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 470, 
                    "offsetInEndSection": 677, 
                    "text": "proximal myotonic myopathy (PROMM) and type 2 DM (DM2) but without the DM1 mutation, showed linkage to the 3q21 region and were recently shown to segregate a (CCTG)(n) expansion mutation in intron 1 of ZNF9."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12970845", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 859, 
                    "offsetInEndSection": 905, 
                    "text": "All patients have the DM2 (CCTG)(n) expansion."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12577208", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 195, 
                    "text": "Myotonic dystrophy type 1 is a neuromuscular, degenerative and progressive disease, with an autosomal dominant pattern of inheritance, variable expressivity and incomplete penetrance."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12577208", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1174, 
                    "offsetInEndSection": 1259, 
                    "text": "The worldwide intergenerational behavior of the DM1 mutation is similar in Costa Rica"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8154209", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 99, 
                    "text": "Dystrophic myotonia is a sufficiently rare disease inherited mainly by the autosomal dominant type."
                }
            ], 
            "triples": [
                {
                    "o": "myotonic dystrophy", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A1189440"
                }, 
                {
                    "o": "Myotonic Dystrophy", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A12058083"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A12058083", 
                    "p": "http://www.w3.org/2008/05/skos-xl#prefLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C0027126"
                }
            ], 
            "type": "factoid"
        }, 
        {
            "body": "Is it safe to take isotretinoin during pregnancy?", 
            "concepts": [
                "http://www.biosemantics.org/jochem#4165261", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0007565", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015474", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011247", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D061685", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011259"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23559397", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21198520", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20436882", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19961047", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18937624", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17214828", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15545101", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12171680", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11445913", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9299599", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9091512", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9439011", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9035347", 
                "http://www.ncbi.nlm.nih.gov/pubmed/7962395", 
                "http://www.ncbi.nlm.nih.gov/pubmed/1473624", 
                "http://www.ncbi.nlm.nih.gov/pubmed/2102396", 
                "http://www.ncbi.nlm.nih.gov/pubmed/2923442", 
                "http://www.ncbi.nlm.nih.gov/pubmed/3162748", 
                "http://www.ncbi.nlm.nih.gov/pubmed/3209676", 
                "http://www.ncbi.nlm.nih.gov/pubmed/3501432", 
                "http://www.ncbi.nlm.nih.gov/pubmed/3459732", 
                "http://www.ncbi.nlm.nih.gov/pubmed/3162101"
            ], 
            "id": "51640b4a298dcd4e51000050", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23559397", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 83, 
                    "text": "Isotretinoin is a remarkably effective drug for severe, recalcitrant acne vulgaris."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23559397", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 134, 
                    "offsetInEndSection": 185, 
                    "text": "a number of important adverse effects were reported"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23559397", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1253, 
                    "offsetInEndSection": 1483, 
                    "text": "even the most recent pregnancy prevention program (iPledge) is no more successful than prior programs; there will likely always be a small number of female patients becoming pregnant while receiving isotretinoin for acne vulgaris."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21198520", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 11, 
                    "offsetInEndSection": 75, 
                    "text": "Isotretinoin has revolutionized the management of acne vulgaris."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21198520", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1225, 
                    "offsetInEndSection": 1383, 
                    "text": "The adverse effect(s) that led to patients stopping isotretinoin were cheilitis (22 patients), mood change (13), tiredness (12), eczema (6) and pregnancy (2)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20436882", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1133, 
                    "offsetInEndSection": 1369, 
                    "text": "Downregulation of FGFR2b-signaling by isotretinoin explains its therapeutic effect in acne. Downregulation of FGFR2b-signaling during the first trimester of pregnancy disturbs branched morphogenesis and explains retinoid embryotoxicity."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19961047", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 379, 
                    "text": "The isotretinoin, a 13-cis-retinoic acid, has revolutionized the management of severe treatment-resistant acne and it has been widely used for a range of dermatological conditions, in 90% of the time in young women between 13 and 45 years of age. This agent has severe teratogenic effects, as serious craniofacial, cardiovascular, thymic and central nervous system malformations."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19961047", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 412, 
                    "offsetInEndSection": 757, 
                    "text": "malformations is 3-5%, but it increases to almost 30% in women exposed to isotretinoin during the first trimester of pregnancy. Generally, patients in treatment with isotretinoin avoid eventual pregnancy during assumption and, after its stopping, fertility and foetal development are normal once circulating isotretinoin levels return to normal."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19961047", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1333, 
                    "offsetInEndSection": 1491, 
                    "text": "After 3 months of pharmacological wash out, patient become pregnant and manifested this severe malformation. Woman interrupted gestation, by labour induction."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18937624", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 224, 
                    "text": "Clindamycin phosphate 1.2% together with tretinoin 0.025% as a gel (CTG) is a topical formulation of a fixed and stable combination approved by the FDA for the treatment of acne vulgaris in patients 12 years of age or older."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18937624", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1130, 
                    "offsetInEndSection": 1186, 
                    "text": "Safety of CTG use in pregnancy has not been established."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17214828", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 11, 
                    "offsetInEndSection": 224, 
                    "text": "To estimate the population-based incidence rates of pregnancy, spontaneous and elective abortions, and birth defects associated with isotretinoin use, and to determine predictors of pregnancy while on isotretinoin"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17214828", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 706, 
                    "offsetInEndSection": 833, 
                    "text": "Pregnancies, spontaneous and elective abortions, and birth defects were identified using procedure codes and medical diagnoses."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17214828", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1043, 
                    "offsetInEndSection": 1347, 
                    "text": "90 women who became pregnant while on the drug, 76 terminated the pregnancy (84%), three had a spontaneous abortion (3%), two had trauma during delivery resulting in neonatal deaths (2%) and nine had a live birth (10%). Among the live births, only one had a congenital anomaly of the face and neck (11%)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17214828", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1870, 
                    "offsetInEndSection": 1929, 
                    "text": "elective abortion rates were also much higher in our study."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15545101", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 346, 
                    "text": "Topical antibiotics, isotretinoin or systemic antibiotics are usually used for acne therapy. However, isotretinoin cannot be used during pregnancy because it can cause significant birth defects while systemic antibiotics can have adverse side effects such as gastrointestinal irritation, photosensitivity and tetracycline sensitivity."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12171680", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 211, 
                    "text": "Isotretinoin has been used to treat acne since 1982. Its current indications in the package insert are limited and many physicians still feel uncomfortable prescribing it because of its side effects."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12171680", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1093, 
                    "offsetInEndSection": 1189, 
                    "text": "Aside from its teratogenic effect, isotretinoin is a safe and excellent drug for acne therapy. I"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12171680", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1347, 
                    "offsetInEndSection": 1375, 
                    "text": "a pregnancy test in females."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11445913", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 319, 
                    "text": "Vitamin A and its derivatives, retinoic acid, tretinoin and isotretinoin, are currently used in dermatological treatments. The administration of high doses of this vitamin provokes congenital malformations in mice: cleft palate, maxillary and mandibular hypoplasia and total or partial fusion of the maxillary incisors."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11445913", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 463, 
                    "offsetInEndSection": 905, 
                    "text": "Twelve 60-day-old female Mus musculus were divided into two groups on the 7th day of pregnancy: treated group--1 mg isotretinoin per kg body weight, dissolved in vegetable oil, was administered from the 7th to the 13th day of pregnancy; control group--vegetable oil in equivalent volume was administered orally for the same period. On the 16th day of pregnancy, the females were sacrificed, the fetuses were removed and their heads amputated."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11445913", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1049, 
                    "offsetInEndSection": 1272, 
                    "text": "The results showed that both groups had closed palates with no reminiscence of epithelial cells; however, the first molar germs of the isotretinoin-treated animals showed delayed development compared to the control animals."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9299599", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 123, 
                    "offsetInEndSection": 335, 
                    "text": "Isotretinoin (13-cis-RA) is teratogenic in all species examined; based on administered dose, humans appear most sensitive, followed by (in order or decreasing sensitivity) monkey, rabbit, hamster, mouse, and rat."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9299599", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2575, 
                    "offsetInEndSection": 2685, 
                    "text": "Based on embryonic delivered dose, we suggest that 13-cis-RA is an equipotent teratogen in hamster and rabbit."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9091512", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 153, 
                    "offsetInEndSection": 296, 
                    "text": "its safety in humans is occasionally questioned because oral ingestion of retinoids at therapeutic levels is known to entail teratogenic risks."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9091512", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1131, 
                    "offsetInEndSection": 1197, 
                    "text": "topical tretinoin is not a potential human developmental toxicant."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9439011", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 402, 
                    "text": "Teratogenicity of vitamin A was firstly detected in experimental animals in 1953. Nearly 30 years later, teratogenicity of vitamin A analogue-isotretinoin was reported in humans. Isotretinoin induces serious birth defects of craniofacial and central nervous system, cardiovascular system and thymic malformations--in about 25% of babies exposed during the first trimester of their prenatal development."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9439011", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 526, 
                    "offsetInEndSection": 713, 
                    "text": "high vitamin A intake in pregnant woman: Women who use daily vitamin A supplements during early pregnancy have approximately a two-fold increased risk of giving birth to a malformed baby."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9439011", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1377, 
                    "offsetInEndSection": 1576, 
                    "text": "Vitamin A started to affect development between doses 0.3-0.3 microm [corrected] per embryo. Malformations of head, extremities and heart were detected similarly like in laboratory mammals and in man"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9439011", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1875, 
                    "offsetInEndSection": 1988, 
                    "text": "the minimal embryotoxic doses of vitamin A in mammals were estimated to be between 0.1-1 mg/kg of maternal weight"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9439011", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2060, 
                    "offsetInEndSection": 2665, 
                    "text": "Human epidemiological studies have proved teratogenicity of vitamin A after daily doses 25,000 i.u.-8.3 mg (0.13 mg/kg)- and reduction of its maximum intake has been recommended to 10,000 i.u. per day (0.05 mg/kg). The results about teratogenicity of vitamin A achieved in the chick embryo are in agreement with such a recommendation. Intake of vitamin A in the food is sufficient for pregnant woman in common Czech population. Therefore, an artificial supplementation of vitamin A brings risk of overdosage. If supplementation by vitamin A is unavoidable during pregnancy, B-carotene should be preferred."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9035347", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 461, 
                    "offsetInEndSection": 551, 
                    "text": "a teratogenic dosing regimen with 13-cis-RA [Hummler et al. (1994) Teratology 50:184-193]."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9035347", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2942, 
                    "offsetInEndSection": 3397, 
                    "text": "plasma AUC values of all-trans-RA were 2- to 7-fold higher after all-trans-RA administration (present study) than after dosing with the teratogenic dose of 13-cis-RA. These results strengthen our recent suggestion that the teratogenic effects induced in cynomolgus monkeys by 13-cis-RA treatment cannot solely result from the action of all-trans-RA, but may involve 13-cis-RA and 13-cis-4-oxo-RA, which could act directly or function as transport vehicle."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7962395", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 128, 
                    "offsetInEndSection": 346, 
                    "text": "VITA, among others, is involved in the process of morphogenesis. In contrast, synthetic derivatives of VITA, specifically Tigasone (etretinate, TIG) and Roaccutane (isotretinoin, ROA), are regarded as major teratogens."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7962395", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 706, 
                    "offsetInEndSection": 1087, 
                    "text": "A biphasic maximal inhibition was present at 1 microM concentrations when the retinoids VITA, TIG and ROA were added for 16 h (52, 58 and 57%, respectively; P < 0.01 by one-way analysis of variance). In contrast, the addition of the three retinoids at 1 microM concentrations for 16 h had no significant effect on HCG secretion by placental explants of 11-13 weeks gestational age."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7962395", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1321, 
                    "offsetInEndSection": 1431, 
                    "text": "Inhibition of HCG secretion by retinoids may contribute either directly or indirectly to their teratogenicity."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1473624", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 271, 
                    "text": "Isotretinoin is a potent retinoic acid used in the treatment of skin disorders. Though very effective, it is teratogenic if administered during pregnancy, and its teratogenic effect may be related to the normal activity of retinoids as signalling molecules in the embryo."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1473624", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 390, 
                    "offsetInEndSection": 477, 
                    "text": "defects that includes heart defects, by inhibiting the migration of neural crest cells."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1473624", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 656, 
                    "offsetInEndSection": 804, 
                    "text": "Proliferation in heart tissue of whole embryo cultures was inhibited in medium with 10(-6) M isotretinoin to 62% of the control level in myocardium."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1473624", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1410, 
                    "offsetInEndSection": 1619, 
                    "text": "The results suggest multiple effects of retinoids on growth, morphogenesis, and differentiation of early cardiac tissue, and are discussed in relation to the potential role of retinoids in early embryogenesis."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2102396", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 606, 
                    "text": "Oral administration of 400 mg/kg of 13-cis retinoic acid to 9 day pregnant mice gives rise to important maxillofacial malformations. The first manifestation of teratogenic effect is an increase of density of cell death arising in the dorsal part of the first two branchial arches at day 9.5. These two arches become hypoplastic at days 10 and 11, and the preskeletal anlagen appear too late in comparison to control embryos. Meckel's cartilage is too curvilinear and medially situated. Pre-ossicular and pre-mandibular blastemata develop with spatial distortions which are well analyzable at days 16 and 17"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2923442", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 288, 
                    "text": "Isotretinoin (13-cis-retinoic acid, Accutane) increases the risk of major congenital malformations in infants exposed to isotretinoin during pregnancy. However, there have been no epidemiologic reports to date on the effect of a subsequent pregnancy after discontinuation of isotretinoin."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2923442", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 316, 
                    "offsetInEndSection": 443, 
                    "text": "analysis of pregnancy case reports from patients in whom conception occurred after isotretinoin treatment had been discontinued"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2923442", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 521, 
                    "offsetInEndSection": 699, 
                    "text": "spontaneous and missed abortions from all pregnancies was 9.1% (eight patients), and the incidence rate of congenital malformation among the live births was 5.0% (four patients)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2923442", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 744, 
                    "offsetInEndSection": 968, 
                    "text": "were not significantly different from the rates reported for women of reproductive age in the general population. In addition, the malformations reported were not characteristic of retinoic acid-induced congenital anomalies."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3162748", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 345, 
                    "text": "Keratolenticular dysgenesis (Peters' anomaly) was induced in mice by exposure to the human teratogens, ethanol or 13-cis retinoic acid (isotretinoin, Accutane). Acute teratogen exposure on the seventh day of gestation (corresponding to the third week of human gestation) resulted in an eye malformation incidence of 46% to 100% in day 14 fetuses"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3162748", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 706, 
                    "offsetInEndSection": 904, 
                    "text": "This secondary effect on neural crest derivatives is exhibited in the adult animals as corneal opacities associated with defects in Descemet's membrane and endothelium, and anterior polar cataracts."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3209676", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 38, 
                    "offsetInEndSection": 173, 
                    "text": "13-cis-retinoic acid (13-cis-RA, or isotretinoin) is responsible for various craniofacial malformations in the rodent and human embryo."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3209676", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 290, 
                    "offsetInEndSection": 440, 
                    "text": "In whole embryo culture, 13-cis-RA caused significant overall embryonic growth retardation, especially in the primary and secondary palatal processes."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3209676", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 999, 
                    "offsetInEndSection": 1498, 
                    "text": "subsequent cell growth was decreased at concentrations of 13-cis-RA greater than 1 X 10(-5) M. After a 40-hr treatment period, labeling indices in retinoid-treated cells were significantly lower than control values (25% compared with 40%). Retinoic acid also caused a significant, concentration-dependent decrease in 3H-thymidine incorporation. The inhibitory effect of 13-cis-RA on proliferation of oral-nasal mesenchymal cells appears to be related to the production of craniofacial malformations."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3501432", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 271, 
                    "text": "Reports of adverse human pregnancy outcomes including cleft palate have increased as the clinical use of isotretinoin (13-cis-retinoic acid) and other retinoic acid (RA) derivatives have increased, but the mechanisms by which their effects are exerted are not understood."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3501432", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1199, 
                    "offsetInEndSection": 1827, 
                    "text": "In shelves exposed to EGF and trans-RA early in their development, DNA synthesis appears to terminate prematurely as compared to shelves cultured in control media, and this effect is accompanied by excessive mesenchymal extracellular space expansion. Exposure of shelves to EGF alone is sufficient to block degeneration and induce hyperplasia of the medial epithelial cells but does not induce other ultrastructural changes seen with both EGF and RA. The observed alterations in medial cell morphology could interfere with adhesion of the palatal shelves and may play a role in retinoid-induced cleft palate in the human embryo."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3459732", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 206, 
                    "text": "Recent clinical observations strongly suggest that isotretinoin [13-cis-retinoic acid (cis RA)] is a human teratogen causing primarily heart and craniofacial malformations including ear and palatal defects."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3459732", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1456, 
                    "offsetInEndSection": 1699, 
                    "text": "Our results demonstrate that labeled cis RA enters the tissues of the embryo both in vivo and in vitro. Cis RA inhibited proliferation of the frontonasal mesenchyme cells in primary culture with 31% inhibition occurring at 2 X 10(-5) M cis RA."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3162101", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 536, 
                    "text": "Retinoic acid, an analogue of vitamin A, is known to be teratogenic in laboratory animals and has recently been implicated in a few clinical case reports. To study the human teratogenicity of this agent, we investigated 154 human pregnancies with fetal exposure to isotretinoin, a retinoid prescribed for severe recalcitrant cystic acne. The outcomes were 95 elective abortions, 26 infants without major malformations, 12 spontaneous abortions, and 21 malformed infants. A subset of 36 of the 154 pregnancies was observed prospectively."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3162101", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 639, 
                    "offsetInEndSection": 830, 
                    "text": "Exposure to isotretinoin was associated with an unusually high relative risk for a group of selected major malformations (relative risk = 25.6; 95 per cent confidence interval, 11.4 to 57.5)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3162101", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1360, 
                    "offsetInEndSection": 1568, 
                    "text": "It is possible that a major mechanism of isotretinoin teratogenesis is a deleterious effect on cephalic neural-crest cell activity that results in the observed craniofacial, cardiac, and thymic malformations."
                }
            ], 
            "triples": [
                {
                    "o": "Isotretinoin is a medication used for the treatment of severe acne. It is sometimes used in prevention of certain skin cancers. It is a retinoid, meaning it derives from vitamin A and is found in small quantities naturally in the body. Isotretinoin binds to and activates nuclear retinoic acid receptors (RAR), thereby regulating cell proliferation and differentiation. This agent also exhibits immunomodulatory and anti-inflammatory responses and inhibits ornithine decarboxylase, thereby decreasing polyamine synthesis and keratinization.", 
                    "p": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/description", 
                    "s": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00982"
                }, 
                {
                    "o": "FDA Structured Product Labels", 
                    "p": "http://www.w3.org/2004/02/skos/core#note", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A11572307"
                }, 
                {
                    "o": "Isotretinoin", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A12802988"
                }, 
                {
                    "o": "National Drug File - Reference Terminology", 
                    "p": "http://www.w3.org/2004/02/skos/core#note", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A17902718"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A17902718", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C0022265"
                }, 
                {
                    "o": "Isotretinoin", 
                    "p": "http://www.w3.org/2000/01/rdf-schema#label", 
                    "s": "http://linkedlifedata.com/resource/pubmed/chemical/Isotretinoin"
                }, 
                {
                    "o": "http://www.w3.org/2008/05/skos-xl#Label", 
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A0599177"
                }, 
                {
                    "o": "http://www.w3.org/2008/05/skos-xl#Label", 
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A17035190"
                }, 
                {
                    "o": "http://www.w3.org/2008/05/skos-xl#Label", 
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A18361057"
                }, 
                {
                    "o": "ISOTRETINOIN", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A10769142"
                }
            ], 
            "type": "yesno"
        }, 
        {
            "body": "How many genera comprise the Flaviviridae family?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018067"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22513121", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20470249", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8396675", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19534676", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19035566", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18991746", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22039536", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21249176"
            ], 
            "id": "51651e24298dcd4e51000054", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22513121", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 352, 
                    "text": "Within a project aimed at discovering new Flaviviridae inhibitors, new variously substituted 2-phenylbenzimidazoles were synthesized and evaluated in cell-based assays for cytotoxicity and antiviral activity against viruses representatives of the three genera of the Flaviviridae family, i.e.: Pestivirus (BVDV), Flavivirus (YFV) and Hepacivirus (HCV)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20470249", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 172, 
                    "offsetInEndSection": 340, 
                    "text": "Compounds were tested in cell-based assays against viruses representative of: i) two of the three genera of the Flaviviridae family, i.e. Pestiviruses and Flaviviruses;"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8396675", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 189, 
                    "offsetInEndSection": 368, 
                    "text": "The RNA-stimulated NTPase activity of this protein from prototypic members of the Pestivirus and Flavivirus genera has recently been established and enzymologically characterized."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19534676", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 196, 
                    "offsetInEndSection": 539, 
                    "text": "Compounds were tested in cell-based assays against viruses representative of: i) two of the three genera of the Flaviviridae family, i.e. Flaviviruses and Pestiviruses; ii) other RNA virus families, such as Retroviridae, Picornaviridae, Paramyxoviridae, Rhabdoviridae and Reoviridae; iii) two DNA virus families (Herpesviridae and Poxviridae)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19035566", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 490, 
                    "text": "Forty-three 2-[(benzotriazol-1/2-yl)methyl]benzimidazoles, bearing either linear (dialkylamino)alkyl- or bulkier (quinolizidin-1-yl)alkyl moieties at position 1, were evaluated in cell-based assays for cytotoxicity and antiviral activity against viruses representative of two of the three genera of the Flaviviridae family, i.e. Flaviviruses (Yellow Fever Virus (YFV)) and Pestiviruses (Bovine Viral Diarrhoea Virus (BVDV)), as Hepaciviruses can hardly be used in routine cell-based assays."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18991746", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 360, 
                    "offsetInEndSection": 703, 
                    "text": "Compounds were tested in cell-based assays against viruses representative of: i) two of the three genera of the Flaviviridae family, i.e. Flaviviruses and Pestiviruses; ii) other RNA virus families, such as Retroviridae, Picornaviridae, Paramyxoviridae, Rhabdoviridae and Reoviridae; iii) two DNA virus families (Herpesviridae and Poxviridae)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22039536", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 102, 
                    "text": "The family Flaviviridae consists of three genera \u2013 Flavivirus, Pestivirus and Hepacivirus."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21249176", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 146, 
                    "text": "The Flavivirus, Pestivirus and Hepacivirus genera of the Flaviviridae family each include important human and/or animal pathogens [1]."
                }
            ], 
            "type": "factoid"
        }, 
        {
            "body": "Could Arimidex (anastrozole) cause hot flashes?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019584", 
                "http://www.biosemantics.org/jochem#4266381", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006358"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23452648", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23383974", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23314924", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22677000", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22370325", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21378354", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20975874", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20679610", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18728707", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18072256", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17292609", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15508444", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15494636", 
                "http://www.ncbi.nlm.nih.gov/pubmed/14675683", 
                "http://www.ncbi.nlm.nih.gov/pubmed/14584060", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12902876"
            ], 
            "id": "516523fd298dcd4e51000055", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23452648", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 108, 
                    "text": "More than a third of breast cancer patients undergoing aromatase inhibitor (AI) treatment report joint pain."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23452648", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 789, 
                    "offsetInEndSection": 967, 
                    "text": "In the first 6 weeks, emergence of joint pain was associated with increase in general pain, fatigue, disturbed sleep, hot flashes, vaginal dryness, and decreased sexual activity."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23383974", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 21, 
                    "offsetInEndSection": 138, 
                    "text": "Antiestrogen therapy can cause vasomotor symptoms similar to those occurring during menopause, including hot flashes."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23383974", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 275, 
                    "offsetInEndSection": 455, 
                    "text": "The purpose of this study was to assess the feasibility and safety of acupuncture for treatment of hot flashes in Korean patients with breast cancer receiving antiestrogen therapy."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23383974", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 715, 
                    "offsetInEndSection": 857, 
                    "text": "10 patients with breast cancer who were undergoing antiestrogen therapy with tamoxifen or anastrozole and who were suffering from hot flashes."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23383974", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1118, 
                    "offsetInEndSection": 1199, 
                    "text": "During treatment, severity of hot flashes was reduced by 70%-95% in all patients."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23314924", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 59, 
                    "offsetInEndSection": 188, 
                    "text": "anastrozole has been widely used in Japan as an adjuvant treatment for postmenopausal, hormone-responsive breast cancer patients."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23314924", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 291, 
                    "offsetInEndSection": 435, 
                    "text": "The aim of this study is to evaluate the rate of bone fracture and bone mineral density (BMD) during anastrozole treatment in Japanese patients."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23314924", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1054, 
                    "offsetInEndSection": 1177, 
                    "text": "Musculoskeletal disorders were the most common (26.1\u00a0%), and hot flashes were the second most common adverse event (7.9\u00a0%)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22370325", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 11, 
                    "offsetInEndSection": 177, 
                    "text": "To compare the effect of therapy with anastrozole versus a combination of fulvestrant and anastrozole in women in first relapse of endocrine-responsive breast cancer."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22370325", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 455, 
                    "offsetInEndSection": 592, 
                    "text": "fulvestrant loading dose (LD) regimen followed by monthly injection plus 1 mg of anastrozole daily or to 1 mg of anastrozole daily alone."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22370325", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1178, 
                    "offsetInEndSection": 1373, 
                    "text": "Incidences of prespecified adverse events (AEs) were similar. Hot flashes were more common in the experimental arm: 63 patients (24.6%) versus 35 patients (13.8%) in the standard arm (P = .0023)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22677000", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 414, 
                    "offsetInEndSection": 602, 
                    "text": "The third-generation agents (anastrozole, letrozole, and exemestane) have been shown to be more effective and safer than the selective estrogen receptor modulators tamoxifen and raloxifen."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22677000", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 976, 
                    "offsetInEndSection": 1181, 
                    "text": "AIs are well tolerated and cause a lower incidence of gynecological symptoms (vaginal bleeding, discharge, and endometrial neoplasia), venous thromboembolic events, and hot flashes compared with tamoxifen."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22677000", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1360, 
                    "offsetInEndSection": 1520, 
                    "text": "Mood disturbances, somnolence, anxiety, fatigue, hot flashes, and memory impairment have been reported among patients receiving anastrozole as adjuvant therapy."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21378354", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 342, 
                    "offsetInEndSection": 571, 
                    "text": "Twenty-five PM-BC patients received, in sequence, leuprorelin, taxane-anthracycline induction chemotherapy, radiation therapy, a platinum-based intensification high-dose CT, followed by leuprorelin and anastrazole for five years."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21378354", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 967, 
                    "offsetInEndSection": 1143, 
                    "text": "Grade 4 hematologic toxicity was observed in all patients, no patient showed a decrease of cardiac ejection fraction and hot flashes and arthralgias were of moderate intensity."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20975874", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1551, 
                    "offsetInEndSection": 1826, 
                    "text": "Of the patients treated with anastrozole, 3 (37.5%) reported toxicity, with 1 report each of decreased libido, leg swelling, and depression (12.5%). Toxicity was reported in 2 patients taking letrozole (40%), with both reporting peripheral edema, and 1 reporting hot flashes."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20679610", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 507, 
                    "offsetInEndSection": 652, 
                    "text": "Patients were treated with goserelin 3.6 mg subcutaneous monthly and began anastrozole 1-mg daily 21 days after the first injection of goserelin."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20679610", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1277, 
                    "offsetInEndSection": 1369, 
                    "text": "The most common adverse events were fatigue (50%), arthralgias (53%), and hot flashes (59%)."
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18728707", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 789, 
                    "offsetInEndSection": 1059, 
                    "text": "Tolerability benefits were reported, with anastrozole having significantly fewer thromboembolic events and a lower incidence of vaginal bleeding compared to tamoxifen. No difference was observed between the two treatment in terms of hot flushes, bone fractures, or pain."
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18728707", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 726, 
                    "offsetInEndSection": 1056, 
                    "text": "the rate of adverse events (AE) did not differ with anastrozole compared to tamoxifen in the ATAC trial (68 months median follow-up: respectively 93.9% vs 94.6%, p = ns) while the rate of drug-related AE leading to withdrawal was lower for patients treated with anastrozole (6.5% vs 8.9%, p = 0.0005) (ATAC Trialists\u2019 Group 2005)."
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18728707", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 1967, 
                    "offsetInEndSection": 2135, 
                    "text": "A first series of side-effects appears to be specific and favorable to AIs (hot flushes, gynecologic side-effects and cardio-vascular events including thromboembolism),"
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18728707", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 2350, 
                    "offsetInEndSection": 2477, 
                    "text": "Table 2Summary of adverse events of aromatase inhibitors (AIs)Class effect of AIs:Favorable to AIs\u25e6Hot flushes and night sweats"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18072256", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 319, 
                    "offsetInEndSection": 553, 
                    "text": "These studies were designed to evaluate the safety and efficacy of AIs in the following clinical settings: 1) as initial adjuvant therapy (the Arimidex, Tamoxifen, Alone or in Combination trial, Breast International Group Trial 1-98),"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18072256", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1060, 
                    "offsetInEndSection": 1274, 
                    "text": "AIs were tolerated well, and patients who received them experienced fewer thrombolic events and less endometrial cancer, hot flashes, night sweats, and vaginal bleeding compared with patients who receive tamoxifen."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17292609", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 238, 
                    "offsetInEndSection": 523, 
                    "text": "It has been suggested that the association of AI and GnRh analogues and AI could block the two routes of oestrogen production in males, and therefore this approach could increase efficacy. However, it could also enhance the rate of adverse events (hot flashes, sexual impotence, etc.)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15508444", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 181, 
                    "text": "We reviewed therapeutic effects and harmful side effects in 33 patients with advanced or recurrent breast cancer who underwent treatment with Anastrozole 1 mg/day in our department."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15508444", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1405, 
                    "offsetInEndSection": 1527, 
                    "text": "The most frequent harmful side effects were rise in total cholesterol, general fatigue, hot flashes and arthralgia (9.1%)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15494636", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 151, 
                    "offsetInEndSection": 330, 
                    "text": "We analyzed the changes in frequency and severity of menopausal symptoms in patients receiving tamoxifen or aromatase inhibitors and identified factors influencing these symptoms."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15494636", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 662, 
                    "offsetInEndSection": 816, 
                    "text": "Both first-line tamoxifen and aromatase inhibitors induced an increase in the occurrence and severity of hot flashes (p<0.0001 and p=0.014, respectively)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14675683", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 11, 
                    "offsetInEndSection": 208, 
                    "text": "To evaluate the efficacy and toxicity of the selective aromatase inhibitor anastrozole (Arimidex), we conducted a phase II trial in 53 women with asymptomatic recurrent/persistent m\u00fcllerian cancer."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14675683", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1507, 
                    "offsetInEndSection": 1615, 
                    "text": "Toxicity was modest (grade I) and infrequent, with the most common toxicities being fatigue and hot flashes."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14584060", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 390, 
                    "text": "The first analysis of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial (median follow-up, 33 months) demonstrated that in adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer, anastrozole was superior to tamoxifen in terms of disease-free survival (DFS), time to recurrence (TTR), and incidence of contralateral breast cancer (CLBC)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14584060", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1813, 
                    "offsetInEndSection": 2194, 
                    "text": "in that endometrial cancer (P = 0.007), vaginal bleeding and discharge (P < 0.001 for both), cerebrovascular events (P < 0.001), venous thromboembolic events (P < 0.001), and hot flashes (P < 0.001) all occurred less frequently in the anastrozole group, whereas musculoskeletal disorders and fractures (P < 0.001 for both) continued to occur less frequently in the tamoxifen group."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12902876", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1016, 
                    "offsetInEndSection": 1173, 
                    "text": "reduced nausea, hot flashes, and abdominal discomfort caused almost twice as many patients to prefer to continue with letrozole therapy than with anastrozole"
                }
            ], 
            "triples": [
                {
                    "o": "http://www.w3.org/2008/05/skos-xl#Label", 
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A10338338"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A11917539", 
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C0878174"
                }
            ], 
            "type": "yesno"
        }, 
        {
            "body": "What is the inheritance pattern of Emery-Dreifuss muscular dystrophy? ", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020389", 
                "http://www.disease-ontology.org/api/metadata/DOID:11726", 
                "http://www.disease-ontology.org/api/metadata/DOID:655", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D040582", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D050172"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23349612", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18266676", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16791377", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16585054", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15967842", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12424964", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11863303", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11799477", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11731280", 
                "http://www.ncbi.nlm.nih.gov/pubmed/10080180", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9781539", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9536090", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8042665", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8445613", 
                "http://www.ncbi.nlm.nih.gov/pubmed/2230849", 
                "http://www.ncbi.nlm.nih.gov/pubmed/2163170", 
                "http://www.ncbi.nlm.nih.gov/pubmed/3203701", 
                "http://www.ncbi.nlm.nih.gov/pubmed/3729752", 
                "http://www.ncbi.nlm.nih.gov/pubmed/3701378", 
                "http://www.ncbi.nlm.nih.gov/pubmed/4022362"
            ], 
            "id": "51656c94298dcd4e51000058", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23349612", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 354, 
                    "text": "Emery-Dreifuss myopathy can be associated with a cardiomyopathy and cardiac dysrhythmias. The inheritance pattern of Emery-Dreifuss muscular dystrophy (EDMD) is X linked, whereas EDMD2 is autosomal dominant. EDMD2 is caused by lamin A/C gene (LMNA) mutations that produce alterations in the lamin proteins that are integral to nuclear and cell integrity."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23349612", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 690, 
                    "offsetInEndSection": 890, 
                    "text": "EDMD2 with familial dilated cardiomyopathy and cardiac dysrhythmias in whom LMNA gene sequencing was performed. A novel mutation was identified and additional unusual clinical features were described."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18266676", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 139, 
                    "offsetInEndSection": 471, 
                    "text": ". Loss-of-function truncation mutations in EMD, encoding the nuclear membrane protein emerin, cause X-linked Emery-Dreifuss muscular dystrophy (EDMD) characterized by localized contractures and skeletal myopathy in adolescence, sinus node dysfunction (SND) in early adulthood, and atrial fibrillation as a variably associated trait."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18266676", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1553, 
                    "offsetInEndSection": 1903, 
                    "text": "Mutation of EMD can underlie X-linked familial AF. Lys37del is associated with epithelial cell emerin deficiency, as in EDMD, yet it causes electrical atriomyopathy in the absence of skeletal muscle disease. Targeted genetic testing of EMD should be considered in patients with SND-associated AF and/or family history suggesting X-linked inheritance."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16791377", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 227, 
                    "text": "The Emery-Dreifuss muscular dystrophy is a form of muscular dystrophy that frequently presents early contractures and cardiac conduction defects, caused by emerin deficiency in the inner nuclear membrane of the muscular fibers."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16791377", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 407, 
                    "offsetInEndSection": 448, 
                    "text": "compatible with X-linked inheritance form"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16585054", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 486, 
                    "offsetInEndSection": 567, 
                    "text": "The first patient was a member of a family with molecularly proven X-linked EDMD."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16585054", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1102, 
                    "offsetInEndSection": 1279, 
                    "text": "As these resemble the cardiac features of patients with the autosomal dominant variant of EDMD, we examined the lamin A/C gene, identifying a de-novo mutation in the propositus."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16585054", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2077, 
                    "offsetInEndSection": 2135, 
                    "text": "contribute to disease severity in autosomal dominant EDMD."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15967842", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 357, 
                    "text": "The STA gene encodes emerin and is one of the genes that is affected in Emery-Dreifuss muscular dystrophy (EDMD). Although it has been reported that EDMD caused by the STA gene mutation is associated with X-linked recessive inheritance, the genotype-phenotype correlations, with special reference to cardiac manifestations, are not well defined."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12424964", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 661, 
                    "text": "Emery-Dreifuss muscular dystrophy (EDMD) is a muscular disorder characterized by 1) early contracture of the elbows. Achilles tendons and post-cervical muscles, 2) slowly progressive muscle wasting and weakness with a humeroperoneal distribution, and 3) life-threatening cardiomyopathy with conduction block. Most of families with EDMD show X-linked recessive inheritance with mutations in the STA gene on chromosome Xq28, which encodes a protein named emerin. A rare autosomal dominant form of EDMD (AD-EDMD) is caused by mutations in lamin A/C gene (LMNA) on chromosome 1q21. Both emerin and lamin A/C are located in the inner surface membrane of the nucleus."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11863303", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 451, 
                    "offsetInEndSection": 662, 
                    "text": "Emery-Dreifuss muscular dystrophy is an X-linked recessive myopathy. The patient had no familial background of the disease. This patient might have a sporadic inheritance pattern with severe cardiac involvement."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11799477", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1498, 
                    "offsetInEndSection": 1551, 
                    "text": "autosomal dominant Emery-Dreifuss muscular dystrophy,"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11731280", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 643, 
                    "text": "Emery-Dreifuss muscular dystrophy is characterized by the clinical triad of early onset contractures of elbows, Achilles tendons and spine, wasting and weakness with a predominantly humero-peroneal distribution and life-threatening cardiac conduction defects and/or cardiomyopathy. Two main types of inheritance have been described: the X-linked form is caused by mutations in the STA gene on locus Xq28 and the gene for the autosomal dominant form (LMNA gene) has been localized on chromosome 1q11-q23. Recently, mutations in this LMNA gene have been also found to be responsible for the less frequent autosomal recessive form of the disease."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10080180", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 485, 
                    "text": "Emery-Dreifuss muscular dystrophy (EDMD) is characterized by early contractures of elbows and Achilles tendons, slowly progressive muscle wasting and weakness, and a cardiomyopathy with conduction blocks which is life-threatening. Two modes of inheritance exist, X-linked (OMIM 310300) and autosomal dominant (EDMD-AD; OMIM 181350). EDMD-AD is clinically identical to the X-linked forms of the disease. Mutations in EMD, the gene encoding emerin, are responsible for the X-linked form."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9781539", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 221, 
                    "offsetInEndSection": 258, 
                    "text": "including X-linked Emery-Dreifuss MD,"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9781539", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1492, 
                    "offsetInEndSection": 1714, 
                    "text": "this form is not X-linked Emery-Dreifuss MD. We suggest that these patients represent a severe MD characterized by early onset distal wasting and severe rigidity of the spine, with probable autosomal recessive inheritance."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9536090", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 320, 
                    "text": "Seventeen families with Emery-Dreifuss muscular dystrophy (EDMD) have been studied both by DNA sequencing and by emerin protein expression. Fourteen had mutations in the X-linked emerin gene, while three showed evidence of autosomal inheritance. Twelve of the 14 emerin mutations caused early termination of translation."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8042665", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 75, 
                    "offsetInEndSection": 253, 
                    "text": "One family presented a rare autosomal dominant variant of Emery-Dreifuss muscular dystrophy, another with X-linked recessive inheritance showed unusual intrafamilial variability."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8445613", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 408, 
                    "text": "Emery-Dreifuss muscular dystrophy (EMD) is characterised by (1) early contractures of the Achilles tendons, elbows, and postcervical muscles, (2) slowly progressive muscle wasting and weakness with a predominantly humeroperoneal distribution in the early stages, and (3) cardiomyopathy with conduction defects and risk of sudden death. Inheritance is usually X linked recessive but can be autosomal dominant."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2230849", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 438, 
                    "offsetInEndSection": 691, 
                    "text": "Tendon contractures may be a partial expression of this myopathic disorder, suggesting an autosomal dominant inheritance with variable penetrance. A muscular dystrophy clinically similar to that of the Emery-Dreifuss (EDMD) type can thus occur in women."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2163170", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 334, 
                    "offsetInEndSection": 540, 
                    "text": "Since the disease was diagnosed in 3 brothers, the X-coupled recessive type of its inheritance is assumed. An opinion is advanced that the described form is a clinical variety of Emery-Dreyfus myodystrophy."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3203701", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 48, 
                    "offsetInEndSection": 77, 
                    "text": "Emery-Dreifuss syndrome (EDS)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3203701", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 385, 
                    "offsetInEndSection": 583, 
                    "text": "the term Emery-Dreifuss muscular dystrophy should be avoided. Instead, each case of EDS should be classified as myopathic or neurogenic with X chromosome recessive or autosomal dominant inheritance."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3729752", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 383, 
                    "text": "Emery-Dreifuss muscular dystrophy is a syndrome with five salient features: early and unusual contractures; humeroperoneal muscle wasting; the slow progression of weakness, beginning in childhood; cardiac conduction defects; and X-linked inheritance. We present two cases and detail other reports with a similar constellation of findings with apparent autosomal dominant inheritance."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3701378", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 420, 
                    "offsetInEndSection": 587, 
                    "text": "Emery-Dreifuss muscular dystrophy with proximal weakness in both the upper and lower limbs and X-linked scapuloperoneal muscular dystrophy represent the same disorder."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/4022362", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 329, 
                    "offsetInEndSection": 538, 
                    "text": "There is at least one other report of autosomal dominant transmission of this clinical picture, which had previously only been reported as Emery-Dreifuss muscular dystrophy with X-linked recessive inheritance."
                }
            ], 
            "triples": [
                {
                    "o": "Emery-Dreifuss Muscular Dystrophy", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A17680512"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A17945027", 
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C0410189"
                }, 
                {
                    "o": "http://www.w3.org/2008/05/skos-xl#Label", 
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A17945027"
                }, 
                {
                    "o": "http://www.w3.org/2008/05/skos-xl#Label", 
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A1644284"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/pubmed/Mesh", 
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
                    "s": "http://linkedlifedata.com/resource/pubmed/mesh/Muscular+Dystrophy%2C+Emery-Dreifuss"
                }, 
                {
                    "o": "http://www.w3.org/2008/05/skos-xl#Label", 
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A1644283"
                }, 
                {
                    "o": "Emery-Dreifuss Syndrome", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A1644288"
                }, 
                {
                    "o": "Emery-Dreifuss Muscular Dystrophy", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A1644282"
                }, 
                {
                    "o": "Emery Dreifuss Syndrome", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A1644287"
                }
            ], 
            "type": "list"
        }, 
        {
            "body": "Which are the DNA (cytosine-5-)-methyltransferases inhibitors?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004248"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22398368", 
                "http://www.ncbi.nlm.nih.gov/pubmed/7536414", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22170584", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20808780", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20139415", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19467223", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19322801", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12368098", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12206775", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11838638", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9925782", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9628353", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9207024", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9153756"
            ], 
            "id": "5165932e298dcd4e51000059", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22398368", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 355, 
                    "text": "5-Aza-2'-deoxycytidine (5-Aza-CdR), a nucleoside analog that can inhibit DNA cytosine methylation, possesses potent antitumorigenic activities for myeloid disorders. Although 5-Aza-CdR is known to be incorporated into DNA and inhibit DNA (cytosine-5)-methyltransferases, the precise mechanisms underlying the drug's antineoplastic activity remain unclear."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7536414", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 139, 
                    "text": "The mechanism of inhibition of DNA (cytosine-5-)-methyltransferases by 5-azacytosine is likely to involve methyl transfer to the inhibitor."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7536414", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 268, 
                    "text": "The mechanism of inhibition of DNA (cytosine-5-)-methyltransferases by the mechanism-based inhibitor 5-azacytosine has remained unclear, mainly because of the unavailability of a substrate in which the inhibitor, but not normal cytosine, is present at the target site."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7536414", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 877, 
                    "offsetInEndSection": 1084, 
                    "text": "These results suggest that, when the enzyme binds to 5-azacytosine in the presence of the cofactor, a methyl group is transferred to the N-5 position of the base, resulting in the inactivation of the enzyme."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22170584", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 67, 
                    "text": "Rapid synthesis of new DNMT inhibitors derivatives of procainamide."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22170584", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 244, 
                    "offsetInEndSection": 475, 
                    "text": "Six compounds resulted in potent inhibitors of the murine catalytic Dnmt3A/3L complex and of human DNMT1, at least 50 times greater than that of the parent compounds. The inhibitors showed selectivity for C5 DNA methyltransferases."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20808780", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 82, 
                    "text": "Mechanistic insights on the inhibition of c5 DNA methyltransferases by zebularine."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20808780", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1826, 
                    "offsetInEndSection": 2106, 
                    "text": "Therefore, many DNA methylation inhibitors have been developed. Among them, 5-azacytidine (5-aza-CR, Vidaza\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd) and 5-azadeoxycytidine (5-aza-CdR, Dacogen\u00ae) (Fig. 1) have gained FDA approval for the treatment of myelodysplastic syndrome, a preleukemic bone marrow disorder [8], [9]."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20808780", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 4190, 
                    "offsetInEndSection": 4340, 
                    "text": "It was then described as a DNMT inhibitor [26]\u2013[29], inhibiting DNA methylation [30] and reactivating silenced genes [31]\u2013[33] similarly to 5-aza-CdR."
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20808780", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 10, 
                    "offsetInEndSection": 159, 
                    "text": "Zebularine has been described as a potent inhibitor of DNA methyltransferases forming a permanent covalent complex with the enzymes [26], [27], [28]."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20139415", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2502, 
                    "offsetInEndSection": 3025, 
                    "text": "In cancer cell lines, depletion of DNMT1 with anti-sense inhibitors has been linked with the demethylation of tumour suppressor gene promoters and reactivation of expression (26), indicating that DNMT1 is responsible for this hypermethylation. These results imply that DNMT1 inhibitors may prove to be effective anti-cancer drugs (27,28) and an example of their application in cancer treatment is the DNMT1 inhibitor 5-azacytidine (Vidaza), which has been approved for use in the treatment of myelodysplastic syndrome (29)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20139415", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 4867, 
                    "offsetInEndSection": 5087, 
                    "text": "The therapeutic potential of DNMT1 inhibitors has provided the drive to develop a new assay suitable for the kinetic analysis of cytosine-C5 methyltransferase activity in a format applicable to high-throughput screening."
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20139415", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 5971, 
                    "offsetInEndSection": 6176, 
                    "text": "This simple and practically robust assay is suitable for high-throughput analysis of DNMT1 activity and is likely to provide an efficient method for screening large compound libraries for DNMT1 inhibitors."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19467223", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 157, 
                    "text": "DNA (Cytosine-C5) methyltransferase inhibition by oligodeoxyribonucleotides containing 2-(1H)-pyrimidinone (zebularine aglycon) at the enzymatic target site."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19467223", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 110, 
                    "offsetInEndSection": 346, 
                    "text": "A number of DNA methyltransferase inhibitors are known to reactivate silenced genes; including 5-azacytidine and 2-(1H)-pyrimidinone riboside (zebularine). Zebularine is a more stable, less cytotoxic inhibitor compared to 5-azacytidine."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19467223", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1010, 
                    "offsetInEndSection": 1549, 
                    "text": "ODNs containing 2-(1H)-pyrimidinone at the enzymatic target site are competitive inhibitors of both prokaryotic and mammalian DNA C5 methyltransferases. We determined that the ternary complexes between the enzymes, 2-(1H)-pyrimidinone inhibitor, and the cofactor S-adenosyl methionine are maintained through the formation of a reversible covalent interaction. The differing stability and reversibility of the covalent bonds may partially account for the observed differences in cytotoxicity between zebularine and 5-azacytidine inhibitors."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19322801", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 252, 
                    "text": "DNA methyltransferases (DNMTs) are a family of enzymes that methylate DNA at the C5 position of cytosine residues, and their inhibition is a promising strategy for the treatment of various developmental and proliferative diseases, particularly cancers."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19322801", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 577, 
                    "offsetInEndSection": 813, 
                    "text": "The inhibitory activity of hydralazine toward DNMT may be rationalized at the molecular level by similar interactions within the binding pocket (e.g., by a similar pharmacophore) as established by substrate-like deoxycytidine analogues."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19322801", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 983, 
                    "offsetInEndSection": 1307, 
                    "text": "Despite the different scaffolds of other non-nucleoside DNMT inhibitors such as procaine and procainamide, the current modeling work reveals that these drugs exhibit similar interactions within the DNMT1 binding site. These findings are valuable in guiding the rational design and virtual screening of novel DNMT inhibitors."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19322801", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 983, 
                    "offsetInEndSection": 1307, 
                    "text": "Despite the different scaffolds of other non-nucleoside DNMT inhibitors such as procaine and procainamide, the current modeling work reveals that these drugs exhibit similar interactions within the DNMT1 binding site. These findings are valuable in guiding the rational design and virtual screening of novel DNMT inhibitors."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12368098", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 229, 
                    "text": "Inhibition of HhaI DNA (Cytosine-C5) methyltransferase by oligodeoxyribonucleotides containing 5-aza-2'-deoxycytidine: examination of the intertwined roles of co-factor, target, transition state structure and enzyme conformation."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12368098", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 152, 
                    "text": "The presence of 5-azacytosine (ZCyt) residues in DNA leads to potent inhibition of DNA (cytosine-C5) methyltranferases (C5-MTases) in vivo and in vitro."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12368098", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 342, 
                    "offsetInEndSection": 444, 
                    "text": "Thus, it is important to understand the critical mechanistic determinants of ZCyt's inhibitory action."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12368098", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1133, 
                    "offsetInEndSection": 1470, 
                    "text": "Since methyl transfer can occur only in the presence of AdoMet, these results suggest (1) that the inhibitory capacity of ZCyt in DNA is based on its ability to induce a stable, tightly closed conformation of M.HhaI that prevents DNA and co-factor release and (2) that methylation of ZCyt in DNA is not required for inhibition of M.HhaI."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12206775", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 104, 
                    "text": "Zebularine: a novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12206775", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 192, 
                    "offsetInEndSection": 474, 
                    "text": "The inhibition of cytosine-[C5]-specific DNA methyltransferases (C5 MTases) by oligodeoxynucleotides containing 5-azadeoxycytidine (AzadC) and 5-fluorodeoxycytidine (FdC) provides a well-documented example of mechanism-based inhibition of enzymes central to nucleic acid metabolism."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11838638", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 131, 
                    "text": "Synthesis of oligonucleotide inhibitors of DNA (Cytosine-C5) methyltransferase containing 5-azacytosine residues at specific sites."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11838638", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 120, 
                    "text": "The incorporation of 5-azacytosine residues into DNA causes potent inhibition of DNA (Cytosine-C5) methyltransferases. T"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9925782", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 130, 
                    "text": "Mechanism of inhibition of DNA (cytosine C5)-methyltransferases by oligodeoxyribonucleotides containing 5,6-dihydro-5-azacytosine."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9925782", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 856, 
                    "offsetInEndSection": 1059, 
                    "text": "Substitution of DZCyt for target cytosines in C-G dinucleotides of single-stranded or double-stranded oligodeoxyribonucleotide substrates led to complete inhibition of methylation by murine DNA C5-MTase."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9925782", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1216, 
                    "offsetInEndSection": 1458, 
                    "text": "Oligodeoxyribonucleotides containing DZCyt formed a tight but reversible complex with M.HhaI, and were consistently more potent as inhibitors of DNA methylation than oligodeoxyribonucleotides identical in sequence containing 5-fluorocytosine."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9925782", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1927, 
                    "offsetInEndSection": 2154, 
                    "text": "These results indicate that DZCyt can occupy the active site of M.HhaI as a transition state mimic and, because of the high degree of affinity of its interaction with the enzyme, it can act as a potent inhibitor of methylation."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9628353", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 136, 
                    "text": "Analysis of DNA methylation processes related to the inhibition of DNA synthesis by 5-azacytidine in Streptomyces antibioticus ETH 7451."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9628353", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1022, 
                    "offsetInEndSection": 1215, 
                    "text": "Our results suggest that some of the 5-azacytidine effects on DNA and RNA synthesis might indeed be related to the complex formation and inhibition of a cytosine-specific DNA methyltransferase."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9207024", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 87, 
                    "text": "DNA containing 4'-thio-2'-deoxycytidine inhibits methylation by HhaI methyltransferase."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9207024", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1080, 
                    "offsetInEndSection": 1260, 
                    "text": "The inhibitory effect of the 4'sulfur atom on enzymatic activity may be traced to perturbation of a step in the methylation reaction after DNA binding but prior to methyl transfer."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9153756", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 194, 
                    "text": "Treatment of Schizosaccharomyces pombe with the C5 DNA methyltransferase (C5Mtase) inhibitor 5-azacytidine (5-azaC) has previously been shown to induce G2 checkpoint-dependent cell cycle arrest."
                }
            ], 
            "type": "list"
        }, 
        {
            "body": "Which are the inhibitors of histone methyltransferases?", 
            "concepts": [
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0042054"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23557020", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23011794", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22924785", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22904200", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22781932", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22665483", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22420752", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22357272", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21940714", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21936531", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21546573", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20556507", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20567762", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19860425"
            ], 
            "id": "5166f41a298dcd4e5100005b", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23557020", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 559, 
                    "offsetInEndSection": 722, 
                    "text": "However, in general, HMTs have no widely accepted high-throughput screening (HTS) assay format, and reference inhibitors are not available for many of the enzymes."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23011794", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 143, 
                    "text": "Small-molecule histone methyltransferase inhibitors display rapid antimalarial activity against all blood stage forms in Plasmodium falciparum."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23011794", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 299, 
                    "offsetInEndSection": 675, 
                    "text": "We synthesized a compound library based upon a known specific inhibitor (BIX-01294) of the human G9a histone methyltransferase. Two compounds, BIX-01294 and its derivative TM2-115, inhibited P. falciparum 3D7 parasites in culture with IC(50) values of ~100 nM, values at least 22-fold more potent than their apparent IC(50) toward two human cell lines and one mouse cell line."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23011794", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1323, 
                    "offsetInEndSection": 1486, 
                    "text": "Together, these results suggest that BIX-01294 and TM2-115 inhibit malaria parasite histone methyltransferases, resulting in rapid and irreversible parasite death."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22924785", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 130, 
                    "text": "Synthesis and structure-activity relationship investigation of adenosine-containing inhibitors of histone methyltransferase DOT1L."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22924785", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 159, 
                    "offsetInEndSection": 329, 
                    "text": "A total of 55 adenosine-containing compounds were designed and synthesized, among which several potent DOT1L inhibitors were identified with K(i) values as low as 0.5 nM."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22904200", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 606, 
                    "offsetInEndSection": 773, 
                    "text": "Several new reagents and assays were developed to aid in the identification of EZH2 inhibitors, and these were used to execute two high-throughput screening campaigns."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22781932", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 83, 
                    "offsetInEndSection": 396, 
                    "text": "Of the five histone methyltransferases known to mediate methylation of the lysine 9 residue of histone H3 (H3K9), euchromatic histone-lysine N-methyltransferase 2 (EHMT2; also known as G9a) has been shown to be a primary mediator of H3K9 dimethylation; BIX-01294 has been shown to be a specific inhibitor of EHMT2"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22781932", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 533, 
                    "offsetInEndSection": 675, 
                    "text": "We hypothesised that inhibition of EHMT2 by BIX-01294 would result in reduced levels of H3K9 dimethylation and compromised embryo development."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22665483", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 971, 
                    "offsetInEndSection": 1135, 
                    "text": "We also demonstrate that peptides that mimic SET1 family Win motif sequences inhibit H3K4 dimethylation by the MLL1 core complex with varying degrees of efficiency."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22420752", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 184, 
                    "text": "Studies of H3K4me3 demethylation by KDM5B/Jarid1B/PLU1 reveals strong substrate recognition in vitro and identifies 2,4-pyridine-dicarboxylic acid as an in vitro and in cell inhibitor."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22420752", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1264, 
                    "offsetInEndSection": 1451, 
                    "text": "Inhibition studies of ccKDM5B showed both in vitro and in cell inhibition of ccKDM5B by 2,4-pyridinedicarboxylic acid (2,4-PDCA) with a potency similar to that reported for the HDM KDM4C."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22357272", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1011, 
                    "offsetInEndSection": 1220, 
                    "text": "Treatment with 3-deazaneplanocin A (DZNep), an inhibitor of H3K27me3 and H4K20me3, significantly enhanced the BZLF1 transcription in Raji cells when in combination with an HDAC inhibitor, trichostatin A (TSA)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21940714", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1235, 
                    "offsetInEndSection": 1552, 
                    "text": "All assays allowed profiling of known SET7/9 and LSD1 inhibitors. The results demonstrate that the optimized LANCE Ultra and AlphaLISA assay formats provide a relevant biochemical screening approach toward the identification of small-molecule inhibitors of HMTs and HDMs that could lead to novel epigenetic therapies."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21936531", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 105, 
                    "text": "Selective inhibitors of histone methyltransferase DOT1L: design, synthesis, and crystallographic studies."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21936531", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 145, 
                    "offsetInEndSection": 273, 
                    "text": "We used structure- and mechanism-based design to discover several potent inhibitors of DOT1L with IC(50) values as low as 38 nM."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21546573", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 155, 
                    "text": "Inhibition of histone lysine methylation enhances cancer-testis antigen expression in lung cancer cells: implications for adoptive immunotherapy of cancer."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21546573", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1032, 
                    "offsetInEndSection": 1205, 
                    "text": "Short hairpin RNAs were used to inhibit several histone methyltransferases (KMT) and histone demethylases (KDM) that mediate histone methylation and repress gene expression."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21546573", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1352, 
                    "offsetInEndSection": 1449, 
                    "text": "DZNep, a pharmacologic inhibitor of KMT6 expression, recapitulated the effects of KMT6 knockdown."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20556507", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 296, 
                    "offsetInEndSection": 693, 
                    "text": "Recent evidence shows that S-adenosylhomocysteine (AdoHcy) hydrolase inhibitors (AHI) such as 3-deazaneplanocin A (DZNep) modulate chromatin through indirect inhibition of histone methyltransferases including EZH2. We investigated the biological effects of AdoHcy hydrolase inhibition using DZNep and its structural analogues 3-deazaadenosine (DZA) and neplanocin A (Nep A) in breast cancer cells."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20567762", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 99, 
                    "text": "A chemiluminescence-based method for identification of histone lysine methyltransferase inhibitors."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20567762", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 994, 
                    "offsetInEndSection": 1226, 
                    "text": "The method is particularly well suited for detection of inhibitors acting by the desired histone peptide competitive mechanism and is applicable to testing other HMTs, demonstrated here with the G9a homolog EHMT1, also known as GLP."
                }
            ], 
            "type": "list"
        }, 
        {
            "body": "Is MammaPrint cleared by the United States Food and Drug Administration? ", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017321", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017322", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017326", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017327"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21479927", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19506735", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18786252"
            ], 
            "id": "5168023b298dcd4e51000061", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21479927", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1350, 
                    "offsetInEndSection": 1539, 
                    "text": "Real-time RT-PCR confirmed the 5-gene prognostic signature that was distinct from an FDA-cleared 70-gene signature of MammaPrint panel and from the Oncotype DX recurrence score assay panel."
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19506735", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 2899, 
                    "offsetInEndSection": 3297, 
                    "text": "MammaPrint is the first FDA approved, gene expression-based prognostic test which assess patients\u2019 risk for distant metastasis in women under age 61 with Stage I-II lymph node negative breast cancer. The test was developed by Agendia, a gene expression-based diagnostic company in Amsterdam (http://www.agendia.com/), and was approved by the FDA in February 2007 as an Agendia-only offered service."
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18786252", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 4807, 
                    "offsetInEndSection": 4869, 
                    "text": "a clinical assay MammaPrint\u00ae has recently been cleared by FDA."
                }
            ], 
            "triples": [
                {
                    "o": "MammaPrint", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A17680439"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A17680439", 
                    "p": "http://www.w3.org/2008/05/skos-xl#prefLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C2827401"
                }, 
                {
                    "o": "fda", 
                    "p": "http://www.w3.org/2004/02/skos/core#altLabel", 
                    "s": "http://linkedlifedata.com/resource/#_4F383737393600D"
                }, 
                {
                    "o": "fda", 
                    "p": "http://www.w3.org/2004/02/skos/core#altLabel", 
                    "s": "http://linkedlifedata.com/resource/#_4530503539300011"
                }
            ], 
            "type": "yesno"
        }, 
        {
            "body": "Is it possible to detect survivin protein expression in normal human adult tissues?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014024", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006801"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21371446", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20520718", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18856066", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18425079", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17611626", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17382535", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17204284", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16360419", 
                "http://www.ncbi.nlm.nih.gov/pubmed/14719083", 
                "http://www.ncbi.nlm.nih.gov/pubmed/10626797"
            ], 
            "id": "51680a49298dcd4e51000062", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18856066", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 212, 
                    "text": "Survivin (BIRC5) is one of the members of IAP-family apoptosis inhibitors. The BIRCS gene is expressed in most human embryonic tissues and malignant tumors but not in normal differentiated tissues of adult human."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18425079", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 177, 
                    "offsetInEndSection": 399, 
                    "text": "Survivin is an inhibitor of apoptosis that is undetectable in most terminally differentiated normal human tissues, strongly expressed in embryonic and fetal organs and is strongly expressed in many different human cancers."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17204284", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 237, 
                    "text": "Survivin is a member of the inhibitor apoptosis family that is overexpressed in many malignancies. It has five known alternative splice forms, some of which differ in their antiapoptotic properties and expression levels in human cancers."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16360419", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 400, 
                    "offsetInEndSection": 458, 
                    "text": "survivin is usually not expressed in normal adult tissues,"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21371446", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 855, 
                    "offsetInEndSection": 1409, 
                    "text": "AZD1152-hQPA induced caspase-dependent apoptosis of some cell lines, demonstrated by loss of mitochondrial membrane potential, activation of caspase-9, followed by activation of caspase-3. This effect was accompanied by the inhibition of survivin expression. In vivo efficacy was determined in NOD/SCID/\u03b3c(null) mice implanted with the Ramos human BL cell line. AZD1152 had anti-tumour effects in this murine xenograft model. There preclinical data suggest that the inhibition of Aurora B kinase is a potentially useful therapeutic strategy in BL and HL."
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20520718", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 21507, 
                    "offsetInEndSection": 21968, 
                    "text": "Survivin, an anti-apoptotic protein encoded by BIRC5, to perform immunostaining on a melanoma progression tissue microarray (TMA). This TMA contained 480 cores of tumor tissues representing benign nevi, thin and thick primary cutaneous melanoma, as well as lymph node and visceral melanoma metastasis. As shown in Figure 3C, Survivin expression was low to absent in the majority of the benign nevi but was significantly elevated in all melanomas (p<0.0001, \u03c72)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10626797", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 10, 
                    "offsetInEndSection": 469, 
                    "text": "a novel antiapoptosis gene, i.e., survivin, was identified as a structurally unique member of the inhibitor of apoptosis protein family. Survivin expression is turned off during fetal development and not found in non-neoplastic adult human tissues but is again turned on in the most common human cancers. The antiapoptotic properties of survivin might provide a significant growth advantage in tumors and possibly also contribute to chemoresistance of cancer."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14719083", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 630, 
                    "offsetInEndSection": 1193, 
                    "text": "Further comparison of the distribution of PDEF with other widely recognized cancer-associated molecules showed that PDEF has more restricted distributions than Her-2/neu, Bcl-2, survivin or telomerase in cDNA libraries from normal human tissues and more increased distribution than Her-2/neu, CA-125, Bcl-2, survivin and telomerase in cDNA libraries from brain (except survivin), breast, lung and ovarian tumors. These data together show a better tumor-association for PDEF and suggest that PDEF is a more suitable target for developing specific cancer therapies."
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17611626", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 1453, 
                    "offsetInEndSection": 1804, 
                    "text": "Aggressive (Group 2) melanomas were characterized by upregulation of genes associated with cell cycle progression, DNA replication and repair, and altered expression of apoptosis-related genes including upregulation of the antiapoptotic gene BIRC5/survivin [49] and downregulation of the novel stress-associated apoptosis inducer TRIB3 [50] (Table 1)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17382535", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1053, 
                    "offsetInEndSection": 1750, 
                    "text": "we identified decreased FHIT expression resulting in apoptosis inhibition and decreasing apoptosis associated with abnormal levels of some pro- and anti-apoptotic proteins (Bax, Bcl-2 and Survivin) by TUNEL and TMA. Our results demonstrated that the mutation in the FHIT gene significantly reduced FHIT expression in human CRC. Both TUNEL and TMA experiments demonstrated significantly inhibited apoptosis by down-regulation of Bax and up-regulation of Survivin and Bcl-2. Collectively, these studies identify the mechanism by which an important tumor suppressor gene, FHIT, inactivated specifically in human CRC, and contributes to our understanding of the mechanism of colorectal carcinogenesis."
                }
            ], 
            "triples": [
                {
                    "o": "Survivin", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A10780389"
                }
            ], 
            "type": "yesno"
        }, 
        {
            "body": "What is the function of cryptochrome-1 in mouse?", 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22952936", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22669941", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22170608", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22140039", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21236481", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20825493", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20100521", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20023637", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19858287", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19833968", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19405859", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18974860", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16777965", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16731656", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16061665", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15980066", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15047890", 
                "http://www.ncbi.nlm.nih.gov/pubmed/14712914", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12495442", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12381662", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12121621", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23471982"
            ], 
            "id": "51680a6d298dcd4e51000063", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20023637", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 337, 
                    "text": "Malfunction of the circadian clock has been linked to the pathogenesis of a variety of diseases. We show that mice lacking the core clock components Cryptochrome-1 (Cry1) and Cryptochrome-2 (Cry2) (Cry-null mice) show salt-sensitive hypertension due to abnormally high synthesis of the mineralocorticoid aldosterone by the adrenal gland."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12121621", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 313, 
                    "offsetInEndSection": 554, 
                    "text": "The Cryptochrome 1 and 2 genes are indispensable for molecular core oscillator function, as evident from the arrhythmic wheel-running behavior and lack of rhythmic clock gene expression in mCry1/mCry2 double-mutant mice in constant darkness."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12381662", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 442, 
                    "offsetInEndSection": 1222, 
                    "text": "Among the components driving the mammalian circadian clock are the Period 1 and 2 (mPer1 and mPer2) and Cryptochrome 1 and 2 (mCry1 and mCry2) genes. A mutation in the mPer2 gene leads to a gradual loss of circadian rhythmicity in mice kept in constant darkness (DD). Here we show that inactivation of the mCry2 gene in mPer2 mutant mice restores circadian rhythmicity and normal clock gene expression patterns. Thus, mCry2 can act as a nonallelic suppressor of mPer2, which points to direct or indirect interactions of PER2 and CRY2 proteins. In marked contrast, inactivation of mCry1 in mPer2 mutant mice does not restore circadian rhythmicity but instead results in complete behavioral arrhythmicity in DD, indicating different effects of mCry1 and mCry2 in the clock mechanism"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12495442", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 3431, 
                    "offsetInEndSection": 3604, 
                    "text": "Consistent with their central role in circadian rhythm generation, genetic inactivation of both cryptochromes (cry1,2-/-) results in circadian arrhythmicity in mice [22,23]."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14712914", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 289, 
                    "offsetInEndSection": 574, 
                    "text": "Cryptochrome 1 and 2 gene products act in the negative feedback loop and are indispensable for molecular core oscillator function, as evident from the arrhythmic wheel running behaviour and absence of cyclic clock gene expression in mCry1/mCry2 double mutant mice in constant darkness."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14712914", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 963, 
                    "offsetInEndSection": 1423, 
                    "text": ", when mCry-deficient mice are housed in normal light-dark cycles, a single non-circadian peak in neuronal activity can be detected in SCN slices prepared two hours after the beginning of the day. This light-induced increase in electric activity of the SCN suggests that deletion of the mCry genes converts the core oscillator in an hour-glass-like timekeeper and may explain why in normal day-night cycles mCry-deficient mice show apparently normal behaviour."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15980066", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 142, 
                    "text": "Cryptochrome 1 and 2 act as essential components of the central and peripheral circadian clocks for generation of circadian rhythms in mammals"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15047890", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1288, 
                    "offsetInEndSection": 1500, 
                    "text": "cryptochrome-1 mRNA was found in DA cells, immunocytochemistry was extended to other components of the circadian clock machinery. This analysis showed that DA cells contain the most common clock-related proteins."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16061665", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 193, 
                    "offsetInEndSection": 335, 
                    "text": "Cryptochrome 1 and cryptochrome 2 proteins are core components of the mammalian circadian clock and mice mutated in both genes are arrhythmic."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16777965", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 417, 
                    "offsetInEndSection": 779, 
                    "text": "a domain in the extreme C terminus of BMAL1 that plays an essential role in the rhythmic control of E-box-mediated circadian transcription. Remarkably, the last 43 aa of BMAL1 are required for transcriptional activation, as well as for association with the circadian transcriptional repressor CRYPTOCHROME 1 (CRY1), depending on the coexistence of CLOCK protein."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19405859", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 624, 
                    "offsetInEndSection": 671, 
                    "text": "circadian rhythm protein cryptochrome 1 (CRY1)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19405859", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1576, 
                    "offsetInEndSection": 1678, 
                    "text": "CRY1 is a master regulator of circadian rhythm that regulates the extracellular calcification of MSCs."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19833968", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 362, 
                    "offsetInEndSection": 1010, 
                    "text": "Studying mouse fibroblasts, we demonstrated that the nutrient-responsive adenosine monophosphate-activated protein kinase (AMPK) phosphorylates and destabilizes the clock component cryptochrome 1 (CRY1). In mouse livers, AMPK activity and nuclear localization were rhythmic and inversely correlated with CRY1 nuclear protein abundance. Stimulation of AMPK destabilized cryptochromes and altered circadian rhythms, and mice in which the AMPK pathway was genetically disrupted showed alterations in peripheral clocks. Thus, phosphorylation by AMPK enables cryptochrome to transduce nutrient signals to circadian clocks in mammalian peripheral organs."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19858287", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 866, 
                    "offsetInEndSection": 1242, 
                    "text": "Cytoplasmic hnRNP D levels displayed a pattern that was reciprocal to the mcry1 oscillation. Knockdown of hnRNP D stabilized mcry1 mRNA and resulted in enhancement of the oscillation amplitude and a slight delay of the phase. Our results suggest that hnRNP D plays a role as a fine regulator contributing to the mcry1 mRNA turnover rate and the modulation of circadian rhythm."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20100521", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 546, 
                    "offsetInEndSection": 867, 
                    "text": "more than three mutations of conserved PER2 residues impaired not only binding to CRY1 but also subsequent nuclear translocation, although mutations of non-conserved residues did not affect interaction with CRY1. Thus, the conserved amino acid residues of 1179-1198 in PER2 are apparently responsible for binding to CRY1."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20825493", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 356, 
                    "text": "Cryptochrome 1 and 2 (Cry1 and Cry2) are considered essential for generating circadian rhythms in mammals. The role of Cry1 and Cry2 in circadian rhythm expression and acute light-induced suppression of pineal melatonin was assessed using Cry1 and Cry2 double-deficient mice (Cry1(-/-) /Cry2(-/-) ) developed from the C3H strain that synthesizes melatonin."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21236481", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 119, 
                    "offsetInEndSection": 278, 
                    "text": "Cryptochrome 1 (Cry1), an essential clock component, displays evening-time expression and serves as a strong repressor at morning-time elements (E box/E' box)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21236481", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 713, 
                    "offsetInEndSection": 1037, 
                    "text": "A genetic complementation assay in Cry1(-/-):Cry2(-/-) cells revealed that substantial delay of Cry1 expression is required to restore circadian rhythmicity, and its prolonged delay slows circadian oscillation. Taken together, our data suggest that phase delay in Cry1 transcription is required for mammalian clock function."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22140039", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 635, 
                    "offsetInEndSection": 1123, 
                    "text": "the 24-h mRNA rhythms of the following genes were suppressed in db/db mice compared with control mice: the clock genes period homolog 1/2 (Per1/2) and cryptochrome 1/2 (Cry1/2) and their target genes D site albumin promoter-binding protein (Dbp) and peroxisome proliferator-activated receptor-\u03b3 (Pparg) in the aorta and mesenteric arteries; Dbp in the heart; Per1, nuclear receptor subfamily 1, group D, member 1 (Rev-erba), and Dbp in the kidney; and Per1 in the suprachiasmatic nucleus."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16731656", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 462, 
                    "text": "In mammals, circadian rhythms in behavior and physiology are controlled by a central pacemaker, the SCN, and subordinated clocks throughout the body. On the molecular level, these clocks are based on transcriptional/translational feedback loops involving a set of clock genes that regulate their own transcription. Among the components driving the mammalian circadian clock are the Period 1 and 2 (Per1 and Per2) and Cryptochrome 1 and 2 (Cry1 and Cry2) genes. I"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18974860", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 3407, 
                    "offsetInEndSection": 3437, 
                    "text": "<p>circadian rhythm protein CRY1.</p> <p></p>"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18974860", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 3407, 
                    "offsetInEndSection": 3437, 
                    "text": "circadian rhythm protein CRY1."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22669941", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 611, 
                    "offsetInEndSection": 1380, 
                    "text": "The mammalian clock protein, cryptochrome 1 (CRY1), is degraded via the FBXL3-mediated ubiquitination pathway, suggesting that it is also likely to be targeted by the deubiquitination pathway. Here, we identified that USP2a, a circadian-controlled deubiquitinating enzyme, interacts with CRY1 and enhances its protein stability via deubiquitination upon serum shock. Depletion of Usp2a by shRNA greatly enhances the ubiquitination of CRY1 and dampens the oscillation amplitude of the CRY1 protein during a circadian cycle. By stabilizing the CRY1 protein, USP2a represses the Per2 promoter activity as well as the endogenous Per2 gene expression. We also demonstrated that USP2a-dependent deubiquitination and stabilization of the CRY1 protein occur in the mouse liver."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22952936", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1968, 
                    "offsetInEndSection": 2275, 
                    "text": "The clock gene Period2 (per2)-knockout mice are sensitive to carbon tetrachloride-induced hepatotoxicity [18], but are less sensitive to acetaminophen hepatotoxicity when injected at night-time (20\u223600) with a decreased expression of Cyp1a2, a P450 enzyme gene implicated in acetaminophen bioactivation [19]."
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22952936", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 777, 
                    "offsetInEndSection": 1193, 
                    "text": "Only cryptochrome 1(Cry1) mRNA exhibited marked fluctuation with a 17-fold peak/trough ratio for females and 27-fold peak/trough radio for males during the dark phase. These clock gene expression patterns indicate that the outbred KM mouse livers had typical circadian rhythms and were valid for further investigations. Interestingly, except for Cry1 and Dbp, other four clock genes were highly expressed in females."
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22170608", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 232, 
                    "offsetInEndSection": 614, 
                    "text": "Mammalian circadian clocks are based on a transcription and translation feedback loop in which a heterodimer of the transcription factors circadian locomotor output cycles kaput (CLOCK) and brain and muscle ARNT-like 1 (BMAL1) drives transcription from E-box elements, including that of their own repressors, the Period (Per1, Per2 and Per3) and Cryptochrome (Cry1 and Cry2) genes2."
                }, 
                {
                    "beginSection": "sections.4", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22170608", 
                    "endSection": "sections.4", 
                    "offsetInBeginSection": 18, 
                    "offsetInEndSection": 344, 
                    "text": "whether Cry1 can interact with two NRs known to modulate clock function\u2014the retinoid-related orphan receptors (ROR \u03b1/\u03b2/\u03b3) and Reverb \u03b1/\u03b2. Unexpectedly, we find robust association between Cry1 and ROR\u03b1 and \u03b3 but not with ROR\u03b2 or Reverb \u03b1/\u03b2 though we did reproduce the reported association of PER2 with Reverb \u03b116 (Fig. 1A\u2013B)."
                }, 
                {
                    "beginSection": "sections.5", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22170608", 
                    "endSection": "sections.5", 
                    "offsetInBeginSection": 71, 
                    "offsetInEndSection": 194, 
                    "text": "discovered a robust physical association of Cry1 with the glucocorticoid and androgen receptors (GR and AR, respectively) ("
                }, 
                {
                    "beginSection": "sections.5", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22170608", 
                    "endSection": "sections.5", 
                    "offsetInBeginSection": 454, 
                    "offsetInEndSection": 1092, 
                    "text": "Cry1 represses the ability of GR to drive expression of a luciferase reporter from a GRE-containing promoter (Fig. 1G). Finally, we used a series of deletion mutants of GR to demonstrate that Cry1 interacts with the C-terminus of GR (Fig. 1H), which is required for either activation or repression of transcription in response to ligand. Steroid hormones (glucocorticoids, testosterone, progesterone and aldosterone) are critical regulators of metabolic and reproductive physiology so the possibility that they could be directly regulated by cryptochromes suggests a new mechanism by which circadian clocks modulate physiological rhythms."
                }, 
                {
                    "beginSection": "sections.6", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22170608", 
                    "endSection": "sections.6", 
                    "offsetInBeginSection": 2188, 
                    "offsetInEndSection": 2293, 
                    "text": "<p> Cry1 and Cry2, central regulators of the circadian clock, also directly oppose Dex-induced GR activation.</p>"
                }, 
                {
                    "beginSection": "sections.6", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22170608", 
                    "endSection": "sections.6", 
                    "offsetInBeginSection": 2188, 
                    "offsetInEndSection": 2293, 
                    "text": "<p>Cry1 and Cry2, central regulators of the circadian clock, also directly oppose Dex-induced GR activation.</p> <p></p>"
                }, 
                {
                    "beginSection": "sections.6", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22170608", 
                    "endSection": "sections.6", 
                    "offsetInBeginSection": 2188, 
                    "offsetInEndSection": 2293, 
                    "text": "Cry1 and Cry2, central regulators of the circadian clock, also directly oppose Dex-induced GR activation."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23471982", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 256, 
                    "text": "The mammalian circadian clock is composed of interlocking feedback loops. Cryptochrome is a central component in the core negative feedback loop, whereas Rev-Erb\u03b1, a member of the nuclear receptor family, is an essential component of the interlocking loop."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23471982", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 765, 
                    "offsetInEndSection": 1065, 
                    "text": "By analyzing the Fbxl3 and Cryptochrome 1 double-mutant mice, we found that FBXL3 also regulates the amplitudes of E-box-driven gene expression. These two separate roles of FBXL3 in circadian feedback loops provide a mechanism that contributes to the period determination and robustness of the clock."
                }
            ], 
            "triples": [
                {
                    "o": "function", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A3879881"
                }, 
                {
                    "o": "http://www.w3.org/2008/05/skos-xl#Label", 
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A7582711"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A7582711", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C0542341"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A16996234", 
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C1506397"
                }, 
                {
                    "o": "cryptochrome 1 (photolyase-like) protein, mouse", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A16996234"
                }, 
                {
                    "o": "http://linkedlifedata.com/resource/umls/label/A12066546", 
                    "p": "http://www.w3.org/2008/05/skos-xl#prefLabel", 
                    "s": "http://linkedlifedata.com/resource/umls/id/C0288450"
                }, 
                {
                    "o": "cryptochrome 1", 
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                    "s": "http://linkedlifedata.com/resource/umls/label/A12066546"
                }
            ], 
            "type": "factoid"
        }, 
        {
            "body": "Does triiodothyronine play a regulatory role in insulin secretion from pancreas?", 
            "concepts": [
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0030073", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D050417", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0032024", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0050796", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0046676", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014284", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D010179", 
                "http://www.biosemantics.org/jochem#4275389", 
                "http://www.biosemantics.org/jochem#4249447", 
                "http://www.biosemantics.org/jochem#4054676", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007328", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D061385", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011988", 
                "http://www.uniprot.org/uniprot/INS_LOPAM", 
                "http://www.uniprot.org/uniprot/INS_MYOSC", 
                "http://www.uniprot.org/uniprot/INS_GADMC", 
                "http://www.uniprot.org/uniprot/INS_DANRE", 
                "http://www.uniprot.org/uniprot/INS_VERMO", 
                "http://www.uniprot.org/uniprot/INS_LOPPI", 
                "http://www.uniprot.org/uniprot/INS_APLCA", 
                "http://www.uniprot.org/uniprot/INS_RODSP", 
                "http://www.uniprot.org/uniprot/INS_HORSE", 
                "http://www.uniprot.org/uniprot/INS_HYSCR", 
                "http://www.uniprot.org/uniprot/INS_ATRSP", 
                "http://www.uniprot.org/uniprot/INS_CAVPO", 
                "http://www.uniprot.org/uniprot/INS_ORENI", 
                "http://www.uniprot.org/uniprot/INS_CALMI", 
                "http://www.uniprot.org/uniprot/INS_CANFA", 
                "http://www.uniprot.org/uniprot/INS_CAMDR", 
                "http://www.uniprot.org/uniprot/INS_ORNAN", 
                "http://www.uniprot.org/uniprot/INS_CAPHI", 
                "http://www.uniprot.org/uniprot/INS_CAIMO", 
                "http://www.uniprot.org/uniprot/INS_CHICK", 
                "http://www.uniprot.org/uniprot/INS_CHICH", 
                "http://www.uniprot.org/uniprot/INS_PHYMC", 
                "http://www.uniprot.org/uniprot/INS_LAMFL", 
                "http://www.uniprot.org/uniprot/INS_PIAME", 
                "http://www.uniprot.org/uniprot/INS_SHEEP", 
                "http://www.uniprot.org/uniprot/INS_OCTDE", 
                "http://www.uniprot.org/uniprot/INS_SQUAC", 
                "http://www.uniprot.org/uniprot/INS_PANBU", 
                "http://www.uniprot.org/uniprot/INS_AOTTR"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21914860", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21099301", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20730704", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19021014", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17408701", 
                "http://www.ncbi.nlm.nih.gov/pubmed/1357067", 
                "http://www.ncbi.nlm.nih.gov/pubmed/1537314", 
                "http://www.ncbi.nlm.nih.gov/pubmed/2242013", 
                "http://www.ncbi.nlm.nih.gov/pubmed/3310493", 
                "http://www.ncbi.nlm.nih.gov/pubmed/619228"
            ], 
            "id": "51682382298dcd4e51000066", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21914860", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1105, 
                    "offsetInEndSection": 1320, 
                    "text": "Our findings establish that p43 is an important regulator of glucose homeostasis and pancreatic \u03b2-cell function and provide evidence for the first time of a physiological role for a mitochondrial endocrine receptor."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21914860", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 492, 
                    "offsetInEndSection": 648, 
                    "text": "The p43(-/-) mice had a major defect in insulin secretion both in vivo and in isolated pancreatic islets and a loss of glucose-stimulated insulin secretion."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21099301", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 914, 
                    "offsetInEndSection": 1083, 
                    "text": "We demonstrated that treatment of primary cultures of rat pancreatic islets with T3 results in augmented \u03b2-cell vitality with an increase of their functional properties."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21099301", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1266, 
                    "offsetInEndSection": 1344, 
                    "text": "Nonetheless, the insulin secretion is sensibly augmented after T3 stimulation."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20730704", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 681, 
                    "offsetInEndSection": 946, 
                    "text": "Plasma glucose concentration of the fetal hypothyroid group during intravenous glucose tolerance test was significantly higher (p=0.003) at 5-20 min as compared to the control group, whereas plasma insulin concentration was significantly lower (p=0.012) at 5-20 min"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20730704", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1182, 
                    "offsetInEndSection": 1340, 
                    "text": "Although adult offspring born from hypothyroid mothers were euthyroid, their glucose tolerance and glucose stimulated insulin secretion of islets were altered"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19021014", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1, 
                    "offsetInEndSection": 87, 
                    "text": "hyroid hormones modulate the immune system and metabolism, influence insulin secretion"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17408701", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 999, 
                    "offsetInEndSection": 1190, 
                    "text": "Only T(3) concentrations higher than 250 microM were able to decrease cell viability and proliferation rate, to increase the rate of apoptosis and to reduce glucose-induced insulin secretion."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1357067", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 359, 
                    "offsetInEndSection": 735, 
                    "text": "Islets preincubated with glucose (3.3 mmol/l) and glucagon (1.4 mumol/l) plus theophylline (10 mmol/l), ACTH (0.11 nmol/l), bovine GH (0.46 mumol/l), prolactin (0.2 mumol/l) or tri-iodothyronine (1.0 nmol/l) have significantly lower Ca(2+)-ATPase activity than those preincubated with only 3.3 mmol glucose/l. All these hormones increased the release of insulin significantly."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1537314", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1326, 
                    "offsetInEndSection": 1476, 
                    "text": "T3 (0.2 nM) did not affect insulin secretion in the absence or presence of glucose or in the presence of secretagogues (potassium and glyceraldehyde)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2242013", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 202, 
                    "offsetInEndSection": 373, 
                    "text": "In the perfused rat pancreas, the addition of thyroxine (10 micrograms/dL) or 3,5,3'-triiodothyronine (150 ng/dL) to the perfusing medium did not affect insulin secretion."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2242013", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 374, 
                    "offsetInEndSection": 541, 
                    "text": "The administration of thyroxine (40 micrograms/kg, s.c.) in vivo increased the plasma insulin level from 11 +/- 2 microUnits/mL (mean +/- SD) to 30 +/- 7 microUnits/mL"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3310493", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 626, 
                    "offsetInEndSection": 1003, 
                    "text": "Addition of T3 to the incubation medium, significantly modified the insulin release, but its effect varied according to the glucose concentration in the medium, i.e. it enhanced the insulin release at a glucose concentration between 2 to 8 mmol/l; it has no effect at 12 mmol/glucose, and significantly inhibited the secretion of insulin in the presence of 16.6 mmol/l glucose."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/619228", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 588, 
                    "offsetInEndSection": 630, 
                    "text": "Both T3 and T4 inhibited insulin secretion"
                }
            ], 
            "type": "yesno"
        }, 
        {
            "body": "How does thyroid hormone affect insulin resistance in the heart?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007333", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013963", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0070324", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011988", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0046966", 
                "http://www.uniprot.org/uniprot/THB_PAROL", 
                "http://www.uniprot.org/uniprot/THB_RAT", 
                "http://www.uniprot.org/uniprot/THAA_XENLA", 
                "http://www.uniprot.org/uniprot/THA_CAIMO", 
                "http://www.uniprot.org/uniprot/THBA_XENLA", 
                "http://www.uniprot.org/uniprot/THB_DANRE", 
                "http://www.uniprot.org/uniprot/THB_MOUSE", 
                "http://www.uniprot.org/uniprot/THB_CHICK", 
                "http://www.uniprot.org/uniprot/THB_CAIMO", 
                "http://www.uniprot.org/uniprot/THB_SHEEP", 
                "http://www.uniprot.org/uniprot/THB_LITCT", 
                "http://www.uniprot.org/uniprot/THB_HUMAN", 
                "http://www.uniprot.org/uniprot/THA_NECMA", 
                "http://www.uniprot.org/uniprot/THAA_PAROL", 
                "http://www.uniprot.org/uniprot/THA_PIG", 
                "http://www.uniprot.org/uniprot/THA_RAT", 
                "http://www.uniprot.org/uniprot/THA_SALSA", 
                "http://www.uniprot.org/uniprot/THA_HIPHI", 
                "http://www.uniprot.org/uniprot/THA_PYGAD", 
                "http://www.uniprot.org/uniprot/THA_MOUSE", 
                "http://www.uniprot.org/uniprot/THA_APTPA", 
                "http://www.uniprot.org/uniprot/THAA_DANRE"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22031514", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20883475", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12869545"
            ], 
            "id": "51682c52298dcd4e51000067", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22031514", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1370, 
                    "offsetInEndSection": 1509, 
                    "text": "In diabetic vs. nondiabetic patients T(1)AM concentration was significantly increased (0.232 \u00b1 0.014 vs. 0.203 \u00b1 0.006 pmol/ml, P = 0.044),"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22031514", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1678, 
                    "offsetInEndSection": 1873, 
                    "text": "Our results are consistent with the hypothesis that circulating T(1)AM is produced from thyroid hormones and encourage further investigations on the potential role of T(1)AM in insulin resistance"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20883475", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 98, 
                    "offsetInEndSection": 175, 
                    "text": "exogenous T3 lowered blood glucose in db/db mice, a model of type 2 diabetes."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20883475", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1475, 
                    "offsetInEndSection": 1622, 
                    "text": "T3 potentiated insulin signaling, improved insulin sensitivity, and increased insulin synthesis, which may contribute to its anti-diabetic effects."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12869545", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1244, 
                    "offsetInEndSection": 1327, 
                    "text": "TRalpha P398H mutation is associated with visceral adiposity and insulin resistance"
                }
            ], 
            "type": "summary"
        }, 
        {
            "body": "Does  thyroid hormone receptor beta1 affect insulin secretion?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011988", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0004887", 
                "http://www.uniprot.org/uniprot/THBA_XENLA", 
                "http://www.uniprot.org/uniprot/THB_HUMAN", 
                "http://www.uniprot.org/uniprot/THB_LITCT", 
                "http://www.uniprot.org/uniprot/THB_SHEEP", 
                "http://www.uniprot.org/uniprot/THB_CAIMO", 
                "http://www.uniprot.org/uniprot/THB_CHICK", 
                "http://www.uniprot.org/uniprot/THB_MOUSE", 
                "http://www.uniprot.org/uniprot/THB_DANRE", 
                "http://www.uniprot.org/uniprot/THB_RAT", 
                "http://www.uniprot.org/uniprot/THB_PAROL", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D037042", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013963"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/17293442"
            ], 
            "id": "516c0e08298dcd4e5100006d", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17293442", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 282, 
                    "offsetInEndSection": 434, 
                    "text": "We demonstrated that thyroid hormone T3 rapidly induces Akt activation in pancreatic beta cells rRINm5F and hCM via thyroid hormone receptor (TR) beta1."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17293442", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 890, 
                    "offsetInEndSection": 1014, 
                    "text": "The silencing of TRbeta1 expression through RNAi confirmed this receptor to be crucial for the T3-induced activation of Akt."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17293442", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1149, 
                    "offsetInEndSection": 1385, 
                    "text": "T3 is able to specifically activate Akt in the islet beta cells rRINm5F and hCM through the interaction between TRbeta1 and PI3K p85alpha, demonstrating the involvement of TRbeta1 in this novel T3 non-genomic action in islet beta cells."
                }
            ], 
            "type": "yesno"
        }, 
        {
            "body": "Does thyroid hormone signaling affect microRNAs expression in the heart?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013963", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D035683", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0004887", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0046966", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0070324", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0070327", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011988", 
                "http://www.biosemantics.org/jochem#4250045", 
                "http://www.biosemantics.org/jochem#4275389", 
                "http://www.uniprot.org/uniprot/THB_HUMAN", 
                "http://www.uniprot.org/uniprot/THB_PAROL", 
                "http://www.uniprot.org/uniprot/THB_SHEEP", 
                "http://www.uniprot.org/uniprot/THB_CAIMO", 
                "http://www.uniprot.org/uniprot/THB_CHICK", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D037042", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D037021", 
                "http://www.uniprot.org/uniprot/THA_APTPA", 
                "http://www.uniprot.org/uniprot/THAA_DANRE", 
                "http://www.uniprot.org/uniprot/THAA_PAROL", 
                "http://www.uniprot.org/uniprot/THA_SPAAU", 
                "http://www.uniprot.org/uniprot/THAA_XENLA", 
                "http://www.uniprot.org/uniprot/THB_LITCT", 
                "http://www.uniprot.org/uniprot/THBA_XENLA", 
                "http://www.uniprot.org/uniprot/THB_RAT", 
                "http://www.uniprot.org/uniprot/THB_DANRE", 
                "http://www.uniprot.org/uniprot/THB_MOUSE", 
                "http://www.uniprot.org/uniprot/THA_ELECQ", 
                "http://www.uniprot.org/uniprot/THA_ONCMY", 
                "http://www.uniprot.org/uniprot/THA_NECMA", 
                "http://www.uniprot.org/uniprot/THA_CAIMO", 
                "http://www.uniprot.org/uniprot/THA_PIG", 
                "http://www.uniprot.org/uniprot/THA_RAT", 
                "http://www.uniprot.org/uniprot/THA_SALSA", 
                "http://www.uniprot.org/uniprot/THA_HIPHI", 
                "http://www.uniprot.org/uniprot/THA_PYGAD", 
                "http://www.uniprot.org/uniprot/THA_MOUSE", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014284", 
                "http://www.uniprot.org/uniprot/THA_LITCT", 
                "http://www.uniprot.org/uniprot/THA_HUMAN", 
                "http://www.uniprot.org/uniprot/THA_SHEEP", 
                "http://www.uniprot.org/uniprot/THA_CHICK"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22541436", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22525353", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21149577", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17379774"
            ], 
            "id": "516c1041298dcd4e51000070", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22541436", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 94, 
                    "offsetInEndSection": 364, 
                    "text": "e show that the heart regulates systemic energy homeostasis via MED13, a subunit of the Mediator complex, which controls transcription by thyroid hormone and other nuclear hormone receptors. MED13, in turn, is negatively regulated by a heart-specific microRNA, miR-208a."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22525353", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1179, 
                    "offsetInEndSection": 1240, 
                    "text": "On the other hand, T\u2083 treatment increased miR-350 expression."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21149577", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 906, 
                    "offsetInEndSection": 1079, 
                    "text": "Through a bioinformatics screening using TargetScan, we identified thyroid hormone receptor \u03b21 (TR\u03b21), which negatively regulates \u03b2-MHC transcription, as a target of miR-27a"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21149577", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1336, 
                    "offsetInEndSection": 1441, 
                    "text": "hese findings suggested that miR-27a regulates \u03b2-MHC gene expression by targeting TR\u03b21 in cardiomyocytes."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17379774", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 286, 
                    "offsetInEndSection": 500, 
                    "text": "We found that a cardiac-specific microRNA (miR-208) encoded by an intron of the alphaMHC gene is required for cardiomyocyte hypertrophy, fibrosis, and expression of betaMHC in response to stress and hypothyroidism."
                }
            ], 
            "type": "yesno"
        }, 
        {
            "body": "Does cucumber lower blood sugar in diabetics?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001786", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018553", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003920"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/2620957", 
                "http://www.ncbi.nlm.nih.gov/pubmed/937227", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22897583", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22419465", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21264099", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20614191", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19854256", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19276533", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17650589", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16179750", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11451723", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8569244", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22416705"
            ], 
            "id": "516c220e298dcd4e51000071", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2620957", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 125, 
                    "offsetInEndSection": 411, 
                    "text": "The ethanolic extract of Cucumis sativus Linn, Cucumis melo utilissimum Roxb, Cucumis melo Linn, Benincasa hispida Thunb Cogn and Tricosanthes anguina Nees, when administered in 250 mg/kg dose, orally to rats failed to lower blood sugar or to depress the peak value, after glucose load."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2620957", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 615, 
                    "offsetInEndSection": 952, 
                    "text": "Ethanolic extract of Tricosanthes dioica Roxb plant caused a significant lowering of blood sugar in fasted rats and depressed the peak value in glucose loaded single and longterm fed groups of rats. The ethanolic extract of the aerial part of T. dioica also induced significant depression in the peak values in the glucose loaded models."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/937227", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 979, 
                    "offsetInEndSection": 1087, 
                    "text": "The amount of sucrose in ordinary marinated foods, such as herring, cucumber, and common beet was negligible"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22897583", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 122, 
                    "text": "Dietary saponins of sea cucumber ameliorate obesity, hepatic steatosis, and glucose intolerance in high-fat diet-fed mice."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22897583", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 116, 
                    "offsetInEndSection": 271, 
                    "text": "In this study, we investigated the effects of saponins of sea cucumber (SSC) on high-fat diet-induced obesity, insulin resistance, and fatty liver in mice."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22897583", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 616, 
                    "offsetInEndSection": 879, 
                    "text": "Mice administrated with 0.1% SSC had significantly decreased serum glucose and insulin levels, lower homeostatic model assessment for insulin resistance index, and area under the blood glucose curve, suggesting that insulin sensitivity is enhanced by dietary SSC."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22419465", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 108, 
                    "text": "[Effects of sea cucumber cerebroside and its long-chain base on lipid and glucose metabolism in obese mice]."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22419465", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 145, 
                    "text": "OBJECTIVE: To investigate the effect of sea cucumber cerebroside(SCC) and its long-chain base(LCB) on lipid and glucose metabolism in obese mice."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22419465", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 786, 
                    "offsetInEndSection": 907, 
                    "text": "CONCLUSIONS: Sea cucumber cerebroside and its long-chain base can improve the glucose and lipid metabolism in obese mice."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21264099", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 154, 
                    "text": "Evaluation of the Hypoglycemic Activity of Cucumis metuliferus (Cucurbitaceae) Fruit Pulp Extract in Normoglycemic and Alloxan-Induced Hyperglycemic Rats."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20614191", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 380, 
                    "text": "The hitherto unknown glucose regulating role of three vegetable peels from cucurbitaceae family was evaluated. In a preliminary study, effects of ethanolic extracts of Cucurbita pepo, Cucumis sativus and Praecitrullus fistulosus peels were studied at 250 and 500\u00a0mg\u00a0kg(-1)\u00a0d(-1) for 15\u00a0days in the alterations in serum glucose and in hepatic lipid peroxidation (LPO) in male mice."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20614191", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 900, 
                    "offsetInEndSection": 1086, 
                    "text": "All the three peel extracts nearly reversed most of these changes induced by alloxan suggesting their possible role in ameliorating diabetes mellitus and related changes in serum lipids."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19854256", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 113, 
                    "text": "Antidiabetic activity of aqueous fruit extract of Cucumis trigonus Roxb. in streptozotocin-induced-diabetic rats."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19854256", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 347, 
                    "text": "Cucumis trigonus Roxb. (Cucurbitaceae) fruit is used in the Indian traditional medicine for the treatment of diabetes. Based on a number of reports on the blood glucose level reduction and the other complications of diabetes associated with some Cucurbitaceae plants, the antidiabetic effect of Cucumis trigonus fruit was investigated."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19854256", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 490, 
                    "offsetInEndSection": 632, 
                    "text": "The antidiabetic activity of aqueous extract of Cucumis trigonus fruit was evaluated by using normal and streptozotocin-induced-diabetic rats."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19854256", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1347, 
                    "offsetInEndSection": 1512, 
                    "text": "The aqueous fruit extract of Cucumis trigonus has had beneficial effects in reducing the elevated blood glucose level and lipid profile of STZ-induced-diabetic rats."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19276533", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 190, 
                    "text": "Possible amelioration of atherogenic diet induced dyslipidemia, hypothyroidism and hyperglycemia by the peel extracts of Mangifera indica, Cucumis melo and Citrullus vulgaris fruits in rats."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19276533", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 261, 
                    "text": "Hitherto unknown efficacy of the peel extracts of Mangifera indica (MI), Cucumis melo (CM) and Citrullus vulgaris (CV) fruits in ameliorating the diet-induced alterations in dyslipidemia, thyroid dysfunction and diabetes mellitus have been investigated in rats."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19276533", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 919, 
                    "offsetInEndSection": 1296, 
                    "text": "Rats, treated simultaneously with either of the peel extracts reversed the CCT-diet induced increase in the levels of tissue LPO, serum lipids, glucose, creatinine kinase-MB and decrease in the levels of thyroid hormones and insulin indicating their potential to ameliorate the diet induced alterations in serum lipids, thyroid dysfunctions and hyperglycemia/diabetes mellitus."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17650589", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 136, 
                    "text": "Role of pectin from cucumber (Cucumis sativus) in modulation of protein kinase C activity and regulation of glycogen metabolism in rats."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17650589", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 518, 
                    "text": "The regulatory role of protein kinase C (PKC) in glycogen metabolism in pectin fed rats was investigated. Administration of pectin (5 g/kg body wt/day) from cucumber (Cucumis sativius L.) led to inhibitory effects on PKC activity in the liver of rats. In the brain and pancreas, PKC activity was significantly higher in pectin-treated rats as compared to the control group. Level of blood glucose was significantly lowered and the level of glycogen in the liver was significantly increased in pectin-administered rats."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11451723", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1386, 
                    "offsetInEndSection": 1693, 
                    "text": "Addition of fermented milk (yogurt) and pickled cucumber to a breakfast with a high-glycemic index bread significantly lowered postprandial glycemia and insulinemia compared with the reference meal. In contrast, addition of regular milk and fresh cucumber had no favorable effect on the metabolic responses."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8569244", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 236, 
                    "offsetInEndSection": 461, 
                    "text": "Tolbutamide, Cucurbita ficifolia, Phaseolus vulgaris, Opuntia streptacantha, Spinacea oleracea, Cucumis sativus and Cuminum cyminum decrease significantly the area under the glucose tolerance curve and the hyperglycemic peak."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22416705", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 140, 
                    "text": "Two unsaturated fatty acids with potent \u03b1-glucosidase inhibitory activity purified from the body wall of sea cucumber (Stichopus japonicus)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22416705", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1041, 
                    "offsetInEndSection": 1361, 
                    "text": "In this study, 2 fatty acids with strong \u03b1-glucosidase-inhibitory activity, 7(Z)-octadecenoic acid and 7(Z),10(Z)-octadecadienoic acid, were purified and identified from sea cucumber. Therefore, sea cucumber fatty acids can potentially be developed as a novel natural nutraceutical for the management of type-2 diabetes."
                }
            ], 
            "type": "yesno"
        }, 
        {
            "body": "Which are the families of mammalian DNA-(cytosine-5)-methyltransferases?", 
            "concepts": [
                "http://www.uniprot.org/uniprot/CMT1_DICDI", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004248", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0003886"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22737219", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22140515", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22134929", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22133874", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22088914", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21846773", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21559294", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21549127", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21378119", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20838592", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20679393", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20071334", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19386473", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19173286"
            ], 
            "id": "516c3960298dcd4e51000073", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22737219", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1591, 
                    "offsetInEndSection": 2193, 
                    "text": "In the traditional model at least two different families of MTases were proposed to exist in eukaryotes: one family that is required for de novo methylation of DNA targeting un-methylated DNA, while the other family is specific for hemi-methylated DNA copying the methylation pattern in every replication cycle [2], [12]. In fact this traditional model holds mostly true, however, the de novo DNA nucleotide methyltransferases (DNMT3a/3b) and the maintenance DNA nucleotide methyltransferases (DNMT1) have partially overlapping functions and are supported by a number of other proteins [4], [13], [14]."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22737219", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2626, 
                    "offsetInEndSection": 2779, 
                    "text": "However, there is also a third family of eukaryotic DNA nucleotide methyltransferases (DNMT2) that is widely distributed and highly conserved [19], [20]."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22140515", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 219, 
                    "offsetInEndSection": 358, 
                    "text": "Broadly, eukaryotic DNA methyltransferases can be classified into the Dnmt1 and Dnmt3 families with several subfamilies [3], [4], [5], [6]."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22140515", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1903, 
                    "offsetInEndSection": 2186, 
                    "text": "The Dnmt2 proteins contain all the sequence motifs characteristic for DNA-(cytosine C5)-MTases and the Dnmt2 structure strongly resemble prokaryotic DNA MTases [14], [15], but in contrast to all other mammalian DNA MTases, Dnmt2 does not possess a large N-terminal regulatory domain."
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22140515", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 801, 
                    "offsetInEndSection": 1126, 
                    "text": "However, if such transition happened at all, it must have occurred long before the development of eukaryotic cells, because the wide distribution of the Dnmt1, Dnmt2 and Dnmt3 enzyme families in eukaryotes clearly indicates that all these enzymes were present already in the last eukaryotic common ancestor (LECA) (Fig. 6). I"
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22140515", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 4772, 
                    "offsetInEndSection": 4983, 
                    "text": "Most likely, the eukaryotic Dnmt2, Dnmt1 and Dnmt3 families of methyltransferases had an independent origin in the prokaryotic DNA methyltransferase sequence space and all were derived from MTases of RM systems."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22134929", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 449, 
                    "offsetInEndSection": 529, 
                    "text": "Of the DNMTs, DNMT1 and DNMT3a are most highly expressed in postmitotic neurons."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22133874", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 125, 
                    "text": "DNA methyltransferase 3B (Dnmt3b) belongs to a family of enzymes responsible for methylation of cytosine residues in mammals."
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22088914", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 154, 
                    "text": "Bovine DNA methylation imprints are established in an oocyte size-specific manner, which are coordinated with the expression of the DNMT3 family proteins."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21846773", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 366, 
                    "offsetInEndSection": 754, 
                    "text": "The specific transfer of methyl groups to form 5mC is catalyzed by members of the DNA methyltransferase (DNMT) protein family. Three classes of DNMTs have been identified in mammals: DNMT1, DNMT2 and DNMT3 (including DNMT3a, DNMT3b and DNMT3L isoforms) (3,4). All of them share homologous catalytic domains but differ in their regulatory, protein\u2013DNA- and protein\u2013protein-binding regions."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21559294", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1339, 
                    "offsetInEndSection": 1810, 
                    "text": ".There are three enzymes in the DNA (cytosine-5-)-methyltransferase (DNMT) family: DNMT1, DNMT 3 alpha (DNMT3A), and DNMT 3 beta (DNMT3B). All catalyze DNA methylation activity. DNMT1 is a member of the maintenance-type methyltransferase family, which is responsible for the maintenance of DNA methylation patterns [5]. DNMT3A and the closely related DNMT3B are de novo methyltransferases, which are responsible for the establishment of new methylation patterns [2], [5]."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21549127", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 197, 
                    "text": "The DNMT3B de novo DNA methyltransferase (DNMT) plays a major role in establishing DNA methylation patterns in early mammalian development, but its catalytic mechanism remains poorly characterized."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21378119", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 240, 
                    "text": "Genome-wide patterns of DNA methylation in mammals are established and maintained by a family of three enzymatically active DNA methyltransferases: DNMT1, DNMT3A and DNMT3B, and a fourth catalytically inactive co-factor, DNMT3L."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20838592", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1286, 
                    "offsetInEndSection": 1623, 
                    "text": "This de novo methylation function is assigned primarily to the DNMT3 family of DNA methyltransferases (DNMTs) [9]. This family comprises the two active DNMT3A and DNMT3B enzymes, which are highly expressed at specific developmental times in germ cells and during early development, and mediate genome-wide acquisition of DNA methylation."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20679393", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 182, 
                    "text": "Dnmt2 proteins are the most conserved members of the DNA methyltransferase enzyme family, but their substrate specificity and biological functions have been a subject of controversy."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20071334", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 203, 
                    "offsetInEndSection": 806, 
                    "text": "Occurring exclusively at cytosine within CpG dinucleotides in mammals, DNA methylation is coordinated by a family of DNA methyltransferases (DNMTs)5 comprising DNMT1, -3A, -3B, and -3L. DNMT1 is the \u201cmaintenance\u201d methyltransferase that ensures faithful transmission of methylation profile from maternal to daughter cells during cell division. In contrast, DNMT3A and -3B are de novo methyltransferases that show a degree of specificity in both target sequence and temporal activity (reviewed in Ref. 1). DNMT3L (DNMT3-like) lacks catalytic activity and has a very restricted gene expression profile (2)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19386473", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 265, 
                    "offsetInEndSection": 456, 
                    "text": "This promoter hypermethylation may be mediated not only by DNMT-1 but also by an entire family of de novo DNA-methyltransferases, such as DNA-methyltransferase-3a (DNMT-3a) and -3b (DNMT-3b)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19173286", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 114, 
                    "offsetInEndSection": 494, 
                    "text": "Within the family of DNA methyltransferases (Dnmts), Dnmt3a and 3b establish methylation marks during early development, while Dnmt1 maintains methylation patterns after DNA replication. The maintenance function of Dnmt1 is regulated by its large regulatory N-terminal domain that interacts with other chromatin factors and is essential for the recognition of hemi-methylated DNA."
                }
            ], 
            "type": "list"
        }, 
        {
            "body": "How does dronedarone affect thyroid hormone signaling in the heart?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013963", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0070324", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0010861", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0004887", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011988", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0046966", 
                "http://www.biosemantics.org/jochem#4274245", 
                "http://www.biosemantics.org/jochem#4250045", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D037021", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013974", 
                "http://www.biosemantics.org/jochem#4275389", 
                "http://www.uniprot.org/uniprot/THB_RAT", 
                "http://www.uniprot.org/uniprot/THB_DANRE", 
                "http://www.uniprot.org/uniprot/THB_MOUSE", 
                "http://www.uniprot.org/uniprot/THB_HUMAN", 
                "http://www.uniprot.org/uniprot/THB_LITCT", 
                "http://www.uniprot.org/uniprot/THB_SHEEP", 
                "http://www.uniprot.org/uniprot/THB_CAIMO", 
                "http://www.uniprot.org/uniprot/THB_CHICK", 
                "http://www.uniprot.org/uniprot/THB_PAROL", 
                "http://www.uniprot.org/uniprot/THBA_XENLA", 
                "http://www.uniprot.org/uniprot/THA_PIG", 
                "http://www.uniprot.org/uniprot/THA_RAT", 
                "http://www.uniprot.org/uniprot/THA_SALSA", 
                "http://www.uniprot.org/uniprot/THA_PYGAD", 
                "http://www.uniprot.org/uniprot/THA_HIPHI", 
                "http://www.uniprot.org/uniprot/THA_MOUSE", 
                "http://www.uniprot.org/uniprot/THAA_XENLA", 
                "http://www.uniprot.org/uniprot/THAA_DANRE", 
                "http://www.uniprot.org/uniprot/THA_APTPA", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D037042", 
                "http://www.uniprot.org/uniprot/THA_NECMA", 
                "http://www.uniprot.org/uniprot/THA_SPAAU", 
                "http://www.uniprot.org/uniprot/THA_LITCT", 
                "http://www.uniprot.org/uniprot/THA_HUMAN", 
                "http://www.uniprot.org/uniprot/THA_SHEEP", 
                "http://www.uniprot.org/uniprot/THA_CHICK", 
                "http://www.uniprot.org/uniprot/THA_ELECQ", 
                "http://www.uniprot.org/uniprot/THA_ONCMY", 
                "http://www.uniprot.org/uniprot/THAA_PAROL", 
                "http://www.uniprot.org/uniprot/THA_CAIMO", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014284", 
                "http://www.biosemantics.org/jochem#4275394", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0002154", 
                "http://www.biosemantics.org/jochem#4233556"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21442236", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17535870", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15687816", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12538616", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12063079"
            ], 
            "id": "516d4770298dcd4e51000076", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21442236", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 862, 
                    "offsetInEndSection": 980, 
                    "text": "Administration of debutyl-dronedarone (DBD), a TR\u03b11 antagonist abolished the T3-limiting effect on reperfusion injury:"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17535870", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 739, 
                    "offsetInEndSection": 846, 
                    "text": "Dron affected TR expression in the RA similarly by decreasing TRalpha 1 and beta 1 expression by about 50%."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17535870", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 847, 
                    "offsetInEndSection": 889, 
                    "text": "In the LVW, AM and Dron decreased TRbeta 1"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15687816", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 290, 
                    "text": "Hypothyroid heart displays a phenotype of cardioprotection against ischemia and this study investigated whether administration of dronedarone, an amiodarone-like compound that has been shown to preferentially antagonize thyroid hormone binding to thyroid hormone receptor alpha1 (TRalpha1),"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15687816", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1388, 
                    "offsetInEndSection": 1478, 
                    "text": "dronedarone treatment results in cardioprotection by selectively mimicking hypothyroidism."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12538616", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1253, 
                    "offsetInEndSection": 1391, 
                    "text": "The in vitro and in vivo findings suggest that dronedarone via its metabolite debutyldronedarone acts as a TRalpha(1)-selective inhibitor."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12063079", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 793, 
                    "offsetInEndSection": 925, 
                    "text": "Amiodarone resulted in increased T4, T4/T3 and rT3, whereas dronedarone did not alter the thyroid hormone profile in normal animals."
                }
            ], 
            "type": "summary"
        }, 
        {
            "body": "How does adrenergic signaling affect thyroid hormone receptors?", 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/18622044"
            ], 
            "id": "516d5bdf298dcd4e5100007a", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18622044", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 791, 
                    "offsetInEndSection": 945, 
                    "text": "PE, in the absence of T3, resulted in 5.0 fold increase in TRalpha1 expression in nucleus and 2.0 fold decrease in TRalpha1 expression in cytosol, P<0.05."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18622044", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1600, 
                    "offsetInEndSection": 1763, 
                    "text": "nuclear TRalpha1 is overexpressed after prolonged activation of the alpha1- adrenergic signalling by PE. This response seems to be an ERK kinase dependent process."
                }
            ], 
            "type": "summary"
        }, 
        {
            "body": "How does ranolazine affect calcium handling in the heart", 
            "concepts": [
                "http://www.biosemantics.org/jochem#4202863", 
                "http://www.biosemantics.org/jochem#4202864", 
                "http://www.biosemantics.org/jochem#4260677", 
                "http://www.biosemantics.org/jochem#4000018", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006321", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002118", 
                "http://www.biosemantics.org/jochem#4277675", 
                "http://www.biosemantics.org/jochem#4071295", 
                "http://www.biosemantics.org/jochem#4268168", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006331", 
                "http://www.disease-ontology.org/api/metadata/DOID:114", 
                "http://www.uniprot.org/uniprot/CCAMK_ORYSJ", 
                "http://www.uniprot.org/uniprot/CCAMK_LILLO", 
                "http://www.uniprot.org/uniprot/CCAMK_PEA", 
                "http://www.uniprot.org/uniprot/CCAMK_LOTJA", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009206"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22879384", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23247666", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22709755", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22343711", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22245792", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21741479", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20924097", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19675298", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18439620", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17220471", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17027025", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16781216", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16775092", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8735623"
            ], 
            "id": "517138d98ed59a060a000003", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22879384", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 957, 
                    "offsetInEndSection": 1131, 
                    "text": "Ranolazine and lidocaine (10 \u03bcM) similarly reduced Ca2+i overload and improved left ventricle work recovery in whole-heart models of IR injury or exposure to ouabain (80 \u03bcM)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22879384", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1132, 
                    "offsetInEndSection": 1245, 
                    "text": "Ranolazine (10 \u03bcM), but not lidocaine (10 \u03bcM), reduced RM NCX1.1-mediated Ca2+i overload in ventricular myocytes."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23247666", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 389, 
                    "offsetInEndSection": 583, 
                    "text": "Blockade of the late inward sodium current, late I(Na), offers another target for the treatment of ischemia. Blockade of late I(Na) reduces the sodium and calcium overload that follows ischemia."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23247666", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 728, 
                    "offsetInEndSection": 952, 
                    "text": "Ranolazine, a late I(Na) inhibitor, has been shown to provide both anti-anginal and anti-ischemic benefits without significant alterations in the heart rate and blood pressure in patients with stable coronary artery disease."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22709755", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 12, 
                    "offsetInEndSection": 171, 
                    "text": "Ranolazine is a new antianginal drug that reduces intracellular sodium and calcium accumulation during ischemia, thus potentially limiting myocardial ischemia."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22343711", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1298, 
                    "offsetInEndSection": 1544, 
                    "text": "Detergent extracted fiber bundles from DOCA-salt hearts demonstrated increased myofilament response to Ca(2+) with glutathionylation of myosin binding protein C. Treatment with ranolazine ameliorated the Ca(2+) response and cross-bridge kinetics."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22245792", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1770, 
                    "offsetInEndSection": 1875, 
                    "text": "Ran reduces P(o) of RyR2, desensitizes Ca(2+)-dependent RyR2 activation, and inhibits Ca(i) oscillations,"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21741479", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1583, 
                    "offsetInEndSection": 1748, 
                    "text": "Ranolazine may provide functional protection of the heart during IR injury by reducing cCa2+ and mCa2+ loading secondary to its effect to block the late Na+ current."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20924097", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 11, 
                    "offsetInEndSection": 123, 
                    "text": "Ranolazine is a novel antianginal medication that acts by ameliorating disturbed sodium and calcium homeostasis."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20924097", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 124, 
                    "offsetInEndSection": 248, 
                    "text": "By preventing myocyte sodium and calcium overload, ranolazine also have potential beneficial effects on myocardial function."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19675298", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1560, 
                    "offsetInEndSection": 1734, 
                    "text": "Reduction by RAN of I(Na,L)-induced dysregulation of calcium cycling could contribute to the antiarrhythmic actions of this agent in both reentrant and triggered arrhythmias."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18439620", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1743, 
                    "offsetInEndSection": 2048, 
                    "text": "Moreover, in rabbit myocytes the increases in late I(Na), [Na(+)](i) and [Ca(2+)](i) caused by ATX-II, were significantly blunted by ranolazine. These results suggest that ranolazine may be of therapeutic benefit in conditions of diastolic dysfunction due to elevated [Na(+)](i) and diastolic [Ca(2+)](i)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17220471", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 224, 
                    "text": "Ranolazine is a selective inhibitor of the late sodium current relative to peak sodium channel current, and via this mechanism, it may decrease sodium-dependent intracellular calcium overload during ischemia and reperfusion."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17027025", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1411, 
                    "offsetInEndSection": 1597, 
                    "text": "he beneficial effects of ranolazine in reducing Ca2+ overload and LV mechanical dysfunction during ischemia/reperfusion is consistent with the inhibition of late INa mechanism of action."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16781216", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 219, 
                    "offsetInEndSection": 338, 
                    "text": "Ranolazine is a novel agent that inhibits the late sodium current thereby reducing cellular sodium and calcium overload"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16775092", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1425, 
                    "offsetInEndSection": 1661, 
                    "text": "Ranolazine selectively inhibits late I(Na), reduces [Na(+)](i)-dependent calcium overload and attenuates the abnormalities of ventricular repolarisation and contractility that are associated with ischaemia/reperfusion and heart failure."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8735623", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1386, 
                    "offsetInEndSection": 1632, 
                    "text": "The results indicate that ranolazine, at concentrations which have significantly beneficial effects during ischaemic episodes, only greatly affects whole cell calcium current when facilitated by beta-adrenoceptor or histamine receptor activation."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8735623", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 642, 
                    "offsetInEndSection": 705, 
                    "text": "Ranolazine had only a small effect on the basal calcium current"
                }
            ], 
            "type": "summary"
        }, 
        {
            "body": "How does trimetazidine affect intracellular kinase signaling in the heart?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014292", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020930", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D048848", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0042656", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0008349", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0033161", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D048728", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D048730", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D048748", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D048768", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0004709", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0000185", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0004706", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D048490", 
                "http://www.uniprot.org/uniprot/ALPK2_MOUSE", 
                "http://www.uniprot.org/uniprot/ALPK2_HUMAN", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0042655", 
                "http://www.biosemantics.org/jochem#4250101", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0051390", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0000165", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0043408", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006321", 
                "http://www.biosemantics.org/jochem#4059120", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020929", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0031435", 
                "http://www.uniprot.org/uniprot/M4K2_MOUSE", 
                "http://www.uniprot.org/uniprot/M4K1_HUMAN", 
                "http://www.uniprot.org/uniprot/M4K1_MOUSE", 
                "http://www.uniprot.org/uniprot/M4K4_MOUSE", 
                "http://www.uniprot.org/uniprot/M4K5_HUMAN", 
                "http://www.uniprot.org/uniprot/M4K5_MOUSE", 
                "http://www.uniprot.org/uniprot/M4K3_RAT", 
                "http://www.uniprot.org/uniprot/M4K3_MOUSE", 
                "http://www.uniprot.org/uniprot/M4K3_HUMAN", 
                "http://www.uniprot.org/uniprot/M4K2_HUMAN", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D048670", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D048369", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D048370", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0000197", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D048669", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0004708", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D048688", 
                "http://www.uniprot.org/uniprot/M3K1_ARATH", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0000186", 
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0008545"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20167841", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20383170", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19546072", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15616764"
            ], 
            "id": "5171393e8ed59a060a000005", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20383170", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1121, 
                    "offsetInEndSection": 1377, 
                    "text": "The data suggest that trimetazidine significantly improves cardiac function in db/db mice by attenuating lipotoxicity and improving the oxidation status of the heart. Activation of AMPK and decreased expression of PGC-1 alpha were involved in this process."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20167841", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1405, 
                    "offsetInEndSection": 1751, 
                    "text": "the results demonstrated that TMZ is cardioprotective when administered before reperfusion and that this protection appears to be mediated by activation of p38 mitogen-activated protein kinase and Akt signaling. The study emphasizes the importance of administering TMZ before reflow to prevent reperfusion-mediated cardiac injury and dysfunction."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15616764", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 874, 
                    "offsetInEndSection": 937, 
                    "text": "TMZ induced cardioprotection did not involve p38 MAPK and JNKs."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15616764", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 938, 
                    "offsetInEndSection": 1017, 
                    "text": "Phospho-p38 MAPK and JNKs levels after I/R were not changed with TMZ treatment."
                }
            ], 
            "type": "summary"
        }, 
        {
            "body": "What is the role of SERCA in diabetic cardiomyopathy?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D058065", 
                "http://www.uniprot.org/uniprot/AT2A_CHIOP", 
                "http://www.disease-ontology.org/api/metadata/DOID:9351", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003920", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003924"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22621761", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22590623", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22137362", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19882101", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18492789", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17716638", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12217882"
            ], 
            "id": "51713cb58ed59a060a000006", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22621761", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1311, 
                    "offsetInEndSection": 1409, 
                    "text": "diabetes leads to cardiomyopathy in later stages with hypocontractility and reduced SERCA activity"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22621761", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2238, 
                    "offsetInEndSection": 2398, 
                    "text": "Previous studies with diabetes type 1 models have shown a down-regulation of SERCA2a in the heart associated with a decrease in systolic and diastolic function."
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22621761", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 8881, 
                    "offsetInEndSection": 9001, 
                    "text": "the up-regulation of SERCA2a in the early phase of type 2 diabetes is an important physiological adaptation of the heart"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22590623", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1482, 
                    "offsetInEndSection": 1595, 
                    "text": "diabetic cardiomyocytes displayed reduced SERCA activity and Ca2+ sequestration, as well as impaired NCX function"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22137362", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 919, 
                    "offsetInEndSection": 1115, 
                    "text": "Compared with control group, [Ca(2+)](i) and the expression of CaSR, RyR and SERCA/PLN were decreased, while PKC-\u03b1 and PLN were significantly increased in a time-dependent manner in diabetic group"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19882101", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1070, 
                    "offsetInEndSection": 1492, 
                    "text": "Diabetic rats showed impaired cardiac structure and function compared with control rats. The expression of PKC, PLB increased significantly, while the PPI-1, SERCA-2 and RyR expression decreased. Treatment with breviscapine could reverse the cardiac dysfunction and structure changes in diabetic cardiomyopathy rats, and decrease the expression of PKC and PLB, as well as increase the expression of PPI-1, SERCA-2 and RyR."
                }, 
                {
                    "beginSection": "sections.4", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18492789", 
                    "endSection": "sections.4", 
                    "offsetInBeginSection": 10545, 
                    "offsetInEndSection": 10697, 
                    "text": "Although decreased SR Ca2+ uptake exists, it is offset by an increase in action-potential duration, thereby ensuring that SR Ca2+ content is maintained."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17716638", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 689, 
                    "offsetInEndSection": 888, 
                    "text": "Diabetic Ren-2 rats developed impairment of both active and passive phases of diastole, accompanied by reductions in SERCA-2a ATPase and phospholamban along with activation of the fetal gene program."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12217882", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1538, 
                    "offsetInEndSection": 1651, 
                    "text": "The levels of SERCA and GLUT4, but not PLB, were significantly reduced in diabetic hearts compared with controls."
                }
            ], 
            "type": "summary"
        }, 
        {
            "body": "Name five popular  computer  programs used to identify genes in genomic sequences", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012984", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019542", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015397"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21901742", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21901741", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17332020", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16925832", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15593401", 
                "http://www.ncbi.nlm.nih.gov/pubmed/14965344", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12176826", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11673234", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11738707", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11337477", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9789092", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9253604", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19564452", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19329068", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16925843", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16314312", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15961499", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15924626", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15691859", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15613242", 
                "http://www.ncbi.nlm.nih.gov/pubmed/14764563", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12538242", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12023806", 
                "http://www.ncbi.nlm.nih.gov/pubmed/10779488", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19099578", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16925833"
            ], 
            "id": "51716a438ed59a060a00000a", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21901742", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 164, 
                    "text": "This unit describes how to use the gene-finding programs GeneMark.hmm-E and GeneMark-ES for finding protein-coding genes in the genomic DNA of eukaryotic organisms."
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16925832", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 13, 
                    "offsetInEndSection": 215, 
                    "text": "this paper we present an implementation of three computational pipelines (Fgenesh++, PSF and Fprom) for automatic identification of protein coding genes, pseudo-genes and promoters in eukaryotic genomes"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14965344", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 348, 
                    "offsetInEndSection": 451, 
                    "text": "YACOP parses and combines the output of the three gene-predicting systems Criticia, Glimmer and ZCURVE."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12176826", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 379, 
                    "offsetInEndSection": 594, 
                    "text": "In this paper we have explored the benefits of combining predictions from already existing gene prediction programs. We have introduced three novel methods for combining predictions from programs Genscan and HMMgene"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11673234", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 740, 
                    "offsetInEndSection": 968, 
                    "text": "We describe the data sets on which the experiments were performed, the approaches employed by the five algorithms: GenScan, HMMGene, GeneMark, Pombe and FFG, the methodology of our evaluation, and the results of the experiments."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11738707", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 164, 
                    "offsetInEndSection": 279, 
                    "text": "Phat is based on a generalized hidden Markov model (GHMM) similar to the models used in GENSCAN, Genie and HMMgene."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11337477", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 163, 
                    "text": "We present an independent comparative analysis of seven recently developed gene-finding programs: FGENES, GeneMark.hmm, Genie, Genescan, HMMgene, Morgan, and MZEF."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9789092", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 176, 
                    "offsetInEndSection": 378, 
                    "text": "We have explored the effectiveness when the results of several gene-finding programs were re-analyzed and combined. We studied several methods with four programs (FEXH, GeneParser3, GEN-SCAN and GRAIL2)"
                }, 
                {
                    "beginSection": "title", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16925843", 
                    "endSection": "title", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 98, 
                    "text": "JIGSAW, GeneZilla, and GlimmerHMM: puzzling out the features of human genes in the ENCODE regions"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15924626", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2003, 
                    "offsetInEndSection": 2377, 
                    "text": "The gene prediction tools tested were Ensembl, SGP2 and TWINSCAN. Ensembl is a homology-based method, which builds gene-models using species-specific known sequences and proteins from other species aligned to the genome [13]. SGP2 and TWINSCAN are de novo comparative gene predictors whose only inputs are the genome to be annotated and a second informant genome [3,4,14-16]"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12023806", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 625, 
                    "offsetInEndSection": 690, 
                    "text": "FGENES; Gene-Mark.hmm; Genie; Genescan; HMMgene; Morgan and MZEF,"
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19099578", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 11671, 
                    "offsetInEndSection": 12015, 
                    "text": "The gene sets are labelled as follows: AU: AUGUSTUS, MG: MGENE, CR: CRAIG, AG: Agene, EU: EUGENE, FPC: Fgenesh++C, FP: Fgenesh++, FG: Fgenesh, GE: GeneID, GM: GeneMark.hmm, GX: GENOMIX, GS: GESECA, GN: GLEAN, GL: GlimmerHMM, GR: Gramene, JW: JIGSAW, MK: MAKER (using SNAP), MG: MGENE, NS: N-SCAN, SG: SGP2, SN: SNAP, EX: ExonHunter, EV: Evigan."
                }
            ], 
            "type": "list"
        }, 
        {
            "body": "How many selenoproteins are encoded in the human genome?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D051140"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/12775843", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22943432", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18174224", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15843685"
            ], 
            "id": "517170c48ed59a060a00000d", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12775843", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 448, 
                    "offsetInEndSection": 503, 
                    "text": "The human selenoproteome consists of 25 selenoproteins."
                }
            ], 
            "type": "factoid"
        }, 
        {
            "body": "Are proteasome inhibitors good candidates for treatment of leukemia and solid tumors?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D061988", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007938"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22057347", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17145882", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22353937", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22134540", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22012631", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20219102", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20160034", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19821999", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19712963", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17431003", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16135477", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15169797", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12171876", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23477519", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23181572", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22995770"
            ], 
            "id": "517179718ed59a060a00000e", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22057347", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 824, 
                    "offsetInEndSection": 1115, 
                    "text": "We show that treatment with b-AP15 inhibited tumor progression in four different in vivo solid tumor models and inhibited organ infiltration in an acute myeloid leukemia model. Our results show that the deubiquitinating activity of the 19S regulatory particle is a new anticancer drug target"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17145882", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1126, 
                    "offsetInEndSection": 1464, 
                    "text": "We further found that ATO targets AME via both myelodysplastic syndrome 1 (MDS1) and EVI1 moieties and degrades EVI1 via the ubiquitin-proteasome pathway and MDS1 in a proteasome-independent manner. Our results suggest that ATO could be used as a part of targeted therapy for AME-, AML1/MDS1-, MDS1/EVI1-, and EVI1-positive human cancers."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22353937", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 315, 
                    "offsetInEndSection": 795, 
                    "text": "Previously we had shown the synergic effect of bortezomib and thiostrepton in breast cancer cells in vitro, where sub-apoptotic concentrations of both proteasome inhibitors resulted in synergic increase in cell death when combined as a treatment. Here, we administered such a combination to MDA-MB-231 xenograft tumors in vivo, and found that the effect of complementary proteasome inhibitors reduced tumor growth rates more efficiently than compared with when administered alone."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22134540", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1477, 
                    "offsetInEndSection": 1678, 
                    "text": "Addition of a proteasome inhibitor to anti-hormonal therapy resulted in a clinical benefit rate of 22% in a limited number of patients with endocrine resistant and progressive metastatic breast cancer."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22012631", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 974, 
                    "offsetInEndSection": 1156, 
                    "text": "Here we show that the water-soluble analog of curcumin #12, but not curcumin, in combination with bortezomib could enhance the proteasome-inhibitory effect in multiple myeloma cells."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20160034", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1168, 
                    "offsetInEndSection": 1288, 
                    "text": "Taken together, these data support the clinical development of MLN9708 for both hematologic and solid tumor indications."
                }, 
                {
                    "beginSection": "sections.4", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19821999", 
                    "endSection": "sections.4", 
                    "offsetInBeginSection": 376, 
                    "offsetInEndSection": 810, 
                    "text": "BU-32 is a highly selective and potent inhibitor of 26S proteasome. Preclinical studies currently being conducted by the National Cancer Institute against a panel of 60 cell lines show that BU-32 has broad anti-tumor activity (data not shown), and numerous biochemical studies are currently ongoing to investigate its efficacy as a single agent and in combination with other active anti-tumor agents against a variety of malignancies."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19712963", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1584, 
                    "offsetInEndSection": 1690, 
                    "text": "Bortezomib has minimal activity as a single-agent in the treatment of recurrent platinum-sensitive EOC/PPC"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17431003", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1421, 
                    "offsetInEndSection": 1762, 
                    "text": "Our study indicates a molecular mechanism by which the sensitivity of thyroid cancer cells is regulated by the level of GRP78 as well as preferential induction of GRP78 or CHOP upon treatment with proteasome inhibitors. Our experiments therefore suggest a novel approach toward sensitization of thyroid cancer cells to proteasome inhibitors."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16135477", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1270, 
                    "offsetInEndSection": 1511, 
                    "text": "Bortezomib (PS-341) is a novel antineoplastic agent that is well tolerated at doses not exceeding 3.0 mg (equivalent to 1.75 mg/m2), repeated on D1 and D4 every other week. This dose correlates with 70% inhibition of 20S proteasome activity."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15169797", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1459, 
                    "offsetInEndSection": 1709, 
                    "text": "The maximum-tolerated dose and recommended phase II dose of bortezomib in this schedule is 1.6 mg/m(2). Biologic activity (inhibition of nuclear factor-kappa B-related markers) and antitumor activity is seen in AIPCa at tolerated doses of bortezomib."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12171876", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1038, 
                    "offsetInEndSection": 1278, 
                    "text": "Given the results of this trial, it is safe and reasonable to recommend treatment with PS341 on the schedule used in this trial at 1.56 mg/m2/dose in Phase II trials. Particular care should be taken with patients with preexisting neuropathy"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23477519", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 518, 
                    "offsetInEndSection": 647, 
                    "text": "The successes of proteasome inhibitors in MM are now being translated to other hematologic malignancies, including acute leukemia"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23181572", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 843, 
                    "offsetInEndSection": 1048, 
                    "text": "Such efforts have led to bortezomib, the first FDA approved proteasome inhibitor now used as a frontline treatment for newly diagnosed multiple myeloma (MM), relapsed/refractory MM and mantle cell lymphoma"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22995770", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 383, 
                    "offsetInEndSection": 696, 
                    "text": "We recently reported the impact and mechanisms of carfilzomib and oprozomib, second-in-class proteasome inhibitors with higher specificities and reduced toxicities, against head and neck squamous cell carcinoma (HNSCC). Carfilzomib and oprozomib potently inhibit HNSCC cell survival and the growth of HNSCC tumors"
                }
            ], 
            "type": "yesno"
        }, 
        {
            "body": "Which genes are more frequently affected by somatic mutations in Chronic Lymphocytic Leukemia", 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22675518", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22158541", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22150006", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21642962", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19367498", 
                "http://www.ncbi.nlm.nih.gov/pubmed/10803511"
            ], 
            "id": "5171a1498ed59a060a000012", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22158541", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 333, 
                    "offsetInEndSection": 497, 
                    "text": "Among these genes, SF3B1, encoding a subunit of the spliceosomal U2 small nuclear ribonucleoprotein (snRNP), is somatically mutated in 9.7% of affected individuals."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21642962", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 583, 
                    "offsetInEndSection": 815, 
                    "text": "Further analysis of these mutations in 363 patients with CLL identified four genes that are recurrently mutated: notch 1 (NOTCH1), exportin 1 (XPO1), myeloid differentiation primary response gene 88 (MYD88) and kelch-like 6 (KLHL6)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22150006", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 476, 
                    "offsetInEndSection": 917, 
                    "text": "Nine genes that are mutated at significant frequencies were identified, including four with established roles in chronic lymphocytic leukemia (TP53 in 15% of patients, ATM in 9%, MYD88 in 10%, and NOTCH1 in 4%) and five with unestablished roles (SF3B1, ZMYM3, MAPK1, FBXW7, and DDX3X). SF3B1, which functions at the catalytic core of the spliceosome, was the second most frequently mutated gene (with mutations occurring in 15% of patients)."
                }
            ], 
            "type": "list"
        }, 
        {
            "body": "Which  is the execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017385", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017386", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016415", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D056510"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21714130", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20370891", 
                "http://www.ncbi.nlm.nih.gov/pubmed/14668231", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12804086", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9021270", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16522182", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11301301", 
                "http://www.ncbi.nlm.nih.gov/pubmed/1774068"
            ], 
            "id": "51724fca8ed59a060a000013", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21714130", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 251, 
                    "text": "The problem of finding an optimal structural alignment for a pair of superimposed proteins is often amenable to the Smith-Waterman dynamic programming algorithm, which runs in time proportional to the product of lengths of the sequences being aligned."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20370891", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 204, 
                    "offsetInEndSection": 549, 
                    "text": "The similarities between sequences can be determined by computing their optimal local alignments using the dynamic programming based on the Smith-Waterman (SW) algorithm [1,2]. However, the quadratic time complexity of this algorithm makes it computationally demanding, which is further compounded by the exponential growth of sequence databases"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12804086", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 531, 
                    "offsetInEndSection": 781, 
                    "text": "While this result is not an asymptotic improvement over the original Smith-Waterman algorithm, its complexity is characterized in terms of some sparse features of the matrix and it yields the fastest software implementation to date for such searches."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9021270", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1269, 
                    "offsetInEndSection": 1804, 
                    "text": "If we use N, M and C to represent the size of an amino acid sequence, the size of a structure template, and the maximum cut size of long-range interactions, respectively, the algorithm finds an optimal structure-sequence alignment in O(21C NM) time, a polynomial function of N and M when C = O(log(N + M)). When running on structure-sequence alignment problems without long-range intersections, i.e. C = 0, the algorithm achieves the same asymptotic computational complexity of the Smith-Waterman sequence-sequence alignment algorithm."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11301301", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1277, 
                    "offsetInEndSection": 1470, 
                    "text": "The algorithm is based on fractional programming and its running time is O(n2log n). In practice, normalized local alignment is only 3-5 times slower than the standard Smith-Waterman algorithm."
                }
            ], 
            "type": "factoid"
        }, 
        {
            "body": "Other than protein coding potential, what features set apart long non-coding RNAs from protein coding genes?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D062085", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D022661"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22303401", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23463798", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23319885", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23274483", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22955988", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22546862", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22135294", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22071789", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21915789", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21502407", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21112873", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19895688", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20587619", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17387145"
            ], 
            "id": "5172e9448ed59a060a000018", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22955988", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 546, 
                    "offsetInEndSection": 739, 
                    "text": "Our analyses indicate that lncRNAs are generated through pathways similar to that of protein-coding genes, with similar histone-modification profiles, splicing signals, and exon/intron lengths."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22955988", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 740, 
                    "offsetInEndSection": 845, 
                    "text": "In contrast to protein-coding genes, however, lncRNAs display a striking bias toward two-exon transcripts"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22955988", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 848, 
                    "offsetInEndSection": 979, 
                    "text": "hey are predominantly localized in the chromatin and nucleus, and a fraction appear to be preferentially processed into small RNAs."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22955988", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 980, 
                    "offsetInEndSection": 1166, 
                    "text": "They are under stronger selective pressure than neutrally evolving sequences-particularly in their promoter regions, which display levels of selection comparable to protein-coding genes."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22955988", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1244, 
                    "offsetInEndSection": 1532, 
                    "text": "Comprehensive analysis of their expression in multiple human organs and brain regions shows that lncRNAs are generally lower expressed than protein-coding genes, and display more tissue-specific expression patterns, with a large fraction of tissue-specific lncRNAs expressed in the brain."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22071789", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2985, 
                    "offsetInEndSection": 3210, 
                    "text": ".Compared with protein-coding sequences and small RNAs (e.g., miRNA and snoRNA), lncRNAs are weakly conserved: only approximately 5% of the bases have been estimated to be evolutionarily constrained (Marques and Ponting 2009)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22071789", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 4373, 
                    "offsetInEndSection": 4630, 
                    "text": "A comparative analysis of the expression patterns of intergenic transcripts in brain, heart, testis, and lymphoblastoid cell lines of human and chimpanzee has revealed a tissue-specific conservation pattern, which is similar to that of protein-coding genes."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19895688", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 4171, 
                    "offsetInEndSection": 4342, 
                    "text": "LincRNA exons and their putative promoters were found by Guttman et al. [10] to be better conserved than introns, which is suggestive of the action of purifying selection."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17387145", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 974, 
                    "offsetInEndSection": 1242, 
                    "text": "he proportion of conserved sequence (4.1%-5.5%) in these macroRNAs is comparable to the density of exons within protein-coding transcripts (5.2%). These macroRNAs, taken together, thus possess the imprint of purifying selection, thereby indicating their functionality."
                }
            ], 
            "type": "summary"
        }, 
        {
            "body": "Which metazaon species or taxa are known to lack selenoproteins", 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22943432", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22479358", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19744324", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19487332", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18698431", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16260744", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15843685", 
                "http://www.ncbi.nlm.nih.gov/pubmed/14710190"
            ], 
            "id": "5172f8118ed59a060a000019", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18698431", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 5422, 
                    "offsetInEndSection": 5569, 
                    "text": "ecently, we have shown [19] that one fly, Drosophila willistoni, lacks selenoprotein genes, being the first animal reported to lack these proteins."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18698431", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 5570, 
                    "offsetInEndSection": 5678, 
                    "text": "More recently Lobanov et al. have reported that other insect genomes also appear to lack selenoproteins [20]"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18698431", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 6964, 
                    "offsetInEndSection": 7386, 
                    "text": "We have also analyzed the sequences of all other available insect genomes (the mosquitoes Anopheles gambiae and Aedes aegypti, the honey bee Apis mellifera, the wasp Nasonia vitripennis, the beetle Tribolium castaneum and the silkworm Bombyx mori), and found that, while mosquitoes share the selenoprotein complement of D. melanogaster, selenoproteins have been lost in the wasp, the honey bee, the silkworm and the beetle"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18698431", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 7388, 
                    "offsetInEndSection": 7682, 
                    "text": "Analysis of available sequence data from other arthropoda (including cDNA, EST, protein and genomic data) suggests that the loss of selenoproteins has been confined to the infraclass Endopterygota, affecting species of all orders investigated (Hymenoptera, Lepidoptera, Diptera and Coleoptera)."
                }
            ], 
            "type": "summary"
        }, 
        {
            "body": "Are transcription and splicing connected?", 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23209445", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23074139", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22479188", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21964334", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20808788", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16172632", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15905409", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15870275", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23097425", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22975042", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22156210", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21095588", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17189193", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16921380", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16769980", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15383674"
            ], 
            "id": "517395b98ed59a060a00001a", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23074139", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 476, 
                    "offsetInEndSection": 791, 
                    "text": ", as splicing is often cotranscriptional, a complex picture emerges in which splicing regulation not only depends on the balance of splicing factor binding to their pre-mRNA target sites but also on transcription-associated features such as protein recruitment to the transcribing machinery and elongation kinetics."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23074139", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 851, 
                    "offsetInEndSection": 968, 
                    "text": "recent evidence shows that chromatin structure is another layer of regulation that may act through various mechanisms"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23074139", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 971, 
                    "offsetInEndSection": 1135, 
                    "text": "hese span from regulation of RNA polymerase II elongation, which ultimately determines splicing decisions, to splicing factor recruitment by specific histone marks."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23074139", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1136, 
                    "offsetInEndSection": 1250, 
                    "text": "Chromatin may not only be involved in alternative splicing regulation but in constitutive exon recognition as well"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23074139", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1252, 
                    "offsetInEndSection": 1480, 
                    "text": "Moreover, splicing was found to be necessary for the proper 'writing' of particular chromatin signatures, giving further mechanistic support to functional interconnections between splicing, transcription and chromatin structure."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23074139", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1481, 
                    "offsetInEndSection": 1671, 
                    "text": "These links between chromatin configuration and splicing raise the intriguing possibility of the existence of a memory for splicing patterns to be inherited through epigenetic modifications."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22479188", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1260, 
                    "offsetInEndSection": 1572, 
                    "text": "Whereas the historical view of splicing envisioned a cascade of temporal events initiated by transcription, followed by polyadenylation, and finalized with splicing and export of mRNAs from the nucleus, it is now clear that these pathways are not independent from one another but rather are functionally coupled."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22479188", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1574, 
                    "offsetInEndSection": 1872, 
                    "text": "trong evidence in both yeast and higher eukaryotes demonstrates that recruitment of the spliceosome to intron-containing transcripts occurs co-transcriptionally [3]\u2013[6], mediated at least in part by physical associations between the C-terminal domain (CTD) of RNA polymerase II and the U1 snRNP [7]"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22479188", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1874, 
                    "offsetInEndSection": 2079, 
                    "text": "A growing body of evidence also indicates that the landscape of chromatin modifications encountered by transcribing polymerase molecules can dictate the activity of the spliceosome at various splice sites."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21964334", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 148, 
                    "offsetInEndSection": 285, 
                    "text": "Spliceosome assembly occurs co-transcriptionally, raising the possibility that DNA structure may directly influence alternative splicing."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21964334", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 287, 
                    "offsetInEndSection": 475, 
                    "text": "upporting such an association, recent reports have identified distinct histone methylation patterns, elevated nucleosome occupancy and enriched DNA methylation at exons relative to introns"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21964334", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 477, 
                    "offsetInEndSection": 564, 
                    "text": "Moreover, the rate of transcription elongation has been linked to alternative splicing."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21964334", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 566, 
                    "offsetInEndSection": 827, 
                    "text": "ere we provide the first evidence that a DNA-binding protein, CCCTC-binding factor (CTCF), can promote inclusion of weak upstream exons by mediating local RNA polymerase II pausing both in a mammalian model system for alternative splicing, CD45, and genome-wide"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23097425", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 148, 
                    "offsetInEndSection": 232, 
                    "text": "We recently showed that cotranscriptional splicing occurs efficiently in Drosophila,"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22975042", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 138, 
                    "offsetInEndSection": 221, 
                    "text": "In recent years it became apparent that splicing is predominantly cotranscriptional"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22156210", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 385, 
                    "text": "To determine the prevalence of cotranscriptional splicing in Drosophila, we sequenced nascent RNA transcripts from Drosophila S2 cells as well as from Drosophila heads. Eighty-seven percent of the introns assayed manifest >50% cotranscriptional splicing. The remaining 13% are cotranscriptionally spliced poorly or slowly, with \u223c3% being almost completely retained in nascent pre-mRNA."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17189193", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 720, 
                    "offsetInEndSection": 877, 
                    "text": "We estimate that > or =90% of endogenous yeast splicing is posttranscriptional, consistent with an analysis of posttranscriptional snRNP-associated pre-mRNA."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16921380", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 748, 
                    "offsetInEndSection": 1039, 
                    "text": "Notably, the topoisomerase I inhibitor camptothecin, which stalls elongating Pol II, increased cotranscriptional splicing factor accumulation and splicing in parallel. This provides direct evidence for a kinetic link between transcription, splicing factor recruitment and splicing catalysis."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15383674", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 739, 
                    "offsetInEndSection": 950, 
                    "text": "Recent evidence indicates that transcriptional elongation and splicing can be influenced reciprocally: Elongation rates control alternative splicing and splicing factors can, in turn, modulate pol II elongation."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15383674", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 951, 
                    "offsetInEndSection": 1251, 
                    "text": "The presence of transcription factors in the spliceosome and the existence of proteins, such as the coactivator PGC-1, with dual activities in splicing and transcription can explain the links between both processes and add a new level of complexity to the regulation of gene expression in eukaryotes."
                }
            ], 
            "type": "yesno"
        }, 
        {
            "body": "Which is the most important prognosis sub-classification in Chronic Lymphocytic Leukemia?", 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23468975", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22560084", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20353875", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20090781", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19500131", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19127482", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17786276", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16825496", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16014569", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16083281"
            ], 
            "id": "51739df58ed59a060a00001c", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22560084", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 621, 
                    "offsetInEndSection": 879, 
                    "text": "One of the most reliable prognostic markers in chronic lymphocytic leukemia (CLL) is the mutational status of immunoglobulin heavy variable (IGHV) genes, which defines 2 subsets, mutated CLL (M-CLL) and unmutated CLL (U-CLL), with different clinical courses."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20090781", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 119, 
                    "offsetInEndSection": 268, 
                    "text": "Mutational status of the immunoglobulin heavy chain variable regions (IGHVs) of CLL cells offers useful prognostic information for high-risk patients"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20090781", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 270, 
                    "offsetInEndSection": 496, 
                    "text": "but time and economical costs originally prevented it from being routinely used in a clinical setting. Instead, alternative markers of IGHV status, such as zeta-associated protein (ZAP70) or messenger RNA levels are often used"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19127482", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 109, 
                    "offsetInEndSection": 282, 
                    "text": "Patients with unmutated IgV(H) gene show a shorter progression-free and overall survival than patients with immunoglobulin heavy chain variable regions (IgV(H)) gene mutated"
                }
            ], 
            "type": "factoid"
        }, 
        {
            "body": "What is the relationship between nucleosomes and exons?", 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22954214", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22683623", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21859475", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21289049", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20808788", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20097656", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19823040", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19687145", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19684599", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15862762", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11724736", 
                "http://www.ncbi.nlm.nih.gov/pubmed/9461388", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8918932"
            ], 
            "id": "5173a8b48ed59a060a00001d", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22954214", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 372, 
                    "offsetInEndSection": 557, 
                    "text": "Nucleosomes preferentially are located at the ends of exons, thus protecting splice junctions, with the N9 positions of guanines of the GT and AG junctions oriented toward the histones."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22683623", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 397, 
                    "offsetInEndSection": 691, 
                    "text": "Nucleosomes were found to be preferentially positioned within constitutive exons and/or constitutive portions of alternative exons, which was not associated with gene expression or states of cells but was based on sequence and positively related with the sequence conservation of splicing sites"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21289049", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 375, 
                    "offsetInEndSection": 632, 
                    "text": "Here, we discuss the evidence supporting these ideas, from the first proposal of chromatin affecting alternative splicing, performed 20 years ago, to the latest findings including genome-wide evidence that nucleosomes are preferentially positioned in exons."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20808788", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1728, 
                    "offsetInEndSection": 1950, 
                    "text": "a large number of histone modifications showed higher levels across exons which, for the most part, could be accounted for by nucleosome distribution, with well-positioned nucleosomes on exons accounting for these patterns"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20097656", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1331, 
                    "offsetInEndSection": 1447, 
                    "text": "he general link between nucleosome and gene exon\u2013intron architecture has been suggested in previous studies (11,12)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20097656", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1745, 
                    "offsetInEndSection": 1979, 
                    "text": "Andersson et al. (13) have reported that nucleosomes are well positioned in exons and carry characteristic histone modifications, and Schwartz et al. (14) have described that the chromatin organization marks the exon\u2013intron structure."
                }, 
                {
                    "beginSection": "sections.3", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20097656", 
                    "endSection": "sections.3", 
                    "offsetInBeginSection": 4006, 
                    "offsetInEndSection": 4153, 
                    "text": "We found the common feature that the nucleosome occupation potential is significantly stronger in exons but weaker in their adjacent intron regions"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19823040", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 545, 
                    "offsetInEndSection": 814, 
                    "text": "Here we show, by analysis of data sets from human sperm and T cells and medaka (Japanese killifish, Oryzias latipes) blastulae, that internal exons of genes are characterized by sharply elevated average nucleosome occupancy in comparison to flanking intronic sequences."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19687145", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 376, 
                    "offsetInEndSection": 645, 
                    "text": "sing public data, we here show that there is a higher nucleosome-positioning signal in internal human exons and that this positioning is independent of expression. We observed a similarly strong nucleosome-positioning signal in internal exons of Caenorhabditis elegans."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19684599", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 234, 
                    "offsetInEndSection": 371, 
                    "text": "we have found stable nucleosome occupancy within human and Caenorhabditis elegans exons that is stronger in exons with weak splice sites."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15862762", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 172, 
                    "offsetInEndSection": 289, 
                    "text": "This confirms previously reported findings about preferential positioning of splice junctions within the nucleosomes."
                }
            ], 
            "type": "summary"
        }, 
        {
            "body": "Which histone modifications have been associated to alternative splicing?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017398", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D042421"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23353998", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22455468", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22345622", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22242188", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21358630", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21289049", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21173847", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21057525", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20407423", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20133523", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19687145", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19182803"
            ], 
            "id": "5173b5ea8ed59a060a00001f", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23353998", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 382, 
                    "offsetInEndSection": 706, 
                    "text": "We found that several types of histone modifications including H3K36me3 were associated with the inclusion or exclusion of alternative exons. Furthermore, we observed that the levels of H3K36me3 and H3K79me1 in the cell lines were well correlated with the differences in alternative splicing patterns between the cell lines."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21358630", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 175, 
                    "offsetInEndSection": 337, 
                    "text": "Here we find that elevated levels of trimethylation of histone H3 on Lys9 (H3K9me3) are a characteristic of the alternative exons of several genes including CD44."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21289049", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 724, 
                    "offsetInEndSection": 955, 
                    "text": "he first report shows that a physiological stimulus such as neuron depolarization promotes intragenic histone acetylation (H3K9ac) and chromatin relaxation, causing the skipping of exon 18 of the neural cell adhesion molecule gene."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21289049", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1102, 
                    "offsetInEndSection": 1393, 
                    "text": "Using small interfering RNAs (siRNAs), we increased the levels of H3K9me2 and H3K27me3 in the proximity of alternative exon 33 of the human fibronectin gene, favoring its inclusion into mature messenger RNA (mRNA) through a mechanism that recalls RNA-mediated transcriptional gene silencing."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19687145", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 646, 
                    "offsetInEndSection": 881, 
                    "text": "Among the 38 histone modifications analyzed in man, H3K36me3, H3K79me1, H2BK5me1, H3K27me1, H3K27me2, and H3K27me3 had evidently higher signals in internal exons than in the following introns and were clearly related to exon expression"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19182803", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 498, 
                    "offsetInEndSection": 758, 
                    "text": "We also observe a novel pattern: exons are preferentially marked with H3K36me3 relative to introns. H3K36me3 exon marking is dependent on transcription and is found at lower levels in alternatively spliced exons, supporting a splicing-related marking mechanism"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22455468", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1747, 
                    "offsetInEndSection": 1885, 
                    "text": "Histone modifications such as H3K36me3, H3K79me1, H2BK5me1, H3K27me1, H3K27me2, and H3K27me3 were found to be related with exon expression"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22455468", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2543, 
                    "offsetInEndSection": 2618, 
                    "text": "Other histone methylations, such as H3K4me1, H3K4me3, H3K27me3 and H3K9me1,"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22455468", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 2687, 
                    "offsetInEndSection": 2830, 
                    "text": "H3K4me3 was suggested to affect the AS events of CHD1 [21], and H3K9me3 was found to be associated with the multiple exon skipping of CD44 [22]"
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22455468", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 4907, 
                    "offsetInEndSection": 5061, 
                    "text": "Among the histone methylations we investigate, H3K36me3 (Figure 2a) is the only one that is significantly associated with all types of ASE in all regions,"
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22455468", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 5274, 
                    "offsetInEndSection": 5525, 
                    "text": "The level of H3K4 methylations, including H3K4me1, H3K4me2, and H3K4me3 (Figure 2b-d), is almost all significantly higher in A3SS and A5SS except that the significance of the association of H3K4me3 with ASE is in between 0.01 and 0.05 in some regions."
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22455468", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 5899, 
                    "offsetInEndSection": 6507, 
                    "text": "For the other histone methylations, the level of H4K20me1 (Figure 2e) is significantly higher in A3SS, A5SS and IR; the level of H3K27me3 (Figure 2f) is significantly higher in the exonic region of ES; the level of H3K79me1 (Figure 2g) is significantly higher in A3SS and A5SS, and slightly higher in the intronic region of ES; the level of H3K79me2 (Figure 2h) is significantly higher in ME, A3SS and A5SS, and most region of IR; the level of H3K9me1 (Figure 2i) is significantly higher in A3SS, A5SS and most regions of IR. However, H3K9me3 (Figure 2j) is not significantly associated with any type of ASE."
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22242188", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 4298, 
                    "offsetInEndSection": 4574, 
                    "text": "the strongest univariate candidates [8], [9], [10], [11] e.g. H3K79me1, H3K79me3 and H3K36me3, were all selected as significant by the MCFS, but only H3K36me3 succeeding and preceding the exon were among the 20 highest ranked modifications and thus included in the rule model."
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21173847", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 10261, 
                    "offsetInEndSection": 10501, 
                    "text": "investigation of the fibroblast growth factor receptor 2 (FGFR2) locus revealed cell line-specific enrichment of histone H3 lysine 36 trimethylation (H3K36me3), which was shown to be required to promote the exclusion of one exon of the gene"
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21057525", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 3151, 
                    "offsetInEndSection": 3255, 
                    "text": "H3K36me3 exhibited a spatially reciprocal relationship with H3K79me2, clearly peaking at internal exons."
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21057525", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 3270, 
                    "offsetInEndSection": 3394, 
                    "text": "H3K27me1 was present within active genes20, but exhibited little if any change with respect to exons (Supplementary Fig. 2)."
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21057525", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 4216, 
                    "offsetInEndSection": 4474, 
                    "text": "Across the genome, normalizing ChIP-seq data by MNase-seq data largely removed exon-centered enrichment for most marks (e.g. H3K79me2), but H3K36me3 remained enriched after normalization, peaking near exons and extending on average a few kilobases downstream"
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21057525", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 6093, 
                    "offsetInEndSection": 6215, 
                    "text": "As a control for comparison, H3K27me1 showed little difference up- and downstream of exons or ECRs (Supplementary Fig. 5)."
                }
            ], 
            "type": "summary"
        }, 
        {
            "body": "How are thyroid hormones involved in the development of diabetic cardiomyopathy?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D058065", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013963", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011988", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013974", 
                "http://www.biosemantics.org/jochem#4250045", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D037021", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D037042", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014284", 
                "http://www.biosemantics.org/jochem#4275389"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/8590944", 
                "http://www.ncbi.nlm.nih.gov/pubmed/2059900", 
                "http://www.ncbi.nlm.nih.gov/pubmed/3181644", 
                "http://www.ncbi.nlm.nih.gov/pubmed/2830793", 
                "http://www.ncbi.nlm.nih.gov/pubmed/2934121", 
                "http://www.ncbi.nlm.nih.gov/pubmed/6134470"
            ], 
            "id": "51751ee48ed59a060a000025", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8590944", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 444, 
                    "offsetInEndSection": 501, 
                    "text": "Diabetic animals developed low triiodothyronine syndrome."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2059900", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 940, 
                    "offsetInEndSection": 1448, 
                    "text": "They also showed that diabetes during the final 8 weeks (i) caused a marked impairment in the performance of perfused hearts ex vivo of hypertensive rats but had no measurable effect in the normotensive WKY, (ii) had no effect on arterial pressure of either the normotensive or the hypertensive rats but reduced heart rate of hypertensive animals in vivo, and (iii) caused equivalent hyperglycemia, hypoinsulinemia, and hypothyroidism (depressed serum T3 and T4 levels) of hypertensive and normotensive rats."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2059900", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1449, 
                    "offsetInEndSection": 1728, 
                    "text": "Treatment of diabetic RVH rats with T3 (10 micrograms.kg-1.day-1) in vivo was nearly as effective as insulin therapy (10 U.kg-1.day-1) in preventing the cardiac dysfunction ex vivo and was as effective as insulin therapy in preventing the bradycardia in vivo and the decline loss"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3181644", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 163, 
                    "offsetInEndSection": 252, 
                    "text": "the diabetic state in rats is associated with lowered T3 (triiodothyronine) and T4 levels"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3181644", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 869, 
                    "offsetInEndSection": 997, 
                    "text": "Thyroid status of diabetic animals was normalized by T3 alone or in combination with myo-inositol but not by myo-inositol alone."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3181644", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1368, 
                    "offsetInEndSection": 1440, 
                    "text": "T3 treatment alone did not prevent cardiac dysfunction in diabetic rats."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2830793", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 455, 
                    "offsetInEndSection": 645, 
                    "text": "Untreated diabetic rats exhibited a decrease in spontaneous heart rate and myocardial cytochrome c concentrations concurrent with depressed plasma T3 values compared with untreated controls."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2830793", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 646, 
                    "offsetInEndSection": 845, 
                    "text": "T3 treatment did not improve in vitro cardiac performance (assessed as cardiac output times peak systolic pressure per gram dry heart weight) in hearts from diabetic rats perfused with glucose alone."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2830793", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 846, 
                    "offsetInEndSection": 989, 
                    "text": "Addition of octanoate reversed this depression and improved cardiac function to a greater extent in treated than in untreated diabetic animals."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2934121", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1277, 
                    "offsetInEndSection": 1392, 
                    "text": "As triiodothyronine (T3) treatment has been shown to normalize depression of cardiac myosin ATPase in diabetic rats"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2934121", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1502, 
                    "offsetInEndSection": 1773, 
                    "text": "While diabetic rats treated with T3 alone did not show significant improvement of myocardial function when compared with untreated diabetics, the function of those treated with both T3 and methyl palmoxirate was not significantly different from that in control rat hearts"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6134470", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 950, 
                    "offsetInEndSection": 1125, 
                    "text": "Although the plasma level of thyroid hormone was decreased in the diabetic rat, thyroid hormone treatment did not restore microsomal calcium transport in the diabetic animals."
                }
            ], 
            "type": "summary"
        }, 
        {
            "body": "Which genes are regulated by TRalpha2  in the heart?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006321", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005796", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009206"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/18031713", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15831522", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11731613"
            ], 
            "id": "517539ca8ed59a060a000027", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18031713", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 591, 
                    "offsetInEndSection": 776, 
                    "text": "n FM the reduced mRNA expression of ARB1 (p<0.05, -37%) and ARB2 (p<0.05, -42%) was associated with a reduction of the messenger for TRalpha1 (p<0.05, -85%) and TRalpha2 (p<0.05, -73%)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18031713", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 858, 
                    "offsetInEndSection": 1052, 
                    "text": "hese data reveal that in human heart failure the reduction of beta-adrenergic receptors is associated with reduced expression of both TRalpha1 and TRalpha2 isoforms of thyroid hormone receptors."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15831522", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 620, 
                    "offsetInEndSection": 793, 
                    "text": "Mitigating TRalpha1 effects, both TRalpha2 and TRbeta1 attenuate TRalpha1-induced myocardial growth and gene expression by diminishing TAK1 and p38 activities, respectively."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11731613", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 422, 
                    "offsetInEndSection": 519, 
                    "text": "Selective ablation of TRalpha2 resulted in an inevitable, concomitant overexpression of TRalpha1."
                }
            ], 
            "type": "list"
        }, 
        {
            "body": "Which mitochondrial genes are regulated by thyroid hormone?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013963", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D050259", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011988"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/12225634", 
                "http://www.ncbi.nlm.nih.gov/pubmed/1331777"
            ], 
            "id": "517539e68ed59a060a000028", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12225634", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 76, 
                    "offsetInEndSection": 244, 
                    "text": "We used a polymerase chain reaction (PCR)-based mRNA differential display (DD) analysis to obtain a profile of thyroid hormone-responsive genes in osteoblast-like cells"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12225634", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 503, 
                    "offsetInEndSection": 649, 
                    "text": "At the 2-hour time point, 1 true-positive novel clone was identified and shown to be the mitochondrial gene, subunit 6 of ATP synthase (ATPase-6)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1331777", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 124, 
                    "offsetInEndSection": 549, 
                    "text": "We studied the coordination of the two genomes by measuring transcript levels for nuclear (IV, Va, and VIc) and mitochondrial (II and III) subunits of cytochrome-c oxidase after altering the mitochondrial content of rat muscle and liver by altering the thyroid state of the animals. Tissue levels of these mRNAs were generally decreased in hypothyroid animals and were up-regulated again after thyroid hormone (T3) treatment."
                }
            ], 
            "type": "list"
        }, 
        {
            "body": "Can protein coding exons originate from ALU sequences?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005091", 
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020087"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23374342", 
                "http://www.ncbi.nlm.nih.gov/pubmed/23303787", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21282640", 
                "http://www.ncbi.nlm.nih.gov/pubmed/21188497", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20803091", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20532223", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19393186", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19324900", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18332115", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17594509", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17204284", 
                "http://www.ncbi.nlm.nih.gov/pubmed/18047649", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16027113", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15901843", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15328599", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15099521", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12764196"
            ], 
            "id": "51763a278ed59a060a000030", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21282640", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 152, 
                    "text": "The Alu element has been a major source of new exons during primate evolution. Thousands of human genes contain spliced exons derived from Alu elements."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21282640", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 476, 
                    "offsetInEndSection": 671, 
                    "text": "More than 25% of Alu exons analyzed by RNA-Seq have estimated transcript inclusion levels of at least 50% in the human cerebellum, indicating widespread establishment of Alu exons in human genes."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21282640", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1235, 
                    "offsetInEndSection": 1388, 
                    "text": "his study presents genomic evidence that a major functional consequence of Alu exonization is the lineage-specific evolution of translational regulation."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20803091", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1222, 
                    "offsetInEndSection": 1500, 
                    "text": "Our data suggests that lineage-specific exonization events should be determined by the combination event of the formation of splicing sites and protection against site-specific mutation pressures. These evolutionary mechanisms could be major sources for primate diversification."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20532223", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1009, 
                    "offsetInEndSection": 1113, 
                    "text": "n human, most of the exons that originated from TEs are from the primate-specific transposon called Alu."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20532223", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1966, 
                    "offsetInEndSection": 2124, 
                    "text": "he new exons generated from Alu elements are usually alternatively spliced; these exons comprise \u223c5% of alternatively spliced exons in the human transcriptome"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20532223", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 4320, 
                    "offsetInEndSection": 4568, 
                    "text": "his implies that novelties added to established genes (within established coding sequences, CDSs) are under lower purifying selection if they do not interfere with the original coding sequence, compared to those events that change the original CDS."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20532223", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 5219, 
                    "offsetInEndSection": 5314, 
                    "text": ". We found that exonizations occur preferentially in the beginning of protein coding sequences."
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20532223", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 1987, 
                    "offsetInEndSection": 2222, 
                    "text": "Effects of TE exonization within the first intron are usually neutral with respect to the protein sequence, but can affect signal sequences [41].10.1371/journal.pone.0010907.g001Figure 1Bias toward exonization at the 5\u2032 end of the CDS."
                }, 
                {
                    "beginSection": "sections.2", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20532223", 
                    "endSection": "sections.2", 
                    "offsetInBeginSection": 582, 
                    "offsetInEndSection": 1162, 
                    "text": "e previously suggested that the majority of the TE-derived exons are non-symmetrical because they are still young in evolutionary terms and thus have not yet undergone purifying selection, which eliminates deleterious exonizations. Given a sufficient period of time, some of the currently non-symmetrical exons that are only mildly deleterious will eventually become symmetrical (through small deletions/insertions) and thus will add coding capacity into already established genes. Examples of functional TE-exonizations are exon 8 of ADAR2 gene [60] and exon 8 of NARF gene [47]."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18332115", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 70, 
                    "text": "Exonization of Alu elements creates primate-specific genomic diversity"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17594509", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 425, 
                    "offsetInEndSection": 627, 
                    "text": "more than 5% of the alternatively spliced internal exons in the human genome are derived from Alu, and to the best of our knowledge all Alu-driven exons originated from exonization of intronic sequences"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17594509", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 795, 
                    "offsetInEndSection": 1059, 
                    "text": "Alternatively spliced Alu exons thus enrich the transcriptome, the coding capacity, and the regulatory versatility of primate genomes with new isoforms, without compromising the integrity and the original repertoire of the transcriptome and its resulting proteome."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17594509", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1294, 
                    "offsetInEndSection": 1377, 
                    "text": "Several indications imply that Alu insertions can add new functionality to proteins"
                }, 
                {
                    "beginSection": "sections.1", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17594509", 
                    "endSection": "sections.1", 
                    "offsetInBeginSection": 7768, 
                    "offsetInEndSection": 8149, 
                    "text": "we also observed a higher exonization level within human genome: 0.05% exonization in human both in coding and non-protein-coding genes, versus 0.03% and 0.02% in mouse coding and non-protein-coding genes, respectively (\u03c72; P < 10-16 [degrees of freedom = 1] for protein-coding genes and P < 10-22 [degrees of freedom = 1] for non-protein-coding genes; see Additional data file 1)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15901843", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 845, 
                    "offsetInEndSection": 1158, 
                    "text": "Our data show that, once acquired, some exonizations were lost again in some lineages. In general, Alu exonization occurred at various time points over the evolutionary history of primate lineages, and protein-coding potential was acquired either relatively soon after integration or millions of years thereafter."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15901843", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 131, 
                    "offsetInEndSection": 355, 
                    "text": "Once integrated, they have the potential to become exapted as functional modules, e.g., as protein-coding domains via alternative splicing. This particular process is also termed exonization and increases protein versatility"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15328599", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 125, 
                    "offsetInEndSection": 288, 
                    "text": "alternative \"Alu-exons\" also carry the potential to greatly enhance genetic diversity by increasing the transcriptome of primates chiefly via alternative splicing."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15328599", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 289, 
                    "offsetInEndSection": 528, 
                    "text": "ere, we report a 5' exon generated from one of the two alternative transcripts in human tumor necrosis factor receptor gene type 2 (p75TNFR) that contains an ancient Alu-SINE, which provides an alternative N-terminal protein-coding domain."
                }
            ], 
            "type": "yesno"
        }, 
        {
            "body": "Name the factors required for selenoprotein synthesis in eukaryotes", 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19223320", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16782878", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16230358", 
                "http://www.ncbi.nlm.nih.gov/pubmed/10809727", 
                "http://www.ncbi.nlm.nih.gov/pubmed/20417644", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19467292", 
                "http://www.ncbi.nlm.nih.gov/pubmed/19279205", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17346238", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15208449", 
                "http://www.ncbi.nlm.nih.gov/pubmed/14978508", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11839807", 
                "http://www.ncbi.nlm.nih.gov/pubmed/10444382", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8898393", 
                "http://www.ncbi.nlm.nih.gov/pubmed/8614619"
            ], 
            "id": "51766e438ed59a060a000031", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19223320", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 432, 
                    "offsetInEndSection": 690, 
                    "text": "The tRNASec and the SECIS element, an RNA hairpin in the 3\u2032UTR of selenoprotein mRNAs, and two trans-acting proteins, the specialized translation elongation factor eEFSec and the SECIS Binding Protein 2 (SBP2), are the key players of the recoding machinery ("
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19223320", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 694, 
                    "offsetInEndSection": 1002, 
                    "text": "Specialized protein complexes that involve SECp43, the Phosphoserine tRNASec Kinase (PSTK) and the Sec synthase are recruited to the tRNASec to ensure proper selenocysteine synthesis (2\u20134). Ribosomal protein L30 has also been implicated in this mechanism and shown to compete with SBP2 for SECIS binding (5)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19223320", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 3102, 
                    "offsetInEndSection": 3180, 
                    "text": "SPS2 is the selenophosphate synthetase involved in selenocysteine biosynthesis"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16782878", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 185, 
                    "offsetInEndSection": 323, 
                    "text": "The process requires the Sec insertion sequence (SECIS) element, tRNASec, and protein factors including the SECIS binding protein 2 (SBP2)"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16230358", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 1232, 
                    "offsetInEndSection": 1392, 
                    "text": "Taken together, these data establish the role of SECp43 and SLA in selenoprotein biosynthesis through interaction with tRNA([Ser]Sec) in a multiprotein complex."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17346238", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 254, 
                    "text": "Selenophosphate synthetase (SelD) generates the selenium donor for selenocysteine biosynthesis in eubacteria. One homologue of SelD in eukaryotes is SPS1 (selenophosphate synthetase 1) and a second one, SPS2, was identified as a selenoprotein in mammals."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17346238", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 838, 
                    "offsetInEndSection": 1063, 
                    "text": "These in vivo studies indicate that SPS2 is essential for generating the selenium donor for selenocysteine biosynthesis in mammals, whereas SPS1 probably has a more specialized, non-essential role in selenoprotein metabolism."
                }
            ], 
            "type": "list"
        }, 
        {
            "body": "What are the major classes of retrotransposons active in the human genome?", 
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018626"
            ], 
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23282240", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22923465", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22093876", 
                "http://www.ncbi.nlm.nih.gov/pubmed/22528351", 
                "http://www.ncbi.nlm.nih.gov/pubmed/17431169", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16511833", 
                "http://www.ncbi.nlm.nih.gov/pubmed/16399224", 
                "http://www.ncbi.nlm.nih.gov/pubmed/15867427", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12213770", 
                "http://www.ncbi.nlm.nih.gov/pubmed/12167372", 
                "http://www.ncbi.nlm.nih.gov/pubmed/11343131", 
                "http://www.ncbi.nlm.nih.gov/pubmed/10677855", 
                "http://www.ncbi.nlm.nih.gov/pubmed/2165587"
            ], 
            "id": "517843638ed59a060a000036", 
            "snippets": [
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22528351", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 286, 
                    "text": "Half of the human genome is composed of repeated DNA, and some types are mobile within our genome (transposons and retrotransposons). Despite their abundance, only a small fraction of them are currently active in our genome (Long Interspersed Element-1 (LINE-1), Alu, and SVA elements)."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16511833", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 114, 
                    "offsetInEndSection": 343, 
                    "text": "Since certain types of retrotransposons, particularly members of the Alu, L1, and SVA families, are still active, their recent and ongoing propagation generates a unique and important class of human genomic diversity/polymorphism"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15867427", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 0, 
                    "offsetInEndSection": 155, 
                    "text": "Alu elements are the most successful SINEs (Short INterspersed Elements) in primate genomes and have reached more than 1,000,000 copies in the human genome"
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12213770", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 120, 
                    "offsetInEndSection": 201, 
                    "text": "1 and Alu represent the most prolific human LINE and SINE families, respectively."
                }, 
                {
                    "beginSection": "sections.0", 
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12213770", 
                    "endSection": "sections.0", 
                    "offsetInBeginSection": 202, 
                    "offsetInEndSection": 328, 
                    "text": "Only a few Alu elements are able to retropose, and the factors determining their retroposition capacity are poorly understood."
                }
            ], 
            "type": "list"
        }
    ]
}